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"1 often say that when you can measure what you are speaking about, and express it 
in numbers, you know something about it~ but when you cannot measure it, when 
you cannot express it in numbers, your knowledge is of a meagre and unsatisfactory 
kind; it may be the beginning of knowledge, but you have scarcely, in your 
thoughts, advanced to the stage of science whatever the matter may be. " 
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Abstract 
Since their inception the B-Iactam antibiotics have become one of the most 
important classes of phannaceutical agents, both therapeutically and economically, 
in modern day usage for the treatment of a wide spectrum of bacterial infections. 
However, due to the versatility of bacteria many previously treatable species are 
developing resistance to the antibiotics currently available and so there is ever a 
need to develop more ~-lactam antibiotics, which are effective and yet safe. 
A major drawback to the ~-lactams is the degree of immunologically adverse 
reactions they induce. 
It was the aim of this study to develop both mechanistic and immunological 
methods to enable the prediction of a B-lactam's potential to induce an allergic 
response and to determine if a relationship between these responses and the 
molecular properties of the ~-lactams was present. 
In this study a database pertaining to frequency by which 70 p-lactams induce 
adverse reactions has been compiled and used to produce 27 QSAR models. 
A highly sensitive assay for the quantitation of cross-reactivity between B-lactams 
and serum anti-benzylpenicillin antibodies has been developed and used to 
determine the cross-reactivity potential of 31 ~-lactams and to develop 18 QSAR 
models. 
All of the QSARs developed suggest that the shape and electron separation of the 
~-lactams are crucial to the development and extent of adverse response or cross-
reactivity induced by a specific p-lactam antibiotic, new or old. 
The QSARs developed will enable the design and development of new ~-lactam 
antibiotics which present a significantly lower risk of inducing immunologically 
mediated adverse responses when used therapeutically. 
Two sensitive assays for the quantitative detennination of the cytokines IL2 and 
IL4 in lymphocyte culture supernatants have been developed, and have been shown 
to have a potential use in the prediction of the type of immunological response 
initiated following p-Iactam stimulation of a sensitised individual. 
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1.0 General Introduction 
The J3-lactam antibiotics remain the singularly most important class of antibiotics in 
modem day use. Despite a wide therapeutic index the ~-Iactams have a degree of 
toxicity [1] which manifests primarily as allergic reactions, with immediate 
hypersensitivity constituting the most dramatic and distressing form of allergic reaction. 
The development of new ~-lactam antibiotics therefore, raises the following questions: 
- Is the new drug potentially as sensitising as other drugs currently available? 
- Will the new drug cross-react with other established p-Iactams and so elicit allergic 
reactions in an already sensitised person? [2]. 
The answers to these questions lie in the evaluation of the immunotoxicity of existing 
and new p-Iactam antibiotics. 
Immunotoxicity is a consequence of the interaction of a chemical agent with the immune 
system, which leads to the development of a specific immune response. The 
manifestations of this may be through immunoglobulins (lgE), antibody or immune 
complex, cell-mediated tissue damage or cell-mediated reactions including contact 
sensitisation. All involve an immune response to the drug itself, to a bio-transformation 
product or to modified host tissue giving rise to neo-antigens [3]. The tissue damage 
mediated by these pathways should be recognised in pre-clinical studies and thus trigger 
the need for immunotoxicological function testing. 
Recent advances in biotechnology coupled with those in molecular biology, have 
enabled the specific production of monocJonal antibodies, the use of which has vastly 
improved the assay systems available for immunological studies, and have led to a better 
understanding of the immune system and the role of cytokines in the induction and 
direction of immune responses. This has resulted in a large number of immunoregulatory 
cytokines and growth factors being identified. Thus, analysis of cytokine production by 
immune cell populations, following exposure to an allergen, could be applied in the 
testing of immunological function. 
The competitive nature of the phannaceutical industry demands methods of drug design 
and development that are quick and reliable, yet which produce safe and effective 
compounds. Initial strategies for the immunological assessment of the toxicity and safety 
of medicines have been to select a tiered panel of assays that will identifY the 
immunotoxicological potential of a specific chermcal agent [4]. 
Limited effort has been made within the field of immunotoxicology to compare, refine 
and validate assays [4], so as to provide methodologies which ensure that reasonable 
compounds are developed, dubious compounds are tested more fully and undesirable 
compounds are eliminated from future testing. Thus leading to the production of 
common valid assays for use as screening tools, so leading to the conservation of the 
financial resources required for exhaustive testing, yet ensuring safety and toxicity are 
still investigated thoroughly [5]. 
Dewdney and Edwards [6] proposed that there are two general approaches for the pre-
clinical assessment of a drug allergen's potential immunotoxicity, currently being 
evaluated. One is based on the expectation that it will be possible to develop animal 
models which mimic clinical adverse reactions. The second is a mechanistic approach, 
which assumes that a low molecular weight drug, such as a fJ-Iactam antibiotic, possess 
one or more physico-chernical properties that are responsible for the induction of an 
immunotoxic reaction. 
The EEC (1984) and OEeD (Organisation for Economic Co-operation & Development) 
(1993) guidelines recommend that the assessment of the structural properties of 
allergens should be used where possible to assess potential immunotoxicity [7]. 
As immunotoxicity is a biological activity it should, in principle, be possible to utilise 
quantitative structure-activity relationship (QSAR) techniques in conjunction with 
immunological tests to provide a means of performing a mechanistic assessment of 
immunotoxicity. Thus permitting the identification not only of those structures 
responsible for the activation of an imrnunotoxic response but also the direction of the 
immune response and of those properties of the fJ-lactams themselves which are 
responsible for this directional switching [7]. 
This study has shown that it is possible to develop immunotoxicological assays and to 
generate QSAR models which can be used as screening tools. Extrapolation of the 
results attained and identification of their clinical relevance will enable the prediction of 
simple stfl:lctural changes that will allow the pharmaceutical industry to design and 
develop new and safer fJ-lactam antibiotics [8]. 
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2.0 (3-Lactam Antibiotics 
2.1 Introduction 
Benedict and LangIykke [9] define an antibiotic as "a chemical compound derived from 
or produced by a living organism, which is capable, in small concentrations, of inhibiting 
the life processes of micro-organisms. " 
The J3-lactam antibiotics are therapeutic agents used as the first line of treatment against 
bacterial infections and as such have become clinically and economically, the most 
important class of pharmaceutical agents in modem usage. 
All J3-lactam antibiotics contain, as the name suggests, a J3-lactam ring structure (figure 
2.1), this being a four membered ring which contains an amide functional group. The 13 
suffix stems from the fact that the labelling of the lactam ring carbons (a. and 13), from 
the functional group means that the 13 carbon is that carbon attached to the nitrogen 
function. 
Figure 2.1 The {l-Lactam Ring 
Naturally occurring J3-lactam antibiotics are produced by a wide variety of micro-
organisms, including numerous species of Streptomyces, Nocardia, a few filamentous 
fungi and some unicellular bacteria. 
The natural and scientific interest in antibiotics, as well as their commercial success, has 
led to the identification and isolation of thousands of compounds. However, to be a 
useful antibiotic each compound must be significantly effective against a specific 
pathogen or group of pathogens without producing a significant toxic side effect. Each 
compound must also be stable so that it can be isolated, processed and stored for a 
reasonable length of time prior to use. Each processed compound must also be produced 
in an active dosage, amenable for absorption, detoxification and elimination, and which 
when administered at appropriate intervals will maintain therapy, but which upon 
cessation of administration is rapidly eliminated from the host. These constraints mean, 
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therefore, that of the thousands of likely antibiotics isolated only a few become 
medically available, but these few have been extremely successful and have made the 
antibiotics the most important products of the modem pharmaceutical industry. 
The J3-lactam antibiotics can be divided into five distinct classes: penicillins, 
cephalosporins, c1avulanic acids, monolactams and novel ~-Iactam containing structures. 
The penicillins and cephalosporins are the most effective classes in current use for the 
treatment of infectious diseases. 
2.2 Molecular Mode of Action 
The majority of penicillin and cephalosporin analogues appear to employ an identical 
antibacterial mode of action in which they interfere with the biosynthesis of the 
peptidoglycan component of the bacterial cell waIl [10]. The molecular mode of action 
of the J3-lactam antibiotics is unique and well established [11]. Their action is to inhibit 
the peptidoglycan transpeptidation step of bacterial cell wall synthesis by inactivating the 
DD peptidase and DD carboxypeptidase enzymes involved in the process [11,12,13,14]. 
2.21 Normal Situation 
Most prokaryotic cells are surrounded by a cell wall which is responsible for giving the 
bacteria their shape and for allowing them to survive in hypotonic environments. The 
bacterial cell waIl of both Gram positive and Gram negative bacteria is composed of two 
layers of peptidog!ycan (also called murein sacculus), a carbohydrate backbone, from 
which penta-peptide side chains of Ala-Gly-Lys-A1a-A1a extend. The wall is 
strengthened due to cross-linking between two adjacent murein layers (figure 2.2), in 
which the lysine of one penta-peptide attaches to the penultimate alanine of a penta-
peptide in an adjacent murein backbone, with the removal of the terminal alanine. The 
reaction mechanism of cross-linking occurs in two phases (figure 2.3). This cross-linking 
gives a third dimension so strengthening the cell wall, holding the cell rigid and 
protecting it against osmotic rupture. The whole process is under the control of the 
transpeptidase enzymes. 
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Figure 2.2 
Figure 2.3 
Phase 1: 
Diagrammatic Representation of the Bacterial Cell Wall 
-~~----------~----------A1~~---------A1LJ~~ 
Mechanism ofNonnal Bacterial Cell Wall Synthesis 
Ala-GIY-LYS-~-NH-<;Hl~-t:;:cooH --------------- R-lNH-J:~~NZ 
o Me ~ + 
'---ENZ NH2-CH-COOH 
~e 
Transpeptidase recognises two adjacent alanine ammo acids and acts as a 
nUcleophile, attaching to the carbonyl carbon atom of the penultimate alanine, thus 
causing the breakdown of the C-N linkage between the two alanines, so liberating the 
tenninal alanine. 
Phase 2: 
o o(J Ala-Gly-LYs-~-NH-CH-~-ENZ -------------
Le 1 
o 0 /1 , 
R-C-NH-CH-C + ENZ 
Me J 
NH-Lys 
Lys-NH2 
Lysine is a basic amino acid, the NH2 group of which possess a lone pair of 
electrons, thus allowing it to behave as a nucleophile and fonn a linkage with the 
alanine carbonyl carbon atom on an adjacent pentapeptide. The enzyme is a better 
leaving group than lysine and so the linkage between alanine and the enzyme breaks 
readily with the free enzyme being displaced. 
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2.22 Action of the {3-Lactams 
Tipper and Strominger [11] proposed that the ~-Iactam antibiotics are structural 
analogues of the C-terminal acyl-D-ala-D-ala component of one peptidoglycan strand. 
Park and Strominger [15 J illustrated (figure 2.4) that the f3-lactam antibiotics do in fact 
resemble the ala-ala couple present in the pentapeptide of the bacterial cell wall and that 
the carbonyl group of the f3-lactam ring corresponds to the active carbonyl group in the 
centre of the pentapeptide ala-ala couple. Therefore, when a J3-lactam antibiotic is 
introduced into the bacterial environment, the transpeptidase enzymes (DD-peptidases 
and DD-carboxypeptidases) are unable to distinguish between their natural substrate 
(the pentapeptide) and the J3-lactam antibiotic. The ~-lactams are very strained 
structures, and the effects of resonance within the structure cause the carbonyl carbon of 
the ~-lactam to become more reactive than that of the natural ala-ala substrate couple. 
The enzyme attains a greater affinity for the carbonyl carbon of the J3-lactam and thus 
reacts more readily with it than with that of the natural substrate. The hydroxyl group of 
a serine residue in the active site of the transpeptidase enzyme (figure 2.5) reacts with 
the carbonyl carbon of the J3-lactam, the C-N bond within the J3-lactam ring is cleaved 
and the enzyme binds to the carbonyl carbon atom liberated by the ring cleavage (figure 
2.6). The bound 13-lactam then forms a covalent bond with a serine residue at the 
enzymic active site and the enzyme becomes acylated and inactivated, becoming 
irreversibly bonded to the J3-lactam and forming a f3-lactam tetrahedral-acyl enzyme 
complex~ hence the enzyme is rendered unable to play any part in further reactions and 
so bacterial cell wall synthesis becomes inhibited. 
6 
Figure 2.4 Diagrammatic Representation of the Similarity Between 6-Lactams 
and the Natural Substrate of the Transpeptidase Enzymes 
(Adapted from Rando [16] ) 
The molecule labelled a,tl,X,o,E is the dipeptide and A,B,C,D,E is the corresponding 
portion of benzylpenicillin. 
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Figure 2.5 
KEY: 
Diagrammatic Representation of Possible 
Enzymic j3-Lactam Binding Sites 
(Adapted from Ghuysen et al [17] ) 
Il = Activation sites. Interact with B-lactam acyl side chain or peptide L-R3 residue. 
III = Fixation or acylation site. Nucleophilic attack of J3-1actam C7, or penultimate 
D-alanine residue carbonyl group by an enzyme serine residue. 
IV = Stabilisation site. Interaction with the monocyc1ic thiazolidine part of molecule. 
V = Fragmentation site. Catalyses cleavage of C5-C6 bond. 
VI = Deacylation site. Catalyses the attack of penicilloyl-enzyme or substrate-enzyme 
complexes of serine ester linkage by water or nuc1eophile. 
Figure 2.6 Illustration of the Molecular Mode of Action of the j3-Lactam Antibiotics 
/ RI 
, 
Enzyme 
Enzyme 
2.3 Penicillins 
2.31 Structure and Features 
The penicillins are a class of fl-Iactam antibiotics with a common fused ring structure 
(figure 2.7) which comprises a fl-Iactam ring (A) fused to a sulphur-containing 5 
membered ring, known as a 'thiazolidine ring' (B). An amide group with a variable group 
(R) is attached to the a-carbon of the p-Iactam-ring. Two methyl groups and a carboxy 
group are attached to the thiazolidine ring. 
2.32 History of Development 
Penicillin was first discovered in 1928 by Alexander Fleming, who whilst working with 
Staphylococci bacteria noticed that a contaminating mould was actually killing the 
bacteria. This mould was identified as Penicillium notatum. In 1938 Florey, Chain and 
co-workers extended FJeming's initial findings by isolating, from surface cultures of 
P.notalum, a crude extract which contained antibacterial properties. Clinical applications 
of penicillin commenced in 1941, but use was limited due to problems in producing 
sufficient quantities of active extract. In 1943, with the discovery of 'Deep Culture' 
techniques, crude penicillin antibacterial mixes became widely available. The advent of 
X-ray crystallography allowed the structures of the antibacterial mix constituents to be 
determined. From the original antibacterial mix the four related compounds of penicillin 
X,F,G and K were isolated. 
In November 1944, at a meeting of the Royal Society of Medicine, Florey made the 
prediction that "someday chemists will manipulate the penicillin molecule and improve 
its performance". Fulfilment of this prophecy came fifteen years later, with the isolation 
of the 6-amino-penicillonic acid (6AP A) nucleus [18] and structural analyses which 
showed all penicillins as being derived from an enzymically catalysed hydrolysis reaction 
(figure 2.8) between 6APA and a carboxylic acid. 
A drawback of the original isolate, penicillin-G, was its acid lability, which caused most 
of an oral dose to be destroyed in the stomach. The first acid-resistant penicillin 
discovered was penicillin-V, a natural product, first described in 1948, but not 
discovered as an antibiotic entity until 1953 [18]. Absorption was further improved with 
the production of the semi-synthetic phenoxy-penicillins; phenethicillin, propicillin and 
phenbenicillin. The next advance was the production of derivatives resistant to the 
destructive action of Staphylococcus penicillinase, e.g. methicillin, which therefore were 
effective in penicillin-resistant infections. This was followed by the production of the 
ixazole-peniciUins' oxacillin cloxacillin dicloxacillin and flu cloxacillin, which combined , , , 
penicillinase and acid resistance. 
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Figure 2.7 Common Penicillin Structure 
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Another disadvantage of peniciIlin-G was its low degree of activity against Gram 
negative organisms, except gonococci and meningococci. The development of ampicillin 
represented a great advance in that its action against Gram positive organisms (including 
susceptibility to penicillinase) was similar to penicillin-G but it showed considerably 
greater activity against many Gram negative organisms. 
Attachment of different acid chloride moieties to the acyl side chain of the 6AP A 
nucleus coupled with advances in fennentation technology, has led to the semi-synthetic 
production of thousands of new penicillins, all of which possess different physico-
chemical and antibacterial properties, including stability and activity. An illustration of 
the time scale of penicillin development is given in figure 2.12. 
2.4 Cephalosporins 
The discovery of cephalosporin antibiotics has provided a means of producing semi-
synthetic p-lactam derivatives which are effective against bacterial species showing 
resistance to penicillin antibiotics. 
2.41 Structure and Features 
The cephalosporins are a class of p-Iactam antibiotics which comprise a p-lactarn ring 
fused to a sulphur-containing 6 membered ring, known as a 'dihydrothiazine ring' (figure 
2.9). An amide group is attached to the a.-carbon of the p-Iactarn-ring, and a methyl and 
a carboxy group are attached to the dihydrothiazine ring. Upto 4 variable side chains 
(RI, R2, R3 and R4 respectively) may be attached to the core structure, each of which 
affects cephalosporins' properties. 
2.42 History of Development 
The first cephalosporins were isolated from a mould Cephalosporium acremonium, 
cultivated in 1945 from a sewage outfall in Brotzu, Sardinia [18]. Florey found that the 
crude extract consisted of several antibacterial compounds including, cephalosporin-N 
(a penicillin) and a cephalosporin which resembled a steroid. Due to its occurrence in 
such low concentrations the presence of cephalosporin-C (a natural cephalosporin) was 
not discovered until 1953 [18]. 
Cephalosporin-C was shown to be resistant to Staphylococcus penicillinase (no 
penicillin at this time showed p-lactamase resistance) but it only had 10% of the 
antibacterial potency of the penicillins. 
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Twenty years elapsed before Cephalosporium acreonium was induced to give an 
adequate yield of cephalosporin-C, which could be used in further research and 
development. 
It was discovered that all true cephalosporins comprise a common nucleus of 7-amino 
cephalosporanic acid (7ACA) (figure 2.9). However, production of new cephalosporins 
on an industrial scale, using processes similar to those used for the peni cill ins, was 
expensive. EIi-LiIly discovered it was possible to expand chemically the penicillin 6AP A 
nucleus (which could be produced in vast quantities and cheaply) to produce the 7ACA 
nucleus for the semi-synthetic production of cephalosporins. Reaction of 7 ACA and an 
acid chloride allowed the industrial production of a wide range of semi-synthetic 
cephalosporins (figure 2.10). 
To date more useful semi-synthetic modifications of 7 ACA nucleus have resulted from 
acylation of the 7 amino group with different acids or from nucleophilic substitution or 
reduction of the acetoxyl group. All semi-synthetic cephalosporins possess penicillinase 
resistance, have a wide range of antibacterial potency, differing spectra of activity, and a 
generally low toxicity, so making them a favourable therapeutic for use against bacterial 
infections in penicillin-allergic subjects [19]. 
Cephalosporins in clinical use can be placed into one of five categories (figure 2. I 1), 
based on fJ-Iactamase resistance, metabolic stability and means of administration [20]. 
An illustration of the time scale of cephalosporin development is illustrated in figure 
2.12. 
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Figure 2.9 Cephalosporin Common Structure and Structure Activity Relationships 
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Figure 2.11 Cephalosporin Classification 
(Adapted from O'Callaghan [2]] ) 
NOTE: It was ruled in 1975 that new compounds with names derived from 
'cephalosporin' should be spelt with 'f' instead of , ph' 
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2.5 Drawbacks of6-lactams 
2.51 Immunological Adverse Effects 
Since their initial discovery the Jl-Iactams have rapidly become one of the most 
commonly prescribed drug types in the world [23]. 
Compared with other groups of phannaceutical agents the p-lactam antibiotics have a 
wide therapeutic index, a relatively low toxicity and are rarely associated with serious 
adverse reactions. However, the use of Jl-lactams in human medicine is not without its 
problems, namely the incidence of immunologicaUy related adverse effects which they 
induce. 
An adverse reaction can be described as 'any response to medication, which is undesired 
or unintended by the physician' [23]. 
The f3-1actams are very potent immunogens, in that they are low molecular weight 
compounds and as such function as haptens irreversibly and covaIentIy binding to tissue 
macro-molecules, such as proteins, forming an immunogenic multi-valent hapten-protein 
complex which acts to induce an immune response [1,25,26,27]. These responses range 
in severity from minor symptoms such as dry mouth, cutaneous rash or sleepiness to 
anaphylaxis, drug fever and potentially fatal damage to the bone marrow or liver. Table 
2.1 lists some of the types of adverse reactions which have been reported following the 
therapeutic use of Jl-Iactam antibiotics. Many of these adverse reactions are unlikely to 
involve immunologic reaction mechanisms, but of those which do, urticaria and 
maculopapular rashes are the most frequent and it is suspected that they are brought 
about through allergic reaction mechanisms. The incidence of immunologically mediated 
adverse reactions to Jl-Iactam antibiotics constitutes a major clinical problem which 
complicates their medical management and hence limits their use, as a significant 
proportion of the general population is believed to be pre-sensitised to them []]. 
2.521 Allergic Reactions 
An allergic reaction is the process through which a xenobiotic provokes a specific 
immunological response which results in the development of a tissue damaging 
hypersensitivity reactions [28], and discussed in more detailed in 6.7. 
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Frequency of Allergy: 
During the early years of penicillin therapy, allergic reactions generally affected the skin. 
As early as 1943, urticaria was observed in 2-3% of patients treated with penicillin. 
After 1944 the incidence increased to 6 to 8%. Following the introduction of crystalline 
penicillin, in 1947, the frequency seemed to level offat 1-2% [30]. 
Anaphylactic reactions are the most worrying type of allergic reaction, particularly when 
associated with drug administration, as they have the potential to be fatal [ 1 J. 
Anaphylaxis due to penicillin was first reported by Cormia et al [31] in 1945, and the 
first reported death due to penicillin induced anaphylaxis occurred in 1949 [1]. Today, 
anaphylactic reactions occur in 0.004 to 0.015% of the patients receiving penicillin, with 
the incidence offatal anaphylaxis being 0.0015 to 0.002% [1]. 
It is estimated that today between 0.7 and 10% of the population are allergic to the 13-
lactam antibiotics. Arreaza [32] proposed that possible reasons for this high prevalence 
of allergy can be attributed to: the widespread and sometimes indiscriminate use of the 
drug, to highly reactive degradation products which when combined with tissue proteins 
act as very powerful sensitising haptens, to extensive cross-reactivity among the 13-
lactam drugs which include semi-synthetic penicillins and to a lesser degree the 
cephalosporins, and to the frequent and yet inadvertent sensitisation of the popUlation by 
"hidden" sources of antibiotics, such as milk (breast and animal), soft drinks, 
occupational hazards, mycotic infections, vaccines and in utero placental transfer. 
2.52 Cross-Reactivity 
The p-lactams have a high degree of structural similarity, both in their core nucleus and 
in the side chain structures. It is believed that it is because of these similarities that some 
J3-lactams cross react with serum antibodies previously raised against an others [33]. 
That is, that the antibodies raised against a f3-lactam in pre-sensitised patients recognise 
and react with similar f3-lactams, as if they were the sensitising antibiotic, thus giving 
rise to an allergic type reaction (as explained in 2.51 and 7.231 ). 
The phenomenon of cross-reactivity between f3-1actams in allergic patients is a complex 
problem involving many factors [34]. Although the frequency of allergic cross-reactivity 
amongst f3-lactams, is not generally extensive and the extent differs between individuals, 
the clinical significance of cross-reactivity between different p-lactams is of concern and 
constitutes a serious problem with regard to the choice of a secondary antibiotic for 
administration to f3-1actam-sensitive patients [35,36]. 
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2.6 Future Developments 
Bacteria are well known for being extremely versatile in their ability to circumvent the 
mechanisms by which antibiotics bring about their demise, e.g. penicillinase resistance. 
In the 1990's there has been a resurgence in the number of antibiotic resistant bacterial 
infections observed clinically [37]. There is therefore a continual need to design and 
develop new fl-lactam antibiotics, for the effective treatment both of old and new forms 
of an infection. Increasing efforts are being made to develop new active compounds of 
both wider antibacterial spectra and potency, and diminished levels of toxicity [38]. 
The use of quantitative structure-activity relationship (QSAR) models pertaining to 
antibiotic potency, as developed by Irwin et al [39] and Hansch et al [40], in conjunction 
with those pertaining to toxic and cross-reactive potential (as derived in this work 9.0 
and 10.0), will provided a means of identifYing any relationships existing between the 
structural and / or physico-chemical properties of the J3-lactams and their potential 
potency and toxicity Thus enabling the design and development of a new J3-lactam 
antibiotics by modification of specific molecular features, in such a way as to enhance 
potency and limit its toxicity, whilst also, greatly reducing the use of animal tests and 
development costs. 
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3.0 Computational Chemistry 
3. 1 Concepts and Applications 
In the 1980s a vast increase in the availability of computing power led to an increased 
use of computational chemistry in the area of drug design. Computational chemistry is 
basically the use of computer programmes to give quantitative predictions of chemical 
structure, properties and molecular behaviour, from a knowledge of the molecular 
structure. When allied with the growth in molecular graphics, computational chemistry 
has proved to be a valuable tool for the estimation of a synthesised or unsythesised 
molecule's three dimensional properties [41]. Information generated by computer is 
provided at a fraction of the time and a fraction of the cost needed, than if it were to be 
determined experimental1y. 
The assessment of molecular structure commences with the input of the chemical 
structure of the compound under investigation into the chosen software package, in a 
suitable format e.g. SMILES code, Cartesian co-ordinates or manual graphical entry. 
Calculations are. then performed using mathematical models derived from the classical 
theories of bonding and atomic behaviour, to produce the most geometrically stable 
arrangement of the atoms within the molecule and to calculate the energies associated 
with the 'minimised' conformation of the molecule. The energy calculation is the basis of 
an molecular modelling as energy is inversely proportional to stability (equation 3.1). 
Energy a. 1/ Stability (3.1) 
There are two major advantages in the use of computational chemistry; 
1- it provides the ability to produce meaningful results easily on not yet synthesised 
chemicals or even on chemicals that can not exist under real conditions, as well as for 
those chemicals that are common-place in the laboratory. 
2- vast amounts of information can be produced in relatively short periods of time, at 
tnlfilmUm expense. 
There are two basic approaches for the prediction of chemical structure and properties 
for a given molecule, Molecular Mechanics and Molecular Orbital Theory. 
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3.11 Molecular Mechanics (MM) [42,43J 
MM or free field calculations regard the molecule as a collection of atoms (balls) held 
together by elastic or simple harmonic forces (springs). The forces are described in 
tenns of potential energy functions of the bond lengths and angles, which when 
considered together describe the total potential energy of the molecule. Each potential 
energy function in combination with force field energy describes changes in the energy 
due to the deformation of structural features from the 'natural' condition. 
Different computer programmes employ different sets of potential energy functions. In 
its simplest fonn the energy of a molecule in a force field, E can be represented in the 
form of equation 3.2. 
E = El +Ea +Et +Enb (3.2) 
Where El is the energy of a bond stretched or compressed from its natural length. 
Ea is the energy due to bond deformation. 
Et is the torsional energy due to twisting about bonds. 
Enb is the energy due to non-bonded interactions, including steric hindrance, 
electronic and steric repulsion or attraction and hydrogen bonding. 
There are no strict rules regarding which or how many potential energy functions should 
be used or included in force field calculations. However, there are two classes (as given 
in table 3.1), which comprise five potential energy functions common to most methods. 
It is important to realise that the energy of a molecule has no physical meaning on its 
own, but is purely a measure of intra-molecular strain, relative to a hypothetical 
situation. The relevance of energy lies in its variation, in different structural geometries 
of a molecule, which thus allows predictions regarding to molecular behaviour. 
Table 3.1 Two Classes of Potential Energy Functions. 
Bonded Interactions Non-bonded Interactions 
Bond Length van der Waals interactions 
Bond Angle (represents steric interactions occurring between non-bonded atoms) 
Torsion Angle Electrostatic interactions 
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3.22 Molecular Orbital Theory (MO) 
Molecular orbital theory uses quantum mechanical calculations in the prediction of 
molecular properties. Quantum mechanics lies at the heart of all modern science, its 
equations describe the behaviour of very small objects, i.e. atoms, and provide the only 
understanding of the world of the very smal1. Without these quantum mechanic 
equations there would not have been the ability to design nuclear power stations, lasers 
or to understand DNA and genetic engineering. Schrodinger described quantum 
mechanics in terms of waves ('V), familiar features in the world of physics, and proposed 
that particles are guided by the wave and the strength of the wave at any point in space 
and so in order to solve the problems of quantum mechanics one should measure the 
probability of finding the particle at a particular point [44]. In principle the solution of 
the Schroedinger Wave Equations should provide answers to every chemical problem. 
Unfortunately, a perfect solution of the equations is at present possible only for the 
hydrogen atom, with only approximate solutions for slightly more complicated but still 
small entities. The advent of computing technology has allowed the inclusion of various 
major approximations into the Schroedinger equations, which have allowed for their 
solutions, at an arbitrary level of accuracy, for larger molecules. The techniques for 
solving the Schroedinger Wave Equations are grouped together under the title 
Approximate Molecular Orbital Theory, a summary of available techniques is given in 
table 3.2. As the methods become more approximate, the less computer time they 
require, thus enabling larger molecules (20 to 50 atoms) to be analysed. However, it 
must be remembered that results will become less reliable and so must be treated with 
due caution. 
Table 3.2 Summary of the Various Approximate Molecular Orbital Methods 
(Adapted from Cronin [42] ) 
I 
Increase in 
Accuracy and 
compuler Time 
Hartree-Fock limit ab initio 
Extended basis set ab initio 
Minimum basis set ab initio 
Minimum Neglect of Differential Overlap (MNDO) 
Complete Neglect of Differential Overlap (CNDD) 
Iterative extended Huckel Theory (IEHT) 
Extended Huckel Theory (EHT) 
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3.2 Computational Chemistry in Quantitative Structure-Activity Relationships (QSARs) 
The ability to calculate the minimum energy conformation of a molecule, which is 
assumed to represent the most active conformation, is of extreme value as a tool in 
quantitative and qualitative analysis. Parameters calculated through computational 
chemistry techniques have been shown to be of great value in the development of 
QSARs. 
There are now commercially available complete molecular modelling packages, which 
will find the minimum energy state of a molecule and calculate physico-chemical and 
structural descriptors. 
Examples of such packages are: 
- Chem-X from Chemicai Design Ltd 
- SYBL from Tripos 
- CHARMm from Polygen. 
Furthermore, the pharmaceutical industry itself has developed software tailored to its 
own requirements, such as; 
- COSMIC from SmithKline Beecham. 
- Profiles from Wellcome Corporation. 
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4.0 Quantitative Structure-Activity Relationships (OSAR) 
4. 1 Definition 
Correlation's between structure and activity are important for the understanding and 
development of pharmaceutical agents and for the investigation of chemical toxicity 
[45]. The basis of all QSAR studies is the belief that any change in the molecular 
structure of a compound will alter the physical, chemical and biological properties of 
that compound [46,47]. A QSAR study can therefore be defined essentially as 'the 
development of a statistically significant mathematical model, which relates the obseJVed 
biological activities of a series of compounds to the physico-chemical and structural 
properties of those compounds'. A QSAR will thus aid the understanding of the 
underlying mechanisms of the biological response and may lead to the ability to predict 
the biological activity of new, untested or even hypothetical compounds [45,48]. 
4.2 Historical Background and Developments 
The idea that a relationship exists between the chemical structure of a compound and its 
pharmacological or toxicological properties can be traced back to the nineteenth century 
[49]. In 1858 the Russian chemist and composer, Borodin wrote that 'by comparing 
poisonous substances with each other, one came to realise that their toxicological 
properties and chemical make up are closely related. The first thing to be noted was the 
fact that many substances consist of the same element or take part in similar reactions 
and also exert similar actions in the organism' [49]. 
In 1868, whilst investigating the narcotic effects of analgesics, Crum Brown and Fraser 
[50J postulated that 'the physio-logic action of the analgesic (4)) is a function (f) of its 
chemical structure (c) [51,52] as presented in equation 4.1. 
cj>=f(c) (4.1) 
In 1878, Langley first proposed that drugs act on specific components within the body 
[49J and in 1893, whilst studying a number of simple polar compounds, Richet [53J 
determined that toxicity is a function of the aqueous solubility of the compound itself,. 
thus giving credence to the work ofCrum Brown and Fraser [50]. 
By the start of the twentieth century a dichotomic approach to structure-activity 
relationships was in existence, with ErJich, Landsteiner and Clark [54 J investigating the 
idea that 'chemical constitution was the basis for understanding the biological activity of 
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compounds', whilst Overton, Meyer and Ferguson followed the alternative idea that 'the 
physical properties of organic compounds are of central importance in predicting 
biological activity' [55]. 
In 190 I, Overton [56] and Meyer [57] independently correlated the biological activity of 
narcotics to molecular properties. Overton observed that for a series of simple 
compounds, the toxicity to tadpoles was actually a function of each compound's 
partition coefficient and not the aqueous solubility directly, which is itself governed by 
the partition coefficient. Overton also experimented with alkaloids and commented that 
the difference in the toxic effects of morphine to humans and to tadpoles was due to 
differences in the structure of the proteins in the two organisms and that these proteins 
would form salt-like complexes with morphine. He then suggested that variations in 
toxicity would result from differences in the solubility of these complexes. Although 
Overton did not have the benefit of modem statistical methods, his reported data are as 
reliable as any aqueous toxicity data in modem day literature. His monograph 'Studien 
uber die Narkose' [58] is viewed in numerous scientific fields as the turning point in the 
understanding of the relationships between chemical structure, cell permeability, potency 
and other biological activities. Since its publication this monograph has provided 
impetus and acted as a stepping stone for the work of many researchers in many 
disciplines, and has been of enormous value to modern toxicologists, particularly those . 
involved in QSAR development [59]. 
In 1939, Ferguson [55] formulated a concept linking narcotic activity, partition 
coefficient and thermodynamics. He reasoned that in a state of equilibrium, simple 
thermodynamic principles could be applied to drug activities and so the important 
parameter to consider for the correlation of narcotic activity was the concentration 
relative to saturation. 
In 1942, Bell and Robin published results of a quantitative study of in vitro activity of 
46 sulphonamides. Plotting potency at pH 7.0 against pKa resulted in a biphasic curve. 
They interpreted the curve to rationalise the enhanced potency of the sulphonamides at 
pKa 7.0 and explained that the observed variations were due to the ionisation state of 
the sulphonamide [52]. 
Modem QSAR, in which the physical, chemical and structural properties of a molecule 
are used to predict its biological activity, has more recent origins, taking its present form 
approximately thirty years ago, with the pioneering work of Hansch and his co-workers. 
Developments have been vast and due impart to advances in computing technology. 
In 1962, a number of events occurred which led to the birth of modern QSAR; 
1- Hansen [60] attempted to correlate bactericidal effects with Hammett constants. 
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2- Zharadnick [61] attempted to develop a correlation of biological activity without 
physico-chemical parameters, known as the de novo approach, in which pseudo physical 
numerical values related to biological activity are generated. 
3- Hansch and Fujita [62] developed the concept that the physico-chemical properties of 
a compound influence its biological activity. Their work with herbicides showed that the 
factors of hydrophobicity and electronic effects control the herbicidal activity of the 
compound. They published this relationship as a QSAR (equation 4.2), in which the 
biological activity is represented as the Log 1/ C term. Where C represents the 
concentration of the meta or para substituted phenoxyacetic acid which induces a 10% 
growth of Avena coleoptiles in a 24 hour period. The logarithm of the reciprocal 
biological activity data is used as it best represents a normal Gaussian distribution, thus 
the data is more amenable for statistical modelling. 
LogI/C == 4.081t - 2.141t2 + 2.780 + 3.36 (4.2) 
This work is very important in that it made four major breakthroughs~ 
a- 1t the hydrophobic substituent constant (1t) as defined by equation 4.3 and discussed 
in more detail later in 4.3213. 
1t = Log (partition coefficient of the derivative ) (4.3) 
(partition coefficient of the parent compound ) 
b- in order to measure the partition coefficient (P), they used an octanol-water system. 
There is no perfect system to predict partitioning, but the use of octanol provides a 
model for lipid membranes, as octanol has a long hydrocarbon chain and has a polar 
head group. Today, the n-octanollwater system is the most widely used system for the 
determination of partition coefficient, when experimentally necessary, with relatively 
pure supplies of octanol being readily available. 
For all its numerous advantages this solvent system does have some drawbacks: 
- octanol acts as an acceptor and a donor of hydrogen bonds, i.e. it is amphiprotic. This 
presents problems in the interpretation of what is actually occurring in the biological 
system. It is possible to distinguish between donor and acceptor activities of a 
compound by using an additional solvent pair, which acts only as a proton acceptor e.g. 
propylene glycol dipelargonate (pGDP) or as a proton donor e.g. chloroform. The 
ability to distinguish between acceptor and donor activities enables a full picture of drug 
partitioning to be obtained. 
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- Experimental detennination of partition coefficient is tedious, in that there must be 
mutual saturation of the phases i.e. mixing for five hours, and care must be taken to 
maintain constant temperature and pH and to limit the presence of impurities. Wang and 
Lien [63] have shown also, that the partition coefficient of a compound is dependent on 
the nature and concentration of the buffer used in its evaluation. 
c- the use of more than one parameter (in the final equation 4.2) to describe the 
biological activity (LogI/C) had not been attempted before. This was thus the start of 
the use of multiple regression analysis in the detennination of modem QSARs. 
d- the use of 1( and 1(2 terms together (i.e. a quadratic equation) to describe a biphasic 
relationship between biological activity and LogP was novel and justified by the 
assumption of a normal Gaussian distribution of the biological activity data with LogP. 
4.3 Objective ofQSAR 
The overall objective of any QSAR is to develop a quantitative (mathematical) 
relationship between the biological activities of a series of compounds and the physical, 
chemical and structural properties of the compounds, by the use of statistical techniques 
[48,52]. Such correlations between biological activity and chemical structure are of use 
in assisting the understanding of the underlying mechanisms of the biological activity and 
should enable the biological activities of other, similar, compounds to be predicted [48]. 
In order to establish a QSAR, three components are essential; biological activity data for 
modelling, physical, chemical and structural descriptors and statistical techniques which 
can be used to correlate the biological data and the descriptors. 
4.31 Biological Activity Data 
The prediction and explanation of biological data are the crux of any QSAR analysis. 
Prior to the fonnation of a strong model, accurate, reliable, high quality data of a 
consistent form and pertaining to the biological activity on which to base the 
relationship, are essential, as a good QSAR correlation will not be found if there is 
excessive error in these data. Biological data usually take the form of a measured 
response to a fixed dose or molar concentration of xenobiotic, or a fixed response (e.g. 
LD50) generated over a range of molar concentrations. The data generated maybe 
quantitative ( e.g. x M or y %), semi-quantitative (e.g. +++, -,+,--) or qualitative (e.g. 
response, no-response). Each type of data has its use in QSAR analysis, but requires the 
use of different statistical techniques. The choice of biological data is important and the 
model derived is only as good as the original biological data utilised. 
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4.32 Physical and Chemical Descriptors 
The physico-chemical descriptors can, as a rule, be assigned to one of three categories 
[5], Hydrophobic, Electronic, Steric parameters 
4.321 Hydrophobic Parameters 
The term 'hydrophobic interaction' refers to the tendency of the non-polar portions of 
molecules to associate together when placed in an aqueous environment. It is important 
to realise that this effect is due to the structural properties of water itself [49]. 
Hydrophobicity is therefore, a measure of the relative affinity of a molecule for a non-
polar environment versus its affinity for an aqueous environment. Hydrophobic forces 
are probably the most important when considering the provision of the driving force for 
the non-covalent intermolecular interactions of a molecule in an aqueous solution [64]. 
Several hydrophobicity parameters have been used as predictors of biological activity, 
some of the most common being; partition coefficient, chromatographic parameters and 
solubility. 
4.3211 Logarithm of Partition Coefficient (LogP) 
Partition coefficient is the most important and the most extensively utilised hydrophobic 
parameter. It was first defined by Berthelot and Jungfleisch [65J as "the ratio of 
concentration at equilibrium of a solute distributed between two immiscible phases". 
Partition coefficient determines the equilibrium between an external phase, such as water 
and a biophase such as lipid membranes, and is represented in QSARs as LogP. The 
logarithmic term is used because it represents the free energy of the partitioning process. 
Hansch suggested that molecules which are highly hydrophilic will not readily partition 
from water into lipid molecules, so if the receptor lies within or beyond that lipid 
membrane, a hydrophilic molecule will have a low probability of reaching the receptor 
within a set time. Conversely, molecules of high hydrophobicity will readily partition 
into the first lipid membrane but will be reluctant to pass out of the lipid membrane into 
an aqueous phase and so will be held there, thus slowing the rate of movement of the 
compound to the receptor site. Therefore, there must be some optimum value of LogP 
which would correspond to a maximum probability of the compound reaching the 
desired receptor in a set time interval. That is to say biological activity induced by 
receptor binding is biphasically dependent on LogP, as illustrated in figure 4. 1. 
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4.3212 Chromatographic Hydrophobic Parameters 
Petrauskas [66] and Tomlinson [67] have both utilised chromatographic techniques in 
evaluating of values pertaining to a compounds partitioning ability and subsequently 
used their results in structure-activity studies. 
A- Thin Layer Chromatography 
In reverse phase chromatography the partition coefficient is proportional to R.m, which 
equals l/RF-l. Thus LogP is directly proportional to Log(l/RF-I). 
B- High Performance Liquid Chromatography 
LogP is directly proportional to LogK, where K is the capacity factor of the column as 
defined in equation 4.4. 
Where 
K= t:Jo 
to \ 
t = time taken for a specific compound to elute from the column 
(4.4) 
to = time taken for an unretained compound to elute from the column. 
4.3213 Substituent Hydrophobic Parameters 
An important feature of the partition coefficient is that it is to a first approximation 
additive. Thus the contribution of a single group to the overall hydrophobic character of 
the molecule can be determined from the partition coefficient of the parent molecule and 
that of the corresponding derivation [51]. Hansch and co-workers [68] in this way 
devised a hydrophobic parameter for substituent 7t, as defined by equation 4.3. They 
observed that the measured partition coefficients of compounds of the type 
Ct#5.CH2CH2CH2X, where X is a polar group or atom, were lower than values 
calculated by sununation of the 7t values (equation 4.3). They attributed this to back 
folding of the side chain in such a way as to allow substituent X to interact with the 
aromatic ring. Hansch [69] since proposed that as 7t values are additive, it is possible to 
make good estimates of partition coefficients by summing the relevant published 1t 
values. 
Rekker [70] suggested that the Hansch system makes no distinction for the hydrophobic 
contribution of hydrogen and hence no distinction is made between 1tCH 2 and 7tCH 3 
groups. Using a large database of LogP values he devised an analytical/statistical 
approach for the evaluation of partition coefficient values on the basis of additivity, 
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which utilises fragmental hydrophobic constants (f values), in conjunction with 
correction or interaction factors (F) which allow for proximity effects, the attachment of 
hydrogen to an electronegative centre and cross-conjugation. Values of F are multiples 
of what Rekker tenned his 'magic number' 0.28. 
Leo and co-workers [71] also accepted the wisdom of fragmentation and have 
developed a synthetic approach to the calculation of partition coefficients. They firstly 
defined, very clearly and exactly, what constituted a fragment. They then detennined the 
partition coefficients of a number of small molecules, including hydrogen, from which 
they were able to obtain fragmental constant values. They also found it necessary to 
introduce correction factors, for such things as chain branching, fragments attached to 
aromatic rings and numbers of bonds between fragments. 
The development and improvement of fragmental constant methods has provided a 
means of calculating a compounds LogP values, which has inturn increased the 
knowledge regarding LogP and 1t values. Rekker's approach has since become generaUy 
accepted as the most practical way of calculating LogP values [72]. 
4.3212 Solubility 
Solubility generally is simply a reflection of the partitioning process. As such aqueous 
solubility is inversely proportional to partition coefficient, for liquids (equation 4.5), and 
for solids is a function both of the partition coefficient and the melting point of the 
respective solid [73] (equation 4.6). 
Aqueous solubility has been used as a parameter in numerous QSARs. 
S(aq) a IIp 
logS = aLogP - bMP 
Where a and b are constants. 
(4.5) 
(4.6) 
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4.322 Electronic Parameters 
All properties of a molecule are related to the electron distribution within the molecule 
itself and the behaviour of these electrons. Therefore, any change in the electron 
distribution of a compound will alter the physical, chemical and biological properties of 
that compound. It is, therefore, not suprising that electronic properties have been used 
in quantitative descriptions of biological activity [74 J. 
The electronic effects within a molecule control bond order and govern the susceptibility 
of a given bond to metabolic attack. The inter-molecular interaction forces control both 
the extent and the strength of xenobiotic-receptor interactions [74]. Interaction types 
such as ion-ion, ion-dipole, ion-induced dipole, dipole-dipole, dipole-induced dipole and 
hydrogen bonding. all depend on the electronic distribution within the molecule or 
substituent and the ease with which the distribution can be modified [74]. 
Electronic descriptors are physico-chemical parameters which quantify the electronic 
effects of a molecule or its substituent [52J and are derived from the electronic 
configuration of the molecule [5]. 
Electronic descriptors can be divided into substituent parameters used with a congeneric 
series of compounds, or whole molecule parameters used with a mixed collection of 
compounds. 
4.3221 Substituent Electronic Parameters 
4.32211 Hammett Substituent Constant (a) 
Hamrnett showed that the acid dissociation constants of meta and para substituted 
benzene derivatives could be correlated by equation 4.7. This parameter is applicable to 
many types of reactions or interactions which depend on the degree of electron release 
or withdrawal by the substituent [74]. 
Where 
pax=Log~ 
(KH) 
(4.7) 
p is a series constant pertaining to the type of compound 
and type of reaction / interaction 
KH is the rate or equilibrium constant for the un substituted 
parent compound, 
Kx is the rate or equilibrium constant for the substituted derivative, 
Ox is the substituent constant and refers to the electron directing effect 
of the substituent relative to hydrogen. 
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The Hammett sigrna constant «J) can be used to assign a numerical value for electronic 
effects, as it reflects the electronic effect of a substituent on the electron density of the 
reaction centre of the parent compound. (J is also, a reliable descriptor of the electronic 
nature of the different substituents. However it should be borne in mind that (J values 
are not necessarily additive, as constitutive effects (e.g. steric effects, hydrogen bonding) 
may cause deviation from additivity [64]. The Hamrnett relationship provides a 
quantitative equation which allows comparisons of the relative sensitivity of a reaction 
to electronic or polar effects. Conversely, it provides a method to examine the relative 
electronic effects of different substituents on a parent molecule [64]. 
4.32212 Swain and Luptons Parameters 
In 1968, Swain and Lupton introduced two parameters -F, the field effect or inductive 
parameter and R, the resonance effect, derived by fractionation of the Hammett constant 
into its inductive and resonance components [52]. 
4.32213 Hydrogen bonding and molar refractivity parameters may also be treated as 
substituent electronic descriptors. These two parameter types are discussed in depth 
later in 4.3223 and in 4.3214,4.32223,4.32316 respectively. 
The main drawback of substituent electronic parameters is the basic assumption that the 
substituent has an additive effect with regards to other properties of the whole molecule 
and that any changes are due to the substituent. This assumption has yet to be proven 
and may not in fact operate, so any substituent electronic parameters must be viewed 
with some degree of scepticism. Also, substituent parameters can be used only with 
congeneric series. 
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4.3222 Whole Molecule Electronic Parameters 
Whole molecule electronic parameters overcome the problems of additivity as seen with 
substituent electronic parameters, and also can be used with non-congeneric groups of 
compounds. It is therefore, intrinsically better to utilise whole molecule electronic 
parameters, where possible, as they account for every change occurring in the molecule. 
4.32221 Dipole Moment 
Dipole moment (IJ) is a measure of the partial charge separation occurring within a 
molecule. IJ is described as the magnitude of charge ( e) multiplied by the distance 
between the charge centres (d). However, there is a problem with the use of IJ in that it 
is a vector quantity, and different molecules have different dipole moments acting in 
three different directions. One of these vector directions may be more relevant that the 
total vector quantity. This problem may be overcome by calculating dipole moment 
using say the MOP AC software package, which gives X, Y and Z vector values, as well 
as the total dipole values. 
4.32222 Electron Polarisability 
Electron polarisability (PE) reflects the ability of the electrons in an atom, group or 
molecule to be polarised in the presence of an electric field. This being an implication for 
intermolecular interactions [75]. Polarisability is a constitutive property and so is 
dependent on individual molecular components, as defined by equation 4.8 and in a 
manner similar to molar refractivity (4.32316). 
PE = (n1:.l) x Mw = 
(n2+2) p 
4.32223 Molar Refractivity (MR) 
~7tNa.E 
3 
(4.8) 
Molar refractivity is calculated from refractive index, and thus partly constitutive. The 
units of MR are those of molar volume, and thus it can be considered as a measure of 
molecular bulk (4.32316). However, since it is obtained from refractive index (equation 
4.9), which is itself dependent on electron polarisability (4.32222 and equation 4.8), it 
can also be considered as a measure ofpolarisability [74]. It has been suggested that if 
the MR term in a QSAR has a positive coefficient, it is modelling polarisability, and if it 
has a negative coefficient, then it is modelling bulk [74]. This begs the question of how 
to interpret a QSAR that contains both MR and MR2. Since in most QSARs MR can be 
replaced by a size parameter, it seems likely that it generally models bulk (4.32316). 
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4.32224 pKa 
pKa can be considered as a dual parameter; firstly it reflects the electron directing ability 
of substituents and as such is equivalent to the Hammett constant, and secondly it 
controls the extent of ionisation of a compound, which affects the partition coefficient 
and so reflects the hydrophobicity of a compound. 
It is now possible to calculate pKa with reasonable accuracy using available computer 
software, e.g. HazarciExpert. 
4.32225 Electrostatic Potential 
Electrostatic Potential defines the ease with which the electron cloud about a molecule 
may be moved or polarised. Weinstein has produced a computer package which enables 
the calculation of the electrostatic potential around a molecule and thus enables the 
creation of a contour map of the molecule, in which each contour is represented by lines 
of equal energy of interaction with unit positive charge. 
4.32226 Chemical Shift (NMR) 
The chemical shift of a proton or other nucleus is dependent on the electron density 
around it. Chemical shift is thus a sensitive probe of atomic environment, and can throw 
light on specific interactions with solvent and receptor alike. It has the disadvantage that 
it has to be obtained experimentally using the technique ofNMR spectroscopy. 
4.32227 Molecular Orbital Parameters 
Molecular orbital theory (3.12) is complex and not easy to understand, so use of 
parameters derived from M.O. theory without a full understanding of their meaning can 
lead to problems in their interpretation with respect to biological activity. 
Some parameters which fall into this group are~ 
A- Atomic charge, a whole molecule parameter generally used only in the study of a 
congeneric series of compounds, so the charges on specific common atoms may be 
related. 
B- EHOMO (the energy of the highest occupied molecular orbital) is the energy required 
to remove an electron from the outermost orbital, and is thus the negative of the 
ionisation potential. 
C- ELUMO (the energy of the lowest unoccupied molecular orbital) is the energy 
required to accept an electron into a vacant orbital and is thus a measure of 
electrophilicity . 
D- Heat offonnation, representative of the total energy of the molecule. 
4.3223 Hydrogen Bonding Parameters 
Hydrogen bonding is an important interaction in biological activity, affecting processes 
such as drug-receptor reactions, solubility and partitioning. Hydrogen bonding can be 
classified as both a substituent and a whole molecule electronic parameter. However, 
there is a major problem with the use of hydrogen bonding parameters, this being that 
no one parameter has been developed which quantitatively models hydrogen bonding 
and at the same time is easy to use. Over the years, there have been a number of 
attempts to devise suitable hydrogen bonding parameters. 
4.32231 Sieler's IH Parameter 
Seiler [76J was the first to attempt to develop a hydrogen bonding parameter. He used 
the difference between LogP values measured in an n-octanol/water system and those 
evaluated in a cyclohexanefwater system, in order to produce a numerical parameter 
(lH), which is representative of the group contributions to hydrogen bonding. However, 
since octanol acts both as a proton donor and acceptor, the IH value does not 
distinguish between proton donor or acceptor capabilities. A further problem with IH is 
that it is essentially the difference between LogP values in two solvents and as such must 
reflect polarity as well as hydrogen bonding. 
4.32232 Moriguchi's Ew Parameter 
Moriguchi [77] attempted to overcome the problem encountered by Seiler's parameter, 
by assuming that LogP contained volume and polarity components and by calculating 
the polarity component (Ew). This is the difference between an n-octanoVwater system 
LogP for a polar compound and that of a non-polar compound of the same molecular 
volume. But, as LogP can be factored into volume, polarity and hydrogen bonding 
terms, it is clear that Ew contains both polarity and hydrogen bonding terms. 
4.32233 Fujita et aI's Indicator Variable 
Fujita et al [78] devised a hydrogen bonding indicator variable, which takes a value of 
unity if the molecule or substituent under investigation is capable of hydrogen bonding 
and a value of zero if it is not capable of doing so. It is possible to modifY this method to 
distinguish between proton donor and acceptor capabilities (4.32234). This is a very 
crude measure of hydrogen bonding ability, but since it is easy to use, has been widely 
applied in QSAR studies. 
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4.32234 Charton and Charton's Parameter 
Charton and Charton [79] modified Fujita's approach (4.32233), by using the number of 
hydrogen bonds that the molecule under investigation was capable of forming, in place 
of the simple 1 or 0 approach ofFujita et al. 
4.32235 Yang et aI's Parameters 
Yang et al [80] devised two hydrogen bonding parameters HBl and HB2. HBl being 
very similar to Charton and Charton's parameter. HB2 is defined as the number of atoms 
able to form hydrogen bonds multiplied by the value of the hydrogen-bond energy, the 
whole being scaled by a factor of O. I. Average enthalpy values for each type of 
hydrogen bond are used [80]. 
4.32236 Solvatochromic Parameters 
Kamlet, Taft and Abraham [81,82] have developed a set of parameters known as 
'Solvatochromic parameters', because they were originally developed using 
spectroscopic techniques. They hypothesised that essentially any interaction is a function 
of molecular size (u), polarity (1t *), hydrogen bond acceptor ability (u) and hydrogen 
bond donor ability (~). 
These parameters show excellent correlations with physico-chemical and biological 
properties, such as solubility and toxicity. However, they have a major disadvantage in 
that they require experimental derivation, although some attempts have been made to 
calculate them. 
Dearden [83], examined the vanous types of hydrogen bonding parameters and 
concluded that Fujita's parameter was relatively easy to determine and hence is the most 
widely used parameter, but that Yang's parameters appear to be the least problematic 
and so are currently the best indicators of hydrogen bonding and with HB2 values for 
144 substituents having already been evaluated, it is relatively easy to determine values 
for a range of compounds. 
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4.323 Steric Parameters 
Steric parameters fall into one of two types; size and shape. 
Both the size and shape of a molecule or of a specific substituent are important in the 
control of biological activity [49,74]. Bulky substituents adjacent to the reactive site 
may shield the active site and thus hinder binding and metabolism, or the substituent may 
shield a polar region within the molecule and thus act to reduce the molecule's affinity 
for water or increase its affinity for lipid phases [74]. 
4.3231 Molecular Size Parameters 
4.32311 Molecular Diameter 
This parameter is measured in terms of van der Waals radii and is a measure of size. 
However, it is only an approximation, being accurate only for spherical molecules. 
4.32312 Molecular Weight (Mw) 
Mw is directly proportional to the size of a molecule hence is an accurate and easy 
means of enumerating the size of a whole molecule of substituent, for a homologous 
series of compounds. Molecular weight is also directly proportional to LogP. 
As a measure of volume however, it is unlikely to reflect precisely the group size. 
4.323l3 Molar Volume 
Molar volume is a measure the volume occupied by one mole of compound, which takes 
into account any intennolecular interactions, such as hydrogen bonding, occurring 
within the molecule. 
4.32314 Intrinsic Volume 
Intrinsic volume is simply a measure of the volume of a molecule, usually based on van 
der Waals radii. 
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4.32315 Molar Refractivity (MR) 
MR is a crude steric term (see 4.32223) [75,84J, and is measured using the Lorentz-
Lorenz equation as detailed in equation 4.9 [55,62,64]. 
Where 
MR = (n2::.D x molecular weight 
(n2+2) density 
n is the refractive index 
molecular weight is a molar volume term 
density 
4.32316 Surface Area 
(4.9) 
Surface area is regarded as the surface of a molecule which is available to make contact 
with other molecules, prior to the initiation of a response and so is a very useful 
parameter. Surface area can be measured in a number of ways, the most common are; 
4.323161 The summation of the atomic surface areas is calculated from the van der 
Waals radii. However, since the individual atoms of the molecule may overlap or shield 
regions of the surface, the summation procedure does not give a good indication of the 
effective surface area. 
4.323162 The accessible surface area (ASA) as proposed by Connolly. The ASA value 
is evaluated using a computer program, which effectively rolls a water molecule over the 
calculated van der Waal surface of an energy minimised representation of the molecule 
under investigation [74]. ASA is a very useful parameter, as it gives a true 
representation of the area of the molecule which is actually available for interaction. It 
should be noted that ASA has a constitutive component; for example, the ASA of 1,2-
dichlorobenzene will be smaller than that of 1,3-dichlorobenzene. 
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4.3232 Substituent Size Parameters 
4.32321 Taft's Steric constant (Es) 
Es was originally derived for a series of esters by experimental determination. It is a 
measure of the relative hydrolysis constant of the molecule under investigation. The 
bigger and more bulky the substituent on the molecule the more difficult it is to 
hydrolyse the adjacent bond. Es is therefore directly related to the van der Waals radii 
[5,74]. Es is then an effective molecular descriptor for improving those correlations in 
which 0" is not adequate. 
4.32322 Charton's Upsilon Parameter (y) 
y describes the difference between the published substituent van der Waals radii and the 
van der Waals radius of hydrogen (1.20) [74]. 
4.32323 Parachor (PA) [85] 
PA = Mwxy1l4 (4.10) 
PL-PV 
Y = surface tension Pt = liquid density Pv = vapour density 
(Pv can be ignored as« PL) 
If measurements are carried such that y = 1, then P A = M molar volume 
PL 
PAis very seldom used nowadays. 
4.32324 van der Waals Radius 
The approximate volume of a molecule or substituent can be derived from a modelled 
structure and is defined as the van der Waals radii. Although the calculation of van der 
Waals volume is accurate, its use is limited by its difficulty to reflect the various shapes 
of groups, which means therefore that the results attained inevitably contain errors [5]. 
4.3233 Shape Parameters 
Shape refers to the distribution of molecular 'bulk' according to the molecular 
conformation or the relative position of the constituent atoms. The role of shape in 
determining the biological activity of a compound is implicit in the stereo selectivity of 
biological receptors [52]. 
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4.32331 Sterimol Parameters 
These multi-dimensional parameters were introduced by Verloop, Hoogenstraaten and 
Tipler in 1976 [86]. Since then they have become known as 'Sterimol parameters', after 
the computer program which was developed to perform their calculation. The approach 
arose from a consideration of how to fit a molecule to its receptor site [49]. 
The calculation of Sterimol parameters uses van der Waals radii, standard bond lengths 
and angles evaluated from a reasonable conformation of the molecule, in order to define 
the molecular spatial arrangement, for a given substituent and generates five measured 
values of substituent size (figure 4.2); L corresponds to the length of the substituent 
group, measured along the axis of the bond between the first atom of the substituent and 
the parent molecule; B 1 to B4 are width values and are calculated starting with the 
minimum, Bl, which is measured of the distance from the length axis to the 
perpendicular surface of the substituent group. B4 is a measure of the distance along the 
Bl axis, in the opposite direction. B2 and B3 are measured perpendicular to the Bl and 
B4 axi, respectively. B 1 to B4 can describe non-symmetrical substituents and emphasise 
the directional character of steric effects, whilst simultaneously providing additional 
information regarding the actual conformation of the receptor surface [86]. 
In 1987, a new parameter B5, which corresponds to the maximum width of the 
substituent group, was introduced. 
There are a few criticisms of these parameters, in that they cannot be used as 'true' 
whole molecule parameters, as there is a need to measure L in a specific direction from a 
specific reference point. It is however, possible to evaluate Sterimol parameters for 
virtually whole molecules in a congeneric series. One appoints a common terminal atom 
or group, e.g. hydrogen, to represent the compound and thus the remaining structure 
becomes the substituent. Sterimol parameters are then evaluated from the compound 
(hydrogen atom) along the bond attaching it to the substituent (whole molecule). 
It is important that when determining Sterimol parameters that the molecules under 
investigation are in the same orientation, thus ensuring that comparable measurements 
are attained. 
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Figure 4.2 Diagrammatic Representation of Verloop's Sterimol Parameters 
(Adapted from Hansch and Leo [72] ) 
i) Perpendicular cross-section of the substituent along the L axis 
I 
I I 
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ii) - Vertical section viewed 'down' the L axis 
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4.32332 Molecular Shape Analysis (MSA) 
MSA was devised by Hopfinger [87], and is used in the analysis of a congeneric series 
of molecules. MSA takes the molecule which shows the most activity or is believed to 
fit the receptor best, and superimposes all other molecules of the series onto this 
standard. The area of common overlap is then measured, this being the molecular area 
(or common overlap volume, Vo) which corresponds to the steric requirement of the 
receptor. 
This methodology is not widely used, as it has been superseded by calculation of the 
probable overlap volume. 
4.33 Structural or Topological Descriptors 
The topological or geometric features of a molecule can be used to characterise the 
structure of that molecule in a topological analysis. Features can be generated by 
following certain rules of algorithm, starting with single atoms or bonds as the centres of 
atom or bond centred fragments [88]. The simplest possible descriptors are counts of 
atoms or bonds of specific types within the molecule or fragment. These descriptors 
however, contain very little information regarding the topology of the molecule and 
different molecules may have the same descriptor value [88]. 
In order to differentiate between different molecules and obtain more topological 
information, many different topological descriptors have been devised [88]. The one 
which is by far the most widely used is Randic's Branching Index, refined, developed and 
extended by Kier and Hall as molecular connectivity. 
4.331 Randic's Branching Index 
Randic devised his topological index in 1975 [89], his idea being to assign each atom 
with a numerical value, corresponding to its 'degree of connectivity', this being simply 
the number of other atoms to which it is attached, other than hydrogen. Each bond is 
given a value which is the reciprocal square root of the product of the atomic numerical 
values of the two respective vertices. The major problem with this index is that there is 
no differentiation between carbon and heteroatoms or between single and multiple bonds 
and therefore, the index has limited use in the correlation of biological activities [52]. 
4.332 Molecular Connectivities 
Kier and Hall [90] extended the work of Randic to yield what they term 'Molecular 
Connectivity Indices'. Molecular connectivity parameters (X) contain information about 
the molecular structure and the way in which atoms are connected to one another. 
Molecular connectivity parameters can be readily calculated manually, but are most 
conveniently determined by computer software, such as MOLCONN-X. A simplified 
version of the calculation of molecular connectivity parameters is given in figure 4.3. It 
will be noted that the method of calculation shown in figure 4.3 is independent of the 
nature of the atoms. That is, the method does not discriminate between carbon and 
heteroatoms. In order to overcome this problem Kier and Hall [90] introduced 
modifications that allowed the presence ofheteroatom, double and triple bonds to be 
taken into account. The connectivity values thus obtained are termed valence-corrected 
molecular connectivities (X v). 
Since their introduction molecular connectivity indices have met with much scepticism in 
the QSAR field. The main reason for this is that although they often yield good 
correlations with biological activity, the actual physical significance of the indices is not 
known. Thus no conclusions regarding mechanisms of action can be drawn from them. 
Furthermore, it is extremely difficult to use a QSAR containing X terms to predict other 
bioactive molecules. Nevertheless there is undoubtedly much structural information 
contained within X indices, and it is to be hoped that methods will be developed to 
elucidate it. 
4.333 Kappa Index (K) 
The Kappa Index was devised by Kier [91] to describe different molecular shapes. K is 
based on a count of two bond fragments in a hydrogen suppressed graph i.e. a molecular 
structure with hydrogen atoms removed, relative to the maximum number possible in the 
isomeric star graph. As with X values, K values can be represented in two forms; the 
minimal steric distance (K) and the minimal topological distance (Ka)· 
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Figure 4.3 Simplified Representation of a Molecular Connectivity Calculation 
A- The molecules under investigation are represented as a hydrogen suppressed graph. 
a) CH3CH2CH2CH3 b) CH3CH(CH3)CH2CH3 
B- A numerical value is assigned to each atom, which corresponds to the number of 
non-hydrogen bonds formed by that atom. 
~ ~ /'vI 
1 2 
~I 
1 .. 
C- In order to show how the relationship of these atoms varies in different molecules, 
multiply the adjacent atom values together and place the new numerical value alongside 
the bond adjoining the two respective atoms. 
a) b) 
~ 
D- Determine the reciprocal square root of each bond value. 
a) b) 
O'~7 
E- Sum the reciprocal square root values to obtain a numerical value for the first order 
connectivity (IX). 
a) IX= 1.914 b) lX= 2.269 
Calculations across two or more bonds enables the calculation of higher orders of 
connectivity. 
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4.334 Degree of Flexibility (<1» 
It is possible by mathematical manipulation of the Kappa indices (equation 4.11) to 
determine a numerical value which corresponds to the flexibility of the molecule under 
investigation. 
Where 
<I> = lKa x 2Ka (4.11) 
A 
1 Ka. is the first order minimal topological distance kappa value, 
2Ka is the second order minimal topological distance kappa value, 
A is the number of atoms in the molecule. 
4.335 Minimum Topological Difference (MID) 
MTD is similar to MSA (4.32332), in that MID is the number of non-superimposable 
atoms, when a molecule is overlaid onto a standard reference molecule, which is 
hypothesised to represent the receptor cavity. Different cavity assumptions will give 
different sets of MID values [52]. 
4.34 Statistical Techniques SEE SECTION 5.0 
4.4 Principal steps in the Development ora QSAR 
1- Select a group of compounds which are believed to act in a similar fashion and which 
have a known type of biological activity (these should have a good range of activity and 
descriptor space). 
2- Select a range of chemical descriptors, so all the appropriate properties of each 
compound are represented, as all may be important to activity. 
3- Collect or evaluate, using appropriate protocols and dedicated computational 
software, quantitative values for all biological activities and chemical descriptors. 
4- Input all descriptor and biological activity data into a dedicated statistical database 
and determine by analysis of variance, using a suitable statistical technique (as detailed in 
5.0) if a correlation exists between the biological activity and any combination of the 
descriptor variables. 
5- Validate the resultant QSAR by testing its abiHty to predict the activities of 
compounds not in the training set. 
6- Use the QSAR to assist in the optimisation of the biological activity, i.e. to maximise 
any desired effects, and / or minimises any undesired biological effects [88]. 
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4.5 Restrictions of QSARs 
The success of any QSAR depends on the quality of the data used and the suitability of 
the physico-chemical and structural descriptors utilised [5], and upon the statistical 
techniques used in the analysis [74]. Also, no QSAR can be expected to give reliable 
predictions outside the parameter range of the training set, or reliably to predict the 
activity of compounds which are unlikely to act via the same mechanism as the original 
training set. It is vital that any QSAR be effectively validated. 
QSARs enable the optimisation of specific biological activities by modification of the 
relevant physical, chemical or structural properties of a type of compound for a specific 
pre-determined activity, but they do not enable the design of a new type of compound 
for a new usage. That is QSAR is a lead optimising not a lead generating technique. 
4.6 Advantages and Uses 
The real value of QSAR development has been in the order which it has brought to 
structure-activity data, the understanding of the relationships between physico-chemical 
and structural properties and the biological activity of a compound and the concepts 
which have thereby been developed and which are now being used for rational drug 
design [52]. QSARs have the potential to allow the extrapolation of knowledge from 
agents of known activity to untested or new, yet related, compounds [92]. 
Due to the demands of time, the high cost of testing new compounds for toxicity using 
test animals, and the intrinsic problems that test animals differ from humans in their 
genetic and environmental characteristics, it would be an advantage to be able to 
estimate the toxic response of chemical agents using non-animal approaches [93]. The 
use of QSAR as a screening tool provides such an alternative to animal testing, as 
QSAR can show when further synthesis would yield compounds of equivalent or greater 
toxicity, thus suggesting the cessation of synthesis and any associated animal or ill vitro 
testing [52,94]. 
QSAR is an aid to the conservation of available financial resources for the testing of 
compounds, yet provides a methodology which helps to ensure that questionable 
compounds are either discarded or tested more thoroughly, thus enhancing safety [5]. 
QSARs have been used in a wide range of fields, some of these being; the prediction of 
bactericidal activity, anti-inflammatory activity, analgesic activity, carcinogenicity, the 
prediction of mutagenicity, drug toxicity, environmental toxicity, a.2-antagonism, odour, 
and biodegradability. They are also used to the predict physical, chemical and structural 
properties of compounds, although such correlations are more properly referred to as 
quantitative structure-property relationships (QSPRs). 
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4.61 Examples of some QSARs 
1- Quantitative relationship between the in vitro antibacterial activities (the minimum 
concentration of the antibiotic that inhibits bacterial growth, MIC) of cephalosporins 
and their n-octanollwater partition coefficients [40J 
a) in Staphylococcusaureus MIC = 0.888(LogP)2 + 6.414 LogP + 11.575 
n = 7 r = 0.905 s = 1.447 
b) in Streptococcus pneumoniae MIC = 0.174(LogP)2 + 1.234 LogP + 2.165 
n=7 r=0.717 s=0.545 
2- Bacterostatic activity oftrans-3-benzoyl acrylic acids against Staph. aureus [46] 
C is the concentration of the compound producing the desired biological response. 
Logl/C = 0.7701t - 0.755cr - 0.032 
n=}1 r=0.951 s=0.219 
3- Toxicity ofphenols to fathead minnows [46) 
LCSO is that concentration of compound which results in the death of 50% of the test 
population. 
Log(I/LCSO) = 0.666LogP - 0.0072 I ELUMO + 2.73 
n=34 r=0.960 s=0.192 
4- Inhibition of human dihydrofolate reductase by pyrimidines [46] 
K 1 represents the lowest concentration of pyrimidine which inhibits enzyme activity. 
Log(I/KI) = 0.S91t3, 5 - 0.63 (13. 101[3,5+ I) + O. 191t4 
n = 38 r = 0.879 s = 0.266 
5- Olfactory threshold concentration ofalkanes [47J 
C is the lowest concentration of a compound which can be nasally detected. 
In each model: 
Log(I/C) = 2.57LogP - 0.24(LogP)2 + 1.36 
n=7 r=0.970 s=0.39 
n 
r 
s 
represents the number of compounds in the training set 
is the correlation coefficient of the QSAR. 
is the standard error of the QSAR. 
The latter two values, are discussed in further detail in 5.4 and reflect the statistical 
significance of the QSAR with regards to how well the model fits the biological data 
used in its generation. 
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5.0 Statistical Techniques 
5. I Introduction 
In order to develop a QSAR, it is essential to establish a relationship between the 
biological data and the physico-chemical and structural descriptors of the compounds. 
With the careful application of statistical methods, much more information than is at first 
apparent may be gleaned from the correlation. 
A variety of statistical techniques for use in QSAR development are available, which can 
be divided into two broad categories, depending upon the type of biological activity 
end-point used; a quantitative end point which yields numerical values, and statistical 
methods such as multiple regression analysis are used to correlate the biological data 
with the physico-chemical parameters, and a qualitative end point which yields, for 
example a positive or negative response rather than numerical data, and pattern 
recognition techniques are used to obtain relationships. 
5.2 Linear Relationships 
5.21 Simple Graphical Plots 
If only one descriptor is used in the development of a QSAR, its relationship to the 
biological activity can be expressed as a simple linear graph and the QSAR equation 5. 1 
is obtained as: 
y=mx+c 
Where y represents the biological activity value 
x represents the descriptor value 
m represents the slope of the graph 
c represents the intercept of the line of the graph and the axis. 
5.22 Regression Analysis 
(5.1) 
Historically, in the early 1960's, two sets of workers, Hansch & Fujita [62,69,95] and 
Free & Wilson [96], independently first applied the use of statistical analysis to QSAR 
studies. Each of their respective methods being based on regression analysis. Today, 
regression analysis is the most widely used statistical technique in QSAR [97,98]. 
Regression analysis can be explained in simple terms as 'a search of data for a 
relationship between the dependent variable, Y (biological activity) and one or more 
independent variables, X (descriptors)' and by equation 5.2, which is essentially a 
modified version of equation 5. 1. 
~9 
Y = po + PIX 
Where PI is the slope of the regression line 
po is the intercept 
(5.2) 
The relationship may not be truly rectilinear, but can appear as such due to the segment 
of the data windowed, i.e. the data chosen may be a part of a larger curve. 
The regression line may not initially pass through any of the data points, this is 
overcome with the addition of an error tenn ( figure 5. 1) to the general equation 5.2 
giving the new equation 5.3 
(5.3) 
Where Ei is the mean residual of the observed value Y minus the predicted value Vi. 
When a regression line is fitted to a set of data points the aim is to minimise the 
distances between the points and the regression line, using typically the method of least 
squares, i.e. minimising ~El When fitting a mathematical equation to the regression 
line, it is assumed that the population at large all behave in the same fashion. That is, a 
confidence interval based on Ei is assumed in which the error tenns all have a normal 
distribution (N), as depicted by equation 5.4. If over a range of means the variance is 
homoskedastic (constant) and the regression has effectively modelled the data. In some 
instances the model does not display normal distribution and is said to be 
heteroskedastic. In such cases it may be possible to achieve nonnal distribution by 
mathematically transforming the data to a logarithmic, square-root or inverse (l/y), for 
example. 
Ei - N(~ ,(2) (5.4) 
Where ~ is the mean value of y in regression analysis 
0 2 is the variance 
Regression analysis has a number of advantages, in that it is predictive, easy to 
understand and highlights any outliers. However, it also, has some disadvantages, in that 
the technique needs quantitative data, there are risks of chance correlations and 
coIlinearity between descriptors can lead to instability. Although regression analysis 
relies heavily on continuous parameters, that is to say quantitative data, it is possible to 
incorporate some qualitative responses in to the analysis (i. e. yes or no responses) in 
terms of numerical indicator variables, for example let 1 represent a positive and 0 a 
negative response). 
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5.221 Hansch or Linear Free Energy Approach [99, I 00] 
Hansch et at [69,95], postulated that the biological activity of a molecule is a linear 
function of one or more of three different properties of that molecule, namely its 
hydrophobic, electronic and steric effects. The influence of hydrophobicity is related to 
the probability of the molecule moving between biological environments in order to 
reach the required site of action. The electronic properties of the molecule control the 
ability of the molecule to interact with an appropriate receptor through hydrogen 
bonding, dipole forces etc., and also, in the case of ionisable compounds, control the 
extent of ionisation. Steric properties affect the ability of a molecule to fit the receptor 
site and can also affect the rate of metabolism. 
Model generation is based upon 3 assumptions;-
1- that one can quantitatively measure or calculate molecular physico-chemical and 
structural properties which will detennine the biological activity of a molecule, 
2- that one can quantitatively measure the appropriate biological response, 
3- that one can mathematically describe the relationship between the physico-chemical 
and structural descriptors and biological properties [99]. 
Using these assumptions Hansch et al [69] were able to derive a model (equation 5.5) 
which describes the relationship of the biological activity with the physical, chemical and 
structural properties for a set of compounds. 
Log 1/ C = a(LogP)2 + bLogP +cE +dS +e (5.5) 
Where C represents the molar concentration of the compound under investigation which 
elicits a constant biological response from a given organism. 
LogP represents hydrophobic effects (octanollwater partition coefficient), 
E represents electronic effects, 
S represents steric effects, 
a,b,c,d,e are constants obtained through multi-linear regression analysis. 
The (LogP)2 term was introduced to allow for the observed biphasic dependence of 
biological activity on hydrophobicity. 
The Hansch approach, also known as multiple linear regression, to QSAR is widely used 
within the pharmaceutical industry and other fields of science for the investigation of a 
range of biological effects [99] and also allows quantitative predictions of activity to be 
made, but it suffers from the drawback of the possibility of chance correlations [99]. 
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5.222 The Free-Wilson Approach 
Free and Wilson [96] developed a method for deriving de novo biological substituent 
constants, to be used when for example, physico-chemical parameters are unavailable. 
The method is based on the assumption that in a series of related compounds each 
particular activity is independent of the presence or absence of substituents at other 
positions within the same molecule. Each compound yields an equation, in one of two 
forms, equations' 5.6 or 5.7, and the group contributions are found by solving a set of 
multiple simultaneous equations [101]. 
Biological Activity = ~Aij x Sij + k (5.6) 
Where Aij represents the activity contribution of a substituent i at position j. 
Sij 1 or 0 according to the presence or absence of substituent, i at position j. 
k is a constant, representing the average activity of a series of compounds [96]. 
Biological Activity = Sa + Sb + .... + u (5.7) 
Where Sa,Sb, etc. are the contributions added by the substituents a,b, etc. respectively. 
u is the contribution ofa hypothetical parent compound to the bio-activity. 
An advantage of the Free-Wilson approach is that there is no need to determine physico-
chemical or other properties, as the de novo constant (the additive group constant) 
generated, combines information on all the properties of the substituent. However, a 
disadvantage is that predictions are limited to compounds comprising the parent 
molecule and the substituents contained within the 'training set'. Also, the numerical 
value attained gives no direct information as to the mechanism of action and so can only 
be used to give interpolative predictions. Furthermore, the method assumes that each 
substituent has a constant contribution to activity, irrespective of other substituents. 
This is not necessarily so: For example a chlorine substituent could increase the polarity 
of a derivative of low hydrophobicity, but could decrease the activity of a hydrophobic 
derivative (see figure 4.1). 
53 
5.23 Pattern Recognition or Multi-Variate Analysis [99] 
Pattern recognition methods are being used increasingly more in QSAR [102]. The term 
'pattern recognition' serves to describe any mathematical or statistical method which may 
be used to detect patterns which lie within data sets. Pattern recognition is used to seek 
qualitative correlations between a set of atomic or molecular structure descriptors and 
the presence or absence of specific biological activities, usually in a series of structurally 
related compounds. To appreciate fully the action of pattern recognition, the data matrix 
should be considered as a multi-dimensional information space. For n parameters there 
are n dimensions. Data for each compound are projected into the information space, so 
each is represented by a discrete point. 
The Hansch approach (5.221) requires that the biological activity be expressed in terms 
of hydrophobicity, electronic and steric properties, which requires the use of a number 
of independent variables. Any representation of the relationship would therefore, need to 
be in several dimensions, which is impossible to achieve for more than two such 
variables graphically. The use of statistical computer software is therefore imperative. 
The increased use of computational chemistry and molecular modelling in QSAR has led 
to the development of many software packages which enable the generation of a great 
number of independent variables for each compound (50 to 100 as a matter of routine). 
Hyde and Livingstone [103] termed the subsequently generated data matrices as 'Over 
Square'. Pattern recognition methods are intended for use with data sets containing 
many variables and usually consider alJ variables simultaneously, and so are suited to the 
statistical manipulation of the 'over-square' matrix. 
Some pattern recognition methods have their origins in artificial intelligence research, 
which resulted in the establishment of rules which can be used to classifY a compound 
into a data set based on its biological properties. Two types of data sets are essentially 
involved, a training set for which classification is known and which is used to develop a 
predicitvely capable QSAR and a test set for which the classification is unknown and on 
which predictions are made. A third type of data set, the evaluation set which consists 
of compounds of known classification but which are not used in the model development 
process may also be used to check the validity and credibility of the developed model 
[100]. This concept of training or learning allowed Livingstone [103J to classify pattern 
recognition techniques into the two categories, supervised and unsupervised 
techniques (table 5.1), the major differences being that supervised techniques require the 
involvement of biological data. 
Supervised Learning requires the use of biological data in the process of model 
construction, i.e. the training set is used to produce the rules of classification. 
In supervised learning techniques, if n >/= m then the technique may not work, due to 
failure to invert the matrix or due to mis-c1assification of data. 
Unsupen-ised Learning methods do not need any form of classification to be assigned 
in order for the model creation, i.e. the known activity categories of the 'training set' are 
not utilised. 
In both supervised and unsupervised learning techniques extra variables which do not 
contain useful information may act to obscure meaningful patterns and chance 
correlations also present problems. Chance correlations may present themselves, due to 
the fact that there are many independent (physico-chemical) variables and it is inevitable 
that descriptors may describe the same molecular feature. In such cases statistical 
manipulatio~ such as multiple linear regression analysis may incur the phenomenon of 
collinearity between different independent variables [84], which will result in spurious 
results. Topliss and Costello [104] evolved the 'rule of thumb' for QSAR, that a 
minimum of thirty observations be used to test five variables, in order to minimise the 
risk of chance correlations and that at least five compounds should be included for every 
parameter in the final model. 
Table 5.1 Pattern Recognition Methods used in OSAR. 
(Adapted from Livingstone (105]) 
Supervised Learning Techniques Unsupervised Learnin~ Techniques 
Multiple regression Non-linear mapping 
Discriminant analysis Principal components 
Linear learning machine Factor analysis 
Canonical correlation Cluster analysis 
Adaptive least squares K nearest neighbour 
Some pattern recogrutIon techniques, such as K-nearest neighbours, discriminant 
analysis and SIMCA utilise the properties in the information space to enable quantitative 
distinctions to be made [106]. This is especially beneficial when activity is categorically 
classified, e.g. active or inactive, because the position in the information space of a 
compound of unknown activity relative to compounds of known activity may enable 
estimation of the unknown activity. 
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5.231 Supervised Learning Techniques 
5.2311 Stepwise Multi-linear Regression Analysis (SMRA) 
SMRA is used widely in QSAR. The Hansch approach [95] to QSAR may be performed 
with a few selected parameters or the procedure can employ the process's of stepwise 
and best subsets regression analysis, in order to develop the predictive model of 
biological activity. SMRA is based on measured, predicted or calculated physico-
chemical descriptors and relies on the availability of quantitative biological data. It is 
useful when large numbers of variables are being considered. 
As with all techniques SMRA has its advantages and disadvantages, as outlined in table 
5.2. The empirical nature of SMRA is both advantageous and limiting. The empirical 
equations derived do not require' the prior development of a hypothesis of the 
mechanism of action. Those parameters identified as important in the modelling will or 
could lead to the development of a hypothesis. Martin [64] stated that the empirical 
nature of the equations is limiting, as they provide little feedback to a theoretical 
understanding of the problem and conversely, any hypothesis developed is of no help if 
the equation fails to explain a new data set. 
Table 5.2 Advantages and Limitations of SMRA 
(Adapted from Livingstone [105]) 
Advantages Limitations 
empirical empirical 
predictive chance correlations 
outlier recognition continuous parameters required 
cheap 
SMRA cal1 be performed in one of two directions, namely forwards and backwards. 
In the forward selection method, the calculation commences with the best predictor 
variable and adds successively to the equation those variables with the largest F -to enter 
values. 
In the backward elimination method, the starting point is an equation comprising of 
all the variables and those variables with the lowest F -to enter values are then 
successively removed from the equation. 
56 
Once an equation has been developed it is essential to assess how well the equation fits 
the data used in its generation. This is achieved by attaining the residual value by 
subtracting that value of Y cruculated by the equation from the actual value of the 
dependent variable (Y), for each compound in the data set. 
Examination of the residual values for a complete data set enables the detection and 
identification of any 'outliers', these being any residuals which are far greater, in absolute 
value than the other ones and so which lie three or four standard deviations from the 
mean of all the residuals. 
Since, the function of QSAR is to develop robust and predictive models, it is valuable to 
try and gain insight into reasons why any particular compound behaves as an 'outlier'. 
Devillers and Lipnick [97J ascribed 'outlier' behaviour to one or more of the following; 
1- the biological data represent a lower degree of precision, reflecting one or more error 
sources not associated with other studied compounds, 
2- the biological data reflect a systematic error, 
3- the bio-data represent a different biological end-point than that for other compounds, 
4- there may be errors in the independent (descriptor) variables, 
5- the 'outlier' has one or more physico-chemical property values which places it outside 
the spanned substituent space of the other compounds, 
6- the 'outlier' may yield one or more metabolites. 
An understanding of the cause of 'outlier' behaviour may be of great value in gaining a 
more fundamental insight into the underlying chemical processes governing biological 
action. 
5.2312 Discriminant Analysis (DA) 
Discriminant analysis (DA) is a pattern recognition technique, which has proven to be 
the most general technique available for dealing with semi-empirical or qualitative 
biological data and relating it to 'mixed variables'. It was first used in SAR studies by 
Martin et al [107] in a study of the weighting and statistical significance of various 
physico-chemical properties which could distinguish between agonists and antagonists. 
In discriminant analysis the user has advanced knowledge as to the identity of each 
group, e.g. active or inactive, and sets out to explain and maximise the separation 
between each group using specific predetermined vectors. The data for the individual 
compounds under investigation are projected as definite points into a 'pattern space', 
which is a derived orthogonal co-ordinate system, with the system axes being those of 
the physico-chemical descriptors. In the 'ideru' situation related groups or classes of 
compounds will cluster together in different regions within the 'pattern space' so 
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separating active and inactive compounds into two distinct groups. The regions of 
'pattern space' where related compounds have grouped are then defined using one of 
two basic methods. 
Hyperplane methods are the most widely used and involve the derivation of an 
equation for a plane that will separate the pattern space into distinct regions, each 
representing a region of space where one of the groups or classes of compounds is most 
likely to occur. The optimal linear discriminant function (LDF), a function line 
originating from the origin and which gives minimal overlap between the two clusters 
[93,108]. Solution of the derived equation with respect to each test compound is then 
detennined and then used to assign each untested compound to the appropriate group. 
Distance methods involve the allocation of the untested compound (Q) to the nearest 
group or population, where 'nearness' is a measure of the probability of Q belonging to a 
specific group or class, rather than a metrical measurement. The general distance used is 
the Malhanobis distance. 
5.2313 SIMCA - Linear Learning Machine 
SIMCA is a classification method, which seeks to describe each activity class separately 
by generating a principal component model which describes the individual activity class 
(see section 5.2321). These models can be thought of as 'hyper-boxes' in the n-
dimensional parameter space, that act to enclose all of the compounds of a particular 
class [64]. 
5.2314 K-Nearest Neighbour (KNN) 
KNN makes use of the same matrix of interpoint distances as non-linear mapping and 
cluster analysis (5.31 and 5.2322 respectively) to classify compounds based upon their 
position in a multi-dimensional space [109]. Compounds are assigned to membership of 
a particular group or class on the basis of the class membership of their nearest 
neighbours, in terms of inter-point distances (K). K is normally selected a priori and 
taken as being an odd number, so that a majority vote will decide the class of 
assignment. 
5.2315 Canonical Correlation Analysis (CCA) 
CCA is a multi-variate technique which enables the simultaneous analysis and 
correlation of two data sets [102], the size of which need not be the same. CCA 
calculates a linear combination of responses (q) and a linear combination of descriptors 
(p), such that a pairwise correlation between the two vectors is at a maximum. The next 
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best correlation, which is orthogonal to the previous, is then calculated. The process is 
repeated until the number of correlations is equal to the number of data points in the 
smallest set. Comparison of the correlation scores enables the characteristics of the 
molecular properties to determined and biological data to be assigned relative to the 
data points. 
5.232 Unsupervised Learning Techniques 
5.2321 Principal Component Analysis (PCA). 
PCA is not actually a statistical technique but is a data display technique, which is 
particularly useful at the start of an analysis, where it serves to confirm that a data set 
contains useful information [102]. The process involves the transformation of the 
original data set into a new set of fewer uncorrelated variables, which are linear 
combinations of the originals and are created in such a way as to account all the original 
variation. The effect of the new data set creation is to reduce the total number of 
variables and thus reduce the likelihood of information redundancy, as seen with the 
original data set. The first principal component (PC 1) is a linear combination of the 
values of those descriptors whose variability is as large as possible. Therefore, it is PC 1 
which contains the largest part of the variance of the data set, and subsequent 
components contain progressively smaller amounts of variance, some latter PCs may 
infact contain zero variance. PCs have disadvantages in that they are often difficult to 
interpret, since they are composed of a combination of variables and it is not possible to 
transfer the co-ordinates of a point on a PC plot to values of individual variables. 
5.2322 Cluster Analysis (CA) 
CA is a classification scheme rather than a procedure allowing the prediction of 
biological activity. CA is used to identify those factors which are of importance in 
classifying a compound due to its activity or lack of it [110]. The basis of CA is to 
define a space of k descriptors and to define n compounds within that space in terms of 
their respective descriptor values. Then to calculate the Euclidean distances (dij) 
between each pair of points in the descriptor space. The Euc1idean distances for each 
compound within the data set and their respective similarity to other compounds can be 
displayed pictorially in the form of a dendogram, figure 5.2. Analysis of the dendogram 
enables identification of compounds which are most similar, of the number of groups or 
classes contained within a data set and of the presence of any outliers. 
Hansch and Unger [110] have used CA to identify redundancies amongst substituent 
parameters within a given data set. 
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Figure 5.2 Dendogram Presentation of Cluster Analysis Results 
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In the above case it can be observed that the data falls into three classes; 
1- compounds 7,8 and 9, 
2- compounds 10 to 15 inclusive, and 
3- compounds 2 to 6 inclusive. 
15 
I 
I 
Class 1 (compounds 7,8 and 9) is more similar (closely related) to class 2 (compounds 
10 to 15) than to class 3 (compounds 2 to 6), due to the shortness of the elucidean 
distance between the respective classes. 
The two most similar compounds are 12 and 13, due to the extreme shortness of the 
distance between them. 
Compound 1 is not similar to any of the other compounds and so must be considered to 
be an outlier. 
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5.3 Non-Linear Relationships 
In some cases a linear regression model is inadequate to model the dependence of 
biological activity on an independent variable, e.g. the case of partition coefficient (P) in 
the equation derived by Hansch (4.3211). True non-linear relationships are those which 
cannot be described by any line, straight or not. Sometimes there is a non-linear 
dependence of biological activity on one or more parameters. In such cases appropriate 
transformations of the parameters (biological and / or descriptors) may serve to model 
the data, e.g. by squaring or inverting. 
Kubinyni (111] was able to improve Hansch's model by modifying it in order to account 
for the fact that biological activity and P initially vary in a recti-linear fashion, increasing 
on a Log scale to an optimal value after which the values decrease in a recti-linear 
fashion. That is the model is bi-linear. 
The new model being expressed in terms of equation 5.8. 
Logl/C = aLogP - bLogP(fJP+l) + d (5.8) 
Where fJ is a non-linear term calculated by an iterative procedure. 
P is the n-octanollwater partition coefficient 
a,b and d are linear terms calculated by linear regression. 
5.31 Non-Linear Mapping (NLM) 
NLM is a non-linear technique for the projection of points from an n-dimensional space 
to a two or more dimensional space. NLM operates by comparing the distances between 
pairs of points in the n-space (Dij*) and in the two dimensional space (dij) and seeks to 
minimise the differences between these interpoint distances using an error function (E). 
This has the effect of making similar compounds group together in tighter clusters. 
Analysis of the non-linear map simply suggests that the physico-chemical data contain 
information that will be useful in the classification of the compounds. NLM has the 
advantage that it does not impose a linear combination on the variables, in order to 
produce the two-dimensional display. But it does suffer from a number of 
disadvantages. Since the method relies on the minimisation of a set of interpoint 
distances, it is not possible simply to plot a new compound onto the map; the whole map 
must be recalculated and in some cases the inclusion of a new compound may alter the 
map considerably, although useful patterns are generally preserved [111]. 
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5.4 "Goodness of Fit" of Statistical Models 
The "goodness of fit" of the derived statistical equation, with regard to the biological 
data used in its generation, is expressed by the statistical criterion of 'total sum of 
squares' (SSTOT), and can be defined in terms of equation 5.9. 
Where Yi is the observed value of biological activity, 
y is the mean value of biological activity. 
(5.9) 
Sokal and Rohlf[112] presented a detailed description of the partitioning ofTS in which 
all variations present in the sample can be separated into two parts, in which most 
variation is attributed to differences between groups and the remaining variation can be 
attributed to differences within groups (different individual Y and group mean values). 
Thus, 'total sum of squares' (SSTOT) can be factored into two parts; i) that part 
attributed to the model, termed MS and ii) that part attributed to error or the residual 
part, termed RS. (TS has n-I degrees of freedom, where n is the number of observed 
values of Y and is continuous and so ever increasing. MS has p degrees of freedom, 
where p is the number of independent variables and RS has n-p-I degrees of freedom). 
Further terms of importance in the estimation of a statistical models 'goodness of fit' 
have been derived, and some are detailed below. 
A - Fischer and then Hayslett and Murphy [113] determined that the ratio of RS and the 
number of degrees of freedom, yielded a term for variance (equation 5.10), known as 
'the error mean square' (S2 or s2): 
s2 =RS 
n-p-I 
(S.lO) 
Martin [64] determined that the square root of s2 would gIVe a value (s) which 
corresponds to the standard error of the estimate. 
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B - The global measurement of the quality of a model IS the 'coefficient of 
determination' (r2), which is described in equation 5.11. 
r2 = MS (the regression or model sum of squares) (5.11) 
TS 
Values of r vary between 0 and 1, with 1 being representative of a perfect fit. The 
square root ofr2 gives a value, r which is the 'correlation coefficient'. 
C - Houlton [113] suggested that the 'correlation coefficient of determination' should 
be adjusted for the number of degrees of freedom, the resultant value being termed 
'r2(adj)'. 
D - The Fisher statistic or variance ratio (F value), as described in equation 5.12, allows 
the estimation of whether the obtained relationship is statistically significant. The larger 
the value of F the greater the probability that the derived equation is actually modelling 
the data and is not due to chance correlations. Analysis of the 'F' distribution allows a 
choice of confidence limits to be established. If F = 0 then there is no relationship 
between x and y, and the larger F the greater is the significance of the realtionship 
between x and y. 
F(variance ratio) = MS (model/regression mean square) (5.12) 
s2 (residual! error mean square) 
E - Standard error s of coefficients of each variable, as well as r2 and F are used in initial 
tests (prior to validation), to allow determination of whether the relationship determined 
is strong or weak. Strong relationships have high r2 values (preferably over 0.9), low s 
values (preferably less than 0.3) and highly significant F values. If such a strong 
relationship is indicated, it can be concluded that the QSAR derived has modelled the 
relationship well and that with careful use, it may provide useful information with regard 
to the biological mechanism of molecular action and may allow predictions of biological 
response to be made for new related compounds. However, QSARs with weak 
relationships present low r2 values, high s values and less significant F values. In such a 
case it can be concluded that the model is unsuccessful and interpretations made using 
the model should not be made. 
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F- Validity plots [98] 
Plot 1 is a plot of the difference between the observed biological effect and the value of 
biological activity predicted by the model (Ei) against the values of biological activity 
predicted by the model. 
If the points are evenly distributed about a central zero line then the plot is termed 
homoscedastic and signifies that error is reasonably consistent throughout all the 
biological data used in the generation of the model and the model is said to be valid. If 
the points appear to diverge from or converge upon the zero line then the plot is termed 
heteroscedastic and signifies that any change in stimulus will proportionately affect the 
response, that is to say that a large scope for error exists within the biological data and 
therefore the model is invalid. If the data are heteroscedastic it means that if the overall 
variance is based on all of the data, then for the regions where the variance is small, the 
variance will be overestimated, in regions where the variance is large, it will be 
underestimated by the overall variance. 
Plot 2 is a plot of the difference between the observed biological effect and the value of 
biological activity predicted by the model. The plot illustrates the probability that all the 
error terms will have an equal distribution about a regression line through the data 
points and so is a test of normality. 
A linear plot shows the error to have a normal distribution about the linear line and 
therefore suggests the model is valid. A skewed plot shows that the distribution of error 
is not normal and therefore suggests that the model is not valid. 
Analysis of the graphical plots in conjunction with the statistical properties, such as r2, 
produced during regression analysis show how well the model fits the data used in its 
development, but they do not provide any information as to the predictive powers of the 
model, this is attained by assessment of the models validity. 
5.5 Validation of Statistical Models 
The statistical validation of models has been increasingly recognised as a vital step in the 
development ofa QSAR. Currently there are two methods of validation in common use. 
The first method and possibly the more appropriate, involves the separation of data into 
two data sets. One the 'training set', which is used to develop the QSAR model, and the 
other is an 'evaluation set', which is not used in the model development, but is used to 
validate the model. The predictability of the model is tested by calculating the biological 
activity of the 'test set' and comparing the resultant calculated activities with actual 
measured activities of those same compounds. 
The second method of validation is known as 'leave-one-out' or as 'cross-validation'. The 
model is developed using the entire data set. Validation is performed by excluding one 
or more compounds from the data set and the model is recalculated. The recalculated 
model is used to predict the biological activity of the excluded compound(s). The 
process is repeated until each compound has been omitted from the data set and its 
biological activity been calculated using the alternative model. The deviation of the 
calculated biological activities from those evaluated in the original model, gives an 
indication of the predictability of the original model [1 14]. 
Wold [115] proposed that a model's 'predictive significance' can be evaluated from the 
values of Predictive REsidual Sum of Squares (PRESS) and Sum of Squares of response 
values (SSY), as generated through 'Ieave-one-out' cross-validation procedures, in 
accordance with equation 5. 13. 
PRESS = Predictive significance 
SSY 
Where values < 0.4 indicate predictive significance. 
(5.13) 
Baroni et al [116] have shown, using equation 5.14, that it is possible from the 
predictive significance to calculate a value indicating the model's predictive validity 
called the 'cross-validated coefficient of determination' (r(CV)2). 
r (CV)2 = 1 - Predictive significance (5.14) 
In accordance with the above proposal of Wo Id and the equation ofBaroni (1 - 0.4) a 
threshold of predictive validity would be a r(CV)2 value of 0.6. Below which the model 
is not valid. Clemetis [46] has proposed that a r(CV)2 value of 0.1 indicates predictive 
validity. Clearly the value of r(CV)2 chosen as the threshold of predictive validity is 
open to variation and currently is ultimaltely set at a level determined by and at the 
discretion of the model generator. 
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6.0 Immunology 
6. 1 Introduction 
The immune system is a multifunctional adaptive system which is classically 
concerned with maintenance of host defence mechanisms, is responsible for the 
process's of self and non self recognition, homeostasis, immuno-surveillance, 
specificity and memory [117] and as such is a tightly regulated, highly organised 
complex network of interacting organs, tissues, cells and molecules which act in 
concert in an ordered and regulated fashion in order to give rise to a specific 
adaptive immune response following the recognition of materials within the system 
as foreign or changes in the antigenic environment [7,118,119]. 
The delicate balance of the immune system is regulated by a network of events 
which in turn are controlled by the differential secretions of cytokines from specific 
cells and by the genetic capabilities of the host itself [118]. 
An ideal immunologic response is one that adequately deals with insults whilst 
protecting the host in such a way as not to overreact and bring about adverse 
immunologic responses (immunotoxicological responses), such as allergy, 
immunosuppression, reduced immunocompetance or autoimmunity. 
6.2 History of Immunological Ideas 
The history of immunological ideas must have begun with the wives' knowledge 
that some recognisable childhood infections only struck once, and later when people 
began to recognise that persons with pock marked faces did not develop a second 
case of smallpox. Hence, the eighteenth century epidemic of smallpox, throughout 
Europe gave immunological ideas' pre-eminence [120]. 
The history of virolisation as a deliberate attempt to provoke immunity and the first 
effective immunisation performed by Edward Jenner in 1796 [] 20], in which a 
vaccination with cowpox was utilised as a means of protecting against smallpox, is 
known to all. The first general scientific method of immunisation against infectious 
diseases was provided by Pasteur in 1880 [120], when he protected fowl against 
chicken cholera by inoculating them with attenuated virus. He explained his results 
by suggesting that "immunisation had 'exhausted' something necessary for the 
proliferation, in vivo, of the virulent virus". 
Also, around this time a new problem became universal recognised that of bacteria 
and pathogenic resistance. 
In 1882 Elie Metchinkoff (a Russian zoologist) [120], performed a senes of 
experiments in which he identified the role of motile cells within transparent starfish 
larva in the process of protection from foreign intruders. He showed that the 
mechanism of this protection was through leukocytes of the host engulfing the 
invading micro-organism, a process he termed 'phagocytosis' [120]. This work 
provided the starting point for the study of cellular immunity. 
In 1894 Pfeffier and Isaeff [120] described the importance of the humoral defence 
mechanism, known as the 'Pfeffier phenomenon', and concluded that this was the 
main defence mechanism of an organism. 
Controversy between the cellular and humoral theories of immunity existed until 
1903 when Almorth Wrights' ideas on opsonins lead to the recognition of the 
complexity of the processes and cellular types involved in immunity [120]. 
Further immunological theory developed as something concerned with a wider field 
than just immunity to infection [7]. In 1898, Bordet [120] recognised the immune 
lysis of foreign red cells, and in 1904 Landsteiner [120] discovered the ABO blood 
groups. From these works came the realisation that only foreign material was 
antigenic and thus added new problems to the understanding of the immunological 
processes, and the main stream of immunological thought became concerned with 
the antibody. By 1930 it was clear that antibodies were associated with serum 
globlins. From this Lederberg developed the 'instructive' theory of antibody 
formation. Landsteiners work in the 1930s was of importance in establishing a 
chemical basis for the specificity of the immune pattern and the suggestion that 
antibodies were produced by the body, by some impression of a complementary 
pattern on normal serum globin during its synthesis. 
In the 1940s Pauling [120] began to relate immunological ideas and the developing 
biochemical principles, and the development of quantitative biochemical techniques 
in place of the medical immunological techniques of titration. Between 1940 and 
1955 there was a rapid technical advance in immunology, with Tiselius' simple 
electrophoresis, Ouchterlonys' visualisation of Antigen-Antibody precipitation 
reaction on agar and with Williams and Grabar's combination of the latter in the 
development of immunoelectrophoresis [121 J. 
Over the past 40 years, numerous advances in technology and theory have enabled 
vast amounts of information on the immune system, and its actions in response to 
infection to be amassed and have provided the current knowledge. However, to 
date not all the problems regarding the exact structure, function or relationships of 
all the immunological components, have been solved and much work still needs to 
be performed if all the answers are to be found. 
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6.3 Immunity 
There is a number of biological defence mechanisms that protect an individual from 
potentially harmful material and micro-organisms (122]. These mechanisms can 
roughly be divided into two types: Innate immunity which is the first line of defence 
a foreign molecule encounters on entering the bodily environment, such as the 
physical barriers of the skin, mucus, enzymes and lysozymes. Adaptive immunity 
which develops in response to contact with and repeated challenge by an infectious 
agent, it comprises components which have the ability to recognise variations in the 
structure offoreign material and to remember them thus eliminating foreign material 
initially and on subsequent occasions. 
The two types interact and regions of commonality exist, but it is adaptive 
immunity, because of its ever changing and adaptive nature, which is of the most 
interest to the immunologist. 
6.31 Adaptive Immunity 
The adaptive immune system continually develops throughout life and comprises 
two distinctly derived but not entirely independent systems (figure 6.1): Cell-
mediated Immunity, in which the presence of foreign matter stimulates cytotoxic 
cells to produce sensitised lymphocytes which act against the invading matter and 
Humoral Immunity, in which specific antigen stimulated B Iymphocytes produce 
plasma cells which subsequently produce specific immunoglobulins (antibodies) that 
act to eliminate the specific foreign agent, via a number of mechanisms, including 
the neutralisation of toxins and viruses, the assistance of cell lysis and opsonisation 
and chemotaxis. 
6.4 Immunohistology 
Both anatomically and functionally the immune system comprises three malO 
compartments; the stem cell pool which is distributed evenly throughout the blood 
and bone marrow, the primary lymphoid organs which are involved in the 
development and normal ontgeny of the T and B Iymphocytes, and the secondary 
lymphoid organs which comprise the centres of cell mediated humoral responses the 
spleen and the lymph nodes, as well as the mature functioning lymphocytes and 
accessory cells [122]. 
Figure 6.1 Illustration of the Differential Derivation of the Two Systems 
of Adaptive Immunity 
(Adapted from Vos [123] ) 
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6.4] Lymphoid Organs 
The lymphoid system comprises those bodily tissues or organs in which 
lymphocytes reside, which are responsible for the production of the immooe cell-s 
and maintenance of their presence within the circulatory systems of blood and 
lymph, these being primarily the thymus, the spleen and the lymph nodes . 
6.411 The Thymus 
The thymus is an epithelial organ, originating from the third bronchial pouch during 
embryogenesis and which has migrated to the mediastinum which comprises two 
regions (figure 6.2) the cortex and the medulla. The cortex is densely honeycombed 
with pockets..()f proliferating lymphocytes and can be sub-divided into outer and 
deeper regions. The outer cortex is composed of specialised nurse cells which 
contain the primary 1ymphocytes. T.he deeper cortex COHtains dendrit~ cells which 
express the major histocompatablity class 11 molecules (MHC 11), essential for T 
cell activation. The medulla is irregularly infiJtrated by lymphocytes and other cells 
associated with blood vessels, i.e. macrophages. Within the medulla are thymic 
epithelial cells or interdigitating cells responsible for the secretion of several 
honnones which act to influence T -lymphocyte development and differentiation, the 
most prominent honnones being; four types of Thymopoietms, -twenty-five types of 
Thymolysins, Thymielin and Thymic humoral factor. 
Precursor T ceHs from the bone marrow enter the thymus nurse cells which then 
migrate down through the thymus cortex and medulla, so enabling, differentiation 
and development of the precursor T cells to into different types of virgin T-
lymphocytes; Thelper, T suppresser and T cytotoxic cells. 
Only a small proportion (1 %) of the virgin T -Iymphocytes produced in the thymus 
will leave via the blood system aDd migrate to the lymph node. The remainder are 
eliminated / degraded by the Hassells' corpuscles of the thymus medulla. 
6.412 TM Spleen 
The spleen is a highly vasculated organ, comprising two regions (figure 6.3), the red 
which acn as a storage reservoir for surplus red blood ceUs and breakdown 
damaged cel1s, and white pulp which represents the aggregation of the white blood 
cells around the afferent blood vesseis, creating a shemh known as the Periarteriola 
lymphatic sheath, which acts to screen the blood for the presence of any foreign 
matter and if necessary generate an immune response. 
Figure 6.2 Diagram of the Internal Structure of the Thymus 
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6.413 The Lymph Node 
Lymph nodes are the small rounded dynamic structures, found in the lymphatic 
system, which serve ~ a centre-for complex processes ofiocal immunity 1122]. 
Each lymph node has a classical kidney shape (figure 6.4) with an internal structure 
comprising three distinet regions; the cortex, the -paracortex and the medul1a, and 
consists of a 3D stromal network which forms an intricate lattice which supports the 
migratory cells responsible for the production and -secretion of Iymphocytes and a1so 
serves as a filtration unit removing waste products and bacteria. 
The cortex is populated by" primary fotlicuiar ~Us which contain large numbers of 
lyrnphocytes. It is in these follicular cells that the Iyrnphocytes (mainly the Thelper 
cells) replicate by clonal expansion. The paracortex is the primary site of T 
lymphocyte and macrophage localisat4Gn within the lymph nodes. Whilst the 
T cytotoxic and T suppresser cells are found mainly in the medulla. 
Lymph fluid enters the nodes via the afferent lymphatic vessels which communicate 
with the subcapsular sitruses, aRy antigem in 'the lymph fluid are recognised and 
taken up by the Langerhan cells of the lymph node and are presented to the 
macro phages and Iymphocytes, thus initiatiRg an immunological response. 
6.5 Cellular Components of the Immune System 
An individual immune response tc a particular ant~n ~ the result -of interacting 
factors mediated through numerous different cell types, each with its own particular 
function. An celft; of the immune sys~ develop from a common precuf'S6r,1he 
pluripotent stem cell, present in the bone marrow (figure 6.5), via one of two 
differentiation pathways [122l, giviftg me to myeloid and lymphoid cell lineages 
respectively. The myeloid lineage gives rises to cells such as the mononuclear and 
polymorphonuclear leukocytes, mast odls, platelets, basophils, eos;nopfHls and 
neutrophils. Whereas the lymphoid lineage differentiates into two distinct cell lines 
producingB and T Jymphocytes [122:). 
6.51 Pluripotential Stem Cell 
The Pluripotential Stem Cell also known as the Haemopoietic cell, is found in the 
bone marrpw aoo is the sour-ce of almost all the ~Is involved in immuROklgical 
responses and also, gives rise to cells of the haematopoietic system, including 
erythrocytes and platefets and families of inactive oet1s [i 2 7]. 
6.52 Macrophages 
The macrophages or blood monocytes arise from the common myleoid progenitor 
the monoIWclell1" phagocyte. Macrophages are -phagocytic cells present In 
abundance in the liver, lung, in the lining of the spleen sinusoids, and the lymph 
node medull~ sinuses, and are also found throughout -the connective tissue aAd 
around the basement membranes of blood vessels [128]. The major role of the 
macrophage is to proviee defence against bacteria, virnses and proto~a, through 
the phagocytosis of foreign cells, antigen presentation in order to stimulate 
lymphocyte activity, the secretion of over sixty mediator substances which act to 
modulate the immune system, and in aid the activation of the cells of the immune 
system. 
6.53 Polymorphnuclear Leukocytes 
Polymorphonuclear feukocytes -or graftUlocyte6 constitut-e 70% of the circulating 
population of leukocytes, and can be sub-divided into neutrophils, eosinophils, 
basophils aAd Rlast ceHs. Neutrophils are -the ffi()st abundant and aTe involved in the 
digestion of micro-organisms. Eosinophils are phagocytic cells which collect at the 
sites of allergic f"eactiom, the granules of whK:b are lysosomat Basophils are 
analogous to the tissue mast cells in that their granules contain histamine and 
heparin. Mast ~s ean be sub-divided into those fotmd in-the connective tissue and 
those associated with the mucosa, and are responsible for the release of chemical 
mediators following anti genie stimulation, ·ie. rustamine wbtcb initmte t-he classica1 
symptoms of drug induced hypersensitivity. 
6.54 Lymphocytes 
Lymphocytes are the most significant cells of the immune system, being of central 
importance to the functioning of the immune system. Lymphocytes constitute 20"10 
of the leukocyte population and occur in three main sizes; small, medium and large. 
Lymphocyt.Ds are ail morphologically identi~, but it ~ possible 10 differentiate 
them into T and B lymphocytes (figure 6.6), on the basis of their differing routes of 
production and their extremely different fimctions / eff.oots. Both types continuously 
circulate within the body, passing out of the blood into the lymphatic circulation, 
through the lymph nodes and the spJeen, following preferential migration pathways: 
T -Iymphocytes preferentially migrate to the peripheral lymph nodes and are vital for 
the effectiYe functioning of the immtme ~stem as they are responsible for the 
continuous surveillance of antigenic insult, communication and co-operation 
between cell types, controlling the proffferation and differentiation of antigen 
specific cells, selecting the distribution of effector cells to the sites of antigen 
exposure, and for effecting the reci1'culation of generated memery ceits. 
B-Iymphocytes preferentially migrate to mucosa associated lymphoid tissue 
(MAL T) found in the lining of the gastro-intestinai tract, tooslls, etc. 
Both Band T Iymphocytes work in conjunction, via multiple molecular 
communica,tjon mechanisms, to bring about the immunological processes and to 
regulate the production and activation of other immunological cell types such as the 
macro phases, mast oet1s, platelets, eosinophi1s and basophils 1127]. 
6.541 T-Lymphocytes 
The T cell line of lymphocytes originates from the thymus and develops into three 
morphologically identical classes -()f T cen, the helper, cytotmc.ic and suppresser 
cells. It is possible to distinguish between the different classes due to unique surface 
molecules present -on the respective ceih;. These -surfaee markers are termed CD 
markers and are defined by a cluster of monoclonal antibodies all reacting with the 
same molecule, e.g. CD3 marks the antigen receptOf on all classes ofT -cell, '"CD4 
marks The1p~ cells and CD8 marks T cytotoxic cells. 
Each different T -cell class has a specific immunological function; T helper cells (Th) 
aid cell amplification, T cytotoxic -cells(T c) destroy target matter and T supressor 
cells (Ts) act to sw.it-ch.off ~ within.the ~mmune system. 
The T cell population can be sub-divided into two distinct functional types, CTL 
which proHferate aad directly kill antigen--bearing target cells following stimulation, 
and HTL which secrete cytokines and proliferate in response to antigenic 
stimulation, with the assistance of T helper cells [129]. 
Figure 6.6 Diagram of Lymphocyte Production, Activation and 
Immune Response Initiation 
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T -Iymphocytes are antigen specific and therefore have a receptor for antigen 
recognitiOft (figure 6.7), w1lich is a heterodimer C01lsisting of an -acidic amino acid 
chain (45-55 KDa ) and a basic amino acid chain (40-50 KDa) linked by a 
disulphide bond on the T cell surface [127]. The receptor is unable to recognise the 
antigen alone but recognises the antigen in association with MHC 11, so prior to 
recognition the T lymphocytes must be activated, the antigen modified and 
presented 
Mature T -Iymphocytes are inactive, once the presence of an antigen has been 
detected it is necessary to -ectivate the l1HrtuPe lymphocytes, ~ this to occur the 
presence of a macrophage is essential. The macrophage, acts as an antigen 
presenting cell, taki:ftg up the antigen ptmgocytically and ~ng it into particles, 
known as antigenic detenninants. Some of these antigenic detenninants, when 
excreted, adhere to the outer membrane of the macrophage, where they are 
expressed along with MHC 11 as an antigenic complex. The antigenic complex is 
recognised by circulating Thelper Iymphocytes, which in turn bind to the antigenic 
detenninants expressed on the macrophage, and initiate T cell activation. 
Thelper cells stimulate the macrophage to secrete a lymphokine, known as 
Interleukin-l (IL 1), which acts to enhance the metabolism of other T helper cells in 
the surrounding area, which in response secrete the lymphokine Interleukin-2 (IL2) 
which enables Iymphocyte recognition of the foreign (antigenic) matter. Upon 
antigen recognition the Jymphocytes proliferate and differentiate into one of two cell 
types; an effector cell which produces a variety of antigen sensitive and regulatory 
cells which act by secreting specific substances known as lymphokines, which act to 
bring about a specific cell mediated immune response (figure 6.6) and memory cells 
which enhance recognition and reaction should a second infection occur. 
6.5411 T Helper CeUs 
T helper celJs are defined by the possession of the membrane determinant CD4 [7]. 
Mosmann et al [131] categorised CD4+ Thelper cells into two subcIasses~ Thl and 
Th2 clones, which are in turn responsible for the development of two different types 
of immune response [132]. These cell clones probably represent the most 
differentiated forms of T lymphocytes derived from a common precursor during an 
immune response. Femandez-Botran et al, [133] showed that following antigenic 
stimulation the Thelper clones (Thl and Th2) proliferate synergistically, with a 
marked difference in the respective responses showing within a few days of 
stimulation, Thus, distinction between Thl and Th2 was possible on the basis of the 
cytokines secreted following activation (figure 6.8) [131,132,134]. 
Th I clones secrete the cytokines, Interleukin-2 (IL2) a T cell growth factor which 
plays an important role in the clonal expansion of the T cells and Interferon-gamma 
(IFN-y) which has numerous actions including anti-viral activity, macrophage 
activation, B cell activation and stimulating the differentiation and secretion of 
polyclonal IgM, inhibition oflgGI and IgE secretion and the enhancement of IgG2 
secretion. Together IL2 and IFN-y act to initiate the cell mediated delayed 
hypersensitivity reactions. 
Th2 clones secrete the cytokines, Interleukin-S (IL5), Interleukin-6 (IL6) and 
Interleukin-4 (IL4) which is involved in the activation, proliferation and 
differentiation of B and T cells, in inducing resting B cells to increase their 
expression of MHC n and of low affinity receptors for the Fc portion of IgE, and 
act as co-stimulator of B cells in the presence of anti-immunoglobulin so inducing 
the production ofIgG and IgE antibodies. 
IL4 is the only cytokine that regulates 19E production and the initiation of humoral 
immediate hypersensitivity reactions. 
Both clones secrete the cytokines Interleukin-3 (IL3), Granularcyte macrophage 
coloney ~imu1ating factor (GM-CSF), Tumour necrosis factor (TNF) and 
Preproenkephlin and other specific induction proteins. 
The nature and properties of a2, HA, IFN-y and some other cytokines are 
discussed more fully later in 6.6. 
The observation that HA and ll..2 are secreted by distinct Thelper clone suggests 
that different activation requirements for the two T clones may play an important 
part in the mechanism by which the relative production of IL4 and IL2 and 
ultimately the selection of the Ig isotypes secreted in humoral immune responses are 
regulated [129,131]. The concentration of the cytokines IL4 and IL2 may provide a 
particular selection pressure and so direct the type of cells stimulated and the form 
of the immune response initiated [130]. 
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Figure 6.8 Diagram of the Differential Cytokine Secretions by Th 1 and Th2 clones 
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6.6 Cytokines 
The pioneering work of Be se do sky, Sorkin and co-workers [135J showed there to be 
in existence a two way communication of information between the components of the 
immune system and between the immune system and the hypothalamic pituitary-
adrenal axis, the vehicle of communication being the cytokines. 
The term 'Lymphokine' was introduced in 1969 to describe the cell free soluble 
signalling factors generated following the interaction of sensitised lymphocytes and a 
specific antigen, which act either as a paracrine secretion, having a local effect on other 
cell types or as an autocrine secretion, having an effect on the cell secreting it. The 
term since has often been used less discriminately to denote proteins from a variety of 
cen sources which affect the growth or functioning of many cell types [136]. In an 
attempt to develop a system of nomenclature based on the ability of a protein to act as 
a communication signal between different populations of leukocytes Cohen et al [13 7J 
proposed the term 'Cytokine' and participants of the second international Iymphokine 
workshop proposed the tenn 'Interleukin'. Balkwill and Burk [138] proposed the lucid 
and useful definition 'Cytokine is one term for a group of protein cell regulators 
variously called Iymphokines, monokines, interleukins or interferons, which are 
produced by a wide variety of cells in the body and which play an important role in 
many physiological responses and are involved in the pathology of a range of diseases 
and have therapeutic potential'. Vilcek and Le [136] proposed the alternative definition 
'Cytokines are regulatory proteins secreted by the white blood cells and a variety of 
other cells in the body; the pleiotropic actions of cytokines include numerous effects on 
cells of the immune system and modifications of the inflammatory responses'. Both 
definitions suggest cytokines are a diverse collection of molecules, however Vilcek and 
Le [136], proposed that all cytokines comprise a common set of basic features, they 
are simple polypeptides or glycoproteins with molecular weight less than 30 KDa, their 
production is regulated by various inducing stimuli at the level of transcription or 
translation, is transient, their action radius is short, is produced following binding of 
cytokine to specific high aftinjty cell surface receptors and is autocrine or paracrine. 
The range of actions displayed by individuaJ cytokines is broad and diverse. They may 
act as; inducers or regulators of cell growth, division and differentiation or as 
stimulators of cell movement and directing migration, as controllers of cell function 
and of cellular interactions via induced changes in the expression of membrane 
determinants, such as MHC antigen adhesion molecules and as receptors for the 
cytokines themselves [119]. Another action is that they either lead to an increase or 
decrease in the levels of production of other cytokines. 
1'3 
The cytokines of interest in this work are those secreted by the Thelper Iymphocytes, 
following drug administration and so play an important role in the initiation of the 
immune response. The Thelper cells secrete a number of cytokines, which can be 
classified into two groups, the interleukins (IL) and the interferons (IFN). 
6.61 Interleukins 
Interleukin means 'between leukocytes'. The term Interleukin was coined in order to 
free the nomenclature of soluble communicating from the constraints associated with 
the definitions derived from a single bioassay. 
Over the last 20 year's knowledge pertaining to the activity of the T -Iymphocytes has 
expanded significantly to include infonnation regarding the direct effects of cytokines 
on the growth and differentiation of T & B Jymphocytes, Natural Killer Cells, 
Monocytes, Macrophages, LAK cells and Oligodendrocytes. This increased knowledge 
base has thus, lead to more investigations to be perfonned and more detailed 
information regarding the actual responsible cytokines to be gleaned. The main 
interleukins released by the Thelper cells are IL2, IL3, IL4 and IL5, each of which has 
a different function or effect. 
6.611 Interleukin 1 
IL2 was first identified by Morgan and co-workers in 1975 (139] as a bone marrow 
derived T cell growth factor. IL2 is a 15.5 to 17 KDa soluble sialoglycoprotein, 
comprising a 133 amino acid polypeptide chain which contains a single intramolecular 
disulphide bridge between amino acids 58 and 108. This bridge is important in 
maintaining the active confonnation of the molecule (140,141]' The overall 
arrangement of the amino acids within the ll..2 structure (figure 6.9) has generated a 
molecule comprising of 6 alpha-helical domains (A to F). IL2 is produced by the 
resident T cells of the lymphoidaJ organs drained at nonmucosa) tissue sites, the 
axillary, inquinaJ and brachial lymph nodes and the spleen [140, I 41 ]. The main roles of 
IL2 are the pr~pentiation of T cell proliferation via binding to a specific IL2 cell-
surface receptor [142,143,144], the amplification of activated T cells, the proliferation 
ofT cytotoxic cells, the induction ofNAT killer cells, oflymph killer cells and ofB ceIJ 
proliferation and differentiation. 
6.612 Interleukin 3 
1L3 in humans is a 133 amino acid heavily gJycosylated polypeptide chain, which acts 
on the broadest range of target ceUs within the haematopoietic system of any cytokine 
promoting the formation of erythroid, megakaryocyte and mast celJ colonies. IL3 also 
has a special ability to stimulate growth of early stem cells and progenitors of mast 
ceUs and megakaryocytes [145]. 
6.613 Interleukin 4 
IL4 was identified in 1982 and is a 144 amino acid soluble glycoprotein produced by 
the resident T cells of the Iymphoidal organs, drained at mucosal tissue sites such as 
the Peyers patches, cervical, periartic and parathymic lymph nodes [146]. IL4 is 
secreted in response to allergen-induced cross-linking of 19E at the Fc receptor and 
acts as a B cell growth ceU factor initiating the synthesis of IgE and IgO 1 type 
imrnunoglobulins and plays a part in mast ceU degranulation. 
6.614 Interleukin 5 
IL5 is a 40-45KDa glycoprotein, unique with regards other cytokines in that it has a 
disulphide linked homodimer. as is a B cell growth factor which initiates the synthesis 
of IgA type antibodies and also stimulates amplification of the eosinophiJIia cell lineage 
and possibly activates the basophil ceIJs [147]. 
6.615 Interleukin 6 
IL6 is a multifunctional cytokine which is believed to play an important role in host 
defence, through regulating various aspects of immune and inflammatory responses, in 
the regulation of B Iymphocyte differentiation, acute-phase protein synthesis and 
haematopoiesis and may also be an important co-factor in T-cell function [148]. 
6.62 Interferons 
Interferons are a second sub-group of cytokines. They are the major class of cytokines 
which contribute to the first line of anti viral defence. There are three main interferons 
Cl, Il & y. IFN Cl & 13 play a major role in the host resistance to viral infections prior to 
the activation ofthe immunological mechanisms [J 49]. 
6.621 Interferon - Gamma 
IFN-y is released by T -helper Iymphocytes following sensitisation by anti-viral agents. 
Following its release it augments phagocytosis, activates monocytes, enhances NI( 
activity, stimulates T -cytotoxic cells, MHC n expression, B cell growth and the 
synthesis of IgG2a type antibodies. 
7.0 Immunotoxicity 
7.1 Introduction 
In the main drugs are designed to prevent or ameliorate disease; it is, however, a well 
recognised and accepted fact that no drug is completely safe and that some form of 
subjective adverse reaction will be a feature of any pharmaceutical therapy. It is 
therefore the premise of toxicological investigations to enable the development of 
safer compounds, whether they be therapeutic, industrial or agrochemical [150]. 
Toxicologists have only recently come to appreciate that the dynamics of the immune 
system with the ongoing processes of cell proliferation and differentiation [151] 
make it a major target for a xenobiotic [152] and thus of the resulting chemically 
induced toxic damage. The recognition of the immune system as a significant target 
organ of xenobiotic toxic insult and in the realism of the need to examine the 
modifications within the immune system in response to therapy, in conjunction with 
routine toxicity studies and the efforts of scientists such as; Drs Arnos, Bees, Berlin, 
Dean, Gibson, Hubbard, Luster, Mullen, Parke, Smith and Sprecifico, [153] has lead 
to the development a new discipline termed Immunotoxicology [154]. The term 
immunotoxico)ogy was coined in order to distinguish the new immunotoxicologists 
from the pre-existent immunopharamacologists. Imrnunotoxico)ogy is therefore a 
relatively new discipline which marries together the fields of immunology and 
toxicology and draws from other relevant areas of science in order to analyse the 
way in which the immune system functions in health and in disease states and 
attempts to construct a framework for the interpretation of the effects of a broad 
spectrum of xenobiotics on the immune system [117]. In general immunotoxicology 
provides important information, which gives an additional dimension to the safety 
assessment and also, provides major input into the development of our basic 
knowledge of the immune system through the use ofxenobiotic probes [155,156]. 
The favoured definition is that 'immunotoxicology is the study of the interaction of a 
xenobiotic with the immune system' [157], this accommodates the two main areas of 
the discipline, the ability ofaxenobiotic to compromise an immune function or 
'classical immunology' and the provocation by a xenobiotic of specific tissue 
damaging immune responses or allergens. 
7.2 Immunotoxic Drug Reactions 
The interaction of drugs with the immune system may result in various forms of 
toxicity [157] arising from tissue damage via immunological mechanisms. In 
susceptible individuals a variety of xenobiotic agents may stimulate an immunotoxic 
response, resulting in the generation of the undesirable effects associated with 
immunosuppression, autoimmunity or allergy [157). 
7.21 Immunosuppression 
The presence of a parasitic infection or of a specific drug may generate antibodies 
within the host which interfere with different process's across the spectrum of 
immunity, causing disruption of the lymphoid tissues or organs directly in such a way 
as to cause reduction of normal immuno-activity, by increasing the number and 
activity of T suppresser cells or inhibiting the proliferation and / or activity of T helper 
celJs and hence antibody generation. Thus, any invasion of the host by another 
foreign agent will meet limited resistance or may even go unchallenged, so causing 
exaggerated disease states [122]. An example of a disease state due to 
immunosuppression is AIDS, where the mv virus acts to suppress the immune 
system components in such a way that other diseases, which are nonnaJIy effectively 
combated by the immune system, such as the pneumonia's, or some rare illnesses are 
able to infect the patient, in most with a fatal outcome. 
7.22 Autoimmunity 
The immune system contains an extensive repertoire of specific Band T cells that are 
directed against self components. A breakdown or malfunction in the mechanisms 
controlling their activity, and their tolerance of self, may lead to the host producing 
large quantities of antibodies direct against itself, thus resulting in auto;mmunity 
[158]. The earliest example being 'Hashimoto's Thyroiditis' where the thyroid gland 
has become excessively infiltrated with inflammatory lymphoid cells, which produce 
auto-antibodies. These auto-antibodies, mayor may not be organ specific, and act to 
produces a range of disease states (table 7.1), however, overlaps do exist. Common 
target organs affected in organ specific disorders include the thyroid and adrenal 
glands, the stomach and the pancreas. Non-specific organ disorders affect the skin, 
the kidneys, the muscle and the joints. 
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7.23 Allergy 
In 1906 von Piquet [159] proposed the term 'allergie' to denote a deviation of 
immunity from the original state or a 'changed reactivity' of an individual. Allergic 
diseases are a diverse group of pathological conditions characterised by 
immunological mediated adverse or tissue damaging responses [160] following 
exposure of a susceptible individual to a sensitising industrial, environmental or 
pharmaceutical xenobiotics [161] by inhalation, ingestion, injection or skin contact, 
as opposed to a response due to pharmacological idiosyncrasy, direct toxicity 
overdose, interaction between drugs, [162,163] and which induces a specific immune 
reaction [I 54J localised in a particular organ or tissue. 
7.231 Hypenensitivity Reactions 
Hypersensitivity reactions are amongst the most common allergic drug reactions 
occurring in humans [6], the severity of which are of great concern to both the health 
authorities and pharmaceutical companies. 
The term hypersensitivity denotes an immunologic sensitivity to a specific allergen in 
which the expression of the beneficial adaptive immune responses occurs at excessive 
levels or in inappropriate forms, causing irreparable tissue damage, disease or 
pathology to host tissue [119,159]. 
Coombs and Gell classified hypersensitivity reactions into four different classes, on 
the basis of their immunologic pathogenesis, Type I (Immediate), Type 11 (Antibody 
dependent), Type ill (Immune-complex mediated) and Type IV (Delayed). 
In practice, as with most immunologic responses, there is a degree of overlap 
between these reaction types, such that no one reaction type generally occurs in full 
isolation. The two types of chemically induced allergy which pose the most concern 
and are therefore of greatest significance to the toxicologist are immediate and 
delayed hypersensitivity [129], with delayed hypersensitivity being the most 
frequently encountered health problem. Whilst both immediate and delayed 
hypersensitivity result from the sensitisation of a specific immune response by a 
chemical allergen followed by its subsequent provocation by the same or a 
structurally similar allergen, they are mechanistically very different [129]. 
7.2311 Immediate Hypenensitivity Reactions 
Immediate hypersensitivity reactions are humoral reactions in which an 19E antibody 
response is directed against an innocuous allergen, resulting in the release of 
pharmacological mediators such as histamine from 19E sensitised mast cells and 
which manifest themselves within 15 - 20 minutes. Immediate hypersensitivity is a 
haptenic system occurring in three phases [134] (figure 7.1): 
Phase 1: The sensitisation of mast cells by the drug (allergen). 
Mast cells are storage cells for granules containing potent inflammatory, repair 
materials and strong pharmacologically active materials, such as heparin, histamine, 
serotonin and kinin protease [158]. Sensitisation occurs as a result of an allergen 
stimulating B-lymphocytes, under the assistance of Thelper cells and IL4 secretions, 
to synthesise and secrete 19E type immunoglobulins active against the allergen. 
These 19E antibodies upon secretion bind via their Fc region to the mast cells thus 
causing sensitisation. 
Phase 2: (Mast cell activation) A second challenge by the allergen (drug) leads the 
IgE immunoglobulins, adhered to pre sensitised mast cells, acting as cellular 
receptors for the multi-epitope allergen [161]. Upon binding of the allergen it may 
cross-link with another 19E immunoglobulin receptor causing stabilisation and 
subsequent degranulation of mast cells, [163] leading to the release of the cellular 
mediators into the circulatory system. 
Phase 3: (Effector Phase) The release ofpre-formed or newly synthesised mediators 
(such as histamine, heparin, eosinophil-chemotatic factor, leukotrienes, platelet 
activating factor, arachidonic acid metabolites, high molecular weight neutrophil-
chemotatic factor, kinin generating protease's, prostaglandin's and thromboxane's), 
causes vasodilation, increases endothelial cel1 permeability, leading to inflammation 
and redness and also causes constriction of bronchiole smooth muscle cells, 
promoting the shortness of breath, all of which are associated with the clinical 
symptoms of an allergic response. 
Figure 7.1 Diagrammatic Representation of the Cellular Events in an Immediate 
Hypersensitivity Reaction 
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7.2312 Delayed Hypersensitivity Reactions 
Delayed or Contact hypersensitivity reactions, are cell-mediated immune responses, 
in which epidermal sensitisation results in dermatitis. The process occurs in two 
stages (figure 7.2): 
Primary or Induction Phase in which a small sensitising antigenic agent, such as 
simple chemicals, metal elements, rubber, poison ivy, passes through the skin tissue 
where it interacts and is processed by the proteins of the epidermal Langerhan cells. 
The Langerhan cells are the dendritic cells of the epidermis and as such play a vital 
role in cutaneous immune responses [164]. The Langerhan cell-allergen complex 
migrates from the skin through the draining afferent lymphatic's to the regional 
lymph nodes, undergoing both phenotypic and functional changes during migration, 
which renders it highly immunogenic and transfers it into a potent antigen-presenting 
cell [164]. In the regional lymph nodes an immune response is initiated which results 
in an increase in the population of allergen sensitised T lymphocytes and which with 
the assistance of sensitised T helper cells, release a range of mediators causing the 
initiation of a mild immune response in the lymphoid organs but not in the tissues. 
The Elicitation or Challenge Phase. A subsequent exposure to the same, a closely 
related or structurally similar allergen causes the provocation of an accelerated and 
more aggressive immune response at the site(s) of exposure [161]. During this 
secondary exposure a variety of cell types are capable of presenting the allergen to 
the circulating primed or reactive memory T -lymphocytes and hence initiate a local 
immune response [134] in the skin tissue with the classical symptoms of redness, 
oedema, irritation and in severe case's tissue damage about the site of exposure may 
result. 
Figure 7.2 Diagrammatic Representation of the Cellular Events of Delayed Hypersensitivity 
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7.24 Cross-Reactivity 
The recognition of an allergen by an antibody raised in vivo to a different, yet similar 
chemical antigen, may lead to the phenomenon of cross-reactivity, in which the new 
antigen is recognised by the immune components as the sensitising allergen and the 
nonnal process's of Immediate or Delayed immune activation, as previously explained, 
are initiated leading to the development of unexpected immunotoxic reactions. Cross-
reactivity between new therapeutic compounds and antibodies is a major factor 
governing a pre-sensitised patient's susceptibility to develop a serious clinical subjective 
adverse reaction in response to a supposedly safe alternative therapy [165]. 
7.3 Immunotoxicoiogical Assessment 
There is a need to identifY those chemicals possessing the potential to sensitise the 
immune system or to initiate an immunotoxic reaction in pre-sensitised patients and 
which pose a hazard [166]. The prospective identification of potentially sensitising 
chemicals is still in its infancy. Over the last decade well characterised, but not 
necessarily well validated irnrnunotoxicological assessment methods have been reported 
[7], such as the guinea pig maximisation test, the Buehler occluded patch test, 
determination of immunoglobulin and serum protein titres (i.e. albumin, IgG, 19E), 
murine local lymph node assay, haematology profile (i.e. red and white blood cell 
counts), enzyme analysis (i.e. creatinine, alkaline phosphoatase, CPK, SGPT), 
histological analysis (i.e. body and organ weights, organ and tissue analysis) and T-
Iymphocyte marker analysis (CD4, CD8), plaque and Mishell-Dutton assays for antibody 
response, graft-versus-host rejection, flow cytometry specific ceJ] type counting, 
complement analysis (levels and activity), molecular analysis of gene expression (DNA, 
mRNA) and polypeptide identification [3,156,167,168,169,170]. 
As no single test can completely asses the immune function and imrnunotoxicity of a 
xenobiotic[168}, therefore Vos [123], Luster et aI [4], DeWeck [2] and Hadden [153] 
have each proposed a tiered approach for immunotoxicity assessment, as outlined in 
figure 7.3. The first tier includes the assessment of non-functional parameters, such as 
the quantitation of immune cells, cell viability, serum immunoglobulins, organ weights, 
histopathological assessment, CeU-mediated immune response assay and plaque forming 
assay. Subsequent tiers include functional tests, immune competence and host resistance 
studies, all of which are chosen on the basis of the results obtained in the first tier of 
testing (3,7,15 I]. 
95 
Figure 7.3 Outline ofa Tiered Panel ofImrnunotoxico)ogical Tests [171] 
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In this study the aim is to evaluate both immunoglobulin levels (1 0.0) and cytokine 
secretion profiles (I I .0) following antibiotic simulation, and therefore the assays of 
interest and which are discussed in detail herein are the enzyme linked immuno-sorbent 
assays (7.31) and the murine local lymph node assay (7.32). 
7.31 Immunoassays 
Antibodies have long been used as diagnostic reagents, but it is only in the last 30 years 
that their use in the assessment of the immunological system has been fully realised and 
acted upon. 
The basis of any immunoassay is the formation of an antibody-antigen complex, 
followed by estimation of the bound verses free components by use of labelled reaction 
components [172]. Immunoassays were first introduced in 1960 with an assay for 
thyroxin, which was based on the strategy of saturation analysis, in which limited 
amounts of antibody are reacted with excess of labelled antigen. Mile & Hales 
introduced the use of labelled antibodies in the immunometric type assay. Here excess 
antibody is added to standard concentrations of antigen. The bound and free 
components are then separated the bound antibody estimated. No matter how low the 
concentration of antigen if sufficient antibody is used, some level of complex fonnation 
will result over a given time and thus be detected [173]. 
Recent advances in antibody technology have led to the production of highly specific, 
multi-epitope monoclonal antibodies in very pure forms, which have enabled the use of 
two reagent systems in immunoassays, thus increasing assay specificity and sensitivity 
whilst reducing interference. This coupled with the fact that at almost every step of the 
general assay procedure it is possible to select from a wide range of reagents and 
techniques, have given an enonnous methodological flexibility to immunoassays and 
have enabled the development of a range of procedures enabling the assessment of 
extensive immunological components [174, I 75, 176]. 
7.311 Enzyme Immuno Assays 
Enzyme Immuno Assays (EIAs) were developed in the 1960's to enable identification 
and localisation of antigens in histological preparations [174]. Observations that it was 
possible to immobilise either the antibody or the antigen onto a solid phase led to the' 
modification of the strategy to enable the quantitative determinations of immuno 
reactants in test-tubes, using enzyme rather than radio labelled reactants. EIAs are based 
on two important biological phenomena [174,175, 177, 178]~ the extraordinary 
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discriminatory power of antibody for a specific antigen and the high catalytic power and 
specificity of enzymes. EIAs lend themselves to a wide range of analytical applications, 
including the quantitation of immunoglobulins and drugs [175,178]. 
EIAs can be classified into two main types: 
Heterogeneous assays that involve an enzyme label as a means of detection and in which 
it is necessary to separate bound and free antigen using solid phase systems [I 79]. 
Homogenous assays that do not require the separation of the two antigenic phases 
because the process of binding the antigen to the antibody on the solid phase acts to 
modify the activity of the enzyme label in such a way as to enable the detection of the 
bound antigen in the presence of the unbound antigen. 
7.3111 Enzyme Linked ImmunoSorbent Assay (ELISA) 
ELISAs are Heterogeneous EIAs, which are adaptable and diverse group immunoassays 
in current usage. The first ELISA techniques were described in the early 1970s by two 
groups of workers - Engvall & Perlmann [176] and Schuurs & Vann Weemann [175]. 
The assays were developed to ease the process by which bound antigen is separated 
from free antigen and also to introduce labels for detection other than the radio-labels. 
The basic principles of an ELISA are the reaction of the immunoreactants and the 
subsequent detection of the reaction using a suitable enzyme label. 
ELISAs have numerous advantages they have increased sensitivity, detectability and 
specificity, generate highly reproducible results, give objective evaluation, are highly 
versatile (variety of enzymes available for the detection of various antibodies), use 
monoclonal antibodies to their full advantage, use small concentrations of sample and 
reagents, have increased reagent shelf life, have lower operating costs (reagents, 
equipment), have no need of specialist training, reagents, storage and disposal 
procedures or equipment and have reduced health risk. 
There are two basic types of ELlS A, Competitive & Non-Competitive assays. 
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7.31111 Competitive ELISAs 
The general method for a Competitive ELISA (figure 10.7) involves the binding of the 
antibody to the walls of a plastic well and the subsequent addition of the test and 
labelled antigens, which compete with each other to bind with available bound antibody. 
After a suitable reaction time the reaction well is washed to remove any unbound 
reagents. The amount of enzyme-antigen-antibody complex bound is measured by 
monitoring an enzymic reaction. following the addition of a suitable substrate, under 
controlled conditions. In this method a second assay is run concurrently, in which no 
test sample in added, only the labelled antigen. By comparing the amount of labelled 
antigen detected in each assay type it is possible to determine the amount of test antigen 
bound and so evaluate the concentration of test antigen in a given sample. 
7.31112 Non-Competitive ELISA 
The double sandwich assay is the most useful and most commonly used assay of this 
type. The procedure is (figure 7.4) the binding of antibody to the walls of a plastic well, 
washing to remove excess antibody, addition of antigen that binds to the bound 
antibody, washing to remove excess antigen, addition of a second antibody conjugated 
to an enzyme label, is added which bind to the antigen, washing, addition of a suitable 
enzyme substrate determination of the concentration of product formed. 
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Figure 7.4 Diagrammatic Rmresentation ora Non-Competitive ELISA 
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7.32 Animal Models 
The sensitising potential of chemicals is currently assessed using a variety of animal 
models, such as the Guinea Pig maximisation test [180], the Buehler Occluded Patch 
test [181], Mouse Ear swelling test and the Mouse Local Lymph Node assay [182], all 
of which employ a biphasic protocol of an Induction phase, in which the respective 
animal is sensitised and an Elicitation phase, where the animal is challenged with a test 
chemical [183]. For the guinea pig tests the sensitising potential is detennined by 
evaluation of the frequency of challenged induced erythematous skin reactions by visual 
assessment. For the Mouse Ear Swelling test (M:EST) sensitising potential is determined 
from changes in ear thickness following chalIenge. For the Mouse Local Jymph Node 
Assay sensitising potential is evaluated by quantitation of radioactive material or of 
specific cytokines following culturing of the draining lymph node Iymphocytes. 
Until recently the species of choice for the routine predictive toxicological assessment 
has been the guinea pig [160], however, the guinea pig does not have a well 
characterised IgE antibody [183] and so provides no provision for the determination of 
immediate hypersensitivity. The mouse, by virtue of its extensive use in experimental 
studies for the advancement of our knowledge of the cel1ular and molecular process 
involved in an immune response [160], has a well-characterised 19E immune response, 
which also, has the advantage of being induced and regulated in a manner similar to that 
seen in man [184], thus the mouse as an animal model lends itself to use for 
detennination of sensitising potential and of Immediate hypersensitivity. Therefore 
recent attention has focused on the mouse as an alternative model, for routine 
determination of immunotoxicity, with the mouse Local Lymph Node assay (mLLNA) 
being at the forefront of current development. 
7.321 Lympb Node Assay 
The murine local lymph node assay (rnLLNA) was first developed at the ICI Central 
Toxicology Laboratory and is based on the understanding that a chemical causes both 
skin sensitisation and lymphocyte proliferation, in the lymph nodes draining the site of 
exposure, during the Induction phase of hypersensitivity reactions [185]. The mLLNA 
can be used with the incorporation of radio-labelled thymidine to assess the proliferative 
responses in the lymph nodes or can be used to asses the differential cytokine secretion 
patterns exhibited by the Tbelper lymphocytes following chemical challenge. 
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An outline mLLNA is: 25J.d of test chemical, in a suitable vehicle, is applied to the 
dorsum of each ear of each mouse in the test group.(a control group are treated with 
vehicle only) on three consecutive days. Single sex mice of either the strain BALB/c or 
CBAfea, at between 6-10 weeks of age are used. Five days after the first topical 
exposure the mice are sacrificed and the draining (auricular) lymph nodes are excised 
and pooled. (If assessment of sensitivity is by radio-active determination of lymphocyte 
proliferation then radio-active thymidine is injected into the mouse at day 5 prior to 
sacrifice). Single cell suspensions of the lymph nodes, from each test group, are 
prepared. The pooled Lymph Node Cells (LNCs) are pel1eted by centrifugation, washed, 
re suspended and cultured in a suitable culture medium, with the test material. After a 
suitable incubation time has elapsed the relevant end-point is quantitated and sensitising 
potential determined [148,182,185]. The mLLNA, therefore provides an alternative 
predictive test for the identification and possible quantitation of the sensitising potential 
of topically administered chemical agents. 
Evaluation and validation of the mLLNA by the pharmaceutical industry is still on 
going. It is hoped, by the developers, that the assay, may in time prove to be relatively 
rapid, robust, cost effective and reliable, and wilJ be adopted as a routine assay within all 
immunotoxicology laboratories and by the respective authorities. 
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8.0 Proposed Aim of the Study 
The current general schemes of immunotoxicological testing, performed within the 
phannaceutical industries, are complex. time and resource consuming. 
Ultimately, it is hoped to develop QSARs that reliably model J3-lactam immunotoxicity 
and which may be used to predict the immunotoxic potential and the direction of 
triggering of the immune system by 'new' antibiotics of the tJ-lactam class. Use of these 
QSARs in the early stages of drug development and immunotoxicity studies wiJI 
provide a means of better safety assessment, as well as highlighting those compounds 
that will have a high immunotoxic or cross-reactive potential. Thus indicating the need 
to test these suspect compounds more extensively or to eliminate them completely from 
further development, so saving time and resources without a reduction in drug safety. 
It was the aim of this study is to use QSAR and immunological techniques to develop a 
means for the mechanistic assessment oftJ-lactam antibiotic imrnunotoxicity. 
The works concentrated on the penicillins and cephalosporins, as a range of 
compounds and vast amounts of data regarding structures and extensive clinical trials 
were available. 
The starting point of the study was to use the dedicated techniques ofQSAR to identify 
any structures within the JJ-Iactams which may be responsible for activation of the 
immune system, and thus the development of an allergic reaction and to develop 
statistically valid QSARs that will enable the prediction of a new fJ-lactam antibiotics' 
potential a1lergenicity to be made. 
The second aim of the study was to develop an ELISA technique which would provide 
a means of generating quantitative data with regards a compound's potential to cross-
react with anti-benzylpenicillin serum antibodies in pre-sensitised animal models, and 
again use the techniques of QSAR to determine the molecular properties of importance 
and to produce statistically significant models which will enable valid predictions of 
potential cross-reactivity for new compounds to be made. 
Finally, using the knowledge of the differential patterns of cytokine secretion released 
in response to the differential stimulation of the immune system, it was hoped to 
develop an in vitro protocol for the quantitative analysis of cytokine production, 
particularly interleukin-2 and interleukin-4 following specific antibiotic simulation. This 
cytokine analysis may thus provide an indication as to the direction of triggering of the 
immune system induced by specific tJ-lactam antibiotics, as well as a further insight into 
the phenomenon of cross-reactivity. 
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9.0 Prediction of the Freguency of~-Lactam Induced Adverse Reactions 
9. 1 Introduction 
Since their first clinical use penicillin and cephalosporin antibiotics have become 
amongst the most commonly prescribed drugs in the world [186,187]. However, 
despite their vast antibacterial spectrum of activity and wide therapeutic index the t3-
lactam antibiotics are also responsible for initiating a vast array of adverse responses, 
some of which may be allergic reactions [188]. Initially these adverse reactions were 
attributed to impurities in the crude preparations. However, subsequent studies have 
shown that samples free of any contamination still elicit adverse responses and so 
suggest that it is the compounds themselves which are responsible for eliciting the 
problem reactions [187]. 
An adverse response (AR) is defined as 'any response to medication which is noxious 
and unintended and that occurs at doses used in therapy' [189] and can be classified 
into two types~ Type A (augmented) reactions, which are pharmacologically 
predictable from the known activity of the drug and Type B (bizarre) reactions, 
which are unpredictable, rare, not dose related and may be clinically serious [190]. 
An allergic reaction can be defined as 'the adverse, tissue-damaging and sometimes 
fatal consequences of the stimulation of specific immune responses to an exogenous 
antigen' [7]. In toxicology it is allergic reactions resulting from immune responses to 
chemicals and drugs which are of the greatest relevance. The allergy may take a 
variety of forms, including immediate and delayed hypersensitivity reactions, as well 
as various types of comparatively ill-defined reactions which may resemble other 
reaction types. 
Padlan [191] hypothesised that a compound's intrinsic immunogenicity, i.e. its ability 
to initiate an immunological response, arises from an overall structural property 
exclusive to that compound. As penicillin and cephalosporin antibiotics are structural 
analogues it should be possible to relate their immunotoxic potential to a common 
structural feature(s). It is therefore the aim ofthis work to explore such possibilities 
using quantitative structure-activity relationship (QSAR) studies. 
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9.2 Generation of a Data-Base Pertaining to the Frequencies of (3-Lactam Antibiotic 
Induced Adverse Reactions 
9.21 Method 
In order to determine the frequency of allergic reactions initiated in man, in response 
to the therapeutic use of a specific Jl-Iactam antibiotic, it was decided to review all 
relevant published clinical trial literature. The review was perfonned using 'Medline" 
cited references, relevant phannaceutical publications such as 'Merck Index' [192], 
Martindale's Pharmacopoeia [193], Therapeutic Drugs [194], the US Pharmacopoeia 
[195], the Encyclopaedia of Antibiotics [196J, and Antibiotic and Chemotherapy 
[197], as well as via communication with the manufacturing companies and 
specialists in the field. 
A review of the literature showed there to be no uniformity in the protocols adopted 
for the recording of adverse reaction frequencies. It was decided therefore, in order 
to attain a complete picture of the scope and frequencies of adverse reactions 
exhibited in response to specific Jl-Iactam therapy, that the data reviewed should 
encompass world-wide clinical trials of all types (comparative, retrospective, double-
blind, etc.), using both healthy and clinically ill (suffering a range of disease states), 
volunteer and hospitalised subjects of both sexes, ranging in age from new-born to 
elderly, with a study duration of between 4 and 50 days. 
It is very difficult in some cases to differentiate between drug allergies and 
idiosyncratic reactions, and thus a level of confusion between what is an adverse 
response or an allergic reaction has arisen, with the term 'allergic reaction' often 
being applied in an uncritical fashion to all adverse reaction resulting from drug 
therapy, whether it be a recognised side-effect, a toxic effect or an immunologicaJIy 
mediated response [26]. It is for this reason, therefore, that in this study it was 
decided to detennine the frequency of all adverse responses initiated by specific 13-
lactam antibiotics as well as the frequency of observed 'true' allergic reactions. In the 
context of 'true' allergic reactions to the Jl-Iactam antibiotics it is those reactions 
which are immunologically mediated which are of the most significance. Jl-Iactam 
allergies may be classified on the basis of the immune mechanism involved~ 
neutralisation, cytotoxic, immune complex, granulomatus, immediate or delayed type 
hypersensitivity [32]. 
Anaphylaxis is the most serious allergic reaction of the Jl-Iactam antibiotics to the 
individual, as it may have fatal consequences. But it occurs rarely and is not usually 
reported in clinical trial data; the frequency of anaphylaxis was therefore omitted 
from this study. 
I~ 
The majority of allergic reactions commonly manifest themselves clinically as 
cutaneous lesions, with urticaria being indicative of 19E-mediated immediate 
hypersensitivity reactions and maculopapular or morbilliform rashes as well as 
pruritis and erythematous exanthemas being indicative of non-lgE mediated 
responses. It is appreciated that detennination of the frequency of urticaria and 
therefore IgE mediated reactions would be very beneficial, as these reactions play a 
significant part in patient morbidity and mortality [198]. This was not possible for 
every compound investigated, as in the majority of clinical trials it is the presence of 
'rash' that is recorded and not the specific types of cutaneous lesion [199]. The 
frequency of all cutaneous rashes was determined and assumed to be indicative of 
the frequency, of all allergic (immunologically mediated) reactions. 
Although drug-induced disruption of the lower gastro-intestinal tract is not 
immunologically mediated and is not therefore an allergic reaction, it is a significant 
side-effect exhibited in response to ~-lactam therapy, and as the literature reviewed 
specifically reported its frequency, it was decided to include it in the data 
compilation and subsequent modelling. 
All the above detailed adverse responses investigated are of the sub-type A. No 
responses of sub-type B were investigated, as their occurrence is rare and mayor 
may not be as a result of the specific antibiotic. 
The data gleaned from the literature reviewed for each of the peniciUins and 
cephalosporins were mathematically manipulated in accordance with equation 9. 1, in 
order to generate values of percentage frequency of adverse / allergic reaction which 
were comparable. This was not possible in all cases as the number of patients 
involved in the trial and / or the number of patients eliciting a specific response were 
not always given in all the literature. In cases where only one reference is cited 
percentage frequencies quoted therein were used. In those cases where more than 
one reference is cited but not all the references provided the required patient 
numbers, average frequency values for each specific response were calculated only 
from those studies giving patient numbers. 
% frequency = I Number of patients in trials eliciting reaction x 100 (9.1) 
I Total number of patients in trials 
9.22 Results & Discussion 
Initially the literature was reviewed in order to glean information for as many 
penicillins and cephaJosporins as possible, complete data sets were obtained for 70 
~-Iactam antibiotics (28 penicillins and 42 cephalosporins), spanning numerous years 
and areas of development. It was felt that this was a suitably sized data base for the 
project and particularly for QSAR analysis. Appendix 1 lists the structures of the 70 
JJ-Iactams reviewed. Some compounds (penicillins N, BT, 0, S, amyl penicillin, 
clometocillin, diphenicillin, fenbenicllin and hydroxybenicillin) were eliminated from 
the study on the grounds that they were found to be severely toxic or of an 
insufficient antibacterial potency during development and so were not tested in the 
clinical situation. For other compounds (hetacillin, BLP-1645, phenethicillin, 
sulbenicillin, cefazaflur, cephanone, ceftioflur, ceftezole and cefepimizole) complete 
clinical data sets were unavailable, but infonnation on these compound structures 
were collected so that they could be used as 'test' compounds for the developed 
QSARs. 
In total, data from over 600 clinical trials, pertaining to the therapeutic use, efficacy 
and safety of 70 specific fJ-Iactam antibiotics were combined to produce a data base 
of reaction frequencies which it was felt, reflected a comprehensive therapeutic 
picture. 
The recalculated percentage frequency values of all ARs, cutaneous rash and GI 
disruption for each of the 28 penicillins and 42 cephalosporins investigated are given 
in tables 9.1 and 9.2 and presented graphically in figures 9.1 and 9.2 respectively. 
The data are presented more specifically with regard to the type of antibiotic 
(penicillin or cephalosporin) and mode of administration (oral or parenteral) in 
figures 9.3, 9.4,9.5 and 9.6. 
Examination of the data shows the extent of AR and 01 frequencies to be quite 
similar for both the penicillins (2.6<J01o to 37.00 % AR and 0.42% to 13.33% Gl) and 
the cephalosporiDs (1.10% to 34.18% AR and 0.00% to 16.46% GI). 
However, for cutaneous rash, and therefore allergic reactions, the frequencies 
observed for the penicillins (0.00% to 10.88%) are considerably lower than those 
observed for the cephaJosporins (0.00% to 22.00%), showing a trend equivalent to 
that proposed by Norrby [200]. 
These relationships are maintained when the compounds are sub-classified on the 
basis of their mode of administration, with values for oral penicillins and 
cephaJosporins ranging respectively, from 2.69% to 23.21 % and 1.88% to 34.18% 
for AR, from 0.00% to 8.77% and 0.00% to 18.81% for cutaneous rash and from 
0.53% to 12.59% and 0.23% to 16.46% for GI disruption, and levels for parenteraJ 
penicillins and cephalosporins ranging respectively, from 3.45% to 37.00 % and 
I.lOO/o to 29.84% for AA, from 1.10010 to 10.88% and 0.00010 to 22.00% for 
cutaneous rash and from 0.42% to 13.33% and 0.00% to 8.30% for GI disruption. 
It can also be seen from these respective values that it appears that the parenteral 
antibiotics are slightly more allergenic than are the orals, this relationship being in 
agreement with the world survey of Sullivan et al [201], who proposed that the 
differing safety levels are due in part to the lower doses given orally and to different 
absorption levels. 
At first glance it is somewhat surprising that the parenteral antibiotics cause any GI 
disruption, let alone at such high levels as given here, as the nature of their 
administration (intravenously or intr~uscuIarly) prevents absorption in the GI tract 
which is necessary if a direct effect is to be had on the gut flora, so causing GI 
disruption. However, parenteral administration is systemic and thus exposes the 
whole of the gut secretory cells to the antibiotic via its blood supply; thence high 
levels of the antibiotic may pass into the gut along its entire length, hence affecting 
the flora. Also, parenteral antibiotics undergo biliary excretion [200J, which has 
more profound effects on both the aerobic and anaerobic faecal flora than do renally 
cleared antibiotics, so inducing significant levels of GI-disruption. In some instances 
biliary excreted antibiotics may cause an increased secretion of biliary salts into the 
Gl tract, where their increased concentration, rather than the antibiotic [202] affects 
the flora. 
The age, sex, state of health, and state of renal capabilities of each individual coupled 
with the presence of any additional medications will also have a bearing on the level 
ofGI-disruption incurred as a result of antibiotic therapy. 
Comparison of the data obtained for each individual JJ-Iactam showed there to be a 
wide variation in the frequencies of adverse responses reported in different studies by 
different investigators in different laboratories worldwide. This occurrence is 
disturbing and indicates a lack of uniformity in the methods used for the evaluation 
of adverse. effects. It is likewise suprising that reported frequencies vary quite 
significantly from country to country [186,200]. Many factors, such as diet and 
genetic varaition, may account for this latter variation. It is also important to 
recognise that each of the respective JJ-Iactam antibiotics was administered 
therapeutically over a range of different dosages. These facts suggest that the. data 
generated in this study, being obtained by reconciling the results of numerous trials 
perfonned in a variety of centres, undoubtedly contain substantial errors. These 
errors may impair the derivation of significant QSARs and mean that any model 
derived will not be definitive and thus will provide only an indication as to the 
molecular properties and biological mechanisms which lie be~nd the induction of an 
adverse response. 
Table 9.1 Frequencies of Adverse Remonses Due to 28 Penicillin Antibiotics 
Penicillin Percentage Incldence of Adverse References 
Generic Name Effect & Number of Persons in 
Combined Trials (nl 
AR* Rash * GI* 
AmdinociJJin 6.53 (337) 4.01 (299) 0.89 (33?} 203,204 
AmdinociUin pivoxil 6.00~O) l.00_<NG) 3.33 (NG1 205 
Amoxycillin 15.70(5235) 2.92 (5235) 2.55(4121) 206-212 
_~icillin 16.91_{l5341 4. 72J}902) 12.59 (344~ 206-208,210,212-226 
APalcillin 9.96 (241) 5.83 (241) 0.4~2411 227-242 
AzidocilJin 23.21 (NO) 3.75 (NO) 5.63 (NO) 243 
Azlocillin 17.51 (1262) 2.9311262} 1.74 (1262) 244-247 
Bacampicillin 8.93 (918) 2.71 (1476) 1.56(14761 208,210,212,248,249 
1:1--.1. licillin 6.70 (1553) 2.10 (1553) 2.50 (1201) 2S0,25 I 
Carbenicillin 18.57 (168) 6.561183) 0.78 (l2~ 224,244,25] -257 
Cardinacillin 13.00 (NG) 0.80j!iOl 5.00(NGl 258-259 
Carfecillin 5.05 (NO) 2.560 (NO) 0.53 (NO) 260,261 
CicJacillin 10.03 (1286) 1.74J27631 4.65J371~ 211,213,225,226,262-265 
Cloxacillin 37.00 (79) 1.50(NG) 2.50 (NG} 207,265-268 
DicJoxacillin 6.92 (NG) 0.80jNGl 3.70jNG1 269,270 
EpiciIlin 7.44 (215) 0.93 (215) 6.05 (215) 271-273 
Flucloxacillin 36.67 (30) 3.33 J30} 13.33130) 267,274 
LenampiciIlin 3.89 (1261) 0.7911261} 1.27 (l26U 275-298 
Methicillin 16.38 (254) 10.88 (193) 12.20 (4Ql 248,251,267,299-301 
MezJocillin 7.88 (1369) 2.73f1369) 1.98113691 245-247,251,252,302-304 
Nafcillin 12.28-<57) 8.771571 6.11 (229) 248,299-301,305,306 
Oxacillin 20.20 (129) 2.50 (80) 2.00 (50) 25 ],2661300,307,308 
Phenoxymethylpenicillin 2.69 (1749) 2.10 (1749) 2.53 (17491 309-312 
Piperacillin 5.77 (2528) 1.27 (2043) 2.49 (2528) 207,244,247,253,254,309, 
313-317 
Pivampicillin 11.22 (508) 3.21 (2929) 1.74 (29291 206,208,210,212,249,318-321 
Talampicillin 20.69 (55) 2.18 (1282) 1.49 (1282) 208.210,212,214,216,217,322, 
323 
Temocillin 3.45 (232) 2.50 (40) 0.52(192) 324-327 
Ticarcillin 13.50 (NO) I.lOJ~(jJ 1.70 (NO) 248251,328 
* KEY: See end of Table 9.2 
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Figure 9.1 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 28 Penicillin Antibiotics 
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Table 9.2 Freguencies of Adverse Re5J>onses Due to 42 Cq>haloSj>orins 
Cephalosporin Percentage Incidence of Adverse References 
Generic Name Effect & Number of Persons in 
Combined TrialsJuJ 
AR* Rash· GI* 
Cefacetrile 13.33 (266) 0.00 (2661 1.67(266) 329,330 
Cefaclor 3.08 (2469) 1.17 (2986) 2.72 (5554} 207,24~,331-337 
CefadroxiJ 7.36(2812) 0.48(14611 0.48 (1461) 24~338-340 
Cefaloglycin(e} 34.18 (79) 5.06 (79) 16.46 (7~ 341,342 
Cefamandole 8.52 (1713) 1.70 (1278) 0.80 (1278) 249,313i34~344 
Cefatrizine 18.81 (101) 5.9411011 4.95110IJ 345 
Cefazolin 5.87 (1397) 1.57 (1397) 0.36JJ39D. 346-350 
Cefepirome 15.00 (60) 5.00 (60) 3.33 (60) 351 
Cefixime 2.42 (1984) 0.15 _(1984) 0.45fl9841 352,353 
Cefinenoxime 3.1112641) 0.84f40151 0.76126411 354 
Cefinetzole 1.10 (1207) 0.58J70()l 0.27 (70Q) 355,356 
Cefininox 2.11 (2089) 1.15 (20891 0.48J208~1 357 
Cefodizime 3.60 (1531) 0.92 (1279) 1.40 (1279) 358-394 
Cefonicid 12.99 (2094) 1.96 (2094) 2.10J2094) 250,395-397 
Cefoperazone 15.39 (5593) 2.54 (134) 3.21 (235) 206,269,344,398-405 
Ceforanide 2.02 (1534) 1.65 (1534) 1.00 _(1534) 406 
Cefotetan 4.76 (4954) 1.29 (4954) 2.68 f4954} 407,408 
Cefotaxime 4.64 (13585) 1.82 (13585) 1.11 (13585) 331,332,344,346,347,403, 
409-423 
Cefotiam 4.03 (37) 0.00 (257) 0.391257) 207,424-428 
Cefoxitin 6.19 (6399) 2.45 (1276) 0.93 (4508) 206,248,250,317,331,340,344, 
349,429-430 
Cefpiramide 3.86 (856) 1.29(8561 1.05 (856) 431-437 
CefPodoxime 9.86 (2727) 0.51 (2343) 4.28 (2594) 334,438-455 
Cefprozil 1.88 (319) 0.90_{3191 1.45 (298) 337,456457 
Cefroxadine 7.70(NG) 1.30(NG) 2.20~Gl 458 
CefsuJodin 22.00 (NG) 5.'s0 (Ill) 8.30 (Ill) 459 
Ceftazidime 7.77 (13465) 2.60 (10384) 1.86 (5223) 331,399,460-468 
Cefteram 3.20 (438) 0.00 (220) 3.611271) 469-474 
Continued over page 
III 
Table 9.2 Continued 
Cepbalosporin PerteDtage Incidence of Biological Effect & References 
Generic Name the Number of Persons in Combined Trials 
(n) 
AR Rash GI 
Ceftibuten 8.40(119) 0.00-<92) 5.40 (92) 241 332,333,475 
Ceftizoxime 10.87 (2943) 0.92 (2943) 0.78 (2943} 331,343,344,399 
Ceftriaxooe 5.41 (28260) 1.24(29334) 2.54 (24354) 331,450,476-479 
Cefuroxime 3.70(19081 0.83 (1939) 0.72 {19391 207,248J 309,480,481 
Cefuroxime-axetil 8.96 (1283) 1.16 (1283 3.58 (1283) 309,482-487 
Cefuzonam 7.82(2316) 3.26 (928) 0.23 _(928) 358,425,485-502 
Cephalexin 15.00 (NO) 1.00 (NO) 0.33 (NG) 309,503 
Cephaloridine 19.00 (NO) 1.00 (NG) O.OO(NG) 504,505 
Cephalothin 10.00 (290) 2.00 (501) 0.70 (290} 266,307 348,398,504,506,507 
Cephamycin 7.50 (NG) 0.00 (NO) 2.50 (NG) 258,331,508 
Cephapirin 29.84 (124) 0.00 (124) 0.80 (124) 509 
C~hradine 7.36 (516) 4.19 (430) 2.45 (490) 274,510,511 
Flomoxef 3.12(1058) 1.61 (1058) 0.76 (1058) 512-540 
Latamoxef 10.59 (10674) 2.40 (18308) 2.36 (14810) 250,331,344,399,405 
T-2588 3.56 (1152) 0.35 (1152) 1.22 (1152) 541-572 
* KEY: 
all adverse reactions associated with drug therapy AR = 
Rash = 
GI = 
skin rash, pruritus, eruption or urticaria associated with drug therapy 
GI disruption, primarily diahorrea associated with drug therapy 
NG = no data pertaining to patient numbers. 
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Figure 9.2 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 42 Cephalosporin Antibiotics 
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Figure 9.3 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 15 Oral Penicillin Antibiotics 
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Figure 9.4 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 13 Parenteral Penicillin Antibiotics 
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Figure 9 .5 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 17 Oral Cephalosporin Antibiotics 
Cefuroxime-Axetil 
Cefroxadine 
Cefprozil 
Cefpodoxime 
CefPiramide 
Cefmenoxime 
Cefixime 
Cefatrizine 
Cefaloglycin 
Cefadroxil I •••• : 
Cefacior 
o 5 10 15 20 25 
30 
Percentage Incidence 
35 
• All Adverse Drug Reactions • Cutaneous Rash • GI Disruption 
l~ 
Figure 9.6 Relative Frequencies of Adverse Reactions Exhibited by the General 
Population in Response to Therapy with 25 Parenteral Cephalosporin Antibiotics 
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9.3 Development ofQSAR Models of~-Lactam Allergenicity 
9.31 Method 
9.3 11 Biological Activity Data Generation 
The data pertaining to the percentage frequency of all subjective adverse reactions, 
cutaneous rash and GI disruption (section 9.2) were utilised as the biological data 
for QSAR development. The data were subdivided on the basis of type and mode of 
administration giving nine data sets, table 9.3, for analysis. 
Percentage data are not normally distributed and so are virtually impossible to 
model statistically, therefore, the biological data within each data set were 
mathematically transformed (by taking logarithms, square root, square and inverse) 
in order to ensure that the data were nonnally distributed and thus suitable for 
statistical manipulation. Nonnal distribution was detennined by analysis of the value 
of skewness (Sk) as generated by univariate statistical analysis of the transfonned 
bio-data, perfonned using the relevant sub-routine within the TSAR programme 
(version 2.2) [546], operated on a Silicon Graphics Personal Iris workstation. 
Values ofSk > -1 and <1 were taken to be indicative ofa nonnal distribution. 
9.312 Calculation of De script or Variables 
Prior to initiating an immunologically mediated adverse response, the compounds 
bind with a tissue macromolecule and the fJ-Iactam ring is opened (as discussed in 
7.231), consequently altering the properties of the molecule. Currently the full and 
exact molecular structure of these protein bound compounds, and suitable 
computing facilities to model the complete protein bound antibiotic and generate 
suitable physico-chemical parameters are not available, so it was decided to 
detennine the physico-chemical parameters for each of the native 13-lactam 
antibiotics using their known molecular structures. 
An inherent problem with QSAR studies is that it is usually not possible for the 
investigator to know in advance which physico-chemical parameters will best model 
the biological effect under investigation. One method of overcoming this problem is 
to generate a large number of parameters which describe a range of properties, and 
then to employ a suitable statistical technique which will select those parameters 
that best correlate with the biological activity. 
"t 
Table 9.3 Data Sets for OSAR Analysis 
I1 Data Set # Compounds Biological Data j # Compounds in Data Set 
1 All ~-Lactams All ARs 70 
Cutaneous Rash 70 
GI Disruption 70 
2 All Oral J3-Lactams All ARs 32 
Cutaneous Rash 32 
GI DisrupJion 32 
3 All Parenteral Jl-Lactams All ARs 38 
Cutaneous Rash 38 
Gf Disruption 38 
4 All Penicillins All ARs 28 
Cutaneous Rash 28 
GI Disruption 28 
5 Oral Penicillins All ARs 15 
Cutaneous Rash 15 
GI DisruPtion 15 
6 Parenteral Penicillins All ARs 13 
Cutaneous Rash 13 
GI Disruption 13 
7 All Cephalosporins All ARs 42 
Cutaneous Rash 42 
GI Disruption 42 
8 Oral Cephalosporins AJI ARs 17 
Cutaneous Rash 17 
GI Disruption 17 
9 Parenteral Cephalosporins All ARs 25 
Cutaneous Rash 25 
Gf Disruption 25 
rr, 
The structures of the 70 fJ-lactams were entered as S~ES (Simplified Molecular 
Input Line Entry System) codes into the Cobra programme (version 3.0 ) [573], run 
on a Silicon Graphics Personal Iris workstation. SMILES is a simple chemical 
notation system designed for modem chemical information processing. SMILES 
encodes the molecule in the form of a simple hydrogen-suppressed string. Each 
atom is represented by its atomic symbol. Lower case notation implies aromaticity, 
with branches shown in parentheses. Cyclic structure are represented by breaking a 
bond within the ring structure and designating the ring opening bond with a digit 
immediately following the atomic symbol and the same digit at the ring closure 
bond. Other symbols used include =. representing a double bond and # representing 
a triple bond. The molecule can be written from any starting point, as long as the 
connectivity of the molecule is maintained. Therefore, many different but equally 
valid codes for the same molecule may exist. 
Several conformations relative to each of the SMILES codes were generated, the 
conformation labelled Cl_I_I. pdb was assumed to be the conformation of the 
lowest energy and was the conformation used in further analysis. Appendix 2 details 
the SMILES codes used in this study for each of the 70 J3-lactam antibiotics used in 
the model generation process. The conformations were imported into and pictorially 
displayed in the Pimrns programme (version 1.45) [574], where they were checked 
for correct conformational arrangement and were energy minimised, in the 
COSMIC sub-routine [575], using the MIN02 quasi Newton-Raphson method, until 
the root mean square of the energy was reduced to its lowest possible point, this 
being between 50 and 70 KcaJ/mole for the J3-lactams. The energy minimised 
conformations were fitted to the fJ-lactam nucleus of the benzylpenicillin structure, 
thus ensuring all structures were in the same orientation, and thus would produce 
comparable parameters from shape, topological and vectorial analysis. 
The structures were imported into the TSAR program [576] (version 2.0) and 
various relevant physico-chemicaJ and structural parameters generated therein. 
Further parameters were generated using programs run interactivley on a Western 
Systems 486 PC, supported by a V AX Mainframe: 
Medchem (version 3.54) [576] was used to generate values of the n-octanoVwater 
partition coefficient (CLogP) and molar refractivity (MR). 
MOPAC (version 2.0) [577] was used to calculate partial atomic charges for the 
compounds using the MNDO routine, with the keywords Iscf, ami, mmok, polar, 
enpart and nointer being employed. Whole molecule parameters of HOMO (highest 
occupied energy level) and LUMO (lowest unoccupied energy level) energies, 
dipole moment, total electronic energy of the minimist:d molecule, and the 
poJarizability were also evaluated. 
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Indicator values of hydrogen bonding were calculated manually in accordance to the 
method ofYang et al as outlined in 4.32235, using published fragment values [80]. 
The respective parameter values for each antibiotic were entered manually into a 
TSAR database. 
Appendix 3 lists the 84 descriptor variables generated and used in the model 
generation procedure. 
In order to reduce the possibility of chance correlations, as may occur when large 
numbers of physico-chemical (desciptor) variables are utilised, each of the 
parameters was correlated against the others using the peA analysis routine, 
available within TSAR. If correlations were produced in which the multiple 
correlation coefficient (R2) > 0.8, one or more of the cross-correlated parameters 
were removed from the database prior to statistical analysis, so that no cross-
correlated parameters were used in the model generation procedure (the correlation 
matrices for each model (biological data and descriptor variables) generated are 
presented in appendix 4). The selection criteria used for the selection of a descriptor 
variable to remain in the data set was based on the variables utility, that is the ability 
to interpret its significance biologically. 
(TSAR, Cobra and Pimms are all available within the CHEST package from Oxford 
Molecular Ltd., Oxford,UK.). 
9.3 13 Data Analysis 
Initially for the larger data sets (all tl-Iactams, all penicillins and all cephalosporins) 
each repective class of biological data, were correlated using stepwise regression 
analysis (available within TSAR) against a selected majority of the physico-chemical 
and structural descriptors (some of the descriptors related specifically to the 
cephalosporins, i.e. R2 side chain properties, and so were not relevant for use in the 
generation of models pertaining to all Jl-lactams or penicillins). Those descriptors of 
most significance in each case were noted. Each class of biological data within each 
of the three data sets was then regressed against selected combinations of those 
descriptors showing the most significance using the regression routine in TSAR. 
For the smalJer data sets (orals and parenterals) each class of biological data was 
regressed directly against combinations of those parameters showing significance 
for the larger data sets and if necessary with additional parameters thought to be of 
relevance. 
9.314 Determination of models' significance 
For each data set the resultant models' statistical significance was detennined by 
examination of the values of the correlation coefficient (r), and the standard error of 
the estimate (s) and of the validity plots of predicted biological values against actual 
biological values and residual values against predicted biological values. These two 
plots were also used in conjunction to determine if any compound was behaving as 
an 'outlier'. An 'outlier' can be defined as any compound which following statistical 
analysis lies a significant distance away form the resultant regression line and other 
compounds used in the model generation. That it to say the biological activity 
predicted by the model varies significantly from the actual biological activity, i.e.! 
the residual variance is significantly greater for this compound than for other 
compounds used in the model generation. 
If a compound was seen to be acting as an outlier and a valid reason could be found 
to explain this behaviour, the regression analysis was repeated without that 
compound and the significance of the new model examined. 
The models' significance with regards their predictive powers was evaluated via the 
1eave-one-out' cross-validation procedure within the TSAR regression analysis and 
determined from the value of the cross-validated regression coefficient (r(CV)2). 
Wold [115] has proposed that values ofr (CV)2 greater than 0.6 indicate that the 
model is predictively valid, but Clementi [46] has suggested a lower cut-off value of 
0.1 as being indicative of predictive ability. 
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9.315 Data Randomisation 
As the initial stepwise regression parameter selection procedure comprised a large 
number of descriptor variables, it is possible that any given equation developed may 
be the result of a chance correlation with the biological data. In order to ensure this 
was not so, once a significant model was developed the biological data were 
randomised (the descriptor variables being left as they were) some twenty times and 
re-input into the data base. Regression analysis against the previously highlighted 
descriptors was repeated and the value of the resultant 'new' regession coefficient 
determined. If the value ofr was >0.6 for any of the randomised models this would 
indicate that the original model could have been a result of a chance correlation and 
therefore was not valid. However, if the value of r for each of the randomised 
models was significantly below that of the original model it could be concluded that 
the original model was not derived by chance and that it is a true reflection of the 
physico-chemical properties which control that specific biological response. Thus it 
can be used to predict the frequency of the given biological response for new, 
untested or hypothesised compounds and used to aid investigations into the 
biological systems responsible for initiating a specific response. 
9.32 Results and Discussions 
9.321 Assessment of the Biological data 
The percentage frequency values of all Ms, cutaneous rash and GI disruption for 
the p-Iactams analysed are given in tables 9.1 and 9.2. 
Transformation and univariate analysis of the respective biological data sets (as 
outlined in table 9.3) generated data with a range of skewness values and 
distribution, as given in tables 9.4, 9.5 and 9.6 for each biological response 
respectively. Examination of each respective transformation for each related data 
set (all ARs, cutaneous rash and GI disruption) showed that in all cases one 
transformation generated normalJy distributed data for all the related data sets, i.e. 
LoglO transformation of cutaneous rash due to all J3-lactams. In order to ensure 
continuity between related data sets and the resultant models it was decided for 
each data set (all ARs, cutaneous rash GI disruption) to adopt that transformation 
which resulted in vaid values of skewness for ail the repective sub-data sets (all 13-
lactams, all oral ~-Jactams, all parenteral J3-lactams, all penicillins, oral penicillins, 
parenteral penicillins, all cephalosporins, oral cephalosporins and pareanteral 
cephaJosporins). 
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Table 9.4 Univariate Skewness Values Generated Following Various 
Mathematical Transformations of the AR Biological Data 
Data set Skewness value (Sk) for the 
transformation of 
%1 LO~lO %1 oP'/01 %12 
All p-lactams 1.478 -0.153 0.681 2.812. 
All Oral fJ-Iactams 1.355 -0.041 0.619 2.869 
All parenteral p-Iactams 1.418 -0.241 0.656 2.518 
All penicillins 1.264 -0.063 0.604 2.316 
All oral penicillins 0.386 -0.359 0.047 0.923 
All parenteral penicillins 0.996 0.088 0.592 1.465 
All cephalosporins 1.621 -0.034 0.798 2.994 
All oral cephalosporins 1.912 0.336 1.120 2.902 
All parenteral cephalosporins 1.206 -0.207 0.506 2.427 
%1 represents the percentage incidence. 
respective 
1/%1 
2.326 
1.131 
2.591 
1.362 
1.311 
1.053 
1.950 
0.735 
2.138 
In this instance it was the LoglO transformation which generated normally 
distributed data for each of the sub-data sets. Therefore, Log} 0 data were used in 
the generation of the QSAR models pertaining to the frequency of all ARs. 
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Table 9.5 Univariate Skewness Values Generated Following Various 
Mathematical Transformations of the Cutaneous Rash Data 
Data set Skewness value (Sk) for the 
transformation of: 
%1 Lo~ho %1 ./'%1 %12 
All t3-lactams 1.821 -1.873 0.337 3.978 
All Oral 6-lactams 1.010 -1.628 0.088 2.046 
AII.parenteral 6-1actams ].731 -2.105 0.383 3.124 
All penicillins 1.648 0.122 0.893 2.729 
AIl ora] penicillins 0.363 -0.253 0.017 1.165 
AIl -'parenteral penicillins 0.950 0.140 0.578 1.5 I] 
AIl cephalosporins 1.323 -1.404 0.]52 2.234 
AI) oral cephalosporins 1.554 -0.890 0.663 2.078 
All parenteral cephalosporins 1.113 -] .807 -0.230 2.140 
%1 represents the percentage incidence. 
respective 
1/%1 
2.892 
2.650 
3.000 
0.908 
0.580 
0.728 
1.965 
1.544 
2.199 
In this instance it was the square root (.i) transformation which generated normally 
distributed data for each of the sub-data sets. Therefore the square root data were 
used in the generation of the QSAR models pertaining to the frequency of 
cutaneous rash. 
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Table 9.6 Univariate Skewness Values Generated Following Various 
Mathematical Transfonnations of the 01 Disruption Data 
Data set Skewness value (Sk) for the 
transfonnation of 
%1 Log10 %1 ~ol %12 
All J3-lactams 2.647 -1.212 1.216 4.424 
All Oral J3-lactams 2.215 -0.412 0.917 3.621 
All parenteral J3-lactams 2.498 -1.231 1.421 3.376 
All penicillins 1.539 -0.079 0.840 2.216 
All oral.penicillins 1.525 -0.321 0.632 2.674 
All parenteral penicillins 1.366 0.261 0.968 1.652 
All cephaJosporins 3.290 -1.296 1.373 5.372 
All oral cephaJosporins 2.426 -0.194 1.155 3.3 ]2 
All parenteral cephalosporins 2.424 -1. 743 0.898 4.028 
%1 represents the percentage incidence. 
respective 
1/0,1" T 
7.950 
2.608 
5.662 
1.592 
2.114 
0.989 
5.988 
1.899 
4.402 
In this instance it was the Log]O transformation which generated normally 
distributed data for the majority of the sub-data sets. Therefore the LoglO data were 
used in the generation of the QSAR models pertaining to the frequency of 01 
distribution. 
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9.322 Regression analysis 
A total of 84 physico-chemical descriptors (listed in appendix 3) were generated 
and input into the TSAR data base along with the biological data. 
A summation of the final results attained from regression analysis (including a 
description of the preliminary validation plots) and from cross-validation analysis 
for each of the 27 models under investigation is given in table 9.7. It can clearly be 
seen, from the results summation, that statistically significant and predictively valid 
QSAR models have been generated for the majority of the data sets (models 9.1 to 
9.27 inclusive). A summary of the physico-chemical and structural parameters used 
in each of the final models generated is presented in table 9.8, full parameter 
descriptions are given along with the full model. 
Appendix 4 presents a listing of the relevant data (compound names, biological and 
physico-chemical parameter values, residual and predictive values, and the 
subsequent correlation matrices, as wel1 as representations of the two validity plots 
for each individual model produced. 
Table 9.7 Summation of Regression Statistics. Plots and Cross Validation Results 
Data Set Biological D # # 5 plot plot 
Resoonse p!UCU1Cl outliers r r2 I 2 
All All ARs (loglO) 70 8 3 0.642 0.412 0.267 sk hetro 
~-1actams Rash (or) 70 8 5 0.731 0.534 0.492 lin homo 
GI Disrpn. (loglO) 70 7 I 0.684 0.468 0.355 sk hetro 
Oral All ARs(lo~lO) 32 4 3 0.790 0.624 0.196 lin homo 
~-Iactams Rash (.() 32 4 4 0.895 0.800 0.294 I. homo 
GI Disrpn. _(lo..&W) 32 4 3 0.780 0.609 0.190 sk homo 
Parenteral All ARs (logIO) 38 3 4 0.732 0.535 0.230 lin homo 
I}-lactams Rash (~) 38 4 1 0.789 0.622 0.453 lin homo 
GI Disrpn. (loglO) 38 2 3 0.784 0.615 0.248 lin hetro 
All All ARs (loglO) 28 3 2 0.627 0.393 0.216 sk homo 
Penicillins Rash (r) 28 4 1 0.857 0.134 0.341 lin homo 
GI Disrpn. (loglO} 28 3 1 0.893 0.798 0.160 lin homo 
Oral All ARs(logI0) 15 2 1 0.786 0.618 0.177 lin homo 
Penicillins Rash (-1") 15 1 1 0.907 0.823 0.181 lin homo 
GI Disrpn. (logIO) 15 2 0 0.841 0.106 0.138 sk homo 
Parenteral All ARs (logI0) 13 2 0 0.872 0.760 0.166 lin homo 
Penicillins Rash (t/") 13 2 I 0.843 0.711 0.404 lin hetro 
GI Disrpn .. (lOg I 0) 13 2 1 0.928 0.861 0.174 lin homo 
All All ARs (loglO) 42 3 8 0.852 0.725 0.190 lin homo 
Cephs Rash(J) 42 4 4 0.7% 0.633 0.368 lin homo 
GI Disrpn. (loglO) 42 4 3 0.814 0.663 0.312 sk homo 
Oral All AR£ (loglO) 17 1 3 0.859 0.737 0.167 lin homo 
Cephs. Rash (r) 17 2 4 0.950 0.902 0.213 lin homo 
GI Disrpn. (loglO) 17 2 4 0.840 0.706 0.162 sk homo 
Parenteral All ARs (loglO) 25 3 4 0.885 0.782 0.178 lin homo 
Cephs. Rash (.f') 25 3 1 0.834 0.695 0.317 lin homo 
GI Disrpn. (loglO) 25 4 1 0.902 0.813 0.260 sk homo 
Key: 
sk - data are skewed about the line of best fit, so the error disribution is not nonnal. 
lin - data are linear, so the distribution of error is normal. 
hetro - data are heteroskedastic about the zero line, so there is a large scope 
for variation, the model is not a good fit with regard to the data used in its 
construction. 
homo - data are homoskedastic about the zero line, there is even distribution of 
variation, the model is a good fit with regard to the data used to construct it. 
121 
r (CV)2 
0.090 
0.303 
-0.078 
0.527 
0.602 
0.380 
0.370 
0.233 
0.539 
0.269 
0.634 
0.782 
0.475 
0.765 
0.499 
0.585 
0.425 
0.768 
0.576 
0.560 
0.240 
0.382 
0.844 
0.376 
0.648 
0.564 
0.565 
Table 9.8 Summary of the Descriptor Variables Used in the QSAR Models Generated 
Bioll'gical Parameters used in the QSAR models for each respective data set 
Response 
All (l-lactams All Oral All Parenteral All Penicillins Oral Penicillins Parenteral All Cephalosporins Oral Parenteral 
~-lactams ~-lactams Penicillins Cephalosporins Cephalosporins 
AlIARs flexibility of R 1 CLogP " R I Amino groups RI Hyrdogen bond CLogP CLogP Hydrogen bond CLogP 1# RI Amino groups 
(Log 1 0) " RI Amino groups Dipole Vector Z Charge C of Il-ring donor ability R I Hydrogen bond Sterimol B2 of acceptor ability SS Cefinetazole Sterimol L of R2 
I R3 Indicator SS Cefmetazole carbonyl group Flexibility of RI donor ability whole molecule Total Dipole SS Cephapirin # Oxygen atoms 
R4 Indicator SS Cephapirin SS Flucloxacillin S Lipophilicily BP N Amino groups RI Charge C of (l-ring 
1# Oxygen atoms Sterimol B3 of R2 carbonyl group 
I 
SS Cefmetazole 1# R2 N atoms 
SS Flucloxacillin 1# R2 Ox. atoms 
SS Cephapirin SS Cefmetazole 
SS Cephapirin 
Cutaneous Sterimol B2 SS Benzylpen. Sterimol B2 ss Benzylpen. SS Benzylpen. Sterimol B3 Administllllion ID Log H2O so\. Dipole Vector Z 
Rash SS Benzylpenicillin Log IUO Sol. 1# Carbons in RI Sterimol R3 SS Methicillin SS Cefacetrile SS Cefatrizine SS Cefacetrile 
<r> 11 Carbons in RI SS Ceftibuten Log IUO Solubility Administration ID SS Cefepirome SS Cefepirome 
l~ IUO Solubility SS Cefatrizine SS Methicillin SS Methiciltin SS Cefatrizine 
SS Methicillin 
SS Cefepirome 
SS Cenihuten 
SS Cefatrizine 
-
Continued over page 
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Table 9.8 Continued 
Biological Parameters used in the QSAR models for each respective data set 
Response 
! All ~-Iactams All Oral All Parenteral All Penicillins Oral Penicillins Parenteral All Cephalosporins Oral Parenteral 
6-1actams J!-Iactams Penicillins Cephalosporins Cephalosporins 
Gl Disrupn. 11 R I Methyl groups Surface Area 11 RI Methyl groups Surface Area Surface Area Surface Area Dipole vector Z Total Dipole Dipole Vector Z 
(Log to) 11 Sulphur atoms Total Dipole SS Cefsulodin 11 R I Methyl gps. 11 RI Methyl gps. 11 R I Methyl gps Swn of charges on SS Cephalexin Swn of charges on 
Sum of charges on RI Hydrogen Administration ID carbonyl carbonyl oxygens . 
carbonyl oxygens acceptor ability oxygens SS Cephalexin 
Kappa3 11 R I Methyl gps SS Cephaloridine 
Ionisation ptJ SS Cephalexin 
Administration ID 
SS Cephaloridine 
.~ 
- -----------
_._-
- .-
L-________ . __ 
'----- - ~.------ - - -- --
Full descriptions of each parameter and the full models follow. 
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9.3221 OSAR Models of AR Frequencies 
9.32211 All fi-Lactam Antibiotics 
The log} OAR data has a skewness value of -0.153 indicating nonnal distribution and 
that the data is suitable for modelling. Stepwise regression against 70 physico-chemical 
and structural parameters highlighted fourteen descriptors which correlated with the 
transformed biological data. Regression analysis with the eight most significant 
descriptors yielded model 9.1, which described only 41% of the information contained 
within the biological data, indicating that the model was not statistically significant. 
The cross-validated r2 for the resultant model (0.09) showed that the model was not 
predictively valid. The lack of a significant correlation between the AR data of all the 
p-lactams assessed may be due to the fact that the data contained information 
pertaining to numerous biological responses, which are brought about via numerous 
biological mechanisms. Also the different antibiotic types (peniciJJins or 
cephalosporins) and modes of administration (oral or parenteral) may lead to the 
responses being brought about via differing biological mechanisms. Each of these 
different biological mechanisms may be initiated in response to a different physico-
chemical property or combination of properties of the antibiotics under invesigation. 
Therefore the generation of a simple linear model which correlates the complexity and 
diversity of such an array of biological mechanisms is probably not possible. 
Three compounds, azidocilJin, cefaloglycin( e) and cefuroxime, appear to be behaving 
as outIiers. Azidocillin was determined to be an outlier on the premise that it was the 
only p-Iactam containing an azido (N=W=N-) functional group, the exact properties 
of which were problematic to model using Cobra and Pimms. Cefaloglycin( e) was 
believed to be an outIier by virtue of the fact that the biological data pertaining to the 
frequency of ARs due to this compound were disproportionately high compared with 
the other antibiotics. It was believed that this may adversely effect the model 
generation process. Cefuroxime is with the exception of its prodrug cefuroxime-axetil, 
the only p-lactam in which the RI five membered heterocyclic ring substituents 
contains a strained oxygen component atom. In equivalent compounds the oxygen 
atom is replaced with a sulphur atom. It was felt that the presence of the oxygen may 
differentially affect the electron distribution within the molecule, thus making accurate 
comparisons with other compounds impossible. The additional ~ substituent on the 
prodrug may act to rectifY the disproportionate electron distribution, so enabling 
comparisons to be made with this compound,therefore cefuroxime was believed to be 
an outlier. 
Model 9.1 
LoglOAR due to = -O.06(O.028)FlexR] - O.178(O.083)#AminoR I 
all fl-lactam antibiotics - 0.405(0.075)R3I - O.202(O.045)~I + 0.065(0.059)#Ox 
- 1. 1 83(0.J03)SSCefinet + 0.801(0. 767)SSFluclox 
+ 1. 166(0.327)SSCephap + 1.178(0.876) 
n=67 r=O.642 r2=O.412 s=O.267 F=5.007 probability=6.13-5 r(CV)2=O.090 
Where: FlexR 1 is the flexibility of the RI acyl side chain of the antibiotic, 
calculated in TSAR and in accordance with equation 4.10. 
#AminoR) is the number of amino groups within the R] side chain 
R31 is an indicator variable of value 1 or 2 pertaining to the absence or 
presence, of a substituent group at the R3 position of the fl-ring. 
~I is an indicator variable of values 0, ] or 2 pertaining to the 
presence of either no atom, a hydrogen atom or another substituent, 
respectively, at the ~ position. 
#Ox is the number of oxygen atoms present within the molecule. 
SSCefinet is a measure of the shape similarity of the antibiotic to that of 
cefinetazole, this antibiotic giving the lowest frequency of ARs. 
SSFluclox is a measure of the similarity in shape of the antibiotic to 
flucloxacillin, this penicillin giving the highest frequency of ARs. 
SSCephap is a measure of the similarity in shape of a antibiotic to 
cephapirin, this cephalosporin antibiotic, in the regression data set, giving the highest 
frequency of ARs (cephaloglycin results in the highest frequency of ARs of the 
cephaolsporins but is an outlier and so is not significant with regard to the final model). 
Shape similarity is detennined through a TSAR/Asp (version 3.01) interface and is 
calculated in accordance to the method of point counting as proposed by Meyer. 
Values of similarity obtained range between 0 and 1, with values approaching 1 
indicating increased similarity to the chosen lead compound. 
9.32212 All Oral p-Lactam Antibiotics 
The value of skewness for the Log lOAR data for all the oral Jl-lactams is -0.041 and as 
such indicates that the data are normally distributed and so suitable for modelling. 
Regression analysis of the biological data against combinations of the descriptor 
parameters highlighted as significant for all Jl-Iactams (9.32211) and other parameters 
considered to be of relevance to oral compounds, yielded the statistically significant 
and predictively valid model 9.2, which comprised four descriptors and modelled 62% 
of the variance contained in the biological data. 
Azidocillin and cefaloglycin, both oral antibiotics, were ommitted as outliers for the 
reasons given in 9.32211. Carfecillin was also isolated as an outlier as it is the only oral 
Jl-Iactam which possess an R] substituent comprising two independent benzene rings. 
It was felt that the flexibility of the bonds attaching the two rings would make accurate 
and comparible shape parameter determinations problematic. 
Model 9.2 
Log IOAR due to 
all oral tJ-Iactams 
= -0.912(0.031)CLogP + 0.214(O.081)DVz 
10 100 
- 3.316(0.331 )SSCefinet + 2.267(O.542)SSCephap 
+ 1.648(0.250) 
n=29 r=O.790 r2=O.624 s=O.196 F=9.943 probability=3.89-5 r(CV)2=0.527 
Where: CLogP is the logarithm of the octanol-water partition coefficient 
calculated in Medchem, version 3.54. 
DVz is a numerical value pertaining to the dipole moment and therefore 
eJectron directing in an arbitary vector Z of the molecule. 
SSCefinet is a measure of the shape similarity of the given antibiotic to that 
of cefinetazole, the antibiotic giving the lowest frequency of ARs. 
SSCephap is a measure of the similarity in shape ofa given antibiotic to 
cephapirin, the oral antibiotic in the regression data set giving the 
highest frequency of ARs (cephalogJycin results is the highest frequency 
of ARs of the oral cephaolsporins, but is an outlier and so not 
significant with regard to this final model) 
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9.32213 All Parenteral (3-Lactam Antibiotics 
The skewness value for the 10glOAR data of parenteral p-Jactams is -0.241 indicating 
the data are normally distributed and so suitable for modelling. 
Regression analysis of the biological data against combinations of the descriptor 
parameters highlighted as significant for all J3-lactams (9.32211) and other parameters 
considered to be of relevance to parenteral compounds, yielded a statistically 
significant and predictively model 9.3, comprising three descriptors which modelled 
54% of the information contained within the biological data. 
Cefuroxime is an parenteral antibiotic and is determined to be an outlier for the reasons 
as given in 9.32211. Cefepirome, cefinetazole and cefsulodin were also eliminated from 
the regression procedure as outliers. Cefepirome because it is the only parenteral 
compound possessing a fused heterocyclic ring substituent at the R 2 position. It was 
felt that this substituent, being quite large, may have an adverse bearing on the 
compound's similarity to flucloxacilIin which does not have a substituent group at the 
R2 position, thus adversely affecting its ability to enter a binding site and therefore 
being deleterious to the fitting of this compound's frequency data to the regression 
model. Cefinetazole is believed in this instance to be a justifiable outlier on the basis of 
the fact that it the only p-Iactam which contains an R I straight chain substituent which 
terminates in a carbon triple bonded to a nitrogen atom. It was felt that the electron 
distribution and charge about this nitrogen atom would not be effectively modelled, 
thus affecting the accuracy of some of the descriptors. Cefsulodin was removed as an 
outlier due to the fact that it comprises a charged nitrogen containing heterocyclic ring 
in the R2 substituent. It was not possible to generate relevant parameters which related 
the effects of this charge. 
Model 9.3 
LoglOAR due to =-0.312{0.037)#AminoRI -1.296(0.029)ChargepC*=O 
all parenteral f3-lactarns + 1.516(0.112)SSFlucIox + 3.703(0.152) 
n=34 r=0.732 r2=O.S35 s=O.230 F=11.52 probability=2.52-5 r{CV)2=0.370 
Where: #AminoR] is the number of amino groups found in the RI acyl side chain. 
Chargef3C*=Q is the charge on the carbonyl carbon of the f3-lactam ring 
multiplied by a factor of 10 and as determined using Pimms. 
SSFlucJox is a measure of the similarity in shape of the given antibiotic to 
tlucloxacillin, this penicillin antibiotic giving the highest frequency of ARs. 
The descriptor variables included in model 9.3 suggests that as with the oral p-Iactams 
(model 9.2), it is some type of shape dependent binding process which governs both 
the initiation and extent of stimulation of the biological mechanism( s) responsible for 
bringing about the development of adverse responses to parenterally adminstered 13-
lactam antibiotics. 
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9.32214 All Penicillin Antibiotics 
The Log 1 OAR data pertaining to the frequency of ARs due to all penicillin antibiotics 
has a skewness value of -0.063, indicating it to be nonnally distributed an so suitable 
for modelling. 
Stepwise regression of the L08IOAR data against 70 chosen descriptors highlighted 
three parameters which correlated with the biological data. Regression analysis of the 
Log} OAR data with respect to the three highlighted descriptor variables yieled model 
9.4, which modelled only 391'10 of the variance present in the biological data. 
Two compounds, azidocillin and flucloxacillin were eliminated from the data set as 
outliers. Azidocillin was assumed an outlier for the reasons given in 9.32211. 
Flucloxacillin was regarded as an outlier as it produces a significantly higher frequency 
of ARs compared with the related compounds oxacillin and dicloxacillin. FlucloxacilIin 
differs as it is the only penicillin containing a fluorine group in its structure and it is 
believed that it is the presence of this fluorine atom which by some means causes an 
increase in the frequency of ARs induced. 
Model 9.4 
Log lOAR due to 
all penicillins 
= 0.208(0.029)HBDRl - 0.073(0.020)F1exRI 
+ 0.412(0.115)SBPLipo + 1.009(0.181) 
n=26 r=0.627 r2=O.393 s=O.293 F=7.744 probability=O.009 r(CV)2=0.269 
Where: HBDR 1 is the hydrogen bond donor ability of the RI acyl side chain as 
evaluated by the method ofYang et al [80]. 
FlexR 1 is a measure of the the flexibility of the RI acyl side chains of the 
antibiotic, calculated in TSAR and in accordance with equation 4. ] O. 
SBPLipo is a measure of the similarty in liphophilicity of the given penicillin 
antibiotic to benzylpenicillin determined through a TSAR. Values of 
between 0 and I were obtained, with values approaching 1 indicating 
increased Iiphophilic similarity to benzyJpenicillin.(chosen because it is 
believed that the majority of the population are sensitised to this penicillin 
rather than others, as a result of its wide and extended use). 
11& 
Examination of the model statistics shows that there is still some 60% of the biological 
variance not accounted for by the descriptors presented in the model. 
The lack of statistical significance is probably because the data represent both orally 
and parenterally administered penicillins, which possibly initiate ARs via different 
biological mechanisms, the activation of which is dependent on different physico-
chemical properties. The integral properties of the oral and parenteral penicillins which 
govern the processes of absorption, transportation, distribution and excretion, by 
virtue of the nature of the compound itself, will vary significantly and it may be that 
these properties are related to the AR initiation process. If so, it will be impossible to 
fit a simple linear model to these complex and diverse systems. 
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9.32215 Oral Penicillin Antibiotics 
Data relating to the LogIOAR frequency due to oral penicillin antibiotics are normally 
distributed, with a skewness value of -0.359 and thus are suitable for modelling. 
Regression analysis of the LogIOAR data with respect to the three descriptors 
highlighted in 9.32214 and other parameters believed to be of relevance yielded the 
statistically significant and predictively vaild model 9.5, which modened 62% of the 
infomation contained within the biological data. 
Azidocillin was determined to be behaving as an outlier an outlier for the same reasons 
given in 9.3221 I. 
Model 9.5 
Log I oAR due to 
oral penicillins 
= -0.81(0.19)CLogP + 0.203(0.058)HBDR} 
10 
+ 0.686(0.042) 
n= 14 r=0. 786 r2=0. 6 I 8 s=O. 177 F=S. 90 I probability=O. 004 r( CV)2=O. 4 75 
ISI 
9.32216 Parenteral Penicillin Antibiotics 
The Log10AR data for the parenteral peniciUins are normally distributed (Sk= 0.088) 
and as such is suitable for modelling. 
Regression analysis was perfonned using combinations of the three descriptors 
highlighted in 9.32214 and with other parameters which could be of relevance. Model 
9.6 uses two descriptors to model 76% of the variance contained within the biological 
data and is both statistically significant and predictively valid. 
No compounds were found to be behaving as outliers in this data set. 
Model 9.6 
L0810AR due to 
parenteral penicillins 
= 1.207(0.478)CLogP - 2.872(1.038)B2 
10 ]0 
+ 2.115(0.483) 
n=13 r=O.872 r2=O.760 s=O.166 F=lS.84 probability=4.3-4 r(CV)2:::0.585 
Where: B2 is the B2 Sterimol width parameter for the penicillin calculated in TSAR. 
Although it is not possible to evaluate Sterimol parameters for whole molecules, it is 
possible within TSAR to measure values of a substituent from a common bond. In this 
instance the common bond chosen was one of the carbon-hydrogen bonds within the 
first methyl group attached to the thiazolidine ring. Thus the hydrogen atom became 
the "compound" and the remaining structure became the substituent and so an 
indicator of whole molecular shape was evaluated and used in the model, as illustrated 
in figure 9.6a. If another bond were to be used then the generated Sterimol parameter 
would differ from those in the above model, and may not be valid. '. 
The presence of the Sterimol parameter in the model is significant as it may be related 
to the flexibility of the RI acyl side chain, as indicated in figure 9.6a. The larger the RI 
substituent the larger B2, and if the rotational nature of the substituent bonds allows 
the more flexible RI becomes. 
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9.32217 All Cephalosporin Antibiotics 
The LoglOAR data for all the cephalosporins are nonnally distributed (Sk = -0.034) 
and as such are suitable for modelling. Stepwise regression of the LogIOAR data 
against SI chosen physico-chemical parameters highlighted numerous parameters 
which correlated with the bio-data. Regression anlaysis against combinations of the 
eight most significant descriptors yielded model 9.7, which described 73% of the 
variance contained within the data. 
Three compounds cephaloglycin, cefsulodin and cefuroxime were indicated as outliers, 
the reasons being the same as those detailed in 9.32211 and 9.32213. 
Model 9.7 
Log 1 oAR =5.267{l.095)fiA/IOO - 3.35(1 .S20)TD/IO - 2.146(0. 762)#AminoRI 
due to 
all cephalosporins 
+ 2.04(0.190)B3R2/10 - 2.05(0.320)#NRiIO 
- 7.900(O.SOO)#OxR2/IOO - 2.059(O.223)SSCeftnet 
+ l.094(O.37S)SSCephap + 1.227(0.266) 
n=39 r=0.852 r2=O.725 5=0.190 F=9.905 probability=2.5S-7 r(CV)2:=0.S76 
Where: HA is the ability of the whole cephalosporin molecule to accept hydrogen 
bonding, as detennined by the method ofYang et al [80]. 
TD is a measure of the total dipole moment of the cephalosporin, an 
indicatotion of the electron directing occurring within the entire molecule. 
B3R2 is the Sterimol B3 width parameter of the R2 substituent. 
#NR2 is the number of nitrogen atoms contained within the R2 substituent. 
#OxR2 is the number of oxygen atoms present within the R2 substituent. 
The resultant model 9.7 is significant not only statistically but also because some of the 
parameters contained within the model are equivalent to those highlighted as being of 
significance in the induction of ARs by all p-lactam antibiotics, model 9.1. The model 
suggests that more the cephalosporin antibiotic resembles ceftnetazole and the less it 
resembles eephapirin the less likeJty it is to be able to 'fit' the receptor site( s) and 
initiate binding. 
It is interesting to note that with the cephalosporins the R2 substituent has profound 
effects on the induction of ARs, both through its shape and its electronic properties. 
9.32218 Oral Cephalosporin Antibiotics 
The data petaining to the LogIO of the frequency ARs induced in response to therapy 
with oral cephalosporin antinbiotics has a skewnes of 0.336, which suggests normal 
distribution and thus that the data are suitable for modelling. 
Cephaloglycin was determined in 9.32211 to be an outlier and was therefore eliminated 
from the model generation procedure. 
Regression analysis was therefore carried out for 16 of the 17 cephalosporins, using 
combinations of the eight descriptor variables proposed as being significant in 9.32217 
and other physico-chemical parameters believed to be of relevance to oral 
cephalosporins. The resultant model 9.8 effectively modelled 74% of the biological 
variance and was both statistically significant and predictively valid. 
Model 9.8 
Log}OAR due to 
oral cephalosporins 
= -9.995(2.500)CLogP - 4.617(0.817)SSCefrnet 
100 
+ 3.6S7(2.083)SSCephap + 1.564(1.217) 
n= 6 r=0.859 r2=0.737 s=0.167 F=11.23 probability=4.04-4 r(CV)2=O.382 
The model proposes that the two descriptor variables (SScefinet and SS cephap) and 
CLogP are of significance in controlling the induction of ARs by oral cephalosporins. 
The resultant model therefore supports the theory of AR induction as previously 
discussed in 9.32217, that some means of shape dependent receptor recognition and 
binding are responsible for governing the extent and duration of a specific AR 
response. 
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9.322 I 9 Parenteral Cephalosporin Antibiotics 
The skewness value of Log 1 oAR frequency due to parenteral cephalosporins is 
-0.271 and indicates nonnal distribution and that the data are suitable for modelling. 
Three compounds were removed prior to regression analysis, cefuroxime, cefepirome 
and cefsulodin, due to their previously being identified as being outliers (9.3 2211, 
9.32213). 
Regression analysis of the transformed biological data against combinations of those 
descriptors believed to be of relevance yielded model 9.9, which was both statistically 
significant and predictively valid and which modelled 78% of the information contained 
within the biological data. 
Model 9.9 
Log !OAR due to 
parenteral 
cephalosporins 
= -3. 572(0. 652)#ArninoR 1/1 0 - 8.678(2.113)LR2/100 
+ 1.055(0.4141)#Ox/1O - 2.859(0.706)ChargePC*=O 
+ 9.302(1.970) 
n=39 r=0.852 r2=0.725 s=0.190 F=9.905 probability=2.58-7 r(CV)2=0.576 
Where: LR2 is the Sterimol measurement of the length of the R2 substituent. 
In this instance the sterimol parameters were evaluated along the bond attaching the 
R 2 substistuent to the core nucleus of the cephalsoporin, towards the terminal atom of 
the R2 substituent. 
#Ox is the number of oxygen atoms present in the entire cephaolosporin. 
The model has further significance as it contains the parameters #AminoRJ and #Ox 
which were highlighted as being significant in the earlier related model 9.7, and 
ChargepC*=O which was highlighted as being significant in the induction of ARs by all 
parenteral J3-lactams (model 9.3) and a Sterimol shape parameter which is related to 
the R 2 substituent shown to be of significance in model 9.7. 
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Overview of All Adverse Reactions OSARs 
The data pertaining to the frequency of all ARs relate to the development of one 
or more multiple effects, which are initiated through mUltiple reaction 
mechanisms. It has not therefore, been possible to produce models which 'fit' 
exactly to each reaction mechanism. However, it has been possible to some 
extent to produce linear regression equations relating to the frequency of 
responses initiated to the molecular properties of the antibiotics (9.1 to 9.9 
inclusive). 
Of the nine QSARs developed seven present some level of statistical and 
predictive significance, whereas the two remaining (all J3-lactams and all 
penicillins )are not statistically significant. 
Examination of the descriptor variables present in the nine developed models 
(table 9.8 page 129) has enabled the development ofa generalised picture 
pertaining to the molecular properties responsible for initiating such adverse 
responses to be drawn. 
In each instance the derived models comprise a shape, hydrophobicity, electronic 
and / or RI substituent parameter. 
The presence of one or more equivalent descriptor types in each of the individual 
models indicates a pattern of information to be emerging regarding the 
physico-chemicaI requirements for the induction of a AR and hence gives 
credibility to each of the nine mode1s. 
The hydrophobicity parameter, in most cases CLogP, by virtue of its differing 
sign between oral and parenteral sub-groups (negative for orals and positive for 
parenterals), probably accounts for the different absorption requirements of the 
different modes of administration. 
tItS 
The presence of the molecular shape and / or electronic parameters suggests that 
the majority of the adverse reaction types assessed in the data may be induced by 
the binding of the antibiotic to a specific receptor. The shape of the antibiotic 
being that which governs whether the antibiotic has the capability to enter and 'fit' 
with the receptor site, and the electronic property being that which controls the 
extent of binding and thus initiation of the response. 
The presence of parameters relating specifically to the RI acyl side chain 
substituent of the antibiotics, provides some support to previous hypotheses 
[579,580] that the RI substituent is predominant in controlling the inductions of 
ARs. 
However, due to the complexity and diversity of the biological mechanisms 
involved in giving rise to all the AR responses, it was not possible, using these 
data, to generate models which provided information as to the location or nature 
of the receptor sites, as these Could be numerous. Further analysis into the 
frequencies of specific responses, i.e. cutaneous rash, may lead to the generation 
of regression models which can be used more specifically in determining the 
exact biological mechanisms giving rise to them. 
However, it must be remembered that the biological data used must, by virtue of 
their nature, contain substantial error, and it may be that the correlations obtained 
represent the limit of useful information that can be extracted. 
9.3222 OSAR Models of Cutaneous Rash Frequency 
9.32221 All 6-Lactam Antibiotics 
The square root transformation of the biological data pertaining to the frequency of 
cutaneous rash for all the 70 ~-Iactam antibiotics under investigation presented a 
skewness value of 0.337, therefore showing them to be normally distributed and so 
suitable for modelling. 
Stepwise regression against 70 descriptor variables indicated twelve which were 
related to the cutaneous rash data. Regression analysis against combinations of the 
eight most significant descriptors produced the statistically siginificant and predictively 
valid regression model 9.10, which modeUed only 53% of the variance contained with 
the biological data. This is probably due to the fact that the data contains information 
relating to both oral and parenterally adminstered ~-lactam antibiotics, which possess 
differing physico-chemical and structural properties that may cause them to act via 
different mechanisims. Also, the data relate to both penicillin and cephalosporin 
antibiotics which may induce cutaneous rash via different biological mechanisms. 
Four compounds (epicillin, cephaloglycin, cefuzonam and cefroxadine) were isolated 
as acting as outIiers. Epicillin and cefroxadine were believed to be acting as an outliers 
because they are the only compounds to contain a heterocyclic rather than a benzene 
ring within the R I acyl side chain. This structural variation confers differing properties 
on the structures, affecting overall molecular shape, and the flexibility of the R I side 
chain, as well as affecting the electron distribution within the molecules. Cephaloglycin 
was removed as an outlier on the basis of the reasononing given in 9.32211. 
Cefuzonam was belived to be an outlier because in the R 2 side chain the nitrogen atom 
of other equivalent substituents is replaced by a sulphur atom, which will confer 
different electronic properties on the compound, so restricting its statistical 
comparision. 
Model 9.10 
.J"'Rash due to = 1.236(0.835)B2 + 1.092(0.942)SSBP+ 0.453(0. 127)#CR I 
all f3-lactam antibiotcs - 1.843(0.528)LogH20s01 + 5. 138(2.314)SSMeth 
+ 2.624(1.000)SSCefepir - 3.1 I 8(0. 844)SSCeftib 
+ 1.816(0.5 12)SSCefatriz - 5.321(1.336) 
n=66 r=O.73 1 r2=O.534 s=O.492 F=8.159 probability= 1.452-7 r(CV)2=0.303 
Where: 
SSBp is the shape similarity of the antibiotic to benzylpenicillin, the supposed 
sensitising ~-Iacat~ as detennined in TSAR. 
#CR I is the number of carbon atoms in the RI acyl side chain. 
LogH20sol. is a measure of the antibiotics water solubility, calculated using the 
MicroQSAR programme PC Version [581 J. 
SSMeth. is a measure of the shape similarity of the antibiotic to the parenteral penicillin 
methicillin, the antibiotic responsible for inducing the greatest frequency of 
cutaneous rash. 
SSCefepir. is a measure of the shape similarity of the antibiotic to the parenteral 
cephalosporin cefepirome, the parenteral cephalosporin responsible for 
inducing the highest frequency of cutaneous rash. 
SSCeftibut. is a measure of the shape similarity of the antibiotic to the oral 
cephalosporin ceftibuten, the oral cephalosporin responsible for inducing the 
lowest frequency of cutaneous rash. 
SSCefatriz. is a measure of the shape similarity of the antibiotic to the orall 
cephalosporin cefatrizine, the oral f3-lactam responsible for inducing the highest 
requency of cutaneous rash. 
9.32222 All Oral ~-Lactam Antibiotics 
The transformed biological data have a skewness value of 0.088, thus indicating that 
they are nonnally distributed and therefore suitable for regression analysis. 
Four compounds (epicillin, cephaloglycin, cefuzonam and cefroxadine) were previously 
(Model 9. 10) isolated as acting as outIiers and were removed from the data set prior to 
analysis, for the reasons as outlined in 9.32221. Regression analysis with combination 
of the those parameters highlighted in model 9.10 which were believed to be of 
relevance yielded model 9.11 which was both statistically significant and predictively 
valid and which modelled 80% of the variance contained within the biological data. 
Model 9.11 
J'Rash due to = 2.025(1.088)SSBp - 1.412(0.283 )LogH20s01 
oral ~-Iactam antibiotcs - 2.053(0.419)SSCeftib + 2. 868(2.602)SSCefatriz 
- 1.128(1.130) 
n=28 r=0.895 r2=0.800 5=0.294 F=23.06 probabiIity=2.24S-8 r(CV)2=0.602 
The derived model suggests that for oral ~-Iactam antibiotics there is a positive 
realtionship between the incidence of rash and the similarity in shape of the oral 
antibiotic with benzylpenicillin and cefatrizine, and a negative realtionship with the 
similarity in shape to ceftibuten and water solubility. 
The less the oral antibiotic ressembles benzylpenicillin (the major sensitising agent) and 
cefatrizine (that oral antibiotic giving rise to the greatest frequency of cuatneous rash) 
and the more it resembles ceftibuten (that oral antibiotic inducing the least amount of 
cutaneous rash) the more likely is the antibiotic not to be recognised by the antibody 
and bind in the shape specific receptor sites and therefore, the lower will be the 
resultant frequency of cutaneous eruptions induced. The data set contains information 
pertaining to both penicillins and cephaIosporins and it may be that the specific 
antibody involved in the recognition of these subtly different antigenic types, this may 
be reflected in the need for three shape parameters in regression model 9.11. 
9.32223 All Parenteral (3-Lactam Antibiotics 
The skewness value of the square root transformed data within this set was 0.383, 
indicating them to be normally distributed as so suitable for regression analysis. 
No compound was found to be behaving as an outlier and so regression analysis and 
model generation were carried out using each of the 38 parenteral fJ-Iactams. 
Regression analysis was performed using combinations of those descriptor variables 
highlighted as being relevant in 9.32221 (model 9.10) and produced the regression 
model 9. 12 which was marginally statistically significant, describing only 56% of the 
biological variance, and only slightly predictively valid. The lack of statistical 
significance and predicability may be due to an inability to produce a linear model 
which describes differences in the biological reaction mechanisms adopted by the 
penicillins and cephalosporins. Alternatively it may be that is was not possible to model 
the different biological mechanisms involved in giving rise to different reaction 
responses, i.el different types of cutaneous rash. 
The model is however, useful in that it provides some support to the previously 
derived related, yet more generalised model of cutaneous rash (9.10), in that the 
descriptors utilised are equivalent to some of those signified therein, thus indicating 
similar mechanisms to be operating, as would be expected. 
Model 9.12 
JRash due to 
parenteral 
B-Iactam antibiotcs 
= 2.005(1.317)B2 + 1.051(0.218)#CRI 
10 10 
-1.647(0.927)LogH20sol + 5.883(1.098)SSMeth 
- 4.607(0.842) 
n=38 r=0.748 r2=0.559 s=0.490 F=l0.46 probability=9.03-6 r(CV)2=O.233 
9.32224 All Penicillin Antibiotics 
The square root transformation of the biological data pertaining to the frequency of 
cutaneous rash exhibited following therapy with 28 penicillin antibiotics gave a 
skewness value of 0.893, indicating them to be normally distributed and so suitable for 
modelling. Regression analysis of the data was performed against combinations of 
those physico-chemical parameters found previously to be of significance in the 
modelling of cutaneous rash (models 9.10, 9.11 and 9.12), plus others which were 
believed to be of relevance. The statistically significant and predictively valid 
regression model 9.13, which described 73% of the variance contained within the 
biological data was generated. 
TicarciJIin was isolated as being an outlier on the basis that it is given at a therapeutic 
dose (20glday) which far exceeds that of the other penicillins (averaging between 2 and 
5g1.day). Therefore, the frequency of rash reported in the clinical trials may be dose 
dependent and not a true or comparable frequency. Appendix 5 details the therapeutic 
dose levels of each of the 70 tJ-lactams. 
Model 9.13 
.rRash due to 
all penicillin 
antibiotics 
= 2.54(0. 19)5SBP + 3.64(0.48)B3 
10 
+ 6.36(l.21)Admin + 5.34(O.83)SSmeth - 9.15(4.08) 
10 
n=27 r=O.857 r2=0.734 5=0.341 F=15.18 probability=1.601-6 r(CV)2=0.634 
Where: B3 is the StermioI B3 width measurement of the whole molecule. 
In this instance the parameter is a measure of the width of the whole molecule as 
measured from the carbonyl bond of the f3-1actam ring. 
Admin is an indicator variable pertaining to the mode of administration 
of the penicillin, where 3 indicates oral and 4 parenteral. 
The regression model generated (9.13) yet again highlights the importance of the shape 
of the antibiotic itself in contro11ing the extent of cutaneous rash induced. In this 
instance there is a negative relationship between the incidence of rash and the similarity 
in shape of the penicillin to benzylpenicillin (the primary sensitiser) or methicilJin (that 
penicillin which induces thee greatest frequency of rash). 
This model also suggests that the mode of administration (oral or parenteral) of the 
penicillin is of significance when coupled to the shape of that penicillin, in governing 
the frequency of rash induction. This would be expected on the basis of the effects 
which the differential absorption, transportation and distribution requirements of the 
oral and parenteral penicillins would have on rash induction by the respective 
compounds. 
Separate examination of the different administration modes may therefore yield more 
significant and more biologically significant and explainable regression models. 
I~ 
9.32225 Oral Penicillin Antibiotics 
Univariate statistical analysis showed the square root tranformed data to have a 
skewness value of 0.017, indicating that they are normally distributed and suitable for 
statistical modelling. 
Epicillin was removed from the data set prior to regression analysis, as it was believed 
to be an outlier for the reasons previously stated in 9.32221. 
Regression analysis of the biological data of the remaining 27 penicilIins against 
combinations of the the physico-chemical parameters signified in 9.32224 (model 9. 13) 
as be~ng of importance, yielded the regression model 9. 14 which consisted of one 
descriptor and which was both statistically significant, modelling some 82% of the 
variance presented in the biological data, and predictively valid. 
Model 9.14 
~Rash due to oral penicillins = 3.824(O.263)SSBP - 1.754(0.182) 
n=14 r=O.907 r2=0.823 s=O.l81 F=SS.73 probability=4.728-6 r(CV)2=0.765 
The model suggests that the frequency of cutaneous rash as exhibited in response to 
therapy with oral penicillins is directly related to the similarity in shape of the pencillin 
to benzylpenicillin. The more the penicillin resembles benzylpenicillin the greater the 
frequency of cutaneous rash it will induce. This relationship is displayed pictorially in 
figure 9.7. (Note: the molecules presented are in the same oreintation and so the 
shapes presented are directly comparable). 
The model is also biologically significant as it can be related back to the biological 
situation in vivo, since the majority of the population are believed to be already 
sensitised to benzylpenicillin (BP) as a result of environmental exposure [I] and thus 
possess antibodies against benzylpenicillin. A second administration of benzylpenicillin 
or a structurally similar compound wiU lead to the initiation of a hypersensitivity 
reaction, as discussed in 7.231. If another oral penicillin is administered, its shape 
similarity to the sensitising benzylpenicillin will govern the extent of allergic reaction 
initiated. An oral penicillin which is very similar in shape to benzylpenicillin will be able 
to occupy the same epitope on the antibody and so will be fully recognised by the anti-
benzylpenicillin serum antibodies; a full allergic response will result, giving high levels 
of cutaneous rash. Penicillins which bear less similarity in shape to benzylpenicillin will 
be recognised by or fit with only part of the antibody epitope, thus only a fractional 
allergic response will result, giving lower incidence of cutaneous rash. Penicillins with 
only slight similarity in shape to benzylpenicillin wiU not be recognised by the 
antibodies or fit with any part of the epitope and so no reaction and hence no rash will 
result from their use. 
Figure 9 7 Re re entation of the Relation hi Between the Fre uegfY of Clltaneou 
Rash Induced by Oral Penicillins and Their Sha e Similarit to BenbY~nicjllin 
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9.32226 Parenteral Penicillin Antibiotics 
The skewness value of 0.578 obtained for the parenteral pencillin cutaneous rash 
frequency data showed them to be normally distributed and so suitable for analysis. 
Ticarci1Jin was removed from the data set prior to analysis as an outlier, the reasons 
being the same as those outlined in 9.32221. 
Regression analysis of the transfonned biological data against combinations of those 
descriptor variables highlighted as significant in 9.32224 (model 9.13) produced the 
statistically significant and predictively valid model 9. 15, which modelled 71 % of the 
infomation contained within the biological data. 
Model 9.15 
J"Rash due to 
parenteral penicillins 
= 4.76(0.88)B3 + 5.90(2.06)SSMeth - 5.86(1.72) 
10-
n=12 r=O.843 r2=O.711 5=0.404 F=11.09 probability =0.002 r(CV)2=0.425 
The model clearly suggests that there is a positive relationship between the frequency 
of cutaneous rash initiated by a parenteral penicillin and the shape of the molecule 
itself In this instance it is the similarity in shape of the parenteral penicillin to 
methicillin (that parenteral penicillin giving rise to the greatest frequency of rash) 
coupled with a SterimoI width measurement which are the significant controlling 
factors. The more the parenteral penicillin resembles methicillin and the greater the B3 
width the higher will be the resultant fequency of cutaneous rash induced. The need for 
two shape descriptors may relate to the nature of the receptor site, in that one 
parameter alone is unable to fully represent all aspects of the receptor. The nature of 
the Sterimol parameters prevent identification of the exact region of the molecule 
modelled by each respective parameter and thus restricts the ability hypothesize as to 
the receptor requirements. 
9.32227 AIl Cephalosporin Antibiotics 
The square root transformed data pertaining to the frequency of cutaneous rash 
induced by cephalosporin therapy produces data which are normally distributed, having 
a skewnes value of 0.152, and thus which are conducive to regression analysis. 
Two cephalosporins (cephaJoglycin and cefuzonam) were eliminated from the data set 
prior to analysis on the grounds that they behaved as outliers. CephaJoglycin and 
cefuzonam were for of the reasons given in 9.32221. Two further compounds 
ceftibuten and cepharnycins were found during analysis to be behaving as outliers. 
Ceftibuten was believed to be acting as an outJier because it is administered at a much 
lower therapeutic dose (O.4g/day) than other cephalosporins (average dose 4g1day), as 
a result of which its plasma concentration at its half-life is also much lower (6j.1g1ml) 
compared with the other cephalosporin antibiotics (average plasma concentration at 
t1/2 being 120j.1g1mI), detailed in appendix 5. This fact may account for the relatively 
lower frequency of rash. Should ceftibuten be given at equivalent doses the frequency 
may increase considerably. Cephamycin is essentially a group of four cephalosporin 
like fl-Iactams, and it is not clear from the literature whether the frequency data 
presented for cutaneous rash, are for one or a combination of these cephamycins. This 
uncertainty regarding the accuracy of the clinical data is the reason for the omission of 
cephamycin as an outlier. 
Regression analysis against combinations of those descriptors indicated in 9.32221 
(model 9.10) as being of significance, and against others which were thought may be 
relevant, yielded the statistically significant and predictively valid regression model 
9. ]6, which explained 63% of the variance presented in the biological data. 
Model 9.16 
/ Rash due to =2.08(0.06)Admin - 4. 16(0.35)SSCefacet +3.34(0.68)SSCefep 
an cephalosporins 10 
+ 3. 7S(0.71)SSCefatriz - 1.51(0.98) 
n=38 r=O.796 r2=O.633 s=O.368 F=14.25 probability =3.949-7 r(CV)2=0.560 
Where: SScefacet is a measure of the similairity in shape of the antibiotic to the 
parenteral cephalosporin cefacetrile, which is the cephalosporin (in the data set) giving 
rise to the lowest frequency of cutaneous rash. Ceftibuten actually presents the lowest 
frequency but as it was excluded as an outlier its inclusion as a descriptor was felt to be 
unsuitable. 
The model indicates that the more the cepahJosporin resembles both cefepirome and 
cefatrizine and the less it resembles cefacetrile, in shape, the greater will be the 
frequency of cutaneous eruption which will result. The model also proposes that, when 
coupled to the shape of the cephalosporin, the type of administration (oral or 
parenteral) is significant in governing the overall extent of rash induced. This factor 
probably relates to the different adsorption, transportation and distribution 
requirements of the oral and parenteral cephalosporins prior to their reacting with the 
specific receptor site. 
The relatively low correlation coefficient is probably related to the fact that the 
cutaneous rash data are a combination of the frequencies presented by both oral and 
parenteral cephalosporins, the reaction mechanism( s) or physico-chemical properties 
responsible for which may vary slightly, thus limiting the ability to 'fit' a better model to 
them. Analysis of the individual administration types should enable the production of 
more statistically significant and biologically explainable models. 
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9.32228 Oral Cephalosporin Antibiotics 
The skewness value attained from univariate analysis of the square-root transformed 
biological data, pertaining to the frequency of cutaneous rash due to oral 
cephalosporins (Sk=0.663) showed the data to be normally distributed, and hence 
suitable for further statistical analysis. 
Three compounds, cephalogIycm, cefuzonam and cefroxadine, were believed to be 
outliers and so were removed from the data set prior to regression analysis for the 
reasons given in 9.32221. During analysis cefuroxime-axetil was found to be behaving 
as an outlier. The reasoning for this was that it is a pro-drug of the parenteral 
cephalosporin cefuroxime and as such has an increased plasma half-life (tIl2) of some 
six hours, which far exceeds that of any other oral cephalosporin (other oral cephs. t 1/2 
= one hour, detailed in appendix 5). This prolonged time of the compound being in 
circulation may lead to an increased initiation of the immunological reaction 
mechanisms, than would be the case iftl/2 were equivalent to other cephalosporins. It 
was therefore assumed that the reported frequencies of cutaneous rash for cefuroxime-
axetil could be erroneous and not suitable for comparative statistical analysis. 
Regression analysis against combinations of those parameters previously suggested as 
being relevant, enabled the generation of the stastisticaIly significant and predictively 
valid model 9.17, which describes 90% of the biological variance. 
Model 9.17 
/ Rash due to 
oral cephalosporins 
= -4.469(0.537)L.QglhQml + 4.S83(O.80S)SSCefatriz 
10- -
- 2.600(0.547) 
n=13 r=0.950 r2=0.902 5=0.213 F=46.21 probability =2.304-6 r(CV)2=0.844 
The model suggests that cutaneous rash due to oral cephalosporins is a combination of 
a positive relationship with shape similarity to cefatrizine, and a negative relationship 
with water solubility, which may relate partitioning or to bioavailability, e.g. low 
solubility generally means a low rate of dissolution. Hence there ia a tendency for less 
polar compounds to have a greater rash inducing effect. 
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9.32229 Parenteral Cephalosporin Antibiotics 
A skewness value of -0.230, for the square-root transformed rash data, suggests 
normal distribution and indicates that the data are suitable for statistical modelling. 
Regression analysis produced model 9. IS which was statistically significant and 
preidictively valid, and which described 70% of the biological variance contained 
within the data. 
Cephapirin was eliminated from the data set as an outlier, on the grounds that it was 
the only parenteral cephalosporin which possessed a nitrogen atom in a RI pyridine 
ring substituent, thus adversely effect the properties of cephapirin, so rendering it 
unsuitable for inclusion in the model generation process. 
Model9.IS 
/ Rash due to 
parenteral cephalosporins 
= -7.224(I.SOO)DVz - 3. 190(0.634)SSCefacet 
100 
+ 2.614{l.002)SSCefep + 1.653(1.076) 
n=24 t=O.834 r2=O.695 s=0.317 F=IS.21 probability =1.136-5 r(CV)2=0.564 
The model proposes that the more the compound resembles cefacetrile, and the less it 
resembles cefepirome in its structural shape, the more unlikely it is to be able to 
interact with the receptor and initiate a response. The negative relationship with dipole 
moment suggests that a repulsion effect may be in existence. The greater the 
magnitude of the dipole Z vector the more the compound is repulsed at the receptor 
surface and thus the initiation of the cutaneous reaction mechanism is restricted. 
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Overview of Cutaneous Rash OSARs 
Nine models (9.10 to 9 .18 inclusive) pertaining to the incidence of cutaneous 
rash have been developed. Five of these models show significant statistical and 
predictive validity, two show partial statistical significance and twoare of limited 
statistical significance. 
However, examination of the descriptor variable in each respective model (table 
9.8 page 129), indicates a high degree of consistency in the parameters present. 
The main constituent parameter types are ones which relate to the molecular 
shape and the hydrophobicity of the antibiotic. 
The presence of a shape descriptor is of significance in that it indicates that 
cutaneous rash is possibly induced as a consequence of some form of shape 
specific receptor binding. Such a reaction mechanism supports the hypothesis 
that cutaneous rash is initiated via the specific binding of the antibiotic with a 
pre-existing circulating antibody, as would be expected if, as assumed, the 
responses are mediated through the immediate or delayed hypersensitivity 
immunological mechanisms. 
As with the QSARs pertaining to all ARs (page 143/4) the hydrophobicity term, 
when present, may possibly reflect differences in the absorption characteristics of 
the antibiotics. 
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9.3223 OSAR Models ofGI Disruption Frequency 
9.3223] All ~-Lactam Antibiotics 
The Log 1 0 transformed GI disruption data, for all 70 of the J3-lactams, although 
producing the best skewness value of the four transformations tested gave a Sk value 
of -] .212, indicating that it lay marginally outside the boundaries of norma) distribution 
and that statistical analysis may not yield models of such high levels of statistical 
significance. 
Sepwise regression against 70 descriptors hightlighted a number which were related to 
the biological data. The final model was derived, by regression analysis with respect to 
a combination of the eight most significant descriptor parameters. This yielded model 
9.19 which described only 47% of the infonnation contained within the biological data, 
indicating that the model is not statistically significant. The cross-validated r2 for the 
resultant model (-0.078) showed that the model was not predictively valid. The lack of 
a significant correlation between the GI disruption data of all the J3-lactams assesed 
may be due to the fact that the data contain information pertaining to numerous 
biological responses, which are brought about via numerous biological mechanisms. 
Also, the different antibiotic types (penicillins or cephalosporins) and modes of 
administration (oral or parenteral) may lead to the responses being brought about via 
differing mechanisms. This latter effect is particularly significant as it has previously 
been reported [189,200,202J that compounds administered by different routes are 
excreted via differing routes, which differentially affect the faecal flora, thus initiating 
GI disruption to varying extents. Each of the differing biological mechanisms may be 
initiated in response to a different physico-chemical property or combination of 
properties of the antibiotics under invesigation, therefore the generation of a simple 
linear model which correlates the complexity and diversity of such an array of 
biological mechanisms may not be possible. 
Two compounds (flucloxacillin and cephaloglycin) were identified as acting as outJiers. 
Flucloxacillin was thought to be an outlier on the grounds that the fluorine group 
present in' its structure may adversely affect the flora in such a way as to cause 
superinfection and therefore increased activity, or possibly by direct irritation of the 
gut mucosa, resulting in a higher than expected frequency of disruption. 
Cefaloglycin( e) was believed to be an outlier by virtue of the fact that the frequency of 
GI disruption due to this compound is disproportionately high, at 16.5% compared 
with the other cephalosporins. 
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Model 9.19 
LoglOGI due to = O.311(O.018)#CH3Rl - O. I 13(O.091)#S 
all ~-Iactam antibiotics - 0.383(0.119)tCcarbonyIOxs - O.128(O.079)K3 
+ 0.128(0.I99)IonptJ - 0.I95(0.071)Admin 
-3 . 133(2. 109)SSCepdalor + 2.085(0.707) 
n=68 r=O.684 r2=O.468 s=O.355 F=7.S35 probability =1.12-6 r(CV)2=-0.078 
Where: #CH3R I is the number of methyl groups in the RI acyl side chain. 
#S is the number of sulphur atoms in the entire molecule. 
ICcarbonylOxs is the sum of the charges on the carbonyl oxygens within 
the whole molecule, as determined in Pirnms. 
K 3 is the Kier and HaIl Kappa 3 topological indices, as calculated in TSAR. 
Ionptl. is a measure of the antibiotic's ionisation potential, generated by the 
MOPAC 6.0 software. 
Admin is an indicator variable pertaining to the mode of administration of 
the ~-lactam, where 3 indicates oral and 4 parenteral administration. 
SSCepdalor is a measure of the shape similarity of the antibiotic to 
cephaloridine, a parenterall3-1actam which does not induce GI disruption. 
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9.32232 Oral (l-Lactam Antibiotics 
The skewness value of -0.412 for the oral 13-lactam LoglO transformed GI frequency 
data indicates that this sub-data set is normally distributed and so should be amenable 
to statistical modelling. Regression analysis of the Log I 0 biological data against 
combinations of those descriptors suggested in 9.32231 as being significant and others 
believed to be relevant, yielded regression model 9.20, which was statistically 
significancant and predictively valid and which described 61 % of the biological 
variance. Three oral antibiotics (cephaIogJycine, cefuzonam and cefadroxil) were 
determined as being outliers. CephaIogJycine for the reason outlined in 9.32231. 
Cefuzonam was beJieved to be an outlier because it was felt the additional sulphur 
atom in the molecule (in the R2 side chain the nitrogen atom of other equivalent 
substituents is replaced by a sulphur atom) may either react with the flora iself inducing 
a response or it may alter the electron distribution in the molecule which in turn affects 
the floral response. Cefadroxil was classed as an outIier because of its high plasma half 
life (12 hours) which would give the compound an extended period to interact. Details 
of comparative t 112 levels given in appendix 5. 
Model 9.20 
LogIOGIof 
orall3-lactams 
= -0.316(0.060)SA - 0.SII(0.134)TD - 0.959(0.561)RlHA 
100 10 10 
+ 0.359(0.083)#CH3R 1 + 1.899(0.173) 
n=29 r=0.780 r2=O.609 s=0.190 F=9.351 probability =6.256-5 r(CV)2=0.380 
Where: SA is a measure of the external surface area of the molecule. 
ID is the total dipole moment and is a measure of electron directing. 
R}HA is the hydrogen bond accepting ability of the RI acyl side chain, 
determined using the method ofYang et aJ [80]. 
#CH3R I is the number of methyl groups in the R}acyl side chain. 
In model 9.19 the shape parameter was that of shape similarity to cephaloridine, but 
this 13-lactam is a parenteral antibiotic and so its properties were not felt to be relevant 
to purely oral compounds. In model 9.20, however, shape is still highlighted as being 
significant by virtue of the presence of the measurement of the antibiotics external 
surface area (SA). The importance of binding interactions is indicated by the presence 
in the model of the electronic related parameter total dipole, and the hydrogen bonding 
parameter. The number of methyl groups in the RI acyl side chain may be an indicator 
of the extent of branching and therefore of the shape or flexibility of the substituent, 
which thus affects receptor recognition, or may reflect some hydrophobic or bonding 
factor. 
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9.32233 Parenteral p-Lactam Antibiotics 
A skewness value of -I. 231 indicates that the Log 10 transfonned data lie outside the 
boundaries of nonnal distribution and so may not be compatible with statistical analysis 
and hence it may not be possible to generate a fully significant model. Regression 
analysis of the transfonned data with combinations of those descriptors indicated 
previously (9.32231) and others believed to be of relevance, yielded the statistically 
significant and predictively valid regression model 9.21 which described 62% of the 
variance shown in the biological data. 
Three parenteral Jl-Iactams were detennined to be acting as outliers. Flucloxacillin on 
the grounds that the presence of the fluorine group in the RI side chain was itself 
adversely affecting the flora and yet its effect was not parametrised as flucloxacillin is 
the only Jl-Iactam to include a fluorine atom. Cephaloridine, although highJighed in 
9.3231 as being a significant compound, was in this instance felt to be inflicting 
untoward bias on the model generation procedure as it causes no disruption to the 
lower GI flora, the only parenteral antibiotic not to do so. Cefamandole is given 
therapeutically at doses in excess of 12 grams per day, a level which far exceeds the 
doses of other parenteral Jl-Iactams, as detailed in appendix 5. The levels of GI 
disruption reported may therefore be a function of this increased dosage and so it was 
deemed safer to remove it as an outlier. 
Model 9.21 
LoglOGI due to = 4.934(0.535)#CH3RI + 2.711(0. I 87)SSCefsul - 1.948(0.109) 
all parenteral Jl-Iactams 10-
n=35 1-0.784 r2=O.615 s=0.248 F=2S.SS probability =1.686-7 r(CV)2=0.539 
Where: SSCefsul. is a measure of the shape similarity of the parenteral Jl-Iactam 
with the parenteral cephalsporin antibiotic cefsulodin ,which is responsible 
for inducing the highest frequency of GI disruption of the compound in 
the data Set. (FIucloxacillin is responsible for inducing the greatest 
disruption but is an outlier and so was not felt to be a relevant parameter). 
The model indicates that the more the shape of a compound resembles that of 
cefsulodin coupled with the more methyl groups it possesses in its R I acyl side chain, 
the greater will be the resultant level of GI disruption it induces. 
The fact that it has been possible to produce this valid model with data with slightly 
worse than a nonnaJ distribution casts some doubt over its true worth. However, the 
distribution may mereJy be a reflection of the errors present in the data used, and it 
may be that the use of more accurate data would Jead to the generation of a model of 
yet greater validity. 
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9.32234 AIl Penicillin Antibiotics 
The Log 1 0 transformed Gl disrpution data pertaining to all penicillin antibiotics were 
shown through univariate statistical analysis to be normally distributed (Sk=-0.079) 
and so are suitable for regression analysis. 
Flucloxacillin was removed from the data set as being an outlier for the reasons 
oultined in 9.32233. 
Regression anlaysis was carried out with combinations of those parameters indicated as 
significant in 9.343231. Analysis yielded the statistically significant and predictively 
valid regression model 9.22, which modelled 80% of the information contained witin 
the biological data. 
Model 9.22 
Log10Gl due to 
all penicillins 
= -0.416(0.043)SA.. + 0.532(0.043)ttCH3Rl 
100 10- -
- 0.41S(0.030)Admin + 3.047(0.242) 
n=27 r=0.893 r2=0.798 s=0.160 F=30.34 probability=1.97-8 r(CV)2=O.782 
The model indicates a positive realtionship with the size and extent of branching of the 
RI acyl side chain is of significance. It may be that in this instance the number of 
methyl groups represents the extent of branching occurring in the side chain and thus, 
is a crude measure of shape. This is perhaps why a further size indicator, in this 
instance surface area, is also required. 
The model suggests that the smaller the surface area of the penicillin the greater the 
frequency ofGl disruption it will induce. 
Examination of the different administration modes may yield more significant and more 
biologically explainable regression models. 
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9.32235 Oral Penicillin Antibiotics 
The LoglO transformed Gl disrpution data pertaining to the oral penicillin antibiotics 
were shown to be nonnally distributed (Sk = -0.321) and so suitable for regression 
analysis. Regression analysis was carried out with combinations of those parameters 
indicated as significant in 9.32234 and yielded the statistically significant and 
predictively valid regression model 9.23, which modelled 70% of the vanance 
contained witin the biological data. 
It was not felt that any of the oral penicillins were behaving as outliers. 
Model 9.23 
LoglOGl due to 
oral penicillins 
= -0.471(0.109)SA,+ 0.308(1.275)#CH3Rl - 2.005(0.351) 
100 10- -
n=15 r=0.841 r2=O.706 s=O.138 F=14.44 probability=3.951-4 r(CV)2=0.499 
The model indicates a positive realtionship with the size and extent of branching of the 
RI acyJ side chain are of significance and a negative realtionship with the surface area. 
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9.32236 Parenteral Penicillin Antibiotics 
The Log 10 transformed GI disruption data pertaining to the parenteral penicillin 
antibiotics were shown through univariate statistical analysis to be nonnally distributed 
(Sk = 0.261) and were so suitable for regression analysis. 
FJucloxacillin was removed from the data set as being an outlier for the reasons 
oultined in 9.32233. 
Regression anlaysis was carried out with combinations of those parameter indicated as 
being significant in 9.32234 and yielded the statistically significant and predictively 
valid regression model 9.24, which modelled 86% of the biological variance. 
Model 9.24 
LoglOGI due to 
parenteral penicillins 
= -O.356(O.031)SA + O.570(O.031~H3Rl+ 1.158(0.171) 
100 10- -
n=12 r=O.928 r2=0.861 s=O.174 F=27.80 probability=4.998-5 r(CV)2=O.768 
The model indicates that for penicillin antibiotics the size and extent of branching of 
the R] acyl side chain are of significance. The smaller the surface area of the penicillin 
the greater the frequency ofGI disruption. 
9.32237 All Cephalosporin Antibiotics 
The LoglO transfonned data for all cephalosporins are not normally distributed (Sk= -
1.296) and so the production of a highly significant statistical correlation with 
descriptor variables is dubious. The Jack of nonnal distribution is most likely to be a 
Jegacy of the errors presented in the clinical data used in the model generation 
procedure. 
Regression analysis of the data with combinations of the descriptors highlighted in 
9.32231 and others believed to be relevant, produced the statistically significant and 
predictively valid regression model 9.25, which described 66% of the biological 
variance. 
Two compounds were eliminated as outliers. CephalogJycin was removed for the 
reasons stated in 9.32231, and cefepirome because the predicted frequency of GI 
disruption is some ten times lower than the reported frequency. This discrepancy may 
be a result of the positively charged fused heterocyclic ring structure which forms part 
of the R2 substituent. Parameterising the effects of this positive charge on the rest of 
the molecular properties was not possible. 
Model 9.25 
Log} OGl due to 
all cephalosporins 
= -0.302(0.670)DVzJlO +O.81O(0.106)LCcarbonyIOxs 
-3.886(2.004)SSCephalor - 2.829(O.567)SSCephalex 
- 0.465(1.102) 
n=40 r=0.814 r2=O.663 s=O.312 F=16.71 probability =5.549-8 r(CV)2=O.240 
Where: DVz is is 8 measure of the electron distribution within the molecule in the 
arbitary Z vector, as evaluated in Pimms. 
SSCephalex. is a measure of the shape similarity to cephalexin, that oral 
cephaolsporin which presents the lowest frequency of Gl disruption. 
The statistical significance of model 9.25 is not particularly high; this may be due in 
part to the lack of nonnal distribution displayed by the data and because the data set 
contains infonnation pertaining to both oral and parenteral cephalosporins, which may 
depend on different properties in order to elicit their response. 
9.32238 Oral Cephalosporin Antibiotics 
The LoglO transformed data displayed a normal distribution (Sk = -0.194) and so were 
deemed suitable for statistical analysis. Regression analysis of the biological data with 
those descriptors previously indicated as being of significance (9.32231/217) enabled 
the generation of the regression model 9.26 which showed both statistical significance 
and predictive Validity and which modelled 71 % of the variance present within the 
biological data. 
F our compounds (cephaloglycin, cefuzonam, cefixime and cefadroxil) were removed 
on the grounds of being outliers, cephaloglycin on the basis of the reason stated in 
9.32231, cefuzonam and cefadroxil for the reasons stated in 9.32232. Cefixime was 
determined to be an outlier as it is administered at a dose of O.4g/day, which is 
markedly less than for any other oral cephalosporin. Dosage levels are detailed in 
appendix 5. It was felt that such low dosing would result in lower levels of GI 
disruption than if cefixime were given at a dose equivalent to other oral cephalosporins 
and therefore that the reported frequency was not comparable with those of other oral 
cephalosporins. 
Model 9.26 
LoglOGI due to = -S.77(2.79)TD - 1.57(O.70)SSCephalex - 0.191(0.490) 
oral cephalosporins 100 
n=13 r=O.840 r2=O.706 s=O.162 F=12.02 probability =0.001 r(CV)2=0.376 
The model suggests the more an oral cephalosporin resembles cephalexin, in shape, 
and the lower its total dipole charge, the less will be the extent of GI disruption 
induced by it. 
9.32239 Parenteral Cej>halosporin Antibiotics 
The data presented were not normally distributed, having a skewness value of -1. 743, 
and so the production of a highly significant statistical correlation with physico-
chemical data is dubious. The lack of normal distribution is most likely to be a legacy 
of the errors presented in the clinical data used in the model generation procedure. 
Cefepirome was removed from the data set as an outiier for the reasons given in 
9.32237. 
Regression analysis of the 10810 transformed bio-data with combinations of those 
parameters previously highlighted as being sigificant (9.3223113/7) enabled the 
prodcution of the statistically significant and predictively valid regression model 9.27, 
which describes 81 % of the infomation contained in the biological data. 
The model proposes, as with 9.32237, that shape dependent and electronic interactions 
are important in controlling the frequency of GI disruption induced by a parenteral 
cephalosporin. 
Model 9.27 
LoglOGI due to 
parenteral cephs. 
=-0.342(0.096)OVzlIO -0.809(0. 181)!:CcarbonyIOxs 
-3.957(1. 192)SSCephalor - 2.816(1.362)SSCephalex 
- 0.501(0.474) 
n=24 r=0.902 r2=O.813 s=O.260 F=20.63 probability =2.460-7 r(CV)2=O.565 
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Overview of GI Disruption OSARs 
Nine models pertaining to GI disruption (9.19 to 9 .17 inclusive) have been 
produced. Five of these models display statistical and predictive validity, three 
show signs of partial significance and one (all p-Iactams) shows limited statistical 
significance. 
On closer examination of the descriptor variables presented in each model (table 
9.8 page 130) it can clearly be seen that six of the models contain a specific 
parameter, namely the number of methyl groups in the RI substituent. This 
parameter may reflect a number of molecular properties, such as branching, size, 
shape, flexibility or hydrophobicity. The remaining three models although not 
specifically containing this #CH,Rl parameter contain related shape and 
electronic parameters. 
A second descriptor common to most models is that of total surface area, which 
probably reflects the size of the antibiotic. 
The exact biological mechanism(s) of action which give rise to GI disruption are 
unclear, and so the precise mode of action and the significance of these 
parameters cannot be detennined. It can therefore, only be hypothesised that 
these parameters are connected with the process of 'fitting' into and binding with 
a specific receptor site, thus initiating the response. 
The nature of the receptor site( s) is not known; it may be a receptor which 
controls the growth and / or replication of the flora. Alternatively, the antibiotic 
may bind in the colon in some way as to impair vitamin K2 synthesis. In either 
case the binding of the antibiotic may act to stimulate the growth offaecal flora, 
thus leading to an overpopulation or super-infection of bacteria, which results in 
GI disruption, a phenomenon seen with Enterococcus faecalis and Clostridium 
difficile [202]. Or the initiation ofGI disruption may be due to direct irritation of 
the intestinal mucosa by the antibiotic itseJf[202]. 
The presence of an indicator as to the route of administration, in the larger 
models, is significant in that it is weD documented [200,202] that the excretion 
profiles associated with the different routes of administration have some bearing 
on the levels ofGI disruption induced, as previously discussed in section 9.22, 
page 108. 
9.323 Data Randomisation 
A problem with using large numbers of descriptors in step-wise regression is that there 
is a significant risk of chance correlations occurring, according to T opJiss and Edwards 
[46,104]. In order to investigate whether this had happened in this work, the biological 
data used in each of the 27 models generated were randomised some 20 times and the 
regression analysis repeated, as discussed in methods section 9.3 15. Examination of 
the resultant regression coefficient values for each randomised model, presented in 
table 9.9, clearly shows that for each of the randomised models the value of r was 
significantly less than that attained for the original model, and in most cases was 
approaching zero. This indicates that the randomised models bear no statistical 
significance and do not model any aspect of the biological information. 
It can be assumed therefore, from these randomised results that all the original models 
produced were not generated by chance, but that the descriptors used reflect the actual 
physico-chemical and structural properties responsible for initiating and controlling 
each specific biological response. 
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Table 9.9 Regression Coeffiecient Values Attained from Randomised Data Analysis 
Model r val ues 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
9.1 0.47 0.17 0.38 0.00 0.21 0.26 0.08 0.29 0.16 0.17 0.38 0.16 0.19 0.02 0.05 0.09 0.33 0.41 0.07 0.15 
9.2 0.36 0.21 0.26 0.24 0.19 0.19 0.45 0.02 0.37 0.03 0.23 0.23 0.21 0.13 0.25 0.09 0.14 0.27 0.10 0.13 
9.3 0.29 0.25 0.14 0.18 0.14 0.13 0.26 0.29 0.41 0.35 0.21 0.17 0.27 0.16 0.32 0.13. 0.01 0.32 0.31 0.03 
9.4 0.30 0.02 0.03 0.02 0.39 0.16 0.05 0.08 0.17 0.18 0.10 0.08 0.21 0.00 0.16 0.09 0.21 0.19 0.11 0.13 
9.5 0.12 0.00 0.00 0.00 0.05 0.19 0.16 0.13 0.00 0.16 0.00 0.00 0.31 0.01 0.08 0.23 0.16 0.09 0.13 0.14 
9.6 0.01 0.31 0.15 0.12 0.16 0.03 0.10 0.16 0.00 0.16 0.06 0.28 0.18 0.13 0.33 0.17 0.13 0.09 0.00 0.00 
9.7 0.26 0.19 0.32 0.25 0.12 0.04 0.15 0.00 0.16 0.29 0.00 0.32 0.19 0.23 0.06 0.02 0.21 om 0.23 0.09 
9.8 0.00 0.21 0.36 0.16 0.13 0.22 0.01 0.10 0.14 0.05 0.08 0.16 0.15 0.18 0.00 0.21 0.19 0.17 0.19 0.11 
9.9 0.00 0.00 0.00 0.00 0.00 0.11 0.02 0.21 0.00 0.16 0.31 0.12 0.01 0.15 0.09 0.18 0.18 0.21 0.29 0.31 
9.10' 0.35 0.00 0.00 0.16 0.21 0.17 0.00 0.03 0.29 0.19 0.00 0.32 0.21 om 0.32 0.09 0.23 0.17 0.15 0.21 
9.11 0.29 0.00 0.12 0.16 0.26 0.21 0.11 0.00 0.10 0.18 0.16 0.00 0.11 0.01 0.24 0.19 0.08 0.31 0.15 0.16 
9.12 0.00 0.23 0.16 0.11 0.16 0.Q3 0.19 0.16 0.00 0.12 0.13 0.00 0.12 0.00 0.26 0.17 0.00 0.19 0.12 0.02 
9.13 0.15 0.12 0.00 0.21 0.36 0.00 0.05 0.00 0.24 O.B 0.01 0.00 0.00 0.14 0.14 0.13 0.23 0.21 0.12 0.15 
9.14 0.23 0.21 0.31 0.12 0.13 0.00 0.05 0.00 0.34 0.00 0.16 0.17 0.26 0.17 0.14 0.18 0.08 0.15 0.10 0.15 
9.15 0.00 0.16 0.00 0.05 0.00 0.08 0.22 0.12 0.00 0.12 0.00 0.13 0.19 0.12 0.01 0.17 0.21 0.21 0.23 0.19 
9.16 0.21 0.12 0.00 0.19 0.Q3 0.00 O.OS 0.09 0.00 0.27 0.04 0.07 O.B 0.00 0.00 0.21 0.00 0.01 0.Q2 0.05 
:::i 
Continued over page 
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Table 9.9 continued 
Model r val ues 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
9.17 0.32 0.15 0.10 0.21 0.16 0.29 0.13 0.09 0.14 0.08 0.01 0.16 0.08 0.11 0.01 0.00 0.07 0.09 0.00 0.07 
9.18 0.14 0.07 0.10 0.21 0.07 0.06 0.12 0.16 0.07 0.31 0.08 0.16 0.02 0.05 0.12 0.08 0.31 0.02 om 0.17 
9.19 0.30 0.29 0.05 0.06 0.11 0.01 0.04 0.26 0.06 0.09 0.26 0.06 0.07 0.17 0.16 0.18 0.03 0.08 0.12 0.16 
9.20 0.12 0.07 0.21 0.16 0.14 0.09 0.03 0.14 0.12 0.13 0.05 0.12 0.31 0.09 0.10 0.15 0.08 0.10 0.01 0.02 
9.21 0.26 0.06 0.13 0.08 0.09 0.00 0.13 0.15 0.17 0.07 0.02 0.08 0.15 0.03 0.05 0.17 0.10 0.03 0.12 0.16 
9.22 0.08 0.17 0.05 0.09 0.17 0.16 0.11 0.02 0.25 0.08 0.02 0.10 0.09 0.14 0.08 0.13 0.01 0.19 0.14 0.09 
9.23 0.34 0.10 0.00 0.11 0.06 0.27 0.\2 0.08 0.06 0.16 0.29 0.11 0.12 0.08 0.13 0.06 0.09 0.15 0.02 0.05 
9.24 0.16 0.06 0.08 0.05 0.16 0.09 0.09 0.01 0.07 0.07 0.00 0.10 0.15 0.08 0.02 0.10 0.09 0.03 0.16 0.12 
9.25 0.19 0.07 0.\5 0.05 0.03 0.17 0.07 0.00 0.19 0.00 0.09 0.08 0.09 0.D7 0.01 0.01 0.12 0.08 0.21 0.06 
9.26 0.07 0.21 0.10 0.17 0.04 0.07 0.09 0.32 0.16 0.06 0.01 0.18 0.\7 0.11 0.06 0.23 0.05 0.11 0.08 0.13 
9.27 o.n\ 0.01 0.19 0.12 0.09 0.00 0.10 0.18 0.17 0.00 0.07 0.20 0.00 0.\3 0.07 0.11 0.16 0.08 0.10 0'(19 
-
...l 
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9.4 Prediction of the Frequencies of ARs for Untested Compounds 
9.41 Method 
During the data generation procedure the chemical structures of nine J3-lactam 
antibiotics (4 penicillins and 5 cephalosporins) were obtained, but little or not 
biological data was gleaned. These structures were input into the modelling 
packages and the relevant physco-chemical and structural parameters generated, as 
in 9.32. The biological activities (frequencies of all ARs, cutaneous rash and Gf 
disruption) for these new compounds were then evaluated using the relevant 
models, as derived in 9.322. 
9.42 Results and Discussion 
The structure, relevant descrpitor variable values generated and the predicted 
adverse reaction frequencies (as both LogIO or.r and the respective % of the 
treated population) as evaluated using the relevant QSARs for each the 4 penicillins 
are given in 9.421 and for the 5 cephalosporins in 9.422. 
In some cases where the mode of administration of the antibiotic was not known, 
several models were used to evaluate the several frequency values for the same 
adverse reaction type. Comparison of these predicted frequencies shows that 
different values are obtained for each model used. However, on closer inspection it 
becomes apparent that the values generated by one of the more general models, i.e. 
aU peniciUins, and one of the more specialised models, i. e. oral penicillins, are of the 
same magnitude, thus suggesting the possible mode of administration and potential 
AR frequency of the antibiotic in question. Comparison of the predicted AR 
frequencies obtained for these test antibiotics with those of related antibiotics, as 
generated in 9.2, shows that the predicted AR frequencies fall within the respective 
reported frequency range, thus giving credence to the predicted values of adverse 
reaction frequencies evaluated from the developed QSARs. 
It is unfortunate that it was not possible to obtain clinical AR frequency data for 
these nine p-Iactam antibiotics, so preventing them constituting a true evaluation 
data set, as comparison of those actual values against the respective predicted 
values, as determined here~ would further add to the credibility and validity of the 
QSARs produced. 
9.421 Predicted AR Frequencies of Untested Penicillins 
Name: HETACILLIN 
Mode of administration: Oral 
Predicted AR Frequencies 
Model Frequency 
All ARs 
Log 10 % 
Oral t3-lactams -0.26 0.55 
Oral penicilIins 0.85 7.00 
CH3 
H3 
;--~-~<'I -OH 
o 
of Adverse Reaction 
Cutaneous Rash GI 
r % Log 1 0 
Ne Ne 4.52 
0.61 0.37 1.02 
Ne = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
Descri tor Variables: 
Parameter Value Parameter 
0.69 
0.66 
0.74 
0.62 
to Cefsulodin 0.60 
Total di le moment 4.28 RI h bond a 
Di ole moment in vector Z -1.66 SumceArea 
RI bu.f .......... bond donor ab' . 5 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
Disruption 
% 
error 
10.39 
Value 
1.06 
NO 
0.65 
0.60 
2 
3 
389.5 
1'7+ 
Name: PHENETHICILLIN 
Mode of administration: Oral 
Predicted AR Frequencies 
Model Frequency 
AUARs 
Log I 0 % 
Oral J3-1actams 0.60 3.98 
Oral penicillins 2.78 error 
OH 
of Adverse Reaction 
Cutaneous Rash GJ 
..r % Log 1 0 
NC NC -1.09 
0.75 0.54 -3.49 
Ne = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
Descri tor VariabJes: 
Parameter Value Parameter 
to Cefinetazole 0.75 CLogP 
Sha e s' . . to Flucloxacillin 0.75 Log H20 solubility 
0.71 Shap~ similarity to Ceftibuten 
0.65 Shape similarity to Cefatrizine 
Di ole moment in vector Z 2.51 # Methyl groups in RI 
Total Di ole moment 4.18 Shape similarity to Cefsulodin 
2 Surface Area 
R I h\ll1rtWNllft 11 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
Disrupti~ 
% 
0.08 
0.00 
Value 
1.75 
NG 
0.74 
0.64 
I 
0.60 
321.6 
"5 
Name: BLP-1654 
Mode of administration: unknown 
Predicted AR Frequencies 
Model Frequency of Adverse Reaction 
All ARs Cutaneous Rash GI 
Log 10 % ..r % Log 10 
All 6-lactams 0.03 1.08 Ne Ne Ne 
Oral fJ-lactams 0.82 6.53 Ne Ne -0.13 
Parent. 6-lactams 5.54 Ne Ne Ne -0.002 
All peniciIlins 0.278 7.72 oral - 1. 76 3.11 -2.71 
parent. - 2.40 5.76 -372 
Oral peniciIlins 0.295 error 1.29 1.66 -2.40 
Parent. penicillins -10.63 error 2.48 6.15 -0.09 
Ne = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
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Disruptiaa 
% 
Ne 
0.74 
1.00 
7.32 
9.74 
0.0 
0.81 
BLP-1654 Descriptor Variables: 
Parameter Value Parameter 
flexibility of R I 10.09 Charge on C ofJ3 ring carbonyl 
# amino groups in RI 4 Similarity to Lipophilicity of Bpen. 
R3 indicator variable I Sterirnol B2 width from CH~ 
R4 indicator variable 1 # carbon atoms in RI 
# oxygen atoms in whole molecule 5 Sterimol B3 width (f3-ring carbonyl) 
Administration ID 3/4 Shape similarity Methicillin 
Shape similarity to Cefinetazole 0.76 CLogP 
Shape similarity to FlucloxacjIJin 0.63 Log H,O solubility 
Shape simiJa!ify to Cephapirin 0.73 Shape similarity to Ceftibuten 
Shape similarity to B~"Z"ib)enicillin 0.80 Shape similarity to Cefatrizine 
Dipole moment in vector Z 1.54 # Methyl groups in RI 
Shape similarity to Cefepirome 0.12 Shape similarity to Cephaloridine 
# sulphur atoms in whole molecule 1 Shape similarity to Cefsulodin 
Sum charge on carbonyl oxygens -1.66 Total Dipole moment 
Corulectivity kappa 3 NG RI hydrogen bond acceptor ability 
Ionisation potential 9.06 Surface Area 
R I hydrogen bond donor ability II 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
m 
Value 
0.29 
0.53 
4.33 
10 
8.31 
0.74 
-0.33 
NG 
0.67 
0.75 
0 
0.72 
0.72 
8.60 
5 
351.3 
Name: SULBENICILLIN 
Mode of administration: Parenteral 
~ (OrrHC 
~ 
Predicted AR Frequencies 
F 
OH 
Model Frequencv of Adverse Reaction 
All ARs Cutaneous Rash GI 
LogIO % .r % Log 1 0 
Parent. Jl-lactams 6.79 error Ne Ne -0.15 
Parent. penicillins 1.08 11.91 -1.91 3.64 2.37 
Ne = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
Descri tor Variables: 
Parameter Value Parameter 
to Methicillin 0.79 CLogP 
to Fluc10xacillin 0.78 Log H~O solubility 
to Cefsulodin 0.66 # carbons atoms in RI 
1 Sterirnol 83 width (j3-ring carbonyl) 
Cha -1.70 Surface Area 
3.88 # methyl groups in RI 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
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DISruptlOl'\ 
% 
0.71 
error 
Value 
0.63 
NG 
8 
7.33 
340.2 
0 
9.422 Predicted AR Frequencies of Untested CepbaJosporins 
Name: CEFAZAFLUR 
Mode of administration: Unknown 
Predicted AR Frequencies 
Model Frequencv of Adverse Reaction 
AllARs Cutaneous Rash Gl 
Log 10 % ..r % LogIO 
All p-lactams 1.27 18.41 Ne Ne NC 
Orall3-lactams 0.78 5.97 Ne Ne Ne 
Parent. p-lactams 4.14 error Ne Ne -0.1 ] 
AIl cephaJosporins -3.92 0.00 oral - 1.11 l.23 -2.15 
parent. - l.74 
1.32 
Ora) cephalosporins 0.98 9.48 Ne Ne 0.26 
Parent. CephaIosporins 7.47 error 1.72 2.97 -0.30 
NC = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
Disruption 
% 
NC 
Ne 
0.78 
0.01 
l.81 
0.50 
CefazaOur :Descriptor Variables 
Parameter Value Parameter 
Flexibility of R] 7.02 # carbon atoms in RI 
# amino groupS in RI 1 Log H..,O solubility 
R3 indictor variabJe 1 Shape similarity to Methicillin 
R4 indicator variable 2 Shape similaritv to Cefeoirome 
# oxygen atoms in whole molecule 4 Shape similaritv to Ceftibuten 
Shape similarity to Cetinetazole 0.70 Shape similaritv to Cefatrizine 
Shape similarity to Flucloxacillin 0.74 Administration Indicator variable 
Shape similarity to Cephapirin 0.72 Shape similarity to Cefacetri/e 
CLogP 0.07 # methyl groups in RI 
Dipole moment in vector Z -6.12 # sulphur atoms in whole molecule 
Charge on C of J3-ring carbonyl 0.29 Sum charge on carbonvl oxygens 
Hydrogen bond acceptor ability 7 Connectivity kappa 3 
Total dipole moment 6.84 Ionisation potential 
Sterimol B3 width of R2 1.93 Shape similarity to Cephaloridine 
# nitrogen atoms in R2 4 Surface area 
# oxygen atoms in R2 0 R 1 hydrogen bond acceptor ability 
Sterimol L of R2 7.48 Shape similarity to Cefsulodin 
Sterimol B2 width (CH~) 5.21 Shape similarity to Cephalexin 
Shape similarity to Benzylpenicillin 0.79 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
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Value 
3 
NG 
0.72 
0.68 
0.7] 
0.67 
3/4 
0.93 
0 
3 
-1.19 
NG 
9.36 
0.72 
NG 
4 
0.68 
0.67 
Name: CEFTEZOLE 
Mode of administration: Unknown 
HO-C 0 
Predicted AR Frequencies 
Model FreQuency of Adverse Reaction 
All ARs Cutaneous Rash GI 
Log 1 0 % .r % Log 1 0 
All f3-Jactams 0.56 3.66 NC NC NC 
Oral ~-Jactarns 0.84 6.87 NC Ne 0.01 
Parent. f}-Jactarns 0.67 4.70 NC Ne -0.29 
All cephalosporins -3.71 error oral-O.25 0.06 -0.88 
parent. -0.04 0.00 
Oral cephalosporins 0.72 S.21 Ne Ne 1.02 
Parent. Cephalosporins 0.37 2.32 1.03 1.07 0.28 
NC = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
ta\ 
Disruption 
% 
NC 
1.03 
0.52 
7.59 
10.52 
1.90 
Ceftezole :Descriptor Variables 
Parameter Value Parameter 
Flexibility of R 1 3.98 # carbon atoms in R] 
# amino groups in RI 1 Log H20 solubility 
R3 indictor variable I Shape simila!i!Y to Methicillin 
R4 indicator variable 2 Shape similarity to Cefepirome 
# oxygen atoms in whole molecule 4 Sha~e similarity to Ceftibuten 
Shape similarity to Cefinetazole 0.69 Shape similarity to Cefatrizine 
Shape similarity to Flucloxacillin 0.69 Administration Indicator variable 
Shape similarity to Cephapirin 0.60 Shape similarity to Cefacetrile 
CLogP 
-1.62 # methyl groups in RI 
Dipole moment in vector Z -7.87 # sulphur atoms in whole molecule 
Charge on C of ~-ring carbonyl 0.29 Sum charge on carbonyl oxygens 
Hydrogen bond acceptor ability 7 Connectivity kappa 3 
Total dipole moment 7.97 Ionisation potential 
Sterimol B3 width of R2 3.41 Shape similarity to Cephaloridine 
# nitrogen atoms in R2 2 Surface area 
# oxygen atoms in R2 0 R I hydrogen bond acceptor ability 
Sterirnol L of R2 8.13 Shape similarity to CefsuJodin 
Sterimol B2 width (CH~) 6.27 Shape similarity to Cephalexin 
Shape similar!tY to Benzylpenicillin 0.74 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
182. 
Value 
3 
NG 
0.72 
0.60 
0.69 
0.60 
3/4 
0.86 
0 
3 
-1.19 
NG 
9.11 
0.71 
347.0 
4 
0.61 
0.78 
Name: CEFI10FLUR 
Mode of administration: Unknown 
Predicted AR Freguencies 
Model Frequency of Adverse Reaction 
All ARs Cutaneous Rash GI 
Log I 0 % r % Lo£lO 
All tJ-Iactams 0.59 3.85 Ne Ne Ne 
Oral tJ-lactams 0.40 2.51 Ne Ne -0.36 
Parent. fJ-lactams 1.51 32.43 Ne Ne 0.28 
AIl cephalosporins -6.66 0.00 oral- 0.28 0.08 -2.21 
parent. - 0.24 
0.49 
Oral cephaJosporins 0.39 2.46 Ne Ne -0.29 
Parent. Cephalosporins -0.09 0.81 0.93 0.86 -0.42 
Ne = Due to the lack of one or more descriptor values it was not possible to 
c8Iculate this frequency, using the respective QSAR model. 
Disruption 
% 
Ne 
0.44 
1.88 
0.00 
0.52 
0.38 
CeftioRur :Descriptor Variables 
Parameter Value Parameter 
Flexibility of R] 7.49 # carbon atoms in RI 
# amino groups in RI 2 Log H,0 solubility 
R3 indictor variable 1 Shape similarity to Methicillin 
R4 indicator variable 2 Shape similarity to Cefepirome 
# oxygen atoms in whole molecule 7 Shape similarity to Ceftibuten 
Shape similarity to Cefinetazole 0.56 Shape similarity to Cefatrizine 
Shape similarity to Flucloxacillin 0.62 Administration Indicator variable 
Shape similarity to Cephapirin 0.64 Shape similarity to Cefacetrile 
CLogP 0.89 # methyl groups in RI 
Dipole moment in vector Z -0.21 # sulphur atoms in whole molecule 
Charge on C of l3-ring carbonyl 0.29 Sum charge OIl carbonyl oxygens 
Hydrogen bond acceptor abilltY_ 10 Connectivity kappa 3 
T oral dipole monient 12.62 Ionisation potential 
Sterimol B3 width of R2 3.59 Shape similarity to Cephaloridine 
# nitro~en atoms in R2 0 Surface area 
# oxygen atoms in R2 2 RI hydrogen bond acceptor ability 
Sterimol L of R2 7.25 Shape similarity to Cefsulodin 
Sterimol B2 width (CH3) 4.93 Shape Similarity to Cephalexin 
Shape similarity to BenzylpeniciJJin 0.72 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
Value 
5 
NG 
0.75 
0.66 
0.62 
0.63 
3/4 
0.8] 
I 
3 
-1.16 
NO 
8.87 
0.69 
414.4 
7 
0.64 
0.64 
Name: CEFEP~IZOLE 
Mode of administration: Unknown 
I~ 
HO--C-:=O 
Predicted AR Freguencies 
Model Frequency of Adverse Reaction 
All ARs Cutaneous Rash GI 
Log 1 0 % J' % Lo~1O 
All t3-1actams 0.60 3.97 Ne Ne Ne 
Oral t3-lactams 1.04 10.99 NC Ne Ne 
Parent. t3-1actams 0.54 3.45 Ne Ne -0.10 
All cephalosporins -4.75 0.00 oral - 0.35 0.12 -2.4 
parent. - 0.31 
0.55 
Oral cephalosporins 0.97 9.27 Ne NC 0.14 
Parent. Cephalosporins 1.07 11.78 1.02 1.05 -0.25 
Ne = Due to the lack of one or more descriptor values it was not possible to 
calculate this frequency, using the respective QSAR model. 
Disruption 
% 
Ne 
Ne 
0.80 
0.00 
1.37 
l.80 
Cefepimizole Descriptor Variables 
Parameter Value Parameter 
Flexibility of R 1 9.40 # carbon atoms in R] 
# amino groupS in RI I Log H,O solubility 
R3 indictor variable 1 Shape similarity to Methicillin 
R4 indicator variable 2 Shape similarity to Cefepirome 
# oxygen atoms in whole molecule 9 Shape similarity to Ceftibuten 
Sh~e similarity to Cefinetazole 0.59 Shape similarity to Cefatrizine 
Shape similarity to FlucIoxacillin 0.S7 Administration Indicator variable 
Shape similarity to Cephapirin 0.53 Shape similarity to Cefacetrile 
CLogP 
-l.56 # methyl groups in RI 
Dipole moment in vector Z -4.47 # sulphur atoms in whole molecule 
Charge on C of f3-ring carbonyl 0.29 Sum charge on carbonyl oxygens 
Hydrogen bond a~tor ability 9 Connectivity kappa 3 
Total dipole moment 7.30 Ionisation potential 
Sterimol B3 width of R2 6.61 Shape similarity to Cephaloridine 
# nitrogen atoms in R2 I Surface area 
# oxygen atoms in R2 3 RI hydrogen bond acceptor ability 
Sterimol L of R2 6.49 Shape similarity to Cefsulodin 
Sterimol B2 width (CH~) 6.45 Shape similarity to Cephalexin 
Sh~e similarity to Benzylpenicillin 0.66 
NG = It was not possible to generated the respective descriptor value, 
using the relevant software. 
Value 
13 
NG 
0.67 
0.53 
0.59 
0.67 
3/4 
0.73 
0 
2 
-1.72 
NG 
8.78 
0.64 
NG 
5 
0.68 
0.62 
Name: CEPHANONE 
Mode of administration: Unknown 
Predicted AR Frequencies 
Model Frequency of Adverse Reaction 
All ARs Cutaneous Rash OJ 
Log 10 % J % Log 1 0 
All JJ-lactams 1.10 12.56 Ne Ne Ne 
OralJJ-lactams Ne Ne NC Ne Ne 
Parent. f3-1actams Ne Ne Ne Ne -0.09 
All cephaIosporins Ne NC oral- 0.56 0.31 NC 
parent. - 0.19 
0.43 
Oral cephalosporins Ne Ne Ne Ne Ne 
Parent. Cephalosporins Ne Ne Ne NC Ne 
Ne = Due to the lack of one or more descriptor values it was not possible to 
caiculate this frequency, using the respective QSAR model. 
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Disruption 
% 
Ne 
Ne 
O.SI 
Ne 
Ne 
Ne 
Cephanone :Descriptor Variables 
Parameter Value Parameter 
Flexibility of R 1 4.67 # carbon atoms in RI 
# amino groups in RI 1 Log H,O solubility 
R3 indictor variable I Shape similarity to Methicillin 
R4 indicator variable 2 Shape similarity to C~~irome 
# oxygen atoms in whole molecule 6 Shape similarity to Ceftibuten 
Shaj>e similarity to Cefmetazole 0.74 Shape similarity_ to Cefatrizine 
Shape similarity to Flucloxacillin 0.73 Administration Indicator variable 
Shape similarity to C_ephapirin 0.59 Shape similarity to Cefacetrile 
CLogP NO # methyl groups in R] 
Dipole moment in vector Z NO # sulphur atoms in whole molecule 
Charge on C of13-rinB carbonyl NO Sum charge on carbonyl oxygens 
Hydrogen bond acceptor ability 9 Connectivit}' kappa 3 
Total dipole moment NO Ionisation potential 
Sterimol B3 width of R2 3.03 Shape similarity to Cephaloridine 
# nitrogen atoms in R2 2 Surface area 
# oxygen atoms in R2 0 RI hydrogen bond acceptor ability 
Sterimol L of R2 9.15 Shap_e similarity to Cefsulodin 
Sterirnol B2 width (CH3) 7.30 Shape similarity_to Cephalexin 
Shape similarity to Benzylpenicillin 0.80 
NG = It was not possibJe to generated the respective descriptor value, 
using the reJevant software. 
.. 
Value 
3 
0.71 
0.61 
0.67 
0.71 
NG 
3/4 
0.87 
0 
3 
NG 
NG 
9.27 
0.67 
342.5 
6 
0.68 
0.68 
9.5 Conclusion 
A data base pertaining to the frequencies of adverse responses exhibited by patients 
following therapy with 70 J3-lactam antibiotics has been collated and the data used 
to develop 27 mathematical models relating the frequencies of specific response 
types to specific physico-chemical and structural properties of the antibiotics 
themselves. 
The models generated for each specific response vary in statistical validity, but each 
appears to utilise appropriate and often equivalent descriptors to model that 
response type (AR, cutaneous rash or GI disruption). 
Oral and parenteral antibiotics present models containing somewhat different 
parameters for the same biological response, probably reflecting the different 
properties each requires to bring about the response in view of their different 
absorption, transportation, distribution and elimination needs. 
The penicillins and cephalosporins also present models containing somewhat 
different parameters, suggesting that each antibiotic type initiates a specific 
biological response via slightly different biological mechanisms which are dependent 
on slightly different structural properties. 
In the majority of instances the model generated includes at least one shape and / or 
electronic parameter, suggesting that in each reaction type some form of receptor 
recognition and binding is at the crux of the reaction initiation procedure, a 
suggestion which is concurrent with theories on immunotoxic reaction mechanisms. 
However, the complexity and diversity of the reactions included within each data 
set precludes receptor identification, typing (immunoglobulin or flora), location and 
mapping or further interpretations as to the exact biological mechanisms involved. 
The models derived provide support to existing theories as to the mechanisms of 
action of the J3-lactam antibiotics, as well as providing a means of predicting the 
possible frequency of an adverse reaction which a new, untested or hypothetical J3-
lactam antibiotic may induce ifused therapeutically. 
Due to the nature of the data used in the model generation procedures the predicted 
AR frequencies are open to some degree of error and so should be used only as 
guidelines or in conjunction with other imunogenicity studies. 
The ability to generate models pertaining to the frequency of adverse reactions and 
physico-chemicaJ properties of a given set of compounds bodes well for future 
research in this field. 
10.0 Prediction of Cross-Reactivity between B-Iactam Antibiotics and 
Anti-Benzylpenicillin Serum Antibodies 
10. I Introduction 
The phenomenon of cross-reactivity between allergens and antibodies raised ill vivo to 
a different previously administered allergen is believed to be a major factor underlying 
the incidence of immunologically mediated adverse reactions, principally the 
hypersensitivity type reactions [33,36]. As such it poses a problem when it occurs 
frequently with phamaceutically administered compounds, such as the 13-lactam 
antibiotics [582]. Cross-reactivity between penicillin and cephalosporin antibiotics is 
well debated [25,33]. A much cited figure, pertaining to cross-reactivity between 
penicillins and cephaJosporins is 8% and was derived from a retrospective study by Petz 
[33]. Yet other studies indicate that little if any cross-reactivity occurs between the 
penicillins and the cephalosporins [25J. 
A variety of approaches for assessing an antibiotic's cross-reactivity potential have been 
developed over. the years [33,584,585,586,587], e.g. measuring total or individual 
immunoglobulin titres. However, the complexity of cross-reactivity, and the difficulties 
associated with such studies, mean that it is difficult to express the extent of cross-
reactivity in quantitative terms [165,188,584,588]. 
The aim of this study: was firstly to develop a quantitative assay for the determination 
of the cross-reactivity potential of different antibiotics and anti-benzylpenicillin serum 
antibodies; secondly, as the penicillin and cephalosporin antibiotics are structurally very 
similar [586], to develop QSARs which correlate the extent of cross-reactivity with 
specific physico-chemical or structural properties of the antibiotics. 
10.2 Development ofaD Assay for the Ouantitative Determination of Cross-Reactivity 
Between (J-Lactam Antibiotics and Anti-Benzylpenicillin Serum Antibodies 
Large numbers of studies, in both humans and animals, have previously been perfonned 
to investigate the extent to which penicillins and cephalosporins cross-react 
[188,584,585,586,589]. Previous experimental studies, by Blanca et al [34] and by 
Petersen & Graham [590], with animaI-raised antisera have demonstrated that cross 
reactions between penicilJin and cephalosporin antibiotics are detectable using Enzyme 
Linked Immuno-Assay (ELISA) techniques. 
In this study an existing ELISA for the detection of anti-benzylpenicillin serum 
antibodies has been modified in such a way as to develop a highly sensitive, reliable, 
competitive ELISA for the quantitative determination of the level of cross-reactivity 
occurring between J3-1actam antibiotics and anti-benzylpenicillin serum antibodies. The 
ELISA used involves binding benzylpenicillin, in the form benzylpenicillin cytochrome-
C (an antigen), to a solid matrix, the capture of antibodies from a serum sample by the 
antigen and the subsequent binding of a detectable immunogJobulin marker. 
Levine [188J stated that an aUergic reaction depends upon the outcome of competition 
for the allergen (in this instance the J3-lactam antibiotic) by several classes of antibodies . 
present in the serum (i.e. within a polyclonal antibody environment). It was felt 
therefore that the ELISA should be developed using whole serum, which contains 
polyclonal antibodies. As with the work of Peters en & Graham [590], serum polyclonaJ 
antibodies from rabbits sensitised, intradennally and subcutaneously, with protein 
conjugated benzylpenicillin in the presence of Freund's adjuvant over a period of ninety 
days (sensitisation's performed on days 0, 21, 56 and 90) were examined, in all 
experiments, for cross reactivity. It was felt that this polyclonal system would best 
mimic the clinical situation and enable extrapolation of the results. Rabbit serum was 
chosen because the rabbit is the species of choice in pharmaceutical immunogenicity 
studies (in that its immune system is similar to that of humans), and so that the results 
gleaned from this study could be used in conjunction with those from other 
immunogenicity studies. 
The assay was subsequently used for the quantitative determination of the extent of 
cross-reactivity occurring between different J3-1actam antibiotics and rabbit serum 
polyclonaJ anti-benzyJpenicillin antibodies. 
10.21 Experiment I: Detection of Serum Anti-benzylpenicillin Antibodies 
10.211 Method 
WelJs of LinbrolTiterk flat bottomed plate (lCN Biomedicals Inc.) were coated by 
addition of SOllt of 10llglmJ benzylpenicillin cytochrome-C antigen, made in coating 
buffer (0.05M carbonate bicarbonate buffer pH9.6 (sigma C3041», and incubated in a 
Stuart Scientific incubator model S 118 for 2 hours at 3 70 C. Prior to each subsequent 
step the wells were washed three times with PTS (phosphate buffered saline pH7. 4 
(Sigma P3813) + 0.01% Tween 20 (polyoxyethylenesorbitan-monolaurate) (Sigma 
P1379», using a a Dynatech MRW automatic plate washer. 
The antigen-coated wells were subsequently incubated with; 
a - 50J,l1 sensitised serum, positive for polycJonaJ anti-benzylpenicillin antibodies 
(RB-BPIOI-IOS) for 1 hour at 370 C at dilution's of 1:200, 1:400, etc. in PTS 
b - 50J,t1 anti-rabbit IgG-Horse Radish Peroxidase Conjugate (Sigma A-8275) at 
1 : 1000 dilution in PTS for 1 hour at 370C 
c - 50J,t1 3,3',5,5' tetramethylbenzidine liquid substrate (TMB) (Sigma T -8540) at room 
temperature until sufficient colour had developed. The reaction was stopped with the 
addition of SOil) O.5M H2S04. Absorbance readings were then taken at 450nm using a 
BioTek EL900 plate reader. 
Controls were established by replacing the anti-benzylpenicillin antibody-positive serum 
(RB:BPlOI-IOS) with normal, antibody free, rabbit serum (NRS) at dilutions of 
1:20,1:40, etc. 
Background absorbance levels were detennined using equation 10.1 
Background = mean absorbance of control at 450nrn + 3 standard deviations (10. I) 
Twelve replicates of assay, using the same rabbit serum sample, were made in order to 
determine the reproducibility of the assay. 
10.212 Results and Discussion 
Graphical representation of the absorbance data, figure 10.], illustrates that the results 
obtained for the detection of rabbit serum anti-benzylpenicillin antibodies in each of the 
twelve replicates and over a range of serum dilutions produces a classical dose-
response relationship. It can also be seen that the results obtained for each replicate are 
very similar with regard to the magnitude of the absorbance level measured, and 
therefore the amount of antibody present, in each respective serum dilution. It can be 
concluded therefore that the assay is very reproducible. 
Figure 10.1 Reproducibility of Benzylpenicillin Cytochrome-C ELISA fortie Detection of Anti-Benzylpenicillin Antibodies in Rabbit 
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10.22 Experiment 2: Adsorption of Benzylpenicillin 
The ability of serum antibodies to bind an allergen, in this case a ~-lactam antibiotic, 
has normally been detennined by adsorbing a high concentration (lOmglml) of the 
antibiotic onto the anti-benzylpenicillin antibody containing serum sample prior to 
ELISA detection of the antibodies. If cross-reactivity between the antibiotic and the 
anti-benzylpenicillin antibodies occurs then the serum antibodies will bind to the 
antibiotic, so being unable to bind with the bound benzylpenicillin cytochrome-C 
allergen in the ELISA. Therefore the absorbance readings for the adsorbed serum will 
be lower than those of a positive control (no antibiotic adsorbed) assessed 
concurrently. 
10.221 Method 
Benzylpenicillin cytochrome-C antigen coating of the ELISA plate was performed as 
previously (10.21). O.Smg, 2.Smg and Smg quantities of native benzylpenicillin (Sigma 
48F -0012 ) were weighed out, using a Mettler AT261 Delta Range Balance (calibrated 
daily). Each sample was then added to S00J.11 samples of anti-benzylpenicillin antibody 
positive serum (RB:BPlOl-105) or normal rabbit serum (negative control), giving 
1 mglmJ, Smglml and 10mglmJ concentrations of benzylpenicillin in each serum sample. 
The serum samples were then incubated for 1 hour at 37°C. 
Immediately prior to addition of the serum samples to the ELISA plate, as in 10.21 , the 
adsorbed serum samples were centrifuged, using a Chemlab refrigerated ALC 4237R 
centrifuge, at 3000rpm for 10 minutes. 
The adsorbed serum samples were then added to the respective wells in place of the 
serum sample in 10.21 and the assay continued as in 10.2] . 
10.222 Results and Discussion 
Graphical representation of the absorbance data, figure 10.2, illustrates that it is not 
possible to Quantitate the levels of antibody which bind to the native benzylpenicillin 
(antibiotic) in the serum during the adsorption procedure. Over the range of adsorbed 
native benzylpenicillin concentrations it is possible only to determine if adsorption, and 
therefore cross-reactivity, has occurred or not. This is probably due to the lack of assay 
sensitivity in that the assay does not enable the detection of slight changes in antibody 
concentration. 
It was considered that increasing the assay sensitivity, by optimising the assay 
conditions about the lower end of the dose-response curve, just prior to its levelling-
off, (e.g. about the serum dilution of 1: 12800) could make the detection of very slight 
changes in antibody concentration possible and thus enable the Quantitation of the 
levels of antibody adsorbed from the serum by the allergen, i.e. Quantitation of the 
extent of cross-reactivity occurring between the antibiotic and the anti-benzylpenicillin 
antibodies. 
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10.23 Experiment 3: Increasing Assay Sensitivity 
10.23 1 Method 
A checkerboard assay, figure 10.3, of the above ELISA (10.21) was performed using 
anti-benzylpenicillin positive serum (RB:BPlOI-I05) at a dilution of 1: 12800 in PTS, in 
order to detennine the optimal concentrations of benzylpenicillin cytochrome-C antigen 
and anti-rabbit IgG conjugated horse radish peroxidase required for the detection of 
low concentrations of polyclonal anti-benzylpenicillin serum antibodies. 
Determination of the optimal reagent concentrations were made by comparison of the 
mean test absorbances, the mean background absorbance and the difference between 
test and background for each set of reaction conditions. Optimal assay conditions occur 
when both the test absorbance and the difference are at a maximum and the background 
absorbance is minimal. 
The optimised assay was then performed with replicates of the same serum sample, to 
ensure increased sensitivity had been attained and reproducibility maintained. 
10.232 Results and Discussion 
Graphical representation of the checkerboard absorbance readings are given in figure 
10.4. The optimal reagent conditions determined were; a 5J.1g/mI concentration of 
benzylpenicillin cytochrome-C and a 1/2500 dilution of anti-rabbit IgG conjugated horse 
radish peroxidase, in PTS. 
Graphical representation of the absorbance results obtained for each of the replicates of 
the optimised ELISA, 10.5, in each case shows the tail end of the classical dose-
response plot at greatly increased absorbance levels, compared to those obtained 
previously (10.211, figure 10.1). In fact a two fold increase in the magnitude of the 
absorbance levels was achieved, that is to say the assay showed a markedly increased 
sensitivity. It is also clear that the absorbance levels and thus antibody titres obtained 
for each replicate are of a similar magnitude for the respective serum dilution'S, thus 
indicating that assay reproducibility has been maintained. 
Figure 10.3 Diagram of the ELISA Plate Layout ofa Checkerboard Assay 
for Determination of Optimal Reagent Concentrations 
for Detection of Antibodies in 1/12800 Diluted Serum Samples 
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Figure 10.4 Checkerboard Optimisation of BPCC ELISA Reagent Concentrations for Maximal Detection of Antibodies in 1112800 Serum 
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Figure 10.5 Reproducibility of the Optimised BPCC ELISA 
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10.24 Experiment 4: Adsorption using the Optimised ELISA 
10.241 Method 
The previous adsorption procedure, 10.31 was repeated using a 1 Omglml concentration 
of native benzylpenicillin in the anti-benzylpenicillin antibody positive-serum and the 
ELISA was perfOmted under the optimal conditions as determined in 10.232. 
10.242 Results and Discussion 
Graphical representation of the absorbance data is presented in figure 10.6, and 
suggests that 10mg of native benzylpenicillin in I mI of serum binds with very few anti-
benzylpenicillin antibodies present in the serum. This result is believed to be incorrect, 
as doses of 1.2mg/mJ of benzylpenicillin have been shown to induce massive 
immunological responses, which suggests that a concentration of 1.2mg/mJ of native 
benzylpenicillin is capable of binding to and reacting with a significantly high 
proportion of anti-benzylpenicillin antibodies present in the serum, so contradicting the 
result obtained here. This therefore suggests that adsorption of an antibiotic into a anti-
benzylpenicillin antibody positive serum sample is not a satisfactory method for 
determining either qualitatively or quantitatively the cross-reactivity occurring between 
a tJ-lactam antibiotic and anti-benzylpenicillin antibodies, present in sensitised serum. 
Modification of the optimised ELISA into a competitive assay could enable the 
development of an assay for the quantitative determination of cross-reactivity between 
f3-lactam antibiotics and polyclonaJ anti-benzylpenicillin serum antibodies. 
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Figure 10.6 Adsorption of Benzylpenicillin as Detected by Optimised BPCC ELISA 
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10.25 Experiment 5: Modification of the Optimised ELISA into a Competitive Assay 
Rather than adsorbing the native antibiotic in the serum and removing any antibiotic-
antibody complexes from the serum prior to analysis and the subsequent detection of 
any remaining free antibodies, it may be possible to measure the extent of adsorption as 
it occurs in a competitive environment, in which the benzylpenicillin cytochrome-C 
bound antigen and the native antibiotic compete directly for a limited number of serum 
antibodies. An illustration of such a competitive assay is shown in figure 10.7. Any 
changes in the absorbance levels obtained for wells containing antibiotic and those not 
containing antibiotic can be attributed directly to the competition, and the difference 
between the two values will reflect the extent of antibody adsorbed by the native 
antibiotic and not the bound benzylpenicillin cytochrome-C antigen. 
10.251 Method 
The ELISA as previously used in 10.24 was modified at step a) in that 25111 of a 
10mglml concentration of native benzylpenicillin in PTS buffer was applied to each well 
followed by 25JiJ of a 1/6400 dilution in PTS of serum containing anti-benzylpenicillin 
antibodies (RB-BPIOl-I05) and the reaction incubated for I hour at 370 C, with slight 
agitation, to ensure equal dispersion of the antibiotic throughout the serum. 
As the serum and allergen were diluted I in 2, once all solutions were present in the 
reaction well at step a), it was essential that the appJied concentrations or dilution's be 
double that required for assessment. 
Controls were established by replacing the anti-benzylpenicillin antibody positive serum 
(RB:BPlOl-105) with nonnal rabbit serum (NRS) at dilution of 1120 and by substituting 
the native benzylpenicillin (antibiotic) solution with PTS alone. Background absorbance 
levels were determined using equation 10. 1. 
10.252 Results and Discussion 
Graphical representation of the absorbance results obtained, figure 10.8, clearly shows 
that the competitive adsorption of a lOmgtmJ concentration of native benzylpenicillin 
causes a flattening of the dose-response CUNe, thus indicating that all the serum 
antibodies have been taken up by the native benzylpenicillin and none by the bound 
benzylpenicillin cytochrome-C antigen. That is to say, the native benzylpenicillin has 
completely inhibited uptake of the serum antibodies by the antigen. If this response 
were to be obtained for an antibiotic other than benzylpenicillin it could concluded that 
the antibiotic had cross-reacted with the anti-benzylpenicillin serum antibodies. It may 
also be possible from the absorbances to determine the extent of cross-reactivity. 
Figure 10.7 Diagrammatic Representation of Competitive BPCC ELISA for 
Quantitative Determination of Cross-Reactivity Between 13-Lactam Antibiotics and 
Anti-Benzylpenicillin Serum Antibodies 
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Figure 10.8 Determination of Cross-Reactivity Between Native Benzylpenicillin and Anti-Benzylpenicillin Serum Antibodies, Using the 
Optimised Competitive BPCC ELISA 
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10.26 Experiment 6: Determination of the Optimal Concentrations of Native 
Benzylpenicillin Resulting in Minimal and Maximal Inhibition 
of Bound Antigen Uptake of the Anti-benzylpenicillin 
Serum Antibodies 
10.261 Method 
A checkerboard assay of the competitive ELISA developed in 10.251 was perfonned 
using a range of native benzylpenicillin concentrations from 20mg/ml to Snglml, in 
order to determine the optimal concentrations of native benzylpenicillin required to give 
maximal and minimal adsorption ~d thus maximal and minimal inhibition of anti-
benzylpenicillin antibody uptake by the bound benzylpenicillin cytochrome-C bound 
antigen. 
10.262 Results and Discussion 
Graphical representation of the absorbance results obtained for each concentration of 
native benzylpenicillin, figure 10.9, shows that different concentrations of native 
benzylpenicillin will produce different degrees of inhibition, as expected when the 
nature of the competitive environment is considered. 
From figure 10.9 it was determined that a 1.0 mglml concentration of native 
benzylpenicillin was the lowest concentration of benzylpenicillin which gave maximal 
adsorption and therefore maximal inhibition. A native benzylpenicillin concentration of 
O.OOlmglml was determined to be the highest concentration of benzylpenicillin which 
resulted in no adsorption and therefore caused the minimal level of inhibition. 
~ 
~ 
Figure 10.9 Determination of the Concentrations of Native Benzylpenicillin Giving Maximal and Minimal Cross-Reactivity, Using the 
Optimised Competitive BPCC ELISA 
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10.27 Experiment 7: Detennination of the Different Levels ofInhibition of Bound 
Antigen Uptake of the Anti-benzylpenicillin Serum Antibodies 
for a Range of Concentrations(molar units) of 
Native Benzylpenicillin 
10.271 Method 
Determination as to what extent concentrations between 15mM and 0.005mM native 
benzylpenicillin will cross-react with rabbit serum anti-benzylpenicillin antibodies, over 
range of serum dilutions, was perfonned using the optimised competitive ELISA 
developed in 10.26. Each concentration was assessed in replicate and average 
absorbance levels for each evaluated. A positive control of 1.0mg/m1 native 
benzylpenicillin was also assessed in order to ensure the assay had worked and to 
enable quantitative determinations of the extent of inhibition due to each concentration 
of benzylpenicillin to be made. 
The level of background absorbance was calculated in accordance with equation 10.1. 
10.272 Results and Discussion 
Graphical representation of the absorbance readings attained, figure 10. 10, illustrate 
that different concentrations of native benzylpenicillin result 'in a range of levels . of 
inhibition of antibody uptake by the bound antigen of between 0 and 1 00 %, as seen 
with the optimisation experiment 10.26. A 3mM concentration of native 
benzylpenicillin can be seen to be the lowest molar concentration of native 
benzylpenicillin which produces 100010 inhibition. 
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Figure 10.10 Graphical Representation of the Different Extents of Adsorption / Cross-
Reactivity of Native Benzylpenicillin at Different Concentrations with Anti-
Benzylpenicillin Serum Antibodies, Determined by Optimised Competitive BPCC 
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10.28 Experiment 8 Ouantitation of the Levels of Cross-Reactivity Occuning 
Between 31 Different 6-Lactam Antibiotics. at an Equivalent Molar 
Concentration. with Polyclonal Anti-benzylpenicillin Antibodies in 
Sensitised Rabbit Serum 
10.281 Method 
Thirty-one (15 penicillins and 16 cephalosporins) of the seventy p-lactams investigated 
in 9.0 were readily commercially available and were obtained for analysis, these being ~ 
Arnoxycillin, Ampicillin, AzJocillin, Bacampicillin, Benzylpenicillin, Cloxacillin, 
Dicloxacillin, Epicillin, Methicillin, Nafcillin, Oxacillin, Ticarcillin, Cefaclor, Cefadroxil, 
CefamandoJe, Cefoperazone, Cefoxitin, Cefsulodin, Ceftazidime, Cefiriaxone, 
Cefuroxime, Cephalexin, Cephaloridine, Cephalothin, Cephapirin, Cephradine, 
Latamoxef (all Sigma), Carbenicillin (Roering), MezlociIlin (Miles), Piperacillin 
(Lederle) and Cefazolin (Beecham). Samples of the remaining thirty-nine compounds 
were not available for ELISA analysis, but their structures were used later in the study 
to evaluate the generated QSARs. 
Each was assayed at a 3mM concentration (details of the weight of each compound 
calculated to give a 3mM concentration are given in appendix 6), with replicates, for 
the extent to which each competed with and thus inhibited the uptake of anti-
benzylpenicillin antibodies from the serum by the bound benzylpenicillin cytochrome-C 
antigen, using the competitive ELISA as developed previously and used in 10.25. 
The average absorbance levels for each compound were evaluated and the background 
absorbance was detennined in accordance with equation 10.1. 
As the antibiotics being assessed were not the true antibody substrate it can be 
concluded that any inhibition was due to cross-reactivity occurring between that 
antibiotic and the anti-benzylpenicillin serum antibodies. As a 3mM concentration of 
native benzylpenicillin was seen earlier to give 100% inhibition it was assumed that this 
was equivalent to 100 % cross-reactivity. Thus the extents to which the remaining 30 
antibiotics cross-reacted with the anti-benzylpenicillin serum antibodies were quantified 
with respect to this benzylpenicillin, and in accordance with equation 10.2. 
% Cross-Reactivity = Av.Abs Antibiotic - Background abs. x 100 (10.2) 
Av. Abs. 3mM BP - Background abs. 
Where: 
Av.Abs Antibiotic is the average absorbance reading obtained for each specific 
antibiotic when assessed at a 3mM concentration. 
Av. Abs. 3mM BP is the average absorbance reading obtained from the analysis of a 
3mM concentration of benzylpenicillin. 
1.10 
10.282 Results and Discussion 
The percentage cross-reactivities evaluated for the thirty-one j3-lactarns (15 penicillins 
and 16 cephalosporins) investigated are presented in table 10.1 and illustrated in figure 
10.11 for the penicillins and figure 10.12 for the cephalosporins. 
The results obtained clearly show that both penicillins and cephalosporin antibiotics do 
cross-react with anti-benzylpenicillin antibodies present in pre-sensitised rabbit serum 
and that they do so to different extents, with carbenicillin showing the greatest level of 
cross-reactivity (other than Benzylpenicillin itself) at 79.4 %, whilst bacampicillin, 
cefaclor, cefadroxil, cefazolin, cefuroxime and latamoxef do not appear to cross-react 
at all. These results therefore support the hypothesis that different j3-lactam antibiotics 
are capable of inducing a large degree of imrnunologically related responses as a result 
of cross-reactivity with existing anti-benzylpenicillin serum antibodies [591]. 
Comparison of the percentage cross-reactivities obtained for the penicillins and 
cephalosporins shows there to be a distinct difference in the extent to which the 
respective sub-populations of j3-1actams cross-react with anti-benzylpenicillin serum 
antibodies. Th~ percentage cross-reactivity values for the penicillins span the whole 
percentage range from ° to 100, whilst the values for the cephalosporins are all below 
15%. These values support the similar observation of Kishiyarna and Adelman [588J, 
that there appears to be substantially less cross-reactivity between cephalosporins and 
peniciUins than between the penicillins themselves. The results suggest therefore. that 
the problem of cross-reactivity exists for both penicillin and cephalosporin antibiotics, 
but that it is less of a problem with the cephalosporins, as they are 'less' like 
benzylpenicillin than are the penicillins. 
The differential levels of penicillin and cephalosporin cross-reactivity, as shown in this 
work, present a similar general pattern of incidence, i.e. that on the whole penicillin 
levels are higher than those of the cephalosporins, as seen with the relative frequencies 
of cutaneous rash induction following therapy, as shown in 9.2. This suggests therefore 
that, as both processes are inununologically mediated, some portion of the extent of 
cutaneous rash exhibited may in fact be attributed to the phenomenon of cross-
reactivity and not entirely to the antibiotic itself In order to try an evaluate the 
proportion of cutaneous rash (allergic reactions) as reported in 9.2 which is due to 
cross-reactivity and not the native antibiotic itself, it is necessary to determine the levels 
of cross-reactivity an antibiotic will induce at its therapeutic dose. 
10.29 Experiment 9: Ouantitation of the Levels of Cross-Reactivity Occurring 
Between 31 Different 6-Lactam Antibiotics. at Concentrations 
Equivalent to their Respective Highest Recommended 
Therapeutic Daily Dose. with Anti-benzylpenicillin Antibodies 
A competitive ELISA has been developed which will enable the quantitation of the 
extent to which different p-lactam antibiotics cross-react with anti-benzylpenicillin 
serum antibodies. The next step in the study was to detennine what portion of the 
frequency of allergic reactions (cutaneous rash) induced by the therapeutic use of J3-
lactam antibiotics may be attributed to the phenomenon of cross-reactivity and not 
directly to the antibiotic itself 
It was decided to evaluate the potential cross-reactivity of different p-Iactams at in 
vitro concentrations equivalent to those given therapeutically, thus enabling the results 
obtained to be related to the clinical incidence of allergic reactions. 
The highest recommended therapeutic daily dose (HR TDD) of benzylpenicillin is 1. Og~ 
an equivalent concentration suitable for the quantitation of cross-reactivity by ELISA 
would be 1.0gll or l.Omglml. A l.Omglml concentration of benzylpenicillin in fact 
equates to a 3mM concentration and therefore can be assumed to give a cross-' 
reactivity of 100010 in the assay, as shown in 10.27. This extent of benzylpenicillin 
cross-reactivity with its corresponding serum antibodies corresponds to the responses 
seen clinically. 
10.291 Method 
The HRTDD, in grammes, for thirty-one commercially available J3-lactam antibiotics 
(15 penicillins and 16 cephalosporins as in 10.28) were obtained [193,592]. 
The concentration in rnglml of antibiotic used in the competitive ELISA was then 
calculated as HRTDD/l000 mglml. Each antibiotic was assayed at this concentration 
using the competitive ELISA as with 10.28, with replicates, for detennination of the 
extent to which it cross-reacted with anti-benzylpenicillin serum antibodies. The 
absorbance readings obtained for each antibiotic were averaged, and the background 
absorbance calculated in accordance with equation 10.1. 
The extent to which each antibiotic cross-reacted with the anti-benzylpenicillin serum 
antibodies was quantified in accordance with equation 10.3, assuming that a I.OmglmJ 
concentration of benzylpenicillin resulted in 100 % cross-reactivity. 
111 
% Cross-Reactivity = Av.Abs Antibiotic - Background abs. x 100 
Av. Abs. 3mM BP - Background abs. 
Where: 
(I 0.2) 
Av.Abs Antibiotic is the average absorbance reading obtained for each specific 
antibiotic when assessed at a mglml concentration equivalent to its HRTDD. 
Av. Abs. I.Omg/ml BP is the average absorbance reading obtained from the analysis of 
a I. OmglmJ concentration of benzylpenicillin. 
10.292 Results and Discussion 
The percentage cross-reactivity results obtained for the 31 tl-Iactams (15 penicillins and 
16 cephalosporins) investigated at concentrations equivalent to their respective 
HRIDD are given in table 10.1 and illustrated graphically in figure 10.11 for the 
penicillins and 10. 12 for the cephalosporins. 
The results show, as with 10.28, that both the penicillin and cephalosporin antibiotics 
cross-react with anti-benzylpenicillin serum antibodies and that they do so to different 
extents. The two levels of cross-reactivity evaluated for eighteen antibiotics are similar, 
given some experimental error, but for ten antibiotics the two levels of cross-reactivity 
are quite different. 
Cirstea et aJ [591] determined that at low concentrations the extent of amoxycillin 
cross-reactivity was substantially lower than that of benzylpenicillin, whilst at higher 
concentrations the extent of cross-reactivity shown by amoxyci11in increased, thus 
reducing the difference between itself and benzylpenicillin, and yet other compounds 
show no such trend. This phenomenon appears to be the case for the ten compounds in 
this study whose cross-reactivities at the two test concentrations differ greatly. 
The exact reasons for these ten discrepancies are not clear; they may be due in part to 
the substantially greater HRIDDs of some of these antibiotics, when compared those 
antibiotics displaying equivalent levels of cross-reactivity at both test concentrations, as 
detailed in appendix 5; or they may be due to the fact that different rabbits respond 
differently to benzylpenicillin, during the sensitisation phase (as do humans). The 
discrepancies therefore, may be a reflection of the varying levels of antibody titre 
present in the different serum samples used in the study. This problem can be overcome 
by repeating each antibiotic assessment with a range of rabbit serum samples and 
determining an average level of cross-reactivity for each test concentration ,thus 
generating data which are indicative of cross-reactivities across the board, eliminating 
113 
individual variation, and not just to a one off response. Other possible reasons for the 
discrepancies may be the denaturation of the antibodies in the serum sample or 
experimental error, such as in the weighing out of the compounds. Time did not pennit 
these possibilities to be investigated in this study. 
The results presented in 10.29 suggest that different Ji-Iactam antibiotics induce allergic 
responses to different extents in the clinical environment, as a result of cross-reactivity 
between the antibiotic and anti-benzylpenicillin poJyclonal antibodies present in the 
serum. The quantitative data produced may be used, in conjunction with the 
epidemiological data presented in 9.2, to enable the detennination of the extent to 
which an allergic response (cutaneQus rash) is due to these cross-reactivity reactions. 
For example, the peniciUin antibiotic azlocillin induces cutaneous rash in 2.9% of the 
popUlation, with some 34.5% of these reactions being due to the cross-reaction of 
azlocillin with anti-benzylpenicillin serum antibodies and not directly due to the 
azlocillin itself 
Although the developed competitive ELISA enables the quantitation of cross-reactivity 
between a tJ-Iactam antibiotic or any other compound and anti-benzylpenicillin 
antibodies, it does not enable identification of those physical, chemical or structural 
properties of the compounds which are responsible for the cross-reactive phenomenon. 
Analysis of the structure-activity relationships of the process should provide a means of 
making such identifications. 
Table 10.1 PerCElltage Cross-Reactivities of 31 I3-Lactarn Antibiotics with 
Anti-benzylpenicillin Antibodies in Pre-sensitised Rabbit Serum. 
as Determined by competitive ELlSA 
Mode of ~-lactam % Cross-reactivity % Cross-reactivity 
administration at concentration at3mM 
equivalent to HRIDD concentration 
I oral Amoxycillin 43.2 +/- 1.2 9.1 +/- 2.4 
2 oral Ampicillin 31.3 +/- 8.1 47.2 +/- 11.5 
3 oral Azlocillin 34.6 +/- 1.1 19.2 +/- 1.8 
4 oral ... 'cillin 0.0 +/- 4.2 18.6 +/- 9.5 
5 oral Dicloxaci1lin 12.9 +/- 3.9 12.7 +/- 5.3 
6 oral ~~ 17.1 +/- 7.1 17.9+/-11.5 
7 parenteral Benzylpenicillin 100.0 +/- 4.3 100.0 +/- 4.6 
8 J'II'eDteral Carbenicillin 86.6 +/- 9.5 79.4 +/- 5.7 
9 parenteral Cloxacillin 32.6 +/- 3.6 46.2 +1- 14.7 
10 parenteral Methicillin 7.6 +/- 4.6 27.7 +/- 9.5 
11 parenteral Nafcillin 9.8 +1- 2.8 14.2 +/- 5.0 
12 parenteral Oxacillin 29.6 +/- 2.1 24.3 +/- 11.9 
13 parenteral pjperacillin 27.3 +/- 7.3 19.2 +/- 8.8 
14 parenteral Ticarcillin 79.2 +/- 1.0 45.3 +/- 7.3 
15 oral Cefaclor 0.0 +/- 10.4 0.0 +1- 14.3 
16 oral Cefadroxil 0.0 +/- 0.5 0.0 +/- 5.2 
17 oral Cepba}exin 14.9 +/- 7.5 19.87 +/- 11.6 
18 parenteral Cefamandole 23.7 +/- 4.8 6.6 +/- 12.2 
19 J'GlrenteraJ Cefazolin 2.8 +/- 6.0 0.0 +/- 5.1 
20 parenteral Cefoperazone 3.2 +/- 1.9 3.5 +/- 1.6 
21 parenteral Cefotaxime 3.5 +/- 2.0 2.6 +/- 0.8 
22 parenteral Cefoxitin 14.3 +/- 4.3 7.0 +/- 9.2 
23 parenteral CefsuJodin 14.0 +/- 0.5 0.8 +/- 8.6 
24 raJ Ceftazidime 9.53 +/- 7.4 11.29 +/- 1.3 
25 parenteral Ceftriaxone 18.1 +/- 1.5 l.l +/- 4.1 
26 parenteral CefiJroxime 14.6 +/- 3.2 0.0 +/- 6.2 
27 parenteral Cepltaloridine 30.5 +/- 0.2 10.7 +/- 4.2 
28 parenteral CepbaJothin 21.7 +/- S.O 11.2 +/- 7.8 
29 parenteral ( .. 14.1 +/- 1.8 12.6 +/- 4.3 LUI 
30 Parenteral (' .L ne 6.3 +/- 1.9 5.6 +/- 1.2 
31 parenteral Latamoxef 6.3 +/- 0.3 0.0 +/- 2.7 
Note: 
The +/- figures noted represent the standard deviation of the individual experimentally derived 
results obtained from the mean percentage cross-reactivities presented in the table. 
Figure 10.11 Comparison of the Percentage Cross-Reactivities of Various Penicillin 
Antibiotics with Rabbit Anti-Benzylpenicillin Serum Antibcx:fies. Detennined by Optimised 
Competitive BPCC ELISA at Two Concentration Levels 
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Figure 10.12 Comparison of the Percentage Cross-Reactivities of Various Cephalosporin 
Antibiotics with Rabbit Anti-Benzylpenicillin Serum Antibodies. Determined by Optirnised 
Competitive SPCC ELlS A at Two Concentration Levels 
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10.3 Quantitative Structure-Activity Relationship Study of the Cross-Reactivity of 
I3-Lactam Antibiotics and Anti-benzylpenicillin Serum Antibodies 
Previous workers [34,583,588] have suggested that the extent cross-reactivity 
between Jl-Iactam antibiotics and anti-benzylpenicillin antibodies is directly related 
to the structural similarity of the RI acyl side chain of the antibiotic to that of 
benzylpenicillin. However, on comparison of the experimental data produced in this 
study (table 10.1) and the chemical structures of the antibiotics tested, no such clear 
cut relationship was found. Both carbenicillin and bacampicillin have R I side chains 
similar both to each other and to that of benzylpenicillin, and although carbenicillin 
cross-reacts at a level approaching 9QO/o, bacampicillin does not cross-react at all. 
This therefore suggests that some other physical, chemical or structural property of 
the Jl-lactam antibiotics, either alone or in conjunction with the similarity of the RI 
side chain to that of benzylpenicillin, is responsible for controlling the extent of 
cross-reactivity with anti-benzylpenicillin serum antibodies. Identification of this 
property or properties should be possible by QSAR analysis, and is the aim of this 
part of the work. 
10.31 Method 
10.311 Biological Activity Data Generation 
The data pertaining to the percentage frequency of cross-reactivity between thirty-
one Jl-lactam antibiotics and rabbit polyclonal anti-benzylpenicillin serum antibodies, 
as generated in 10.2 (at 3mM and eHRTDD concentrations) were utilised as the 
biological data for QSAR development The data were subdivided on the basis of 
type and mode of administration, giving the data sets shown in table 10.2. 
The biological data within each data set were mathematically transformed (as in 
9.311) to ensure the data were normally distributed and suitable for statistical 
modelJing. 
10.312 Calculation ofDescriptor Variables 
The generation of physical, chemical and structural descriptor variables as carried 
out as described in 9.312. 
2.1' 
Table 10.2 Data Sets for OSAR Analysis 
Compound # Compounds in 
each Data Set. 
3mM and eHRTDD 
I A1l6-Lactams 31 
2 AlIOral6-Lactams 9 
3 All Parenteral ~-Lactams 22 
4 AD Penicillins 14 
5 Oral Penicillins 6 
6 Parenteral Penicillins 8 
7 All Cephalosporins 17 
8 Oral Cephalosporins 3 
9 Parenteral CeohaJosporins 14 
10 .313 Data Analysis 
The square-root cross-reactivity data for the 31 J3-lactams were correlated by 
regression analysis, in the TSAR program, against the three adverse reaction data 
sets (all ARs, cutaneous rash, GI disruption) generated in 9.2, in order to determine 
if any relationships between the different data sets, particularly the cross-reactivity 
and cutaneous rash data, were in existence. 
The cross-reactivity data was then further analysed using the procedures described 
in 9.312. 
10.314 Determination of models' significance 
Determination of the statistical significance of the generated models was made as in 
9.312. 
10.315 Data Randomisation 
In order to check the possibility that the models were due to chance correlations the 
biological data were randomised as in 9.312, the models regenerated and the 
resultant r values examined as in 9.312. 
11~ 
J 0.32 Results and Discussion 
10.321 Assessment of the Biological Data 
The percentage frequency values of cross-reactivity with anti-benzylpenicillin serum 
antibodies for the thirty-one 13-lactams analysed are given in table 10.1. 
Transformation and univariate analysis of the biological data sets (as in table 10.2) 
generated a range of skewness values and distribution, given in tables 10.3 and 10.4 
for the 3mM and eHRTDD reaction concentrations respectively. Examination of 
each respective transformation for each data set (3mM or eHRTDD concentrations) 
showed that the square root transformation generated normally distributed data for 
all data sets. 
10.322 Biological Data Correlation Analysis 
Regression analysis of the cross-reactivity data, generated in 10.2, and the adverse 
reaction data, generated in 9.2, showed there to be no significant correlations 
between the data sets. In 43 of S4 correlations the respective r2 generated were 
zero, and the remaining I I r2 values were not significant, being below 0.50, as 
detailed in table 10.5. This indicates that the cross-reactivity data are not directly 
related to any of the adverse reaction data. One would, however, expect to find 
some partial relationship between the cross-reactivity and the cutaneous rash data as 
both are an indication of the level of induction of equivalent immunological 
responses. The lack of a correlation may be due to the fact that the cutaneous rash 
data does not relate exclusively to immunologicaJJy mediated responses but also 
types of rash initiated by non-immunological reaction mechanisms. 
10.323 Regression Analysis 
A total of eighty-four pbysico-chemicaJ and structural descriptors (as listed in 
appendix 3) were generated and entered into the TSAR data base along with the 
square-root transformed cross-reactivity data. A summation of the final results 
attained from regression analysis (including a description of the preliminary 
validation plots) and from cross-validation analysis for the eighteen models 
generated are given in table 10.6. It can clearly be seen, from these results, that a 
statistically significant QSAR has been developed for each of the respective data 
sets, at each reaction concentration. Three of the models lack predictive validity, 
because they were produced using data pertaining to only very few compounds; the 
data therefore, produced a disproportionate bias in the model generation procedure. 
The incorporation of further compounds into the model generation procedure for 
these three models would almost certainly improve predictive validity whilst 
maintaining statistical significance. 
The QSARs generated are presented in models 10.1 to 10.9 for the cross-
reactivities at 3mM antibiotic concentrations and in models 10.10 to 10.18 for 
cross-reactivities of the antibiotic at a concentration equivalent to its highest 
recommended therapeutic daily dose (HRTDD). 
A list of the descriptor variables used in each of the generated models is presented 
in table 10.7. 
Appendix 7 lists the compounds, biological, physico-chemicaJ and structural 
parameter values, actual, predicted and residual square-root cross-reactivity values, 
the correlation matrices, and representations of the two validity plots for each 
model. 
Table 10.3 Univariate Skewness Values Generated Following Various 
Mathematical Transformations of the 3mM Cross-Reactivity Data 
Data set Skewness value (Sk) for the respective 
transformation of 
%Xr Log lO %Xr .r%Xr %Xr2 lfO/oYr 
All tJ-lactams 1.86 -1.594 0.519 3.076 22.478 
All oral Jl-lactams 0.867 -1.100 -0.374 1.869 1.120 
All parenteral Jl-Iactams 1.621 -1.613 0.645 2.463 3.822 
All penicillins 1.206 0.373 0.813 1.809 0.628 
All oral penicillins 1.097 0.519 0.862 1.301 0.280 
All parenteral penicillins 0.680 0.142 0.431 1.042 0.471 
All cephalosporins 0.892 -0.760 0.166 2.030 1.352 
All oral cephalosporins 0.385 0.385 0.385 0.385 -0.385 
All parenteral cephaIosporins 0.329 -1.159 -0.143 0.851 2.645 
%Xr is the percentage cross-reactivity with anti-benzylpenicillin serum antibodies as 
determined experimentally by competitive ELISA (10.2). 
The square root transformation generated normally distributed data for all of the 
sub-data sets and was therefore used in the generation of QSARs pertaining to the 
frequency of cross-reactivity responses at a 3mM concentration of each 13-lactam 
antibiotic with anti-benzylpenicillin serum antibodies. 
Table 10.4 Univariate Skewness Values Generated Following Mathematical 
Transformations of the eHRTDD Cross-Reactivity Data 
Data set Skewness value (Sk) for the respective 
transfonnation of 
%Xr Log1o%Xr JbIoXr %Xr2 l/%Xr 
AlII3-1actams 1.689 -1.839 0.400 2.501 2.470 
Al) oral B-lactams 0.375 0.375 -0.127 0.863 0.375 
All parenteral B-Iactams 1.501 -0.924 0.802 1.920 3.640 
All penicillins 0.859 -2.380 0.038 1.316 2.978 
All oral penicillins 0.616 -1.495 -0.359 1.331 1.620 
All parenteral peniciUins 0.589 -0.052 0.342 0.745 0.706 
All cephaIosporins 0.274 -1.513 -0.533 1.185 l.945 
All oral cephalosporins 0.385 0.385 0.385 0.385 -0.385 
All parenteral cephalosporins 0.130 -1.567 -0.644 0.941 2.539 
%Xr is the percentage cross-reactivity with anti-benzylpenicillin serum antibodies as 
detennined experimentally by competitive ELISA (10.2). 
The square root transformation generated nonnally distributed data for all of the 
sub-data sets and was therefore used in the generation of QSARs pertaining to the 
frequency of cross-reactivity responses of ~-lactams at a concentration equivalent 
to the compounds highest recommended therapeutic daily dose, with anti-
benzylpenicillin serum antibodies. 
Table 10.5 Regression Coefficient Values Obtained from the Cross Correlation 
Analysis of the Cross-Reactivity and Adverse Reaction Data 
The table presented only details those correlations of biological data which 
produced a regression coefficient of greater than zero. 
All of the omitted correlations gave r2 values of zero and presentation of this data 
was felt not to be relevant. 
All Oral Oral Parent. Parent. All Oral 
J3Ls J3Ls f3Ls Pens. Pens. Cephs. Cephs. 
All ARs All ARs Rash Rash 01 All ARs All ARs 
HRTDD%Xr 
- 0.21 - 0.22 0.39 0.15 0.20 
3mM%Xr 0.16 0.49 0.42 - 0.23 0.30 0.17 
Table 10.6 Summation of Regression Statistics. Plots and Cross Validation Results 
Data Set Biological n 11 11 s plot 
Response 
--- ....... 
outliers r r2 I 
All 3mM XRU") 31 4 0 0.805 0.649 1.67 sk 
~Iacwns eHRlDD XR (r) 
" 
0 0.889 0.790 1.22 lin 
Oral 3mM XR (r) 9 2 2 0.935 0.87~ 1.08 sk 
~-Iactams eHRTDD XR (r) 2 0 0.892 0.795 1.36 sic 
Parenteral 3mM XR (./") 22 2 I 0.791 0.626 1.80 sic 
~-Jactams eHRTDD XR <./") 2 1 0814 0.662 1.57 lin 
AU 3mM XR (.r) 14 2 3 0.904 0.818 0.98 lin 
Penicillins eHRTDD XR (r) 2 0 0.930 0.866 1.08 lin 
Oral 3mM XRtJ) 6 I 2 0.924 0.853 0.68 sk 
Penicillins eHRmD XR (r) I 0 0.933 0.870 0.95 lin 
Parenteral 3mM XR{J") 8 2 1 0.954 0.911 0.77 lin 
Penicillins eHRTDD XR (./"') I 0 0930 0.866 1.10 lin 
All 3mM XR (J") 17 2 1 0.818 0.670 0.97 lin 
C~s eHRTDD XR (.r) 2 3 0927 0.860 0.68 lin 
Oral 3mM XJq.rJ 3 1 0 0.823 0.677 1.02 sk 
.Cephs. eHRTDD XR (./") I 0 0.945 0.893 1.00 sic 
Parenteral 3mM XR(./"J 14 2 1 0.870 0.756 076 lin 
Ccphs. eHRTDD XR (J-) 2 1 0.921 0.848 0.62 lin 
~: 
sk - data are skewed about the line of best fit. so the error distribution is not 
normal. 
lin - data are linear, so the distribution of error is normaL 
plot 
2 
homo 
homo 
homo 
homo 
homo 
homo 
homo 
homo 
homo 
homo 
hetro 
homo 
homo 
homo 
homo 
hetro 
homo 
hetro 
hetro - data are heteroskedastic about the zero line, so there is a large scope for 
variation and the model is not a good fit with the data. 
homo - data are homoskedastic about the zero line, there is even distribution of 
variation and the model is a good fit with the data used. 
2Z5 
r (CV)2 
0.418 
0.688 
0.165 
0.365 
0.399 
0.618 
0.742 
0.716 
..Q.568 
0.755 
0.605 
0.700 
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Table 10.7 Summary of the Descriptor Variables Used in the OSARs Generated 
Biological Parameters used in the QSAR models for each respective data set 
Response 
All p-lactams All Oral All Parenteral All Penicillins Oral Parenteral All Oral Parenteral 
Penicillins Penicillins 
3mMXR I Dipole Veotor X \ Sterimol BI_ \ Sutfac .. ,.. \ Surface area \ Surface area Surface area Dipole vector X Dipole vector Y Dipole vector X 
Sterimol B lc=o Accessible Dipole vector X Dipole vector X Dipole vector X Dipole vector Y Dipole vector Y 
Accessible surface area 
surface area 
Admin. ID 
eHRIDD \ Surface area EHOMO Dipole vector X # Methyl grps. # Methyl grps. # R I Methyl grps. Shape Similarity Sterimol B4(C=O) \ Sterimol B4(C=O) 
XR EHOMO Sterimol Sterimol B4(C=O) Admin. ID to benzylpenicillin Dipole vector X 
(..1"") Sterimo\ L(CH3) L(CH3, Sterimol B4(C=O) 
Admin.lD 
~ 
10.3231 QSARs of the Frequency of Cross-Reactivity ofp-Lactam Antibiotics 
at 3mM Concentration with Anti-benzylpenicillin Serum Antibodies 
10.32311 All (l-Lactam Antibiotics 
The square-root transformed data has a skewness value of 0.159 indicating nonnal 
distribution and that the data are suitable for modelling. Stepwise regression against 
seventy physico-chemical and structural descriptors (the remaining 14 descriptors 
applied only to the cephalosporins, so there incorporation here was not felt to be 
relevant) highlighted a number which correlated with the transformed cross-
reactivity data. Regression analysis of the 3mM cross-reactivity data with 
combinations of the most significant descriptor variables, highlighted by stepwise 
regression, yielded the statistically significant and predictively valid model 10.1, 
which described 65% of the information within the biological data. 
No compounds were found to be acting as an outIier. 
Model 10.1 
~XRdueto 
all J3-lactams 
at 3mMconc. 
= -0.223(0.1 5 J)DVx - 1.677(0.413)VBlc=o 
- 5.20S(4.574)ASA + I.S25(0.8SJ)Admin. 
+ 6.114(3.422) 
n=31 r=O.S05 r2=O.649 s=1.665 F=1l.0S probability ::1.64-5 r(CV)2=0.418 
Where: DVx is the dipole moment in vector X. 
VBlc=o is the Sterimol Bl width parameter for the whole molecule 
as measured from the carbonyl oxygen of the J3-1actam ring. 
ASA is the surface area of the molecule accessible to a 
water molecule, determined in COSMIC. 
Admin. ID is an indicator variable pertaining to the mode of 
administration of the f3-Jactam. A value of 3 indicates an oral 
compound and a value of 4 a parenteral compound. 
The model (l 0.1) presents a negative relationship of cross-reactivity between f3-
lactam antibiotics and anti-benzylpenicillin antibodies with structural shape and 
charge separation. This suggests therefore that the phenomenon of cross-reactivity 
between P-Iactam antibiotics and anti-benzylpenicillin serum imrnunoglobulins is 
dependent on the ability of the antibiotic to enter a shape specific receptor site on 
the immunoglobulins and the ability of the antibiotic, once in the receptor, to 
interact and bind via charge-charge interactions, thus initiating the immunological 
response. The model suggests that the whole structure of the JJ-Iactam antibiotic is 
significant in controlling whether it cross-reacts with anti-benzylpenicillin serum 
antibodies, thus causing the induction of an adverse immunological response. This 
partially supports the work of Smith' et al [589] who proposed that cross-reactivity 
is due to the similarity of the bicyclic core structures of the peniciIlins and 
cephalosporins, but contradicts the theories of side chain dependent penici1lin-
cephalosporin cross-reactivity, as proposed by Batchelor [584], Shibata [585] and 
Allemenos [582]. This latter theory may, however, be true when the cross-
reactivities of specific types of P-Iactam (penicillins or cephalosporins) are examined 
in isolation. 
The model also indicates that cross-reactivity is dependent upon the differential 
mode of administration of the p-Iactam antibiotic, suggesting that oral and 
parenteral antibiotics may be recognised by different types of immunoglobulins or 
possess slightly different properties which govern their ability to enter a specific 
receptor site and to bind, so inducing a cross-reactive immune response. 
Differences between the different types of antibiotics (penicillins and 
cephalosporins) and between the oral and parenterally administered compounds may 
account for the vagueness of the descriptors and in the low level of statistical 
significance and predictive validity. Development of QSARs for oral or parenteral 
antibiotics and for penicillins and cephalosporins specifically may yield more 
significant, models. 
10.32312 All Oral a-Lactam Antibiotics 
The square-root transfonned data presented a skewness value of -0.374, which 
indicates that the data are normally distributed and so suitable for modelling. 
Regression analysis of the transfonned cross-reactivity data against combinations of 
the descriptor parameters highlighted as significant for an J3-lactams (10.32211) 
yielded the statistically significant and predictively valid model 10.2, which 
modelled 87% of the variance contained in the biological data. 
Two antibiotics arnoxycillin and epicillin were found to be behaving as outliers. 
Amoxycillin on the grounds of the large range of experimental results and error 
presented both in this study and in those of others [591]. It was felt that the results 
obtained were neither reliable nor accurate and that their incorporation would not 
be conducive to successful QSAR development. EpiciUin was determined to be 
acting as an outlier for the reasons given previously in 9.3222. 
Model 10.2 
rXRdueto 
all ora] f3-lactams 
at 3mMconc. 
= -2.599(1.413)VB lc=o - 8.740(5.42S)ASA 
1000 
+ 15.93(2.396) 
n= 7 r=O.935 r2=O.874 5=1.077 F=13.06 probability =0.006 r(CV)2=0.165 
As with model 10.1 an inverse relationship between the extent of cross-reactivity 
and the shape of the respective oral f3-1actam antibiotic is indicated, thus supporting 
the previous proposal that cross-reactivity is dependent on the binding of the 
antibiotic in a shape-specific receptor site present on one or more serum anti-
benzylpenicillin immunoglobulins. Two shape parameters may be required to 
compensate for the differing shapes of receptor sites on different types of 
immunoglobulin or to compensate for dissimilarities in the receptor sites for 
penicillin and cephalosporin antibiotics. It appears, due to the lack of significance of 
a relevant descriptor in the model, that the distribution of charge within oral 
antibiotics is not a major factor in controlling the cross-reactivity potential of oral 
antibiotics. 
10.32313 AIl Parenteral (3-Lactam Antibiotics 
The skewness value for the square-root transfonned data is 0.645 indicating that the 
data are nonnally distributed and so suitable for modeIJing. Regression analysis of 
the biological data against combinations of the descriptor parameters highlighted as 
significant for all J3-lactams (10.32211) and other parameters felt to be of relevance 
to parenteral compounds, yielded the statisticaUy significant and predictively valid 
model 10.3, which modelled 63% of the information within the biological data. 
CefazoJin was determined to be an outlier on the grounds that it is the only 
parenteral J3-lactam antibiotic which has a 5-membered heterocyclic ring, and an RI 
side chain which comprises 4 nitrogen atoms. It was felt that this distribution of 
nitrogen atoms adversely effects the charge distribution within the X vector, thus 
introducing an error or bias factor into the model generation procedure. 
Model 10.3 
..fXRdueto = -0. 1 87(0.052)SA - 0.493(O.232)DVx 
all parenteral J3-lactams + 1O.050(l.585) 
at 3mM conc. 
n=21 r=O.791 r2=O.626 s=1.798 F=I3.41 probability=2.72-4 r(CV)2=0.399 
Where: SA is the total surface area of the antibiotic, determined in TSAR. 
The descriptor variables included in model 10.3, as with model 10.1, indicate an 
inverse relationship between surface area and internal charge distribution of the 
parenteral antibiotics and cross-reactivity. This suggests that the overall size of the 
parenteral antibiotic may control access of the parenteral antibiotic into a 
benzylpenicillin shape dependent binding site on an immunoglobulin. The smaller 
the overall size of the parenteral antibiotic, the more readiJy it wiU be able to enter 
the receptor site. The charge separation within the parenteral antibiotic may act to 
control the extent of binding within the receptor site. The lower the charge 
separation, in the X vector, the greater the interaction between the antibiotic and 
the receptor surface and so the greater is the extent of immunological response 
initiated. The two properties in conjunction will govern both the possibility and the 
resultant extent of cross-reactive stimulation of the immunologic mechanisms and 
thus the degree of adverse response initiated by parenterally administered J3-1actam 
antibiotics. 
10.32314 All Penicillin Antibiotics 
The square-root data have a skewness value of 0.813 indicating them to be normally 
distributed and so suitable for modelling. Regression of the transformed cross-
reactivity data against those descriptors previously indicated to be relevant in cross-
reactivity (model 10.1) yielded model 10.4, which was both statistically significant 
and predictively valid and which modelled 82% of the variance in the biological 
data. 
Three compounds amoxyciIlin, epicillin and nafcilIin were found to be behaving as 
outliers. Amoxycillin and epicillin for the reasons given in 10.32211. Nafcillin was 
determined to be an outlier as it is the only penicillin tested which contains a 
naphthalene ring in the RI side chain, the size of which may restrict access into the 
immunoglobulin receptor site, to a larger degree than a measurement of surface area 
would predict. 
Model 10.4 
JXRdueto 
all penicillins 
at 3mM conc. 
= -3.927(0.702)SA - 8.l5(J.00)DVx + 16.84(2.52) 
100 10 
n=14 r=0.904 r2=O.818 s=O.979 F=17.99 probability =4.87-4 r(CV)2=O.742 
Model 10.4, as model 10.1, indicates that an inverse relationship exists between the 
extent of cross-reactivity exhibited with anti-benzylpenicillin serum antibodies and 
the overall size and vectorial charge separation of the penicillin antibiotics. This 
supports the proposed hypothesis (10.32211) that cross-reactivity results from the 
binding of the antibiotic within a shape-specific receptor present on the anti-
benzylpenicillin serum immunoglobulins, in that the smaller the size and X-vectorial 
charge separation of the penicillin antibiotic the more readily it can enter and be 
held in the receptor site and thus initiate the immunological responses associated 
with allergy (as detailed in 7.23). 
10.32315 Oral Penicillin Antibiotics 
The square-root data are normally distributed, with a skewness value of 0.862 and 
thus are suitable for modelling. 
Amoxycillin and epicillin are both oral penicillins and were removed from the data 
set prior to regression analysis as outliers for the reasons as given in 10.322 I 1. 
Regression analysis of the cross-reactivity data with respect to the descriptors 
highlighted in 10.32214 yielded the statistically significant model 10.5, which 
modelled 85% of the information contained within the biological data. The model, 
however, lacks predictive validity as a result of the small number of compounds in 
the model generation set and the resultant bias towards fitting with the descriptors. 
This is also reflected in the fact that the probability value is relatively high. It may be 
therefore that this model, although presenting descriptors as highlighted previously, 
is due to chance correlation and so is not a valid QSAR. However, the presence in 
the model of the descriptor pertaining to surface area, as highlighted in other related 
models (models 10.2 and 10.4) and of the same sign (negative) and the lack of a 
charge descriptor (as with model 10.2), suggests that this model is significant in 
modelling the cross-reactivity of oral penicillins and that the model therefore was 
not derived by chance. The model supports the theory, as in 10.32212, that oral 
antibiotics interact via non-charge dependent interactions in order to initiate the 
immunological response. 
The incorporation of cross-reactivity data for further oral penicillins and the 
regeneration of the model will indicate whether model 10.5 is due to chance or 
merely lacks predictive validity because of the low numbers of compounds used. 
Model 10.5 
.rxR. due to 
oral penicillins 
at 3mM conc. 
= -0.81(2.658)~ + 16.15(9.336) 
100 
n=4 r=O.924 r2=O.853 s=O.676 F=ll.64 probability =0.042 r(CV)2= -0.568 
10.32316 Parenteral Penicillin Antibiotics 
The square-root data for the parenteral penicilIins are nonnally distributed (Sk= 
0.431) and as such are suitable for modelling. 
Nafcillin was eliminated from the data set as an outlier for the reasons given 
previously in 10.32214. 
Regression analysis was perfonned using those descriptors highlighted in 10.32214 
and yielded model 10.6, which was both statistically significant and predictively 
valid and which modelled 91% of the variance within the biological data. 
Model 10.6 
r XRdueto 
parenteral penicillins 
at 3mM conc. 
= -0.408(0.139)SA - 0.833(0.225)DVx + 17.69(4.82) 
10 
n=7 r=0.954. r2=O.911 s=O.766 F=20.46 probability =0.002 r(CV)2=O.605 
As with models 10.3 and 10.4 this model proposes that cross-reactivity due to 
parenteral penicillin antibiotics is inversely related both to the surface area and the 
X-vectorial charge separation of the compound. This is consistent with the 
previously proposed receptor binding hypothesis (10.232211). 
10.32317 AI] Cephalosporin Antibiotics 
The square-root data for all the cephalosporins are normally distributed (Sk=O.166) 
and as such are suitable for modelling. Regression analysis of the data against those 
descriptors highlighted in 10.3211, yielded the statistically significant and 
predictively valid model 10.7, which described 67% of the variance contained 
within the data. 
Ceftriaxone was found to be an outlier because with respect to the other 
cephalosporins tested it has a high proportion of nitrogen atoms and carbonyl 
oxygens, which it was felt, adversely influence the charge distribution within the 
molecule, thus disrupting the ability to fit the biological data and the relevant 
parameters accurately. 
Model 10.7 
J"XR due to 
all cephalosporins 
at 3mM conc. 
= -0. 196(0.065)DVx + 0.5 12(0.088)DVy + 0.556(0.145) 
n=16 r=0.818 r2=O.670 s=O.974 F=1l.16 probability =0.002 r(CV)2=0.557 
Where: DVy is the dipole moment in vector Y. 
The model proposes that, unlike the penicillin antibiotics (models 10.4,10.5 and 
10.6), the structural size / shape of the cephalosporin antibiotics is not a major 
factor influencing cross-reactivity with anti-benzylpenicillin serum antibodies, but 
that it is the charge separation within the molecules which controls the extent of 
cross-reactivity, as indicated in model 10.1. There is an inverse relationship between 
cross-reactivity and the X-vectorial charge separation, as seen in models 10.), 10.3, 
10.4 and 10.6, and a positive relationship with the Y-vectorial charge separation. 
The cephalosporins, by virtue of the presence of an R2 side chain, are significantly 
larger than the peniciIJins and therefore it may not be possible for the whole 
cephalosporin molecule to enter the anti-benzylpenicillin immunoglobulin receptor 
sites. Therefore cross-reactivity may be brought about by the attraction of the 
cephalosporin to a region on the immunoglobulin adjacent to the receptor pocket 
and the holding of the cephalosporin there via charge-charge interactions, the extent 
of binding being governed by the Y-vectorial charge separation in the molecule~ this 
may possibly relate to the charge distribution in the R2 side chain. It was not 
possible to ascertain, from the software used, which region of the molecule 
constituted the specific dipole vectors. One can only assume that they are 
comparable regions for all the antibiotics and that they control interactions with or 
near to the immunoglobulin receptor sites. These interactions may then enable the 
remaining regions of the cephalosporin (the side chain [34,582,583,584,585,588] 
and / or the bicyclic core [589]) partially to enter the receptor pocket and initiate 
the immunological reaction mechanisms via X-vectorially controlled charge- charge 
interactions, as proposed by models 10. I and 10.4. 
Should the cephalosporin bind in an incompatible orientation, entry of the RI side 
chain or nuclear core into the receptor pocket will not be possible, thus no cross-
reactive response will be initiated. Alternatively if the relevant region of the 
cephalosporin involved in the X-vectorial charge separation is sufficiently distant 
from the receptor surface the response will be weak if at all. This hit and miss 
receptor site activation may account for the lower levels of cross-reactivity seen for 
the cephalosporins with respect to those of the penicillins (as given in table 10. 1 ), 
which are on the whole capable of complete entry into the receptor pocket. 
10.32318 Oral Cephalo§POrin Antibiotics 
The square-root data have a skewnes of 0.385, which suggests normal distribution 
and thus that the data are suitable for modelling. 
As only three oral cephalosporins were used in the model generation it was felt that 
no compound could be justified as being an outlier. 
Regression analysis using those descriptor variables proposed as significant in 
10.32217 resulted in model 10.8, which effectively modelled 68% of the biological 
variance and was statistically significant. However as with 10.3 2215 (model 10.5) 
the model lacked predictive validity as a result of the small number of compounds 
used in its generation. 
Model 10.8 
..rXRdue to 
oral cephalosporins 
at 3mM cone. 
= 1.233(l.7S4)DVy - 1.236(4.679) 
n=3 r=0.823 r2=O.677 s=1.023 F=2.096 probability =0.285 r(CV)2= -1.363 
The model suggests that the extent of oral cephalosporin cross-reactivity with anti-
benzylpenicillin antibodies is directly related to the Y -vectorial charge separation, as 
discussed for model 10.7. The model, as with those other models derived 
specifically for oral compounds (models 10.2 and 10.5), indicates that the X-
vectorial charge separation plays no part in the initiation of immunological 
responses. 
10.323 19 Parenteral Ce.phalosporin Antibiotics 
The skewness value of the square-root data is -0.143, indicating nonnal distribution 
and therefore that the data are suitable for modelling. 
Cefiriaxone was removed from the data set for the reasons as given in 10.322] 7. 
Regression analysis of the transformed biological data those descriptors highlighted 
in 10.32217, yielded model 10.9, which was both statistically significant and 
predictively valid and which modelled 76% of the information in the biological data. 
Model 10.9 
rXRdueto 
all cephaJosporins 
at 3mM conc. 
= -0. 1 87(O.022)DVx + 0.428(0.065)DVy + 0.887(0.166) 
n=14 r=0.870 r2=0.7S6 s=O.755 F=12.40 probability=0.002 r(CV)2=O.707 
The model indicates that the cross-reactivity of parenteral cephaJosporins with anti-
benzylpenicillin serum antibodies is governed by the charge separation within the 
molecule, as with model 10.7. 
10.3232 OSARs of Cross-Reactivity Frequencies ofll-Lactam Antibiotics at 
Concentrations Equivalent to Their Highest Recommended Therapeutic 
Daily Dose (eHRTDD) with Anti-benzylpenicillin Serum Antibodies 
10.32321 Allll-Lactam Antibiotics 
The square root transfonnation of the biological data presented a skewness value of 
0.400, showing them to be nonnaIly distributed and so suitable for modelling. 
Stepwise regression against seventy chosen descriptor variables indicated that a 
numbers of parameters were related to the biological data. Regression analysis 
against combinations of the six primary descriptors, highlighted by stepwise 
regression, produced the statistically significant and predictively valid regression 
model 10.10, which modelled 79010 of the variance in the biological data. 
No compounds were found to be acting as outliers. 
Model 10.10 
rXR due to 
All p-lactam antibiotics 
ateHRIDO 
= -1.963(0.496)SA - S.466(O.647)EHOMO 
100 
+ 5. 194(0.398)VL(CH3) - 53.60(6.499) 
n=31 r=O.889 r2=O.790 5=1.215 F=23.S6 probability =9.339-9 r(CV)2=0.688 
Where: EHOMO is the HOMO energy of the molecule. 
VL(CH3) is the Sterimollength measurement of the whole molecule, 
as measured from a hydrogen of the first methyl group of the 
thiazolidine or dihydrothiazoline ring common to all the antibiotics. 
As with model 10.1, the model indicates that cross-reactivity of all Jl-Iactam 
antibiotics is inversely proportional to the size and charge of the respective 
antibiotic. As with the model for 3mM concentration (model 10.1) the surface area 
of the antibiotic is significant; however, the vectorial charge separation and the 
Sterimol B3 width (measured from the carbonyl oxygen of the f}-lactam ring) 
parameters of model 10.1 have been replaced in this model by EHOMO and the 
SterimoJ length of the molecule (measured from the a methyl group hydrogen 
common to the bicyclic cores of penicillins and cephalosporins). Although different 
descriptors are highlighted in the model they essentially indicate the same properties 
to be of importance in cross-reactivity, as those in model 10.1, and thus support the 
proposed theory of receptor binding. The reasoning for the different descriptors 
being indicated probably lies in the fact that the relative concentrations of the 
antibiotics at their equivalent highest therapeutic daily dose vary considerably 1 ,m 
that of3mM (as shown in appendix 6), and thus generating a model using the same 
descriptors is unlikely. The fact that the descriptors highlighted are equivalent gives 
great significance to models 10. I and 10.10. 
10.32322 All Oral (3-Lactam Antibiotics 
The square-root transformed biological data have a skewness value of -0.127, thus 
indicating that they are normally distributed and therefore suitable for regression 
analysis. No compound was found to be acting as an outlier and so all nine 
compounds in the data set were used in the model generation process. Regression 
analysis with combinations of those parameters highlighted in 10.32221 (model 
10.10), yielded model 10.11 which was both statistically significant and predictively 
valid and which modelled 80010 of the variance in the biological data. 
Model 10.11 
~XRdueto 
oral ~-lactam antibiotics 
at eHRTDD 
= - 0.550(0.221)(EHOMoxI0) 
+ O.S04(O.OSI)VL(CH3) - 50.99(19.90) 
n=9 r=O.892 r2=O.795 s=1.364 F=I1.64 probability =0.004 r(CV)2=0.365 
The model indicates, as with previous models 10.1 and 10.10, that cross-reactivity 
potential is inversely related to the energy of the molecule. However, previously for 
oral antibiotics (models 10.2, 10.5 and 10.9), energy has not been highlighted as 
significant, and it has been an inverse relationship to shape which has been proposed 
as the controlling property. In this model the shape property is still evident but in 
this case the relationship is positive, i.e. the longer the molecule the greater the 
cross-reactivity potential. The change of relationship (negative to positive) is an 
unexpected manifestation, but could possibly be attributed to the fact that the 
Sterimol length measured in this parameter reflects the ease with which the 
functional group of the RI side chain can enter the receptor pocket without 
hindrance from the bicyclic core. This would therefore, support the RI side chain 
dependen~ theories, proposed by Batchelor [584], Shibata [585] and Allemenos 
[582], which previous models (10.1) seemed to contradict. 
Previous energy descriptors have related specifically to charge interactions, but 
HOMO is a more general energy tenn and may relate to the ease with which the 
antibiotic may interact at the receptor surface via electron donation, and so although 
not previously highlighted the parameter still fits in with the proposed receptor 
binding hypothesis put forward in 10.3221. 
10.32323 All Parenteral O-Lactam Antibiotics 
The skewness value of the square root transformed data was 0.802, indicating them 
to be nonnally distributed and so suitable for regression analysis. NafciIlin was 
determined to be behaving as an oudier for the reasons as detailed in 10.322] 4. 
Regression analysis was performed using combinations of those descriptor variables 
highlighted as being relevant in 10.32221 (model 10.10) and those descriptors 
previously highlighted as being relevant to parenteral antibiotics. Model 10. 12, 
which was statistically significant and predictively valid, describing 66% of the 
biological variance, was produced. 
Model 10.12 
rXRdueto 
parenteral fJ-lactam antibiotics 
ateHRTDD 
= - 0.S99(0.050)OVx + 0.977(0. I 22)VB4c=o 
+ 13.55(1.089) 
n=21 r-0.814 r2=O.662 s=1.566 F=I4.71 probability =1.96-4 r(CV)2=0.618 
Where: VB4c=o is a measure ofthe B4 width of the molecule, 
as determined from the carbonyl oxygen of the ~-Iactam ring. 
The model indicates, as did models 10.3 and 10.10, that the properties of size / 
shape and charge distribution within the molecule, are important in controJling the 
cross-reactivity potential of a parenteral antibiotic, as discussed in 10.3221. The 
Sterimol B4 width (as measured from the carbonyl oxygen of the fJ-lactam ring) 
may be equivalent to the Sterimollength (L) of model 10.11, in that it measures the 
distance of the R I functional group from the bicyclic nucleus of the parenteral 
antibiotic, and both are considered to model shape. Thus, it reflects the ease of 
entry of the parenteral antibiotic into the receptor site, so supporting the proposed 
RI dependence theories of cross-reactivity [582,584,585]. The model indicates, as 
have previous models (10.3, 10.6, 10.9), that the charge distribution in the 
parenteral molecules' X vector has a significant, negative relationship with cross-
reactivity. 
10.32324 All Penicillin Antibiotics 
The square root transformation of the biological data gave a skewness value of 
0.038, indicating them to be normally distributed and so suitable for modelling. 
Regression analysis against those descriptors previously highlighted to be significant 
in cross-reactivity (10.3221 and 10.3222), yielded the statistically significant and 
predictively valid model 10.13, which described 87% of the variance in the data. 
No compound was found to be acting as outlier. 
Model 10.13 
rXR due to 
all penicillin antibiotics 
ateHRTDD 
= -3.140(0.346)#CH3 + 2. 780(0. 980)Admin. 
+ 3.818(3.743) 
n=14 r=0.930 r2=O.866 s=l.079 F=3S.49 probability =5.40-6 r(CV)2=0.716 
Where: #CH3 is the number of methyl groups within the whole molecule. 
Admin. is an indicator variable pertaining to the mode of administration of 
the penicillin, where 3 indicates oral and 4 parenteral administration. 
The model proposes that for the penicillin antibiotics there is a negative relationship 
between the cross-reactivity potential of a compound and the number of methyl 
groups in its structure, i.e. the more methyl groups the lower the cross-reactivity. 
The number of methyl groups may reflect two general properties of the penicillins; 
the hydrophobicity and / or the extent of branching and thus the size, shape or 
flexibility. (It was not possible to yield any valid relationships through the 
correlation of#CH3 groups with either shape orhydrophobicity parameters alone). 
If the latter property is the significant property being modelled, this would support 
the theori.es of cross-reactivity being dependent on the nature of the R I side chain, 
because any variation in the number of methyl groups within a penicillin antibiotic 
occurs in the R I side chain, whilst other parts of the structure do not normally alter. 
Thus any increase in the number of methyl groups may act to alter the shape of the 
substituent so making it unable to enter the immunoglobulin receptor site, or may 
act to shield the reactive centres of the substituent, so restricting binding and 
initiation of the immunological response. The model also proposes, as in 10.3221 I, 
that the mode of administration of the penicillin (oral or parenteral) influences the 
cross-reactivity potential. This suggests that oral and parenteral penicillins may 
cross-react with anti-benzylpenicillin antibodies via slightly different mechanisms, 
which are controlled by slightly different molecular properties. 
10.32325 Oral Penicillin Antibiotics 
Univariate statistical analysis showed the square root transfonned data to have a 
skewness value of -0.359, indicating that they are nonnally distributed and suitable 
for statistical modelling. Regression analysis against the primary descriptor signified 
in model 10.13, yielded model 10.14, which was both statistically significant and 
predictively valid, modelling some 87% of the variance. 
No compound was found to be acting as an outlier. 
Model 10. 14 
~XRdueto 
oral penicillins 
ateHRIDn 
= -2.614(0.518)#CH3 - 1O.85(l.165) 
n=6 r=0.933 r2=0.870 s=0.947 F=26.67 probability =0.004 r(CV)2=0.755 
The model indicates, as with model 10.13, that there is a negative relationship 
between the number of methyl groups in the oral penicillin and its cross-reactivity 
potential. If, as discussed with model 10.13, this is a reflection of the molecular 
shape of the oral penicillin then this model indicates that similar properties to those 
the equivalent 3mM model (l0.5) are controlling the biological response. 
9.32326 Parenteral Penicillin Antibiotics 
The skewness value of 0.342 attained for the parenteral penicillin square-root 
transfonned data showed them to be nonnally distributed and so suitable for 
regression analysis. Regression analysis of the transfonned cross-reactivity data 
against combinations of the descriptor variable highlighted in model 10. 13, 
produced the statisticaJIy significant and predictively valid model 10.15, which 
modelled 870/0 of the infonnation in the biological data. 
No compound was found to be acting as an outlier. 
Model 10.15 
rXRdueto 
parenteral penicillins 
at eHRTDD 
= -3.666(0.891)#RICH3 + 9.059(0.299) 
n=8 1-0.930 r2=0.866 s=1.102 F=38.70 probability =4.362-4 r(CV)2=0.700 
Where: #R 1 CH3 is equivalent to the number of methyl groups within the RI 
substituent of the penicillin. 
The model indicates a negative relationship between the number of methyl groups in 
the R I side chain of the parenteral penicillins and their cross-reactivity potential. 
The more methyl groups present, the higher is the degree of branching and the 
possibility of functional group shielding, so the lower is the possibility of the 
parenteral antibiotic interacting at the receptor surface. This model adds further 
support to the proposed theories of cross-reactivity being dependent on the nature 
of the RI side chain [34,583,588]. 
10.32327 AJI Cephalosporin Antibiotics 
The square root transformed data are normally distributed, having a skewness value 
of - 0.533, and so are suitable for statistical modelling. Regression analysis against 
combinations of those descriptors indicated in 10.32221 as being significant 
generated the statistically significant and predictively valid regression model 10.16, 
which modelled 86% of the variance in the data. 
Three cephalosporins within the data set were found to be outliers. Ceftriaxone for 
the reasons detailed in 10.32217. Cephalexin and cefamandole were classified as 
outliers because of the cephalosporins experimentally tested, their respective 
HRIDDs far exceed those of the other cephaJosporins (detailed in appendix 5). It 
was felt therefore their incorporation would introduce a high bias into the data and 
so the results obtained could be distorted. 
Model 10.16 
~ XR due to = 31.34(2.106)SSBp + 9.96(0.76)VB4c=() 
all cephalosporins at eHRTDD - 34.11(2.042) 
n=14 r=O.927 r2=O.860 s=O.675 F=30.75 probability =1.89-8 r(CV)2=O.819 
Where: SSBp is a measure of the shape similarity of the antibiotic to the 
sensitising antibiotic benzylpenicillin. 
The model indicates that the cross-reactivity potential is directly related to the shape 
of the cephalosporin antibiotics, as proposed previously (models 10.1 and 10.10). 
This, however, contradicts the equivalent 3mM model 10.7, which indicates that 
cephalosporin cross-reactivity is dependent on charge separation within the 
molecule. This model proposes that the shape similarity of the cephalosporins to 
benzylpenicillin is significant. This property is biologically significant as the 
receptor-bearing immunoglobulins were raised against benzylpenicillin and so it 
could be assumed that if a cephaJosporin were to fit the receptor it should bear 
some similarity to benzylpenicillin. In the case of the penicillin antibiotics, which aIJ 
closely resemble each other in shape, fitting into the receptor poses little difficulty~ 
it is interaction at the receptor surface which is the limiting factor. As in this model 
for the cephaIosporins, an additional shape parameter (Sterimol B4 width) is 
required to describe the ability to interact at the relevant receptor surface. If, as 
previously discussed, this 84 parameter relateS to the size and / or shape of the R) 
side chain then this mode) too supports the theories of R] dependence of cross-
reactivity. 
10.32328 Oral Cephalosporin Antibiotics 
The skewness value obtained (0.385) showed the square-root transformed data to 
be nonnalJy distributed, and hence suitable for statistical analysis, but as only three 
compounds were present in the data set this was expected. Regression analysis 
against those physico-chemical parameters previously suggested (model 10. 16) as 
being relevant, enabled the generation of the statistically significant model 10. 17, 
which described 8~/o of the biological variance. As with model 10.8 the model 
lacks predictive validity because of the small number of compounds used in its 
generation. 
No compound could be justified as being an outlier. 
Model 10.17 
rXRdueto 
oral cephalosporins 
at eHRTDD 
= + 1.86(1.53)VB4c=o - 12.40(10.82) 
n=3 r=0.945 r2=0.893 s=1.004 F=8.35 probability=0.I02 r(CV)2=-l.041 
The model indicates, as with the previous model of oral specificity (model 10. 1 1), 
that cross-reactivity is related only to the size I shape of the oral antibiotic, and this 
instance to the Sterimol B4 width of the cephalosporin, as discussed previously 
(models 10.12, 10.16). 
10.32329 Parenteral Cephalosporin Antibiotics 
A skewness value of -0.644 suggests a nonnal distribution and indicates that the 
square-root transfonned data are suitable for statistical modelling. Regression 
analysis produced model 10.18 which was statistical significant and predictively 
valid and which described 85% of the biological variance contained within the data. 
Latamoxef was found to be acting as an outlier; the reason for this was believed to 
be that this compound in the only parenteral cephalosporin in which the 
dihydrothiazoline ring sulphur atom has been substituted with an oxygen, a 
substitution known to affect the structure-activity properties of the cephalosporins, 
as detailed previously in 2.4. 
Model 10.18 
rXR due to 
parenteral cephalosporins 
at eHRTDD 
= - 0.224(0.097)DVx + 3. 190(0. 1 42)VB4c=o 
- 9.917(1.432) 
n=13 r=0.921 r2=0.848 s=0.616 F=25.03 probability =2.36-4 r(CV)2=0.639 
The model indicates, as have previous parenteral models (models 10.3, 10.6, 10. 12) 
that cross-reactivity due to parenteral antibiotics is controlled both by a positive 
relationship with the shape of the compounds and by a negative relationship with 
the charge separation in the X vector of the molecule. The biological significance of 
parameters indicated VB4 and DVx have been discussed previously with regard to 
model 10.12. 
10.333 Data Randomisation 
The biological data with respect to each of the 18 models generated were 
randomised 15 times and the regression analysis with the specific significant 
descriptors repeated. Examination of the resultant regression coefficients, table 
10.8, showed that for each randomised model the value ofr were significantly less 
than that obtained for the original model. This indicates that the original models 
were not generated by chance, but reflect the property responsible for initiating and 
controlling cross-reactivity between the specific class of f3-1actam antibiotic and 
anti-benzylpenicillin serum antibodies. 
Table 10.7 Regression Coefficient VaJues Obtained from 
Randomised Data Analysis 
Model r value 
] 2 3 4 5 6 7 8 9 JO 11 12 13 14 
10.1 0.]6 0.01 0.00 0.06 0.00 0.06 0.00 0.00 0.07 0.02 0.05 0.03 OJJ6 0.02 
10.2 0.Q2 0.01 0.16 0.00 0.00 0.01 0.16 0.00 0.00 0.17 0.01 0.05 0.06 0.12 
10.3 0.05 0.08 0.10 0.15 0.15 0.02 0.00 0.00 0.00 0.01 0.15 0.03 0.12 0.00 
10.4 0.09 0.2] 0.00 0.2] 0.03 0.01 0.]8 0.01 0.03 0,0} 0.16 0.13 0.09 0.02 
10.5 0.10 0.00 0.03 0.07 0.01 0.0] 0.00 0.00 0.06 0.00 0.]4 0.08 0.01 0.10 
10.6 0.02 0.17 0.10 0.0] 0.01 0.06 0.0] 0.02 0.08 0.02 0.20 0.12 0,02 om 
10.7 0.00 0.08 0.02 0.03 0.09 0.00 0.01 0.00 0.01 0.21 0.18 0.14 0.00 0.13 
10.8 0.00 0.00 0.00 0.00 0.00 0.13 0.08 .0.18 0.00 0.18 0.02 0.12 0.10 0.17 
10.9 0.06 0.11 0.00 0.01 0.02 0.09 0.07 0.]4 0.07 0.01 0.11 0.02 0.06 0.00 
10.10 0.14 0.]2 0.03 0.]2 0.00 0.00 0.05 0.19 0.05 0.16 0.02 0.03 0.02 0.00 
10.11 0.10 0.00 0.00 0.00 0.00 0.16 0.01 0.16 0.06 0.14 0.07 0.04 0.09 0.06 
10.12 0.03 0.01 0.10 0.13 0.04 0.02 0.00 0.03 0.12 0.00 0.00 0.08 0.01 0.05 
10.13 0.14 0.00 0.09 0.02 0.13 0.00 0.11 0.20 0.00 0.06 0.08 0.09 0.13 0.03 
10.14 0.10 0.00 0.1 I 0.00 0.00 0.03 0.00 0.00 0.09 0.00 0.06 0.00 0.06 0.12 
IO.lS 0.14 0.01 0.00 0.00 0.14 0.06 0.11 0.00 0.00 0.00 0.13 0.02 0.01 0.00 
10.16 0.00 0.00 0.00 0.00 0.00 0.01 O.DO 0.09 0.04 0.01 0.00 0.00 0.03 0.00 
10.17 0.18 0.00 0.00 0.00 0.01 0.00 0.]4 0.02 0.04 0.00 0.00 0.00 0.00 0.03 
10.18 0.00 0.00 0.02 0.05 0.16 0.07 0.05 0.06 0.09 0.10 0.04 0.02 0.01 0.06 
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10.4 OSAR Prediction of the Extent of Cross-Reactivity Occuning Between 
Untested IJ-Lactam Antibiotics and Anti-benzylpenicillin Serum Antibodies 
10.41 Methods 
Due to certain compounds not being commercially available not all of the IJ-Iactam 
antibiotics previously examined in this study (9.0) were assessed experimentally, 
using the developed ELISA, for the extent with which they cross-reacted with anti-
benzylpenicillin serum antibodies. The necessary physico-chemicaI and structural 
descriptors were calculated for these untested compounds to enable the developed 
QSARs (10.3) to be used to predict each compounds cross-reactivity potential, both 
at a 3mM concentration and at a concentration eHRIDO. 
10.42 Results and Discussion 
The structures of the compounds assessed are given in appendix I. The relevant 
descriptor variable values generated and the predicted cross-reactivity potentials, as 
evaluated using the relevant QSARs for each of the penicillins are given in 10.421 
and for each ofihe cephalosporins in 10.422. 
In those cases where the mode of administration of the antibiotic was not known, 
several models were used to evaluate the several frequency values for the same 
adverse reaction type. 
The predicted values, 10.421 and 10.422 show that the HRTDD models, 
particularly those pertaining to the penicillins, used descriptor variables that are 
integers, so the predicted cross-reactivity values are only semi-quantitative (high, 
medium or low), whereas the 3mM predicted values span the entire range of values 
set by the experimental determinations. Therefore, the 3mM models enable more 
accurate predictions of cross-reactivity potential to be made. The eRR TOO models 
do have their use in that they yield descriptors which can be related to the biological 
situation, and which support previous theories of cross-reactivity. 
Although the cross-reactivities predicted in tables 10.421 and 10.422 cannot be 
verified at present, they nevertheless serve as a guide to the likelihood of cross-
reactivity occurring. 
10.421 Prediction of the Extent of Cross-Reactivity Occurring Between 
Untested Penicillin Antibiotics and Anti-benzylpeniciIJin Serum Antibodies 
Penicillin Descr iptor XRat 3mM XRat 
valu es 
SA #CH3 DVz DVx .r % J' 
Orals 
Amdinocillin-pivoxil 308.4 5 
- -
5.98 35.76 -2.22 
Azidocillin 296.9 2 - -- 6.30 39.66 5.62 
Cardinacillin 406.2 2 - - 2.67 7.12 5.62 
Carfecillin 368.0 2 
- -
3.94 14.33 5.62 
Cyclacillin 300.1 2 
- -
6.19 38.31 5.62 
I -.. .. -icilIin 365.2 3 
- --
4.03 16.24 3.01 
Penicillin-V 308.3 2 
- -
5.92 35.03 5.62 
Phenbenicillin 321.6 3 
- -
5.48 29.99 3.01 
Piyampicillin 409.3 5 
- -
2.57 6.59 -2.22 
Tala_mpicillin 382.5 2 
- -
3.46 11.95 5.62 
Parenterals in Rl 
ApalciJIin 409.7 0 -3.36 -- 3.77 14.22 9.06 
Flucloxacillin 357.4 1 -2.25 
--
6.19 38.33 5.39 
MezlociIlin 421.1 1 1.12 - -1.44 2.07 5.39 
Sulbenicillin 340.2 0 2.81 - 1.47 2.16 9.06 
Temocillin 397.4 0 0.82 
-
0.80 0.64 9.06 
Admin. Unknown 
BLP-1654 all pens. 351.3 2 1.54 5.86 orl.- 0.94 0.87 5.88 
parent.- -1. 73 3.00 8.66 
-oral pen. 2 - 4.49 20.16 5.62 
parenteral pen. 0 - 2.08 4.33 9.06 
eHRTDD 
% 
4.93 
31.58 
31.58 
31.58 
31.58 
9.05 
31.58 
9.05 
4.93 
31.58 
82.07 
29.08 
29.08 
82.07 
82.07 
34.55 
74.96 
31.61 
82.07 
10.422 Prediction of the Extent of Cross-Reactivity Occuning Between 
Untested Cephalosporin Antibiotics and Anti-benzylpenicillin Antibodies 
Cephalosporin Descr iptor XRat 3rnM XRat eHRTDD 
valu es 
DVy VB4c=o DVy 
" 
% ..r % 
Orals 
Cefaloglycine 
-0.04 9.01 
-
1.28 1.65 4.38 19.18 
Cefatrizine 
-0.21 6.31 
-
-1.57 2.47 -0.64 0.41 
Cefixirne 3.33 10.20 
- 2.81 8.24 6.60 43.56 
Cefinenoxime 
-0.56 9.93 
-
-1.93 3.13 6.10 37.2] 
CefPiramide 
-1.41 13.33 - -2.98 8.88 12.43 100 
Cepodoxirne-proxetil 6.29 9.71 
-
6.52 42.51 5.69 32.38 
Cefbrozil 4.84 10.03 
-
4.13 22.37 6.29 39.56 
Cefroxadine . 2.30 6.28 
-
1.60 2.56 -0.70 0.49 
Cefterarn 0.22 9.75 
-
-0.97 0.94 5.71 33.29 
Ceftibuten l.59 9.96 
-
0.12 0.52 6.16 37.95 
Cefuroxime-axetil 
-0.55 9.10 
-
-1.91 3.65 4.55 20.70 
Cefuzooarn 2.52 9.86 
-
1.87 3.50 5.97 35.64 
Cephamycin 
-0.01 9.12 
-
-1.32 1.74 5.71 32.60 
T-2588 1.70 10.72 
-
0.86 0.74 7.57 57.31 
Parenterals 
Cefacetrile 
-1.22 8.01 3.53 -0.29 0.08 -4.95 24.50 
Cefepriome 2.80 9.96 1.02 0.18 0.6] -10.08 100 
Cefmetazole 2.26 9.50 0.32 1.80 3.24 -5.12 26.2] 
Cefininox -2.17 9.48 -3.30 0.32 0.10 -3.88 15.05 
Cefodizime 4.88 )0.95 4.26 2.49 6.20 -3.78 14.29 
Cefonicid -5.09 8.18 -0.84 -1.13 1.28 -7.06 49.84 
Ceforanide 
-2.74 6.59 1.09 -2.28 5.20 -4.27 18.23 
Cefotetan 3.05 9.02 -5.13 3.21 10.69 -5.10 32.49 
Cefotiam 5.51 8.58 4.82 2.35 5.52 -5.53 30.58 
Ceftizoxime 2.2 9.99 3.09 1.25 1.56 -3.34 11.16 
FJomoxef 4.62 8.90 0.73 2.73 7.44 -4.70 22.09 
10.5 Conclusions 
A highly sensitive, reproducible competitive ELISA has been developed for the 
quantitative determination of cross-reactivity occurring between ~-Jactam 
antibiotics and anti-benzylpenicillin serum antibodies. Use of this assay clearly 
shows that cross-reactivity between different JJ-lactams and anti-benzylpenicillin 
antibodies does occur in vitro and that different JJ-Iactams cross-react to different 
extents. If such cross-reactions occur in vivo in pre-sensitised patients, they wil1 
initiate the immune system and may bring about hypersensitivity type reactions, the 
magnitude of which will be governed by the level of cross-reactivity occurring. The 
design of new JJ-Iactam antibiotics Will need to address and overcome this problem. 
The developed ELISA and subsequent results generated are concerned with cross-
reactivity of the J3-lactam antibiotics and po)yclonal anti-benzylpenicillin antibodies 
in pre-sensitised rabbit serum; for this reason extrapolation of the data to the human 
clinical environment must be approached with caution, as the rabbit serum may 
contain different antibodies or antibodies of different specificity. The rabbit is 
currently the species of choice, in the pharmaceutical industry, for pre-clinical 
immunogenicity assessment, and it was for this reason, and so that different 
immunogenicity studies could be related that the ELISA for determination of cross-
reactivity was developed with rabbit serum and not human sera. Pedersen-Bjergaard 
[593], demonstrated the phenomenon of cross-reactivity between cephalothin and 
anti-benzylpenicillin antibodies in human sera, so it should be relatively easy to 
modifY the developed ELISA to asses human polyclonal serum anti-benzylpenicillin 
antibodies cross-reactivity. This modification could be achieved by substituting the 
ELISA components of coating antigen, anti-rabbit IgG horse radish peroxidase 
conjugate for equivalent human specific components. The ELISA may need re-
optimising. Thus assessment of the JJ-Iactams with benzylpenicillin pre-sensitised 
human sera should enable generation of data which can be extrapolated more 
confidentiy to the clinical situation and related to the incidence of allergic response 
foIJowing therapy, in such a way that it will be possible to determine what extent of 
an allergic response is due to the drug itself and what is due to cross-reactivity. 
Replacing the coating antigen with one specific for another antibiotic, e.g. ampicillin 
cytochrome-C, will enable determination of cross-reactivities occurring with other 
serum anti-antibodies. 
The QSARs developed enable the prediction of the cross-reactivity potential of new 
~-Iactam antibiotics to be made, and clearly show that cross-reactivity is a shape-
dependent phenomenon. The models suggest that on the whole it is the nature of 
the RI side chain which controls the extent of cross-reactivity, thus supporting the 
previous theories proposed by Blanca [34,583], Kishiyama [588], AlJemenos [582], 
Batchelor [584J and Shibata [585]. 
Although the descriptors in each model are not identical they can each be related to 
the antibody-antigen reaction scenario, the immunological reaction mechanism 
behind cross-reactivity. The reasons for these different descriptors being selected 
may reflect the polyclonal nature of the serum investigated, in that the serum 
consists of a variety of immunoglobulin types, each of which may present a slightly 
different epitope (receptor site); thus, in order to model these slightly different 
receptors general descriptors are chosen. 
Modification of the ELISA to detect specific serum monoclonal antibody cross-
reactivities, and the regeneration of the QSARs, in conjunction with receptor 
modelling techniques, may enable identification of the specific immunoglobulin 
types involved in cross-reactivity and determination of the more specific antibiotic 
molecular properties responsible for receptor binding, and hence the initiation of a 
cross-reactive response. 
Determination of the immunoglobulin types involved in cross-reactivity reactions of 
different classes of antibiotic (penicillin or cephalosporin, oral or parenteral) will 
enable conclusions to be drawn as to the type of allergic reaction induced 
(immediate or delayed hypersensitivity) by specific compounds to be made ill vitro, 
a technique which will be of importance in drug design, but which currently is in its 
infancy. 
11.0 Determination of Differential Cytokine Secretion Patterns from Sensitised 
Lymphocytes, Following ~-Lactam Antibiotic Simulation 
11. 1 Introduction 
The previous experimental protocols and QSARs developed in this study, 9.0 and 
10.0, enable quantitative predictions to be made as to the extent to which a 13-
lactam antibiotic will induce an allergic reaction (cutaneous rash) directly or via 
cross-reactivity with anti-benzylpenicillin serum antibodies, but they do not permit 
distinctions as to the type of allergic response initiated (immediate or delayed 
hypersensitivity) by the respective 13-lactam antibiotic. 
There is increasing evidence that different classes of allergen, e.g. 13-lactam 
antibiotics, provoke different immune responses which are consistent with the 
preferential stimulation of Thelper 1 and Thelper 2 lymphocyte sub-populations 
[594,595], as discussed in 6.5. Recent advances in the understanding of these 
Thelper celJs and their unique cytokine secretion patterns, in conjunction with the 
knowledge of the function of the specific cytokines, as discussed previously in 6.6, 
have increased knowledge of the role cytokines play in the induction and elicitation 
of an allergic response and in determining the nature and severity of the response 
[596] and have led to the development of methods for the detection of immunologic 
responses induced by various chemicals. 
Immediate and delayed hypersensitivity reactions can be differentiated on the basis 
of the cytokines secreted by the Thelper Iymphocytes following exposure to a 
specific compound, e.g. an antibiotic. Thl cells, if simulated, secrete interleukin-2 
(ll..2) which causes initiation of delayed hypersensitivity reactions, whereas 
stimulation of Th2 cells leads to the secretion of interleukin-4 (IL4) which causes 
the initiation of immediate hypersensitivity reactions. Roux-Lambard and Steiner 
[597] have stated that 'the measurement of differential cytokine levels in biological 
fluids may be helpful in staging and prognosis of a disease'. As far as chemically 
induced immunological reactions are concerned therefore, the immunotoxic 
potential of a chemical agent, both the type and the extent of response induced, can 
be predicted by the quantitation of the specific cytokine (IL2 and IL4) secretions 
from T-lymphocytes following exposure [598,599]. 
Analysis of cytokine production can be applied to at least three situations which are 
relevant to immunotoxicity testing; Firstly, the analysis can be conducted in vivo on 
exposed animals, and tissues such as spleen, thymus and lymph nodes can be 
removed and gross analysis for specific cytokines can be conducted. Secondly, 
analysis can be perfonned on ex vivo material; tissue and cells taken fonn exposed 
animals can be stimulated or manipulated in vitro to determine the effects of pre-
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exposure in vivo on the ability of cells to generate characteristic patterns of 
cytokine production. Finally, analysis can be performed exclusively ill vitro, where 
defined populations of cells can be pre-incubated with a test compound before 
stimulation and cytokine analysis [600]. Since cytokine expression is essential for 
the development of immune responses both in vivo and in vitro, it is possible to 
establish patterns of expression for in vivo immune activation. The effect of test 
chemicals on these characteristic patterns of cytokine expression can then be 
monitored, following in vivo and in vitro exposure. 
There are commercially available inununoglobulins and substrate systems which 
permit the differential detection of cytokines by ELISA, thus enabling distinction 
between the Thelper clones involved and giving an indication as to the direction of 
the immune response activated by a specific compound. Under these conditions 
analysis of cytokines becomes a quantitative marker of immunotoxicity. 
It is the aim of this study to modifY existing ELISA systems in order to develop 
highly sensitive assays for the quantitation of IL2 and ITA levels secreted by lymph 
node cells, and then to use these assays in conjunction with the mouse lymph node 
assay (mLNA) in an attempt to devise a protocol for the quantitative determination 
of D...2 and ITA secretions, following ~-lactam antibiotic exposure. This should 
allow determination of whether a specific antibiotic induces an immediate or 
delayed hypersensitivity reaction. 
It may in the future be possible to perform QSAR analysis on the quantited cytokine 
secretion patterns secreted following stimulation, in order to determine if any 
specific physico-chemical or structural properties are responsible for controlJing 
cytokine release and if so how do they relate to those already determined to be 
important in controlling the elicitaion of an adverse reaction or cross-reactivity. 
Interpretation of these data in conjunction with those of allergenicity and cross-
reactivity, previously generated in 9.0 and 10.0, may enable determination of a more 
complete irnmunotoxicological profile of the ~-lactarns, i.e. is cross-reactivity a Thl 
and / or Th2 phenomenon?, which compound initiates which type immunological 
response (Tb 1 or Th2)1, what specific clinical symptoms are developed in response 
to the different immunological responses?, and what proportion of the 
immunological response, if any, is a result of cross-reactivity? 
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11 .2 Development of Sensitive ELISAs for the Detection of IL2 and IL4 
] ] .21 Test Rationale 
The cytokines IL2 and IL4 are differentially secreted by Th I and Th2 sub-
populations following their relative 'switching on' by a xenobiotic, and therefore 
quantitation of the levels of each cytokine secreted following exposure may enable 
prediction of the type of immune response (immediate or delayed hypersensitivity) 
initiated. Mitchelmore [601] and Flint [602] have developed reliable ELISAs for the 
quantitative detection of standard concentrations of IL2 and IL4 in solution. These 
assays, however, are not sensitive enough for the quantitative detection of the very 
low concentrations of IL2 and IIA or of any slight changes in concentration 
occurring in biological fluids, such as occurs following xenobiotic challenge. 
Application of the ELISA optimisation techniques used previously in 10.2, to the 
IL2 and IlA ELISA procedures may enable quantitative determination of theses 
biological cytokine levels to be made. 
11.211 ll..2 ELISA Standard Protocol 
Wells of an Immunlon4 flat bottomed plate (Dynatech) were coated by addition of 
50~1 of IllglmJ rat IGg2a anti-mouse IL2 antibody (Pharmigen 1816]D clone JE56-
lAI2) prepared in coating buffer (O.OSM carbonate bicarbonate buffer pH9.6) 
(Sigrna C304 I) and incubated in a Stuart Scientific incubator model S 118 for 2 
hours at 3 7oC. Prior to each subsequent step the wells were washed three times 
with PTS (phosphate buffered saline pH7.4 (Sigma P38I3) + 0.01% Tween 20 
(polyoxyethylenesorbitan-monolaurate) (Sigma PI379», using a Dynatech MRW 
automatic plate washer. The reactive sites within the reaction wells were then 
blocked by the addition of 200111 of 10mM phosphate buffered saline containing 
10% bovine serum albumin at pH7.4 (Sigma P-3688), and incubated for l.5 hours 
at 370 C. 
The antigen-coated wells were subsequently incubated with; 
- SOJll of2Snglml recombinant mouse IL2 in PTS buffer (Genzyme MIL-2) 
for I hour at 370 C 
- SOJ.l1 of2.SJlglml biotinylated rat anti-mouse IL2 (pharmingen 18172D 
clone JES6-SH4) for 1 hour at room temperature (RT). 
- 1001l) 2.SmglmJ Avidin peroxidase conjugated antibody (Vector Labs. A-2004) 
for 0.5 hours at RT. 
- 100J,113,3',S,S' tetramethylbenzidine liquid substrate (TMB) (Sigma T-8540) at RT 
until sufficient colour had developed. The reaction was stopped with IOOJ.l1 O.SM 
H2S04. Absorbance readings were then taken at 4S0nm using a BioTek EL900 
plate reader. 
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11.212 IL4 ELISA Standard Protocol 
Wells of an Imrnunlon4 flat bottomed plate (Dynatech) were coated by addition of 
50J,!i of 4J,!glml rat IGg2b anti-mouse IL4 antibody (Pharmigen 18031 D clone 
BVD4-IDll) prepared in coating buffer (O.OSM carbonate bicarbonate buffer 
pH9.6) (Sigma C3041) and incubated in a Stuart Scientific incubator model S118 
for 2 hours at 370 C. Prior to each subsequent step the wells were washed three 
times with PTS (phosphate buffered saline pH7.4 (Sigma P3813) + 0.01% Tween 
20 (poIyoxyethy]enesorbitan-monoIaurate) (Sigma P1379», using a Dynatech 
MRW automatic plate washer. The reactive sites within the reaction wells were then 
blocked by the addition of 200J,!l of 10mM phosphate buffered saline containing 
10% bovine serum albumin at pH7.4 (Sigma P-3688), and incubated for 1.5 hours 
at 370 C. 
The antigen-coated wells were subsequently incubated with~ 
- SOJ.lI of 2J.lglml recombinant mouse RA in PTS buffer (phanningen ] 9231 W) 
for I hour at 370 C 
- SOJ,!1 of2J-LglmJ biotinylated rat anti-mouse IL4 (Sigma 1-1390) for I hour at RT. 
- 100J-L12.SmglmJ Avidin peroxidase conjugated antibody (Vector Labs. A-2004) 
for 0.5 hours at RT. 
- 100J.l13,3',S,S' tetramethylbenzidine liquid substrate (TMB) (Sigma T-8S40) at RT 
until sufficient colour had developed. The reaction was stopped with 100J,!1 0.5M 
H2S04. Absorbance readings were then taken at 450nm using a BioTek EL900 
plate reader. 
Controls for both ELISAs were established by replacing the recombinant mouse IL2 
or IL4 with PTS buffer only. Background absorbance levels were determined using 
equation 10.1. 
The dose-response curves generated by both ELISAs are presented in figure I I . ] 
for the IL2 ELISA and figure 11.2 for the ITA ELISA. 
The technical data sheets for both the ll-2 and ITA ELISA antibodies are given in 
appendix 8. 
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Figure 11.1 Dose-Response Curve generated by Standard IL2 ELISA 
(Adapted from Mitchelmore [601] and Flint [602]) 
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Figure 11 .2 Dose-Response Curve generated by Standard IL2 ELISA 
(Adapted from Mitchelmore [601] and Flint [602]) 
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11.22 Experiment 1: Increasing the Sensitivity of the IL2 and 1L4 ELISAs 
Examination of the dose response curves generated by the IL2 and II.A ELlSAs, 
figures 11.1 and 11.2 respectively, ofMitchelmore [601] and Flint [6021, indicated 
that the tail-end of the respective dose-response relationships starts to occur at 
approximate IL2 and IL4 concentration of 0.5nglml. It was decided therefore that 
optimising the ELISAs about this concentration would increase the assay sensitivity 
sufficiently such that it should be possible to quantitate changes in the IL2 and IL4 
concentrations in biological fluids. 
11.221 Methods and Materials 
Checkerboard assays of the standard IL2 and ITA ELISAs (11.211,11.212), figures 
11.3 and 11.4 respectively, were carried out using concentration ranges of rat anti-
mouse coating and biotinylated antibody, and maintaining the concentration of 
recombinant mouse IL2 or HA at 0.5nglml, in order to determine the optimal 
concentrations of rat anti-mouse coating and biotinylated antibody necessary for the 
detection ofIL2 or HA at concentrations of05.nglml or less. 
Optimal reagent concentrations were detennined, as in 10.2, from plots of mean, 
test and background absorbance readings. Optimal conditions occur when the 
difference between the test and background absorbance is at a maximum. 
11.222 Results and Discussion 
Optimal assay conditions, as determined from the IL2 and IL4 checkerboard plots, 
figUres 11.5 and ] 1.6 respectively, were found to be: 
ll..2 ELISA 
HA ELISA 
2J.1g1ml 
SOpglml 
4J..lglmI 
SOpglmI 
rat anti-mouse IL2 (coating antibody) 
biotinylated rat anti-mouse IL2. 
rat anti-mouse ITA (coating antibody) 
biotinylated rat anti-mouse II.A. 
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Figure 11.3 Illustration of the Plate Layout for the IL2 Checkerboard ELISA 
Recombinant mIL2 Blocking buffer 
I 2 3 4 5 6 7 8 9 10 11 II Biot.ramIL2 
A B B 0 
B IJ!glml 
C 400nJdml 
D 200nJdml 
E 10Ong/mJ 
F 40nJdml 
G 2Ong/ml 
B B B 0 
0 2 1 0.5 0.25 0.1 0 2 1 0.5 0.25 O. 
1 
IlglmI rat anti-mouse IL2 coating antibody 
Figure 11.4 lliustration of the Plate Layout for the IL4 Checkerboard ELISA 
Recombinant mllA Blocking buffer 
I 1 3 4 5 6 7 8 9 10 11 Il Biot.ramIU 
A B B 0 
B 4J.lglml 
C 2JJg/ml 
D IJ.Lg/ml 
E 50Ong/ml 
F 20Ong/ml 
G 10Onjl/ml 
B B B 0 
0 4 2 I 0.5 0.25 0 4 2 1 0.5 0.25 
J.1g1ml rat anti-mouse ITA coating antibody 
KEY: 
Biot.ramIL2/4 - biotinylated rat auti-mouse IL2 or IU 
B - cmtrol blank well 
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Figure 11.5 Optimisation Plot Attained from the JL2 Checkerboard ELlS A 
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Figure 11.6 Optimisation Plot Attained from the ITA Checkerboard ELlS A 
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11.23 Experiment 2: Reproducibility of the Optirnised IL2 and IL4 ELISAs 
11.231 Methods and Materials 
In order to ensure the sensitivity of the ELISAs had been increased and assay 
reproducibility maintained, the IL2 and IL4 ELISAs as outlined in 11.2 11 and 
11.212 were each perfonned four times, using the same reagent and standard 
samples but at the optimal concentrations as determined in 11.22. 
11.231 Results and Discussion 
Graphical representation of the IL2 and IL4 ELISA absorbance readings, figures 
11.7 and 11.8 respectively, both show the tail-end of the classical dose-response 
relationship, with the initial absorbance reading, in each case, at a level greatly 
increased in comparison to the equivalent IL concentration when assayed by 
standard ELISA, figures 11.1 and 11.2. This shows that the sensitivity of both 
ELISAs has been increased. The plots, figures 11.7 and 1 I .8, show the same trend 
for each of the four respective replicates, so illustrating that reproducibility had 
been maintained for both optimised ELISAs. 
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Figure 11 .7 Graphical Representation of the Increased Sensitivity and 
Reproducibility of the Optimised IL2 ELISA 
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Figure 11 .8 Graphical Representation of the Increased Sensitivity and 
Reproducibility of the Optirnised IL4 ELlSA 
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11.3 Determination ofll..2 and lL4 Levels in Lymphocyte Culture Supernatant, 
Following In Vitro Stimulation 
11.31 Test Rationale 
Flint [602] has previously used IL2 / IL4 ELISAs for the detection of ll..2 and ll..4 
concentrations in lymphocyte culture supematants following mitogen stimulation of 
cultured lymph node cells to produce IL2. However, due to the low sensitivity of 
the assays used, quantitative detection of the cytokines was not possible. 
The aim of this experiment was to repeat the procedure followed by Flint [602], but 
to substitute the developed sensitive ll..2 and IL4 ELISAs in place of those used 
previously, in order to show that it is possible to quantitate the levels of IL2 and 
llA generated by a simulated in vitro biological system. 
11.32 Methods and Materials 
11.321 Lymph Node CeH Culture 
Step 1 
Lymph nodes were removed from six exsanginated male mice (strain B6C3Fl, aged 
7-8 weeks) into two containers of sterile lOmM PBS, using aseptic techniques and 
stored on ice until required. This gave two groups oflymph node cells 01 and 02. 
Step 2 
Using a class two fume cabinet and aseptic techniques, each group of lymph node 
cells were macerated through fine meshed sieve and passed through cotton wool 
into centrifuge tube. The volume of each tube was made up to 9 mls with sterile 
PBS. the tubes were then centrifuged for 10 minutes at 1150 rpm at 4°C. The 
supematant was discarded and the pellet resuspended in 9 mls of sterile PB S. 
Centrifugation was repeated for lO minutes at 1150 rpm at 40 C, and the 
supematant again discarded. The pellet was resuspended in 3 mls of RPMI-1640 
culture medium supplemented with 25mM HEPES (N-2-hydroxyethyJpiperazine N-
ethane sulphonic acid (Sigma R-5632), containing 400mglml streptomycin (Sigma 
S-9137), 400mglml ampicillin (Sigma A-Ol66) and 10010 heat inactivated foetal calf 
serum (Gibco) 
The resultant culture was seeded into culture solution in a culture flask and 
incubated for 18 hours [603] in a Labline Radiant Warm Wall incubator at 370 C 
with an atmosphere of 5% C02. 
Prior to incubation 3 mI of a phytohaematagglutinin (PHA) a Th! clone specific 
mitogen [604] were added to the G2 Iymphocyte culture, to stimulate cytokine 
production. 
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Step 3 - Cell viability test 
10J,.l1 of culture solution were removed from the culture flask pre and post 
incubation and added to 1OJ,.l1 of 0.4% trypan blue dye (Sigrna T -8154). The cell 
solution was then applied to a haemocytometer and clear viable ceJls counted. 
Step 4 
Following the 18 hour incubation each of the culture solutions was transferred into 
a centrifuge tube and centrifuged for 10 minutes at 2500 rpm at 40 C. Each 
supematant was then extracted and assayed using the optimised ll..2 and IIA 
ELISAs developed in 11.2 using the supematant in place of the recombinant ll..2 / 4 
sample, for its ll..2 and ll..4 content. Samples were assayed in four replicates. 
However to enable quantitation of the IL2 /4 in the supematant standard known 
concentrations of recombinant ll..2 I 4 were assayed in conjunction with the 
supematant samples, thus allowing for the production of a standard curve from 
which the 1L2 / 4 supematant concentrations could be determined. 
11.33 Results and Discussion 
The trypan blue dye exclusion test for cell viability, both pre and post culture 
incubation, showed an abundance of clear celJs when viewed under the microscope, 
thus indicating that the cells were viable before incubation and retained viability 
during incubation. 
Analysis of the IL2 and IL4 ELISA absorbance levels, given in table 1 1. 1, indicated 
that a quantity of II..2 and HA was present in each of the twelve replicates of each 
culture supematant (01 and G2). The mean concentration of IL2 in the treated 
culture supematant (02) was quantitated from a standard IL2 concentration curve 
generated by IL2 ELISA performed concurrently, figure 11.9. (Table 11.2 presents 
the absorbance readings for each standard II..2 concentration). The mean 
concentration of IL2 in the stimulated culture supematant was evaluated to be 
1.55nglml .. The mean level ll..2 in the untreated culture supematant (G1) was 
negligible, being below the lower limit of the standard curve, so quantitation was 
not possible. From a standard IL4 concentration curve (absorbance readings 
presented in table 11.3), figure 11.10, it was determined that the mean 
concentration of ll..4 in both Gland G2 was negligible, occurring at levels below 
the limits of quantitation from the standard curve. Comparison of the mean 1L4 
absorbance readings for G I and 02, table 11. I, showed the levels of absorbance to 
be equivalent, suggesting that ll..4 secretion remained constant throughout the 
incubation and assay procedures. It was concluded therefore that PHA stimulates 
the IT..2 secreting Thl ceUs and not the Th2llA secreting cells. 
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Table 11.1 Absorbance Readings at 450nrn Obtained Following IL2 and IL4 
ELISA of Stimulated and Unstimulated Lymphocyte Culture Supematants 
Replicate # IL2 IL4 
Background Group I Group 2 Background Grou.£.l Grou.£.2 
1 0.056 0.086 0.747 0.048 0.073 0.074 
2 0.051 0.082 0.836 0.050 0.074 0.073 
3 0.055 0.084 0.759 0.049 0.073 0.076 
4 0.055 0.084 0.861 0.049 0.075 0.075 
5 0.054 0.084 0.743 0.051 0.079 0.076 
6 0.058 0.086 0.855 0.051 0.079 0.078 
7 0.078 0.084 0.641 0.050 0.105 0.096 
8 0.065 0.080 0.0680 0.046 0.107 0.101 
9 0.064 0.099 0.570 0.051 0.109 0.094 
10 0.063 0.079 0.0710 0.048 0.101 0.100 
11 0.066 0.085 0.619 0.048 0.096 0.093 
12 0.051 0.086 0.732 0.047 0.103 0.102 
mean 0.058 0.085 0.729 0.049 0.090 0.087 
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Table] ].2 Absorbance Readings at 450nm for Standard ll..2Concentrations 
Evaluated by IL2 Optimised ELISA 
ll..2 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Mean 
concentration 
2nglmI 1.010 0.947 0.871 0.892 0.930 
Ing/mJ 0.712 0.515 0.428 0.4S3 0.S27 
SOOpg/mI 0.294 0.286 0.238 0.280 0.27S 
250pwmI 0.179 0.180 0.201 0.299 0.21S 
125pg/ml 0.131 0.130 0.]45 0.134 0.135 
62.5pg/mI 0.101 0.101 0.]78 0.]09 0.122 
3].25pg/mJ 0.099 0.098 0.133 0.101 0.103 
IS.63pg/ml 0.087 0.082 0.106 0.092 0.092 
Table 11.3 Absorbance Readings at 450nm for Standard IlAConcentrations 
Evaluated by IL4 Optimised ELISA 
IL4 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Mean 
concentration 
2ng/m] 1.832 1.879 1.988 2.070 ].942 
Ing/mI 1.217 1.242 1.180 1.251 1.223 
500pg/mI 0.770 0.742 0.706 0.613 0.708 
250pg/mI 0.456 0.447 0.391 0.391 0.421 
I 25pg/mJ 0.261 0.271 0.252 0.238 0.256 
62.5pg/mJ 0.175 0.170 0.184 0.179 0.177 
31.2Spwml 0.133 0.135 0.159 0.140 0.142 
lS.63pg/ml 0.111 0.Il2 0.140 0.IS0 0.128 
7. 82pg/ml 0.108 0.099 0.]39 0.125 0.1l8 
3.9Ipg/m1 0.096 0.108 0.]40 0.134 0.199 
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Figure 11 .9 IL2 Standard Concentration Curve and Determination of the 
Average IL2 Concentration Present in PHA Stimulated Lymphocyte 
Culture Supematant 
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Figure 11 .10 ITA Standard Concentration Curve and Detennination of the 
Average ITA Concentration Present in PHA Stimulated Lyrnphocyte 
Culture Supematant 
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11.4 Investigation into a Modified Murine Local Lymph Node Assay (mLNA), 
using Benzylpenicillin. Assessing Cytokine Release following In Vitro 
Challenge of Cultured Lymphocytes with Benzylpenicillin and Assessment 
of Cross-Reacivity with Ampicillin 
1 I.41 Test Rationale 
The updated 1992 Organisation for Economic Co-operation and Development 
(OECD) guideline Number 406, for the testing the skin sensitisation of chemicals 
(i.e. for the induction of delayed hypersensitivity responses), states that the local 
lymph node assay (as described in 7.321) may be used as a first stage test in the 
assessment of a new chemical's and / or its entitie's potential to cause skin 
sensitisation. Use of this model for the classification of positive sensitisers has also 
been permitted by the Health and Safety Executive (HSE). The mLNA relies on the 
fact that sensitising chemicals cause Iymphocyte proliferative responses in the lymph 
nodes draining the site(s) of application. Stimulated proliferating lymphocytes may, 
following topical exposure of a chemical, to secrete specific cytokines which may in 
turn be evaluated and provide an alternative end-point for the mLNA [605]. The 
mLNA coupled with cytokine analysis may therefore provide a means for the 
quantitative determination of whether a chemical induces a Thl or Th2 response. 
It was the aim of this study firstly to sensitise groups of mice to benzylpenicillin, 
using the topical exposure techniques of the mLNA, then to excise the local 
draining lymph node and prepare a single cell suspension of the LNCs, and to 
culture these cells with and without exposure (in vitro challenge) to a potential 
sensitiser, as in 11.3, benzylpenicillin or the structurally similar ampicillin (which 
from 10.292 is known to cross-react in benzylpenicillin sensitised systems)~ 
secondly, to quantitate the levels ofll.2 and IL4 secreted from culture's lymph node 
cells (LNCs) using the optimised ELISA, as in 11.3. Examination of the quantified 
cytokine levels may enable detennination of the sensitising potential of 
benzylpenicillin and ampicillin and give an indication as to whether the responses 
initiated are mediated by Th! (IL2) and therefore indicate delayed hypersensitivity 
or mediated by Th2 (HA) and therefore indicate immediate hypersensitivity. 
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11.42 Methods and Materials 
) 1.421 Murine Local Lymph Node Assay 
11.4211 Animals 
Source 
Species & strain 
Number for study 
Age on Day 0 of study 
Diet 
Accommodation 
Small Animal Breeding Unit, GRD. 
Mouse B6C3FI 
50 males (plus 4 spares) 
7-8 weeks 
Rat & Mouse #1 expanded diet (SOS Ltd.) 
and water supplied ab libitum. 
M 1 cages with disposable cage inserts and 
'Alpha-dri' bedding. 
The mice were randomJy allocated to cages (one mouse per cage to minimise cross-
contamination and fighting) and treatment groups using specialised ramdomisation 
computer software (p ADMAN) and were uniquely identified by an animal number 
tattooed on the tail. The animals were allowed to acclimatise to their experimental 
environment for 5 days. 
I 1.4212 Dosing 
The benzylpenicillin sensitising dosage was determined from the previous work of 
Stejskal et al [606], who used penicillin antibiotics in their work investigating skin 
sensitisation. 
Dosage Preparation: 
- a 4: 1 ratio ethanol / polyethylene glycol (EPG), was prepared by combining 8mls 
of95 % ethanol (BDH 28303) and 2mJ propylene glycol (Sigrna P-lO09), this is the 
vehicle for compound application to the mice. 
- I 5% benzylpenicillin in EPG was prepared by dissolving O. 6g of benzylpeniciHin 
(Sigrna Pen-NA ) in 4mJ ofEPG. 
- 10010 benzylpenicillin was prepared by mixing 2mJ of 15% benzylpenicillin with 
lml ofEPG. 
Dosing Regimen and Observations 
The study comprised four treatment groups, as detailed in table 11.4. 
Animals from groups 2, 3 and 4 received a 25J.11 topical application of the 
appropriate dosing solution onto the internal surface of the pinnae, on days 0, 1 and 
2 of the study, Compound application was performed by Bio-Resources at GRD, 
witnessed by myself 
All the animals were examined twice daily, by Bio-Resources, throughout the 
duration of the study, for signs ofill health or reaction to the treatment. 
274 
The individual body weights of all animals pre-treatment, on day 0, and post-
treatment, on day 5, were recorded, as any significant variation may indicate a toxic 
effect. 
Table 11.4 mLNA Dosage Groups 
Group No. Colour Code Dosage No. Mice 
1 white untreated 10 
2 yellow Ethanol! Propylene glycol (EPG) 10 
3 blue 10010_ (w. v) Benzylpenicillin in EPG 15 
4 red 15%_{w.v} Benzylpenicillin in EPG 15 
Termination: 
On day 5 of the study all the mice were sacrificed by vena cava venepuncture 
exsanguination under deep anaesthesia (isoflurane), performed by Bio-resources at 
GRD, witnessed by myself 
The serum from each mouse was collected into individually labelled containers and 
retained for serological analysis (11.424). 
Immediately following termination, the lymph nodes draining the dosing sites were 
aseptically excised from all mice and placed into specifically labeIJed containers of 
pure RPMI-I640 culture medium (Sigma R-5632). The lymph nodes from five mice 
within each dosing group were pooled in order to give 10 experimental groups for 
Jymphocyte culture, as detailed in table 11.5. The lymph node excisions were 
performed by Miss Su Evans (Immunotoxicology Section GRD), myself assisting. 
11.422 LNC Single Cell Culture 
Culturing of the excised LNCs was carried out as in 10.3 (as ampicillin was to be 
assayed it was not applied to the culture medium as in 10.3), with the addition of 
PHA, lOOllglml benzyJpenicilln and l00llglmJ ampicillin being added to the specific 
experimental groups detailed in table 1 1.5, prior to culturing. 
Cell viability was determined as in 10.3 by trypan blue dye exclusion. The number 
of lymphocytes in the culture was evaluated pre and post culturing, by the 
Haematology Department, GRD, using a HI Techicon Analyser. 
11.423 Quantitation of Culture Supematant IL2 and IL4 Levels 
The concentration of ll..2 and 1l.A in the culture supematant of each experiment a) 
group was detennined by ELISA as in 10.3. 
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ID Nos. 
1-]0 
11-20 
2]-35 
36-50 
Table 11.5 Experimental Groups for Lymphocyte Culture 
Mouse ID Experimental Group No. Dosage in vitro Challenge 
1-5 lA untreated untreated 
6-10 IB untreated I: 1000 PHA 
11-15 2A EPG 100llglmJ BP 
]6-20 2B EPG 100ug/mJ ampicillin 
21-25 3A 10% BP in EPG untreated 
26-30 3B ]0% BP in EPG l00ug/mJ BP 
31-35 3C 10% BP in EPG 1001lg/mJ ampicillin 
36-40 4A 15% BP in EPG untreated 
4145 4B 15% BP inEPG 100UWml BP 
46-50 4C 15%BPinEPG 1001lg/ml ampicillin 
11.424 Determination of Serum Antibody Titres 
The serum samples collected from mice, during exsanguination, in the same dosing 
group were pooled into 4 test groups. 
The IgG antibody titre of each serum group was carried out using the standard 
BPCC ELISA described 10.211, but replacing the anti-rabbit IgG conjugated horse 
radish peroxidase antibody with an equivalent concentration of anti-mouse IgG 
conjugated horse radish peroxidase (HRP) antibody (Sigma A-4416) and replacing 
the positive rabbit sera with the pooled serum samples. 
Note: Three rows on the respective ELISA were treated with IgG positive rabbit 
serum, NRS and PTS alone, and hence the anti-rabbit-IgG HRP antibody was used 
in these rows. This was done to provide a control showing that the ELlSA was 
functioning normally. 
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11.43 Results and Discussion 
1] .431 Observations and Body Weights 
No adverse observations or abnormalities were observed for any animal during the 
course of the study. 
The animal body weights pre and post treatment are presented in table 11.6, and 
show no dramatic changes to have occurred, therefore indicating that all animals 
were in good health throughout the study. 
Table 11.6 Pre and Post Treatment Animal Body Weights 
Animal Pre-treatment Post-treatment Body Weight 
Number Body Weight Body Weight Increase 
(g) (g) (gJ 
01 29.7 30.0 0.3 
02 30.2 31.3 1.] 
03 28.7 29.4 0.7 
04 30.1 31.0 0.9 
05 29. ] 31.1 2.0 
06 28.8 29.7 0.9 
07 30.0 31.1 1.1 
08 26.8 27.0 0.2 
09 29.9 31.1 1.2 
10 29.9 31.4 1.5 
11 26.9 27.8 0.9 
12 25.1 27.0 1.9 
13 25.2 27.5 2.3 
14 26.3 27.1 0.8 
15 25.4 26.1 0.7 
16 22.9 24.4 1.5 
17 23.2 24.1 0.9 
18 24.7 26.1 1.4 
19 24.1 25.8 1.7 
20 27.5 28.7 1.2 
21 23.8 25.6 1.8 
Continued over page 
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Table 11.6 continued 
Animal Pre-treatment Post -treatment Body Weight 
Number Body Weight Body Weight Increase 
(g) (g) (g) 
22 23.4 25.4 2.0 
23 25.1 26.7 1.6 
24 25.7 27.3 1.6 
25 26.2 27.6 1.4 
26 24.4 25.5 1.1 
27 25.6 27.0 1.4 
28 23.7 24.1 0.4 
29 26.5 26.9 0.4 
30 24.6 25.7 1.1 
3] 23.7 24.4 0.7 
32 24.9 25.7 0.8 
33 24.3 25.0 0.7 
34 23.8 25.3 1.5 
35 25.4 26.2 0.8 
36 23.4 24.2 0.8 
37 23.0 24.5 1.5 
38 24.1 25.7 1.6 
39 23.4 24.9 1.5 
40 27.1 28.8 1.7 
41 25.3 27.2 1.9 
42 22.5 23.7 1.2 
43 24.] 24.6 0.5 
44 23.4 23.7 0.3 
45 20.8 21.2 0.4 
46 25.S 26.6 I.] 
47 22.8 24.2 1.4 
48 25.8 27.2 1.4 
49 24.] 25.9 1.8 
50 22.4 23.7 1.3 
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11.432 Lyrn,phocyte Culture and Serological Analysis 
The concentrations of IL2 and IL4 in each tested culture supematant were 
detemrined from standard curves produced by ELISA concurrently, figures 11.1 I 
and 11. 12 respectively. The percentage of viable cells and )ymphocytes were 
counted pre and post culturing and the concentrations of IL2 and IL4 determined in 
each respective experimental group as presented in table 11.7. 
Table 11.7 Table of the Lymphocyte Culture and Serological Analysis Results 
Test Pre-Culture Post-Culture Pre-Culture Post-Culture IL2 IL4 
Group Lymphocyte Lymphocyte %CeU % CeU Cone. Cone. 
Count lO / I Count 10 / I Viability Viability pg/m1 pg/ml 
lA 0.66 0.20 64.3 90.0 0.0 3.5 
IB 2.77 0.54 70.9 3.5 0.0 0.0 
2A 3.82 2.73 62.5 77.4 0.0 0.0 
2B 3.29 0.83 66.7 40.0 0.0 3.7 
3A 3.43 1.59 52.4 38.9 <3.9 <3.9 
3B 5.91 8.43 66.7 23.5 3.9 <3.9 
3C 1.91 0.57 73.3 57.1 <3.9 <3.9 
4A 1.84 0.85 60.0 37.5 40 42 
4B 1.59 0.54 66.7 53.3 200 <3.9 
4C 3.42 2.85 50.0 55.0 <3.9 0.0 
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IgG 
Titre 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Examination of the lymphocyte counts clearly shows that, in each case, during the 
incubation period of cell cUlturing the cell numbers diminished, rather than 
proliferated as was expected. This may be due to some lack of essential nutrient in 
the culture medium, the self degradation of the cells or due to a reduced C02 
supply. The cell numbers obtained are moderate, as is the viability of these cells~ 
these two factors together may explain why such low cytokine levels, compared 
with 11.3, were obtained. That is, if half of the low number cells present are non-
viable, and thus non-cytokine secreting, only a very small number of celJs remain to 
secrete the cytokines, and subsequently the cytokine levels are low. It is also 
apparent from examination of the Iymphocyte cell counts that the numbers of cells 
varied significantly from group to group. This inability to standardise cell 
populations is an common problem when culturing cells and reflects the 
inconsistency in numbers of lymph nodes it is possible to excise from different mice. 
This variation in cell numbers therefore leads to errors in the calculation index and 
restricts the accuracy of comparisons made between the results obtained from 
different cell populations. 
The post-culturing cell viabilities are relatively low (below 75%) and this may be 
due to the excessive time (3 hours) between animal termination, lymph node 
excision and CUlturing, which itself was a legacy of the protocol and the large 
number of animals used. During the time between excision and culturing, it is 
reasonable to assume that some of the LNCs would have died. In future studies of 
this type it may be more pertinent to terminate, excise and culture one test group at 
a time, i. e. only 5 mice, thus reducing the delay and restricting the likelihood of 
excessive cell death. 
The results obtained from Group 1 A indicate that no quantifiable amount of ll..2 
and only a negligible amount of HA were present in the culture supematant. These 
levels were as expected as this group was the negative untreated control group for 
the study. 
Group I B is essentially a repeat of the previously performed PHA Iymphocyte 
stimulation, 11.3, and should therefore have provided a positive control for the 
study. However, upon examination of the cytokine levels evaluated it is apparent 
that some fault has occurred, in that the ll..2 concentration, rather than being of the 
magnitude of I.SSnglmJ as obtained in 11.3, was below the level of quantitation. 
This limited ll..2 secretion is explained by the fact that for this test group the cell 
viability was extremely low at only 3.S%, thus there were only a few ceUs viable 
enough to be stimulated and to secrete IL2. The concentrations of IL4 were also 
below the limits of quantifiable detection. As previously mentioned in I 1.3, PHA 
appears to stimulate only the ll..2 secreting Th 1 ceU suh-population, therefore the 
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experiment contained no positive control for the stimulation of IL4 secreting Th2 
cells. Suitable candidate chemicals for such an IL4 control in future work could be 
oxazalone or 2,4-dinitrochlorobenzene (ONCB), both of which are known Th2 
stimulators [607]. 
Group's 2A and 2B are EPG vehicle and challenge control groups, which, by virtue 
of the lack of IL2 and negligible levels of HA detected, demonstrated that the EPG 
was not responsible for sensitising the LNCs and that without prior sensitisation 
neither benzyJpenicillin nor ampicillin generated a challenge response. 
Group 3A presented a low Iyrnphocyte and viability count, which may be why the 
levels of IL2 and HA obtained were both negligible. However, The fact, that the 
ll.2 concentration, when compared to that of Group I A, appeared to have 
increased marginaUy and the HA levels were unaltered, suggests that the 10% 
benzylpenicillin solution may possibly have caused a mild sensitisation of the 
draining LNCs. 
Group 3B generated marginally greater concentrations of IL2, with little change in 
the llAlevels, t~us suggesting that the sensitised environment presented the in vitro 
challenge with benzylpenicillin stimulated the secretion of more 1L2. The low cell 
numbers and low viability explain why IL2 levels were not of a higher magnitude. 
Group 3C presented IL2 and ITA levels no different from those of Group 3A, 
suggesting therefore that, unlike benzylpenicillin, the challenge of mildly sensitised 
Jymphocytes with ampicillin does not result in further Iymphocyte stimulation and so 
neither the IL2 or ITA secretion is increased. 
Group 4A cytokine levels clearly show that a topical application of 15% 
benzylpenicillin results in LNC sensitisation and induces the secretion of IL2 and 
IL4. 
Group 4B, in comparison to the cytokine levels of Group 4A, shows a greatly 
increased IL2 concentration, of a magnitude equivalent to that of the PHA 
stimulated ll..2 production in 11.3, whilst the ITA concentration is significantly 
reduced. This indicates therefore that the challenge of a benzylpenicillin-sensitised 
system with benzylpenicillin results in the stimulation of the IL2 secreting Th] 
Iymphocyte sub-populations to the detriment of IL4 secretion. Thus benzylpenicillin 
may possibly have induced delayed type hypersensitivity reactions, as has been 
proposed previously [608]. It has been proposed [609] that the possible reason 
behind why the concentration of HA secreted is diminished in both Groups 3 B and 
4B, is that increased concentrations of IL2 act via negative feedback mechanisms to 
suppress the secretion of IL4 and via immunosuppressive mechanisms to down 
regulate the production of Th2 ceUs whilst also acting via positive feedback 
mechanisms to enhan~ the differentiation of virgin Th cells into 1L2 secreting Th I 
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clones. Group 4C, as with Group 3C, presents levels of ll..2 and 114 equivalent to 
the respective A groupings, thus further indicating that ampicillin does not act in 
vitro to stimulate either IL2 or IL4 production. 
The lack of an IgG titre for any of the test groups suggests, at first glance, that the 
application of benzylpenicillin may not have induced the sensitisation of the LNCs. 
However, as previously discussed, the altering ofll..2 and ll..4levels in test groups 3 
and 4 indicates that a sensitisation and stimulatory response were occurring. The 
apparent lack of any IgG may be a result of the five day dosing regimen not being 
long enough to stimulate a significant IgG response. Furuhama et al [610] propose 
that in order to stimulate an IgG response a post-dosing period of twenty days is 
required. Kimber [611] proposes that for the five day dosing regimen of the mLNA 
it would be more meaningful to evaluate the levels of the immunoglobulins which 
are stimulated, i.e. IgM or 19E. IgE is specifically involved in Th2 immediate 
hypersensitivity whilst IgM production is a result of Th 1 stimulation. Therefore the 
evaluation of both these immunoglobulins would provide a rough indication as to 
the direction of the induced immune response. 
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Figure 11 .11 IL2 Standard Curve and Determination of IL2 content of 
Lymphocyte Culture Supematant Sample 
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Figure 11 .12 ITA Standard Curve and Determination of IL4 content of 
Lymphocyte Culture Supernatant Sample 
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11.5 Conclusion 
An assay has been developed which enables the quantitation of IL2 and IL4 levels in 
cultured lymphocyte supematants following mLNA. Further modification and 
optimisation of the assay protocol should enable the quantitative determination of 
ll . .2 and IIA secretion patterns induced by a sensitising agent and how these 
patterns are altered upon in vitro challenge with a second agent. 
The interpretation of the such quantitative measurements of cytokine levels may in 
future pay important dividends with respect to the identification and classification of 
chemical allergens. 
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12.0 General Conclusion 
In parallel with the expanding needs of immunotoxicological evaluation there is a 
need to develop new approaches and new in vitro models [612]. One such novel 
approach is via mechanistic studies, which relate imrnunotoxicity to the physical, 
chemical and I or structural properties of the immunotoxicants themselves, i.e. 
QSAR. Mechanistic studies of irnmunotoxicants in the past have proved to be 
extremely complex [613], but with the recent advances in computing technology 
such studies are now possible. 
In this work, it has been possibl~, using the highly sophisticated and dedicated 
software of QSAR to bring together the approaches of epidemiology, immunology 
and computational chemistry, in such a way as to produce a means for the 
mechanistic investigation of P-Iactam antibiotic immunotoxic potential. 
In this work a database pertaining to the frequency of adverse reactions exhibited in 
the general population foUowing the therapeutic administration of 70 p-Iactams and 
some of their physical, chemical and structural properties, has been compiled and 
used to develop 27 QSAR models, which mathematically relate the potential 
adverse induction of the immune system to the shape and charge separation of the 
antibiotics. The results generated support the hypotheses that immunoJogica1Jy 
mediated adverse reactions are initiated via binding to and stimulation of 
immunoglobulin receptor sites. 
Also, in this study a highly sensitive and reliable immunoassay has been developed 
and used to quantitate the extent by which different J3-lactams cross-react with anti-
benzylpenicillin serum antibodies, both at concentrations of 3mM and at equivalent 
to their respective highest recommended daily dose. The results of which clearly 
show that different f3-lactams cross-react with anti-benzylpenicillin antibodies to 
differing degrees, thus initiating different levels of immunological stimulation. 
QSAR analysis of these results enabled tbe development of 18 models that relate the 
phenomenon of cross-reactivity to the size I shape of the respective J3-1actam. These 
results support the hypotheses of cross-reactivity, as proposed by Batchelor [584], 
Shibata [585], AUemenos [583] and Blanca [34], that f3-lactams cross-react by 
binding to specific epitopes on specific pre-developed immunoglobulins. 
The complexity and diversity of the immunotoxicologically mediated responses 
prevents exact detennination of the specific irnmunocomponents involved in each 
reaction type and of the reaction type induced. 
Receptor modelling may provide information as to the nature of the epitopic site(s) 
involved. 
Protein binding or haptenisation of the ~-lactams is a pre-requisite for allergenicity, 
however, due to the constraints of the software available, it was not possible to 
model the protein bound 13-lactarns or their metabolites. Investigation of these 
derivatives may allow for more specific QSARs or be developed. 
Also, in this study a new in vitro approach for the detennination of the direction of 
stimulation of the induced immunological response (immediate or delayed 
hypersensitivity) by the 13-1actarns, directly or via cross-reactivity has been 
developed. The approach involves the quantitative determination of the levels of the 
1L2 and ll.A cytokines in culture supematant, secreted following in vitro challenge 
of sensitised or unsensitised lymphocytes by a specific 13-lactam antibiotic. 
The use of the QSAR's developed, in this study, in conjunction with the 
immunological assays provide a reliable means for the mechanistic assessment of the 
potential allergenicity, cross-reactivity and the direction of immunological 
stimulation of new or untested 13-lactam antibiotics. 
Use of this information in conjunction with other related data, e.g. antimicrobial 
structure-activity relationships, efficacy and general toxicity, in the early stages of 
new compound design and development will enable the pharmaceutical industry to 
produce the necesS8J)', new b-lactams antibiotics at a fraction of the time and cost, 
whilst maintaining efficacy and minimising toxicity. 
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B B 
H H 
H 
H H 
H B 
H H 
A1 
Name 
12-Carfecillin 
13-Cyclacillin 
14-Cloxacillin 
15-Dicloxacillin 
16-Epicillin 
17-Flucloxacillin 
H /Cl 0 
c-C" 11 at C-c-c C-~ /7 11 11 c-~ N e'CR 
H Cl '0/ 3 
H Bz 0 
e-c" 11 Ht C-CBC-
" ~ I c-e NH2 
Kz H 
Appendix 1 
H H 
H H 
H H 
H H 
H H 
B H 
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Name RI 
R3 R4 
18-Lenampicillin 
H H 
/c-c" ,p 
BC C-~HC_ H -C~I=I-CH3 
'c-c' H H NBz 0 0 
'c/ 
~ 
19-Methicillin OCB3 B / 
c-c, ~ 
B( c-c- H H 
~ ~ C-C 
H 'OCR 3 
20-Mezlocillin ~_~ 0 
~ ~ 11 H H HC C-CHC--
'c--c/ I 
- NH 
H H I 
C=O 0 0 I c(' 11 l(' N-5-CH ! I 11 3 
H'2CH2 0 
21-Nafcillin B B 
£c-c'c H H 
" / C-~ 0 
/ 11 
HC C-C-
~ ~ C-C-OC~CH B . 3 
22-Oxacillin 
B B 
C-C, 0 
( 11 H 
H 
B ;-C-CC-~C- , 11 1\ 
N C B H ,,/'-CH o 3 
23-Phenoxymethyl Penicillin 
B B 0 
C-C, 11 
-at ;-OCHzC-~ , 
c-
H B 
B H 
Name 
24-PiperaciIlin 
2S-Pivampicillin 
26-Talampicillin 
27-Temocillin 
28-TicaciIlin 
H H 
c-c 0 #' '\. 11 
BC C-CBt:-
"C=c/ k 
B H I 
H 
C=o 0 0 
\ JI_~ ~ ~CazCH3 
CH'2-CHZ 
H p.-c 0 
,fT ~ 11 
He C-CHe-
" / I c=C NB 
H H 2 
o 
11 
HC-C-CHC-
11 11 I 
HC CH c 
"S/ /'" o OH 
o 
11 
HC-C-CHC-
" " " 
HC CH 0';:' OH 
'5/ 
H 
H 
-OCH 3 
H 
Appendix I 
H 
H 
H 
AS 
ORINS CEPHALOSP 
On Nucleus Comm 
Name 
29-Cefacetrile 
30-Cefaclor 
c-~ B H ~ r ~C9H _ 
HC / I 
"c C NH2 
31-Cefadroxil 
32-Cefaloglycin 
"'-~"-"ndole 33  ... 
34-Cefatrizine 
H H 
H H ~ r-~9H~-
HC / I 
"c C NHZ H H 
H H g r-~9Be-
BOC / I 
"c C NBZ B B 
o 
11 
-CBz°CC~ 
-Cl 
- Cll.3 
Bfi U 
-CB.! -"-N/ 
B 
H 
H 
H 
H 
H 
B 
d" I Appen IX 
H 
H 
H 
H 
H 
B 
Name 
3S..('efazolin 
36..('efepirome 
37-cefutime 
38..('efmenoxime 
39-Cefmetazo)e 
4O-Cefminox 
41-Cefodizime 
Y-
r-N't-.L B 
5- c~ I ~ 
H N0CBz~-OH 
j'2 9 
CHCHzscRzt-
I 
HO-C 
I 
o 
N-N 
-CHS~ ) 
2 " 
I 
cH:3 
N-N 
I I 
-cy-v 
c~ 
AppeoOlx J 
H H 
H H 
H H 
H 
H 
H H 
A7 
Appendix 1 
El RJ ~ ~ RI 42-Cefonicid 
/j'0 
CBr,-OH H B , ~ ~c-~ ~ N, 0 
H H -CBZSC N BC CTH -
~--' 'C=C/ OH H B 43-Cefoperazone 
N-N 
B "c~ l 11 11 H 
-CIlzS C, fl"N C,¥H-JI, NHrB -
'C-. /C\ 
CHS I 0 HC H 
o n JH' 
HC,,~ 
OH 
44-ceforanide 
H B FHZ~ OB 
H 
N 0 H 
r-~ g 
-CXzS{ \-BC CCHz _ 
~--L 'C=C/ H I 
~ 
4S-cefotetan 
:fJ FH:3 NHzf 5 0 
N, 
H H -C"2S~ ~=C<:>=H!- 11 O=C 
N / OH 
46-cefotaxime 
NOC~ ff 
H H ~-C-~r.- -CRz°CC~ g 1/ d H2N, fH 
5 
47 -Cefotiam 
B 
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Name R} R1 BJ. ~ 
48-Cefoxitin 
BC-CB 0 0 ~ 11 11 11 
H " fCB.zC- -C~OCNH2 -OC~ 
H 
s 
49-Cefpiramide 
B FR.3 
CB C~-~~NBCB1- N -c~sc ') H H 3" I ~-L C=C/ B I ~C" 
OB , iH 
H",=.fH 
hH 
SO-Cefpodoxime-proxetil 
~S) 1H~~~ 1\ H 0 N--C-C M- -C~OCH3 H 
1\ 
c~ 0 CIi:3 
NOCIf:l 
Sl-cefprozil 
/~ 0 
-CH-CHCH] BC \-rBg- H H 
11 lH NH 
HO/'C/ 2 
H 
52-cetroxadine lJa r 
-
OCH3 H 
H 
C iHG-
Hz NH 2 
S3-cefsulodin 
B H 
,C-~ ~ 
RC cc&e- H 
" (I C S-o 
B II'OH 
o 
• 
Name 
54-Cefiazidime 
55-Cefteram 
56-Ceftibuten 
57-Ceftizoxime 
58-Ceftriaxone 
59-Cefuroxime 
o 
C~­
N f " 11 CB NOCIi.3 
"."c.,,/ 
N~ 5 
V'H O J1-Jfi-~-
CH 
CH2 I 
H 
O=C-OH 
~",s" 0 
11 lH~_ H 
N- K~c~ 
C~ V" 0 I N-N:-.. 
/ '\:c OH 1\ !H~_ -CH5~ -C/ 
N- E~c~ 2 N g 
ff ~-~ NOC~ 
-C~OCNHZ 11 J ~ 7,-BC,,?_ I 
o 0 
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H H 
H H 
H H 
H H 
H H 
H H 
AlO 
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RJ R! B£ RI Name . 
6O-Cefuroxime-Axetil 
H H 
-CHCH3 H 
-CHz?Hz 
6cCK 
C-C NOCHa 
11 3 
" 11 ~c-
0 
HC }- 11 
'0 0 
0 
61-Cefuzonom 
~/5 
~-N 
H iJ-)~-l 
-CH s~ 11 H 2 C-N ~OC~ H 
62-Cephalexin 
H 
H H ~ 
H ~-"\fH - -c~ HC / 
"C=C NH
z H H 
63-Cephaloridine 
H 
H 
HC-CH 0 CHr-~ 
B / CB 11 " ~_ 
-UfN / HC" ;:CIi2 
"C=C S 
H H 
64-Cepbalothin 
0 
H 11 H S" 11 
-CKzOCCI\ / -C~C-:~--lB 
65-Cepbamycin 
H 
-oCH3 11"'. 11, ell, L C~OCCB3 
- " 0 
CCHCB2C 
0' kHZ 
66-Cepbapirin 
0 
H 11 H 
B B ~ 
-CHzoCC~ /-"\sc~-
"C=C/ 
H B 
An 
Name 
67-Cephradine 
68-Flomoxef 
NOTE; 
Sot t.he B rin~ 
has been replaced 
with an O. 
69-Latamoxef 
a B 
NOTE; r-~ 9 
S in the aoc~ CTBe--
B rin~ ha~ been Ca=C/ C-OB 
a II 
replaced vit.h 0 0 
in this compound. 
70-T-2S88 
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El ~ 
-c~ H H 
H 
-OC~ H 
H 
At2. 
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APPENDIX 2 SMILES Codes of 70 (3-Lactam Antibiotics 
PENICILLINS 
Amdinocillin (MeciIlinam) CC3(C)SC2C(N=CNl CCCCCC J )C(=O)N2C3C(O}=O 
Amdinocillin-pivoxil (Pivmecillinam) 
CC(C)(C)OC(=O)COC(=O)CIN3C(SCI(C)C)C(N=CN2CCCCCC2)C3=O 
Amoxycillin CC3(C)SC2C(NC(=O)C(N)c Iccc(O)cc I )C(=O)N2C3C(O)=O 
Ampicillin CC3(C)SC2C(NC(=O)C(N)clcccccl)C(=O)N2C3C(O)=0 
ApaJcillin 
Azidocillin 
Azlocillin 
CC5(C)SC4(NC(=O)C(NC(=O)c2mclcccnclc20)c3ccccc3)C(::::O)N4CSC(O)=O 
CC3(C)SC2C(NC(=O)C(N=N=N)c lccccc 1 )C(=O)N2C3C(O)=O 
CC4(C)SC3C(NC(=O)C(NC(=O)NI CCNC 1 =O)c2ccccc2)C(=O)N3C4C(O)=O 
Bacampicillin CCOC(=O)OC(C)OC(=O)CIN3C(SCI(C)C)C(NC(=0)C(N)c2ccccc2)C3=O 
Benzylpenicillin CC3(C)SC2C(NC(=O)Cc I CCCCC 1 )C(=O)N2C3C(O)=O 
Carbenicillin CC3(C)SC2C(NC(=O)C(C(O)=O)c 1 ccccc 1 )C(=O)N2C3C(O )=0 
Cardinacillin 
CC5(C)SC4C(NC(=O)C(C(=O)Oc2ccc I CCCc Ic2)c3ccccc3)C(=O)N4C5C(O)=O 
CarfeciIJin CC4(C)SC3C(NC(=O)C(C(=O)Oclcccccl)c2ccccc2)C(=O)N3C4C(O)=O 
Ciclacillin CC3(C)SC2C(NC(=O)CI(N)CCCCCl)C(=O)N2C3C(O)=O 
Cloxacillin Cc2onc(clcccccICI)c2C(=O)NC4C3SC(C)(C)C(N3C4=O)C(O)=O 
Dicloxacillin Cc 1 onc( cl C(=O)NC3C2SC(C)(C)C(N2C3=O)C(O)=O)c4c(CI)cccc4CI 
Epicillin CC3(C)SC2C(NC(=O)C(N)C 1 =CCC=CC 1 )C(=0)N2C3C(0)=0 
Flucloxacillin Cc looc( cl C(=O)NC3C2SC(C)(C)C(N2C3=O)C(O)=O)c4c(F)cccc4CI 
Lenampicillin 
clcccccIC(N)C(=O)NC2C(=O)N3C(C(=O)OCC4=C(C)OC(=O)04)C(C)(C)SC32 
Methicillin cOe 1 CCCC(OC)C I C(=O)NC3C2SC(C)(C)C(N2C3=O)C(O)=O 
MezlaciUin 
CC4(C)SC3C(NC(=O)C(NC(=O)NI CCN(C I =O)S(C)(=O)=O)c2ccccc2)C(=O)N3C4C(O)=O 
Nafcillin 
Oxacillin 
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CCOc 1 ccc2ccccc2c 1 (C(=O)NC3C(=O)N4C(C(=O)O)C(C)(C)SC43) 
CC 1 =C(C(=O)NC2C(=O)N3C(C(=O)O)C(C)(C)SC32)C( c4ccccc4)=NO 1 
Phenoxymethylpen. CC3(C)SC2C(NC(=O)COc 1 ccccc I )C(=O)N2C3C(O)=O 
PiperaciUin 
CCNI C(=O)C(=O)N(C(=O)NC(c2ccccc2)C(=O)NC3C(=O)N4C(C(=O)O)C(C)(C)SC43)CC I 
Pivampicillin CC(C)(C)C(=O)OCOC(=O)CIN3C(SCl(C)C)C(NC(=O)C(N)c2ccccc2)C3=O 
Talampicillin 
CC3(C)SC2C(NC(=O)C(N)c Icccccl )C(=O)N2C3C(=O)OC40C(=O)c5ccccc45 
Temocillin 
Ticarcillin 
COC3(NC(=O)C(C(O)=(»c 1 ccsc 1)C2SC(C)(C)C(N2C3=O)C(O)=O 
CC3(C)SC2C(NC(=O)C(C(O)=O)C I =CSC=C I )C(=O)N2C3C(O)=O 
CEPHALOSPORINS 
Cefacetrile CC(=O)OCC 1 =C(N2C(SC 1 )C(NC(=O)CC#N)C2=O)C(O)=O 
CefacJor NC(C(=O)NC2C 1 SCC(=C(N I C2=O)C(O)=O)Cl)c3ccccc3 
Cefadroxil NC(C(=O)NC2CISCC(=C(N1C2=O)C(O)=O)C)c3ccc(O)cc3 
Cefaloglycin NC(C(=O)NC2C 1 SCC(=C(N I C2=O)C(O)=O)COC(=O)C)c3ccccc3 
Cefamandole CN IN=NN=C 1 (SCC2=C(C(=O)O)N3C(=O)C(NC(=O)C(O)c4ccccc4)C3SC2) 
Cefatrizine NC(C(=O)NC2C 1 SCC(=C(N 1 C2=O)C(O)=O)CSC3=CN=NN3 )c4ccc(O)cc4 
Cefazolin CC I =NN=C(SCC2=C(C(=O)O)N3C(=O)C(NC(=O)CN4N=NN=C4 )C3SC2)S I 
Cefepirome 
CON=C(CI=CSC(N)=NI)C(=O)NC2C(=O)N3C(C(=O)O)=C(Cn4c5CCCc5c(N)cc4)CSC32 
Cefixime NCI=NC(=CSI)C(=NOCC(O)=O)C(=O)NC3C2SCC(=C(N2C3=O)C(=O)OC=C) 
Cefinenoxime 
CON=C(C(=O)NC2C 1 SCC(=C(N 1 C2=O)C(O)=O)CSC3=NN=NN3C)C4=CSC(N)=N4 
Cefinetazole N#CCSCC(=O)NC 1 C(=O)N2C(C(=O)O)=C(CSC3=NN=NN3(C»CSC21 
Cefininox 
CNIN=NN=CJ(SCC3=C(C(=O)O)N4C(=O)C(OC)(NC(=O)CSCC(N)C(=O)O)C4SC3) 
Appcnw'\2 
Cefodizirne 
CON=C(C 1 =CSC(N)=C 1 )C(=0)NC2C(=0)N3C(C(=0)0)=C(CC4=NC(C )~C(crc =0)0)S4) 
CSC32 
Cefonicid 
OS(=O)(=O)CN IN=NN=C 1 (SCC2=C(C(=O)O)N3C(=O)C(NC(==O)C(O)c4cccc c4)C3SC2) 
Cefoperazone 
CN I N=NN=C 1 (SCC2=C(C(=O)0)N3C(=O)C(NC(=O)C(c4ccc(0)cc4)NC(=O)N5C(==O)C 
(:::()N(CC)CC5)C3SC2) 
Ceforanide 
NCe 1 cccccl CC(=O)NC3C2SCC(=C(N2C3=O)C(0)=0)CSC4=NN=NN4CC(O)=O 
Cefotetan 
CNIN=NN=CI(SCC2=C(C(=O)0)N3C(=O)C(OC)(NC(=O)C4SC(=C(C(=O)N)C(=O)0)S4) 
C3SC2) 
Cefotaxime 
CON=C(C(=O)NC2C 1 SCC(=C(N 1 C2=0)C(O)=0)COC«( )=0)(' 3==CS=C(N)N 3 
Cefotiam 
CN(C)CCN 1 N=NN=C 1 (SCC2=C(C(=O)O)N3C(=0)C(NC(=O)CC 4=CSC(N)=N4)(, 3sr 2) 
Cefoxitin NC(=O)OCC 1 =C(C(=O)O)N2C(=0)C(OC)(NC(=0)CC3=CC=CS3)C 2SC I 
Cetpiramide 
CN IN=NN=C 1 (SCC2=C(C(=0)0)N3C(=O)C(NC(=O)C(c4ccc(O)cc4)NC(=0)( 5:::( 
N=C(C)C=C5(O»C3SC2) 
Cefj>odoxime-proxetil 
COCCl=C(C(=O)OC(C)OC(=O)OCC(C»N2C(=O)C(NC(=0)C(==NOC)(,3=CSC 
(N)=N3)C2SC 1 
CetproziI CC=COC(=O)C 1 =CCSC2C(NC(=O)C(N)c3ccc(O)cc3 }C(=O)N 2 I 
Cefroxadine COC I =C(C(=O)O)N2C(=O)C(NC(=O)C(N)C3=CCC=CC 3)C 2S(, I 
Cefsulodin 
OS(=0)(=0)C(clcccccl)C(=O)NC2C(=O)N3C(C(=O)O)C(Cn4ccc(C(=O)N)cc4)CSC32 
Ceftazidime 
OC(=O)C(C)(C)ON=C(CJ=CSC(N)=NJ)C(=O)NC2C(=O)N3C(C(=0)0)=C(CN4=CC=CC=C 
4)CSC32 
Cefteram 
CON=C(C 1 =CSC(N)=NI)C(=O)NC2C(=O)N3C(C(=O)O)=C(CN4N=NC«()=N4) 
CSe32 
A J~ 
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Ceftibuten NC 1 =NC(=CS l)C(=CCC(O)=O)C(=O)NC3C2SCC=C(N2C3=O)C(O)=O 
Ceftizoxime CON=C(C(=O)NC2C 1 SCC=C(N 1 C2=O)C(0)=O)C3=CSC(N)=N3 
Ceftriaxone 
CON=C(C I =CSC(N)=N 1 )C(=0)NC2C(=0)N3C(C(=0)O)=C(CSC4=NC(=O)C(O)NN4(C» 
CSC32 
Cefuroxime CON=C(C(=O)NC2C I SCC(=C(NI C2=O)C(O)=0)COC(N)=O)C3=CC=C03 
Cefuroxime-axetil 
CON=C(C(=0)NC2C1 SCC(=C(N1 C2=O)C(=O)OC(C)=O)COC(N)=0)C3=CC=C03 
Cefuzonam 
CON=C(C(=O)NC2C 1 SCC(=C(NJ C2=O)C(O)=O)CSC3=CN=NS3)C4=CSC(N)=N4 
CephaJexin CC 1 =C(N3C(SC 1)C(NC(=0)C(N)c2ccccc2)C3=O)C(O)=0 
Cephaloridine OC(=O)C 1 =C(CN2=CC=CC=C2)CSC3C(NC(=O)CC4=CC=CS4)C(=O)N31 
Cephalothin CC(=O)OCC 1 =C(N3C(SC 1 )C(NC(=O)CC2=CC=CS2)C3=0)C(O)=O 
Cephamycin COC2(NC(=O)CCCC(N)C(O)=O)C 1 SCC(=C(N 1 C2=O)C(0)=O)COC(C)=O 
Cephapirin CC(=O)OCC 1 =C(N3C(SC 1 )C(NC(=O)CSC2=CC=NC=C2)C3=0)C(0)=0 
Cephradine CC I =C(N3C(SC I )C(NC(=O)C(N)C2=CCC=CC2)C3=O)C(0)=O 
FJomoxef COC2(NC(=O)CSC(F)F)CIOCC(=C(NIC2=O)C(O)=O)CSC3=NN=NN3CCO 
Latamoxef 
COC3(NC(=O)C(C(O)=0)clccc(0)ccI)C20CC(=C(N2C3=O)C(O)=O)CSC4=NN=NN4C 
T -2588 CON=C(C(=0)NC2C 1 SCC(=C(N 1 C2=O)C(=O)OC(C)(C)C)CN3N=NC(C)=N3) 
C4=CSC(N)=N4 . 
A 16 
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APPENDIX 3 Physico-ChemicaJ and Structural Parameters Generated 
- ClogP 
- Total Surface Area 
- Accessible Surface Area ofwhoJe molecule 
- Electrostatic potential of whole molecule 
- Whole molecule Ionisizatioo potential 
- Whole molecule Superdelocalizability parameters 
- Pka 
- Log water solubility of whole molecule 
- Topological indices of Randic, Weiner & Bonchev of whole molecule 
- Whole molecule Molecular volume 
- Whole molecule Flexiblility 
- Whole molecule Hydrogen Acceptor ability (Yangs) 
- Whole molecule Total Dipole moment 
- Whole molecule. Dipole Vectors (X, Y,Z) 
- Whole molecule Kier Connectivity indices 
- Number of Carbon atoms in whole molecule 
- Number of Nitrogen atoms in whole molecule 
- Number of Oxygen atoms in whole molecule 
- Number of Sulphur atoms in whole molecule 
- Whole molecule Number methyl groups 
- Whole molecule Number hydroxyl groups 
- Whole molecule Homo energy 
- Whole molecule Homo-Lumo Energy 
- Flexibility of the whole molecule 
- Total Lipole of whole molecule 
- Whole molecule Hydropbilicity 
- Verloop Parameters for whole molecule measured from the first methyl group attached to 
the Thiazoline or Dibydrotbiazone ring of molecule 
- Verloop Parameters for whole molecule measured from the carbonyl bond of the P-ring 
- Whole molecule Carbo shape similarity index of compolUlds with benzylpenicillin 
- Whole molecule Carbo indices of Lipophilicity similarity to benzylpenicillin 
- Whole molecule Carbo indices of Refractivity similarity to benzylpenicillin 
- Whole molecule Carbo indices of shape dissimilarity to benzylpenicillin 
- Whole molecule Carbo indices of shape similarity to cefadroxil 
- Whole molecule Carbo indices of shape dissimilarity to cefadroxil 
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- Whole molecule Carbo indices of shape similarity to cefinetazole 
- Whole molecule Carbo indices of shape dissimilarity to cefinetazole 
- Whole molecule Carbo indices of shape similarity to cefacetrile 
- Whole molecule Carbo indices of shape dissimilarity to cefacetrile 
- Whole molecule Carbo indices of shape similarity to cefsulodin 
- Whole molecule Carbo indices of shape dissimilarity to cefsulodin 
- Whole molecule Carbo indices of shape similarity to cefepirome 
- Whole molecule Carbo indices of shape dissimilarity to cefepirome 
- Whole molecule Carbo indices of shape similarity to cefuzonam 
- Whole molecule Carbo indices of shape dissimilarity to cefuzooam 
- Whole molecule Carbo indices of shape similarity to cefroxadine 
- Whole molecule Carbo indices of shape dissimilarity to cefroxadine 
- Whole molecule Carbo indices of shape similarity to ceftibuten 
- Whole molecule Carbo indices of shape dissimilarity to ceftibuten 
- Whole molecule Carbo indices of shape similarity to cefatrizine 
- Whole molecule Carbo indices of shape dissimilarity to cefatrizine 
- Whole molecule Carbo indices of shape similarity to piperacillin 
- Whole molecule Carbo indices of shape dissimilarity to piperacillin 
- Whole molecule Carbo indices of shape similarity to methicillin 
- Whole molecule Carbo indices of shape dissimilarity to methicillin 
- Charge on Nitrogen of j3-lactam ring 
- Charge on Carbonyl carbon of j3-lactam ring 
- Charge on Carbonyl oxygen of P-lactam ring 
- Charge on first Nitrogen of RI substituent 
- Charge on first Carbonyl carbon of RI substituent 
- Charge on first Carbonyl oxygen of RI substituent 
- Charge on first Carbon of R2 substituent 
- Sum of charges OIl c::abonyl oxygens in whole molecule 
- Number of carbooyJ oxygens in whole molecule 
- Surface Area of RI substitueot 
- Hydrogen Acceptor ability of RI substituent (yangs) 
- Hydrogen Doanting ability of RI substitueot (Yangs) 
- Flexibility of R 1 substitueot 
- Kier Connectivity Indices of RI substituent 
- Number of Carboo atoms in the RI substitueot 
- Number of Nitrogen atoms in the RI substituent 
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- Number of Oxygen atoms in the RI substituent 
- Number of Sulphur atoms in the RI substituent 
- Number of Methyl groups in the RI substituent 
- Number ofHydroxyf groups in the RI substituent 
- Number of Amino groups in the RI substituent 
- Surface Area of R2 substituent 
- Molar Volume ofR2 substituent 
- Verloop parameters ofR2 substituent 
- Flexibility of R2 substituent 
- Kier Connectivity Indices of R2 substituent 
- Number of Carbon atoms in the R2 substituent 
- Number of Nitrogen atoms in the R2 substituent 
- Number of Oxygen atoms in the R2 substituent 
- Number of Sulphur atoms in the R2 substituent 
- Number of Methyl groups in the R2 substituent 
- Number of Hydroxyl groups in the R2 substituent 
- Number of Amino groups in the R2 substituent 
- R3 indicator variable 
- R4 indicator variable 
- Penicillin or Cephalosporin indicator variable 
- Ora] or parenteral indicator variable 
A1'l 
I 
2 
3 
4 
5 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
APPENDIX 4 Compounds. Descriptor Values. Actual-Predicted & 
Residual Values. Correlation Matrices and Validity Plots 
for QSARs Generated in 9.3 
ALLARS 
Model9.1 All (3-Lactams 
Flex # R3I R4I #0 SS SS SS Actual 
RI Amino Cefinet Flue Cephap LogJO 
Rl AR 
6.370 0 1 1 3 0.745 0.776 0.757 0.815 
6.370 0 1 2 5 0.768 0.672 0.640 0.788 
5.876 1 I I 5 0.678 0.706 0.605 1.196 
5.511 1 I I 4 0.682 0.714 0.637 1.228 
9.446 0 I 1 6 0.606 0.652 0.616 0.998 
9.007 0 1 I 6 0.724 0.739 0.697 1.243 
5.511 1 I 2 7 0.711 0.639 0.609 0.951 
5.173 0 1 1 4 0.675 0.686 0.608 0.826 
6.588 0 1 I 6 0.692 0.661 0.623 1.269 
8.950 0 I 1 6 0.549 0.675 0.610 1.114 
9.116 0 1 1 6 0.620 0.744 0.690 0.703 
4.905 1 1 I 4 0.717 0.688 0.733 1.001 
6.426 0 1 1 5 0.802 0.889 0.739 1.568 
7.320 0 I 1 5 0.752 0.682 0.745 0.840 
5.969 1 1 1 4 0.678 0.751 0.625 0.872 
6.801 0 1 1 5 0.767 LOOO 0.777 1.564 
5.511 1 1 2 7 0.727 0.685 0.717 0.590 
7.101 0 1 1 6 0.762 0.655 0.750 1.214 
10.78 0 1 1 8 0.751 0.646 0.713 0.897 
6.679 0 1 1 5 0.771 0.734 0.756 ].089 
5.552 0 1 1 5 0.698 0.717 0.642 1.305 
6.405 0 1 1 5 0.741 0.725 0.689 0.430 
11.69 0 1 1 7 0.750 0.773 0.757 0.761 
5.511 1 1 2 6 0.701 0.721 0.709 1.050 
5.51J 1 1 2 6 0.757 0.682 0.816 L316 
6.426 0 2 1 7 0.663 0.763 0.708 0.538 
28 6.426 0 1 I 6 0.706 0.733 0.637 1.130 
Appendix 4 
Predicted Residual 
Log 10 
AR 
1.006 
-0.191 
0.686 0.092 
0.832 0.364 
0.828 0.400 
0.915 0.083 
0.966 0.277 
0.894 0.257 
0.979 
-0.153 
1.00] 0.268 
1.024 0.090 
1.079 
-0.375 
0.915 0.087 
1.134 0.435 
0.980 -0.140 
0.821 0.050 
1.286 0.279 
0.838 -0.248 
l.030 0.184 
0.901 -0.005 
1.051 0.038 
1.058 0.247 
1.017 -0.588 
0.936 -0.] 75 
0.823 0.227 
0.851 0.465 
0.855 -0.348 
1.068 0.062 
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Model 9.1 Continued 
Flex # R31 R.41 #0 SS SS SS Actual Predicted Residual 
Rl Amino Cefinet Flue Cepbap Log 1 0 
Log 1 0 
Rl AR 
AR 
29 5.106 0 1 1 6 0.708 0.699 0.687 1.125 
1.176 -0.051 
30 5.511 0 1 1 4 0.676 0.712 0.639 0.489 
0.836 -0.348 
31 5.876 1 1 1 5 0.685 0.705 0.634 0.867 
0.857 0.010 
33 5.511 1 1 1 5 0.598 0.661 0.571 0.930 
1.052 -0.121 
34 5.876 0 1 1 5 0.619 0.655 0.621 
1.274 0.880 0.395 
35 3.976 1 1 1 4 0.877 0.733 0.743 
0.769 1.007 -0.239 
36 7.486 0 1 1 5 0.751 0.729 0.740 
1.176 0.825 0.351 
37 9.799 1 1 2 7 0.782 0.839 0.746 
0.384 0.672 -0.288 
38 7.486 1 1 1 5 0.777 0.688 0.736 
0.493 0.757 -0.264 
39 9.765 1 2 1 5 1.000 0.750 
0.742 0.041 0.186 -0.145 
40 11.22 0 2 1 7 0.658 0.734 
0.685 0.324 0.375 -0.051 
41 7.486 1 1 1 7 0.789 0.692 
0.640 0.556 0.763 -0.207 
42 5.511 1 1 1 8 0.652 0.698 
0.573 1.114 1.123 -0.100 
43 11.69 0 1 1 7 0.707 0.626 
0.621 1.187 0.711 0.477 
44 6.773 0 1 1 6 0.609 0.686 
0.568 0.305 0.865 -0.560 
45 7.734 1 2 1 8 0.663 0.709 
0.680 0.678 0.617 0.061 
46 7.617 1 1 1 7 0.733 0.700 
0.667 0.667 0.859 -0.193 
47 5.226 1 1 1 4 0.638 0.696 
0.698 0.605 0.954 -0.349 
48 5.005 1 2 1 7 0.776 0.751 
0.727 0.792 0.850 -0.058 
49 10.22 0 1 1 7 0.718 0.622 
0.616 0.587 0.780 -0.194 
50 7.486 0 1 2 9 0.694 0.642 
0.732 0.994 0.870 0.124 
51 5.876 1 1 2 5 0.789 
0.784 0.713 0.274 0.688 -0.414 
52 5.969 1 1 1 5 0.678 
0.734 0.655 0.886 0.907 -0.021 
53 6.767 1 1 1 8 0.660 
0.662 0.605 1.342 1.137 0.205 
54 9.793 0 1 0 7 0.691 
0.705 0.674 0.890 0.992 -0.102 
55 7.486 1 1 1 5 0.808 
0.714 0.692 0.505 0.689 -0.184 
56 8.697 1 1 1 6 0.714 
0.685 0.711 0.924 0.792 0.133 
57 7.486 1 1 1 5 0.790 
0.851 0.718 1.036 0.851 0.185 
58 7.486 1 1 1 7 0.669 
0.722 0.633 0.733 0.921 -0.188 
60 6.569 0 1 2 10 0.647 
0.703 0.648 0.952 1.175 -0.223 
61 7.486 1 1 1 5 0.621 
0.742 0.691 0893 0.932 -0.039 
Continued over page 
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Model 9. ] continued 
-
Flex # R3I RotI #0 SS SS SS Actual Predicted Residual 
RI Amino Cefinet Flue Cepbap Log 10 Log 1 0 
RJ AR AR 
62 5.511 J 1 1 4 0.738 0.715 0.734 1.176 0.876 0.300 
63 5.005 0 1 0 4 0.797 0.780 0.761 1.279 1.300 -0.022 
64 5.005 0 J I 6 0.754 0.721 0.715 1.000 1.178 -0.]78 
65 9.869 0 2 1 9 0.800 0.768 0.704 0.875 0.645 0.230 
66 7.038 0 I 1 6 0.742 0.777 1.000 1.475 1.447 0.028 
67 5.969 1 1 1 4 0.662 0.730 0.524 0.867 0.706 0.161 
68 9.759 0 2 1 6 0.688 0.710 0.661 0.494 0.494 4.94-4 
69 6.953 0 2 1 8 0.716 0.713 0.622 1.025 0.715 0.310 
70 7.486 1 I 2 7 0.651 0.652 0.618 0.511 0.667 -0.115 
Correlation Matrix Model 9.1 
Flex # Amino R31 ~I #Ox SS SS SS Log I 0 
RI RJ Cefinet Flue C~hap_ AR 
Flex RJ 1.0 -0.132 0.254 -0.121 0.438 0.030 -0.043 0.039 -0.25 ] 
# Amino RJ 1.0 -0.168 0.234 -0.130 -0.150 -0.082 -0.160 -0.260 
R3I 1.0 -0.108 0.323 0.160 O. 117 0.043 -0.338 
.&iI 1.0 0.284 0.009 -0.127 0.026 -0.167 
#Ox 1.0 -0.136 -0.230 -0.090 -0.053 
SS Cefinet 1.0 0.368 0.543 -0.136 
SS Flue 1.0 0.435 0.124 
SS CfI)hap 1.0 0.149 
J,oglOAR 1.0 
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Model 9.2 Oralll-Lactams 
CLogP DVZ SS Ceftnet SS Cephap Actual Predicted Residual 
Lo81O LogJO 
AR AR 
2 
-1.988 0.43 0.768 0.640 0.788 0.743 0.035 
3 
-1.936 0.83 0.678 0.605 1.196 0.966 0.230 
4 
-1.269 1.35 0.682 0.637 1.228 0.975 0.253 
7 0.600 1.54 0.724 0.697 1.243 0.805 0.438 
8 
-2.038 4.3 0.711 0.609 0.951 0.949 0.002 
11 
-1.901 
-0.96 0.549 0.610 1.114 1.363 -0.249 
13 
-1.123 
-0.64 0.717 0.733 1.001 1.021 -0.020 
15 2.269 
-2.03 0.752 0.745 0.840 0.593 0.247 
16 
-1.356 
-2.56 0.678 0.625 0.872 0.885 -0.0]4 
18 
-0.274 
-4.51 0.727 0.717 0.590 0.791 -0.201 
23 1.879 0.56 0.741 0.689 0.430 0.593 -0.164 
25 
-0.316 1.36 0.701 0.709 ].050 0.989 0.061 
26 
-2.874 -0.40 0.757 0.816 1.316 1.241 0.075 
30 4.115 -2.59 0.676 0.639 0.489 0.424 0.064 
31 
-1.350 0.31 0.685 0.634 0.867 0.944 -0.077 
34 0.000 
-0.56 0.619 0.621 1.274 0.991 0.283 
37 1.311 
-0.85 0.782 0.746 0.384 0.608 -0.224 
38 0.979 7.44 0.777 0.736 0.493 0.810 -0.317 
49 
-2.082 
-4.77 0.718 0.616 0.587 0.758 -0.172 
50 
-0.374 -2.33 0.694 0.732 0.994 0.990 0.004 
51 3.120 
-0.18 0.789 0.713 0.274 0.188 0.086 
52 
-1.791 -0.83 0.678 0.655 0.886 0.859 0.027 
55 
-1.933 -1.62 0.808 0.692 0.505 0.679 -0.174 
56 0.000 
-1.12 0.714 0.711 0.924 0.868 0.056 
60 0.251 1.69 0.647 0.648 0.952 0.985 -0.032 
61 2.544 5.01 0.621 0.691 0.893 1.030 -0.17 
62 -1.673 2.35 0.738 0.734 1.176 1.068 0.108 
65 
-2.054 1.91 0.800 0.704 0.875 0.819 0.056 
70 0.133 -3.77 0.651 0.618 0.551 0.797 -0.246 
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Correlation Matrix Model 9 ") 
.-
C~p DVZ SS Cefinet SS Cephap LoglO AR 
CLogP 1.0 -0.049 0.007 0.174 -0.501 
DVZ 1.0 -0.002 0.078 0.314 
SS Cefinet 1.0 0.584 -0.428 
SS Cepbap 1.0 -0.050 
Log 1 0 AR 1.0 
Model 9.2 VaJidity Plots 
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M d I o e 9.3 Parenteral 8-Lactams 
#RI Amino P-ring carbonyl SS Flue Actual Predicted Residual 
Groups C Charge LoglOAR LoglOAR 
I 0 0.281 0.776 0.815 1.238 
-0.423 
5 0 0.276 0.652 0.998 1.115 -0.1] 7 
9 0 0.285 0.686 0.826 1.050 
-0.224 
10 0 0.287 0.661 1.269 0.986 0.283 
14 0 0.284 0.889 1.568 1.371 0.198 
17 0 0.287 1.000 1.564 1.500 0.064 
19 0 0.285 0.665 1:214 1.003 0.2] ] 
20 0 0.285 0.646 0.897 0.989 -0.093 
21 0 0.285 0.734 1.089 1.123 -0.033 
22 0 0.285 0.717 1.305 1.097 0.209 
24 0 0.285 0.773 0.761 LI82 -0.421 
27 I 0.303 0.763 0.538 0.933 -0.395 
28 0 0.287 0.733 1.130 1.095 0.035 
29 0 0.289 0.699 1.125 1.018 0.1D7 
33 J 0.29J 0.661 0.930 0.934 -0.004 
35 1 0.29] 0.733 0.769 1.043 -0.275 
40 0 0.310 0.734 0.324 0.487 -0. ]62 
41 1 0.291 0.692 0.556 0.669 -0.113 
42 1 0.291 0.698 J.l14 0.990 0.123 
43 0 0.291 0.626 1.187 0.881 0.303 
44 0 0.291 0.686 0.305 0.660 -0.355 
45 1 0.309 0.709 0.678 0.462 0.216 
46 I 0.292 0.700 0.667 0.668 -0.002 
47 
. 1 0.291 0.696 0.605 0.675 -0.070 
48 J 0.309 0.751 0.792 0.837 -0.046 
54 0 0.291 0.705 0.890 0.689 0.201 
57 1 0.291 0.851 1.036 0.910 0.126 
58 I 0.291 0.722 0.733 0.715 0.0]9 . 
63 0 0.291 0.780 1.279 1.115 0.164 
64 0 0.291 0.721 1.000 1.025 -0.025 
66 0 0.291 0.717 1.475 1.110 0.365 
67 1 0.291 0.730 0.867 0.717 0.140 
68 0 0.310 0.710 0.494 . 0.762 -0.268 
69 0 0.310 0.713 1.025 0.767 0.258 
Model 9.3 Correlation MAtrix 
#RI Aminos J3_-rin~ C carbon~ Ch~1Xe 
# RI Amino Groups 1.0 0.233 
_13-ring C carbonyl Ch2l"1M 1.0 
SS Flue 
Log 1 oAR 
Model9,3 Validity Plots 
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AppendIx 4 
SS Flue Log 1 oAR 
-0.057 -0.549 
-0.018 -0.461 
1.0 0.373 
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Model 9.4 All Penicillins 
R1HBD RI Flex SLipoBP Actual Predicted Residual 
Ability LogJOAR LO-.811lAR 
1 
-1 6.370 0.939 0.815 0.722 0.093 
2 
-1 6.370 0.875 0.778 0.696 0.083 
3 2 5.876 0.451 1.196 1.180 0.016 
4 1 5.511 0.752 1.228 1.123 0.105 
5 2 9.446 0.917 0.998 1.110 -0. 112 
7 3 9.007 0.366 1.243 1.123 0.121 
8 1 5.511 0.932 0.951 1.197 -0.246 
9 0 5.173 1.00 0.826 1.042 -0.216 
10 I 6.588 0.988 1.269 1.141 0.128 
1I I 8.950 0.881 1.114 0.924 0.190 
12 0 9.116 0.935 0.703 0.727 -0.023 
13 I 4.905 0.240 1.001 0.956 0.045 
14 1 6.426 0.925 1.568 1.127 0.441 
15 1 7.320 0.925 0.840 1.062 -0.222 
16 I 5.969 -0.127 0.872 0.727 0.145 
]8 1 5.511 -0.11 I 0.590 0.767 -0.177 
19 0 7. 101 0.894 1.214 0.857 0.357 
20 3 10.78 0.287 0.897 0.960 -0.063 
21 0 6.679 0.919 1.089 0.899 0.191 
22 I 5.552 0.908 1.305 1. 184 0.121 
23 0 6.405 0.928 0.430 0.922 -0.493 
24 3 11.69 0.232 0.761 0.871 -0.109 
25 1 5.511 0.939 1.050 1.200 -0.150 
26 1 5.51 I 0.953 1.316 1.206 0.110 
27 0 6.426 0.886 0.538 0.903 -0.366 
28 I 6.426 0.854 1.130 1.098 0.033 
Model 9.4 Correlation Matrix 
RIHBD RI Flex SLi~_BP LoAlllAR 
RIHBD 1.0 0.545 -0.503 0.278 
RI Flex 1.0 -0.163 -0.130 
SLiJ)o BP 1.0 0.201 
Log 1 oAR 1.0 
Appendix 4 
Model 9.4 Validity Plots 
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Model 9.5 Oral Penicillins 
RIHBD CLogP Actual Predicted Residual 
Ability LoglOAR Log 1 OAR 
2 -1 -1.988 0.778 0.644 0.134 
3 2 -1.936 1.196 1.248 -0.052 
4 1 -1.269 1.228 0.991 0.237 
7 3 0.600 1.243 1.246 -0.002 
8 1 -2.038 0.951 1.054 -0.103 
11 1 -1.901 1.114 1.042 0.071 
12 0 -2.942 0.703 0.924 -0.221 
13 I -1.123 1.001 0.980 0.022 
15 1 2.269 0.840 0.705 0.135 
16 1 -1.356 0.872 0.998 -0.127 
18 1 -0.274 0.590 0.911 -0.321 
23 0 1.879 0.430 0.534 -0.104 
25 1 -0.316 1.050 0.914 0.136 
26 1 -2.874 1.316 1.121 0.195 
Model 9 5 Correlation Matrix 
RlIfBD CLogP Log) oAR 
RIHBD 1.0 0.175 -0.371 
CLogP 1.0 0.618 
Log1OAR 1.0 
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Model 9. 5 Validity Plots 
>. 
u 
e 
:: 
~ 
"" ~
<'0' j~ 
'i 
t$ ] 
c.. 
0.3 
0.2 
0.1 
u 
:: 
iii 0 :> 
iii 
:: 
:2 ~.l 
:J 
~ 
~.2 
.0.3 
-0.4 
Plot Predicted Log AR Frequencies against 
Actual Log AR Frequencies for Oral Pencillin Antibiotics 
1.4 "'---~'--'-____ _ 
1.2 
I 
0.8 
0.6 
0.4 
0.2 
0 
0 
• 
• 
• 
• • 
• 
• • 
• 
• 
• 
• 
0.2 0.4 0.6 0.8 1.2 
Actual Log AR Frequency (%) 
Plot Residual Values Against Predicted Log AR 
Frequencies for Oral Penicillin Antibiotics 
• 
• 
• • • 
• 
• 
0.2 0.4 0.6 0.8 1 1.2. 
• • 
• 
• 
• 
Predicted Log AR Frequency (%) 
* 
1.4 
1.4 
A!1 
Appendix 4 
Model 9.6 Parenteral Penicillins 
CLogP Sterimol B2 Actual Predicted Residual 
(CH~) Log 1 oAR Log 1 oAR 
1 
-0.519 0.408 0.815 0.881 0.066 
5 3.911 0.503 0.998 1.142 0.144 
9 1.683 0.389 0.826 1.201 -0.375 
10 1.572 0.428 1.269 1.075 0.193 
14 2.469 0.313 1.568 1.515 0.053 
17 2.734 0.313 .1.564 1.546 0.018 
19 1.710 0.415 1.214 1. 131 0.083 
20 0.000 0.416 0.897 0.921 -0.025 
21 2.214 0.476 1.089 1.015 0.074 
22 1.802 0.426 1.305 1.110 0.195 
24 0.550 0.455 0.761 0.874 -0.113 
27 -0.174 0.554 0.538 0.502 0.036 
28 1.218 0.419 1.130 1.060 0.070 
Model 9 4 Correlation Matrix 
CLogP Sterimol B2 (CH~) Log1(lAR 
CLogP 1.0 -0.224 0.630 
Sterimol B2(CH3) 1.0 -0.728 
LoglOAR 1.0 
Model 9. 6 Validity Plots 
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Predicted Log AR Frequencies for Parenteral Penicillin 
Antibiotics 
1.8 ~------------------
1.6 
-~ 1.4 
~ 
6 1.2 
:::s go 
"" ex:
< ! 0.8 
1 0.6 
~ 
... 0.4 ~ 
0.2 
• 
• 
•• 
• 
•• 
• 
• • 
• 
.. 
O+-------~------~--------~----~ 
t) 
:::s 
~ 
~ 
~ 
11 
er: 
o 0.5 1.5 
Actual Log AR Frequency (%) 
Plot of Residual Values Against Predicted 
Log AR Frequencies for Parenteral Penicillin Antibiotics 
2 
0.2 ....---------------------------.. 
0.1 
0 
... 
• • • 
• 
-0.1 0.5 
_. 
I 1.5 
• • 
-0.2 
-0.3 
-0.4 • 
Predicted Log AR Frequency (%) 
Appendix 4 
2 
Appendix 4 
Model 9.7 All Cephalosporins 
-
w.mol Total Rl# SterimoI #N #0 SS SS Actual Pred. Residual 
HA Dmole Amino B3R2 R2 R2 Cefinet Cepbap Log 1 0 Log 
-
10 AR AR 
]'9 6 0.159 0 1.915 0 2 0.708 0.687 1.125 1.015 0.110 
10 6 0.721 I 1.800 0 0 0.676 0.639 0.489 0.761 "{).272 
1.1 9 0.207 1 1.948 0 0 0.685 0.634 0.867 1.097 ..{).230 
12 5 0.494 0 5.556 4 0 0.598 0.571 0.930 1.030 -0.100 
14 5 0.100 1 4.989 3 0 0.619 0.621 1.274 1.048 0.226 
35 5 0.942 0 3.583 2 0 0.877 0.743 0.769 0.502 0.266 
.16 10 0.758 I 4.447 2 0 0.751 0.740 1.760 1.044 0.132 
J7 7 0.590 1 1.000 0 0 0.782 0.746 0.384 0.593 -0.210 
~8 lJ 0.884 1 3.585 4 0 0.777 0.736 0.493 0.412 0.081 
.19 10 0.601 0 3.585 4 0 1.000 0.742 0.041 0.216 ..{).] 74 
~O 10 0.788 1 3.586 4 0 0.658 0.685 0.324 0.581 -0.257 
~l 6 0.750 1 4.398 1 2 0.789 0.640 0.556 0.685 -0.129 
~2 10 0.706 0 5.669 4 2 0.652 0.573 1.114 0.899 0.215 
~3 6 0.469 0 5.050 4 0 0.707 0.621 l.l87 0.819 0.369 
"-44 5 0.700 1 4.987 4 2 0.609 0.568 0.305 0.446 -0.] 4 I 
~5 9 0.962 I 4.922 4 0 0.663 0.680 0.678 0.726 -0.048 
~6 6 0.654 I 2.007 0 2 0.733 0.667 0.667 0.580 0.086 
~7 8 0.877 1 5.966 5 0 0.638 0.698 0.605 0.781 -0.175 
~8 9 0.596 0 3.437 1 2 0.776 0.727 0.792 1.035 -0.244 
~ 8 0.750 0 5.408 4 0 0.718 0.616 0.587 0.878 "{).291 
.20 10 0.604 J 2.081 0 1 0.694 0.732 0.994 ].053 -0.060 
~l 6 0.959 1 1.000 0 0 0.789 0.713 0.274 0.367 -0.093 
.22 6 1.014 1 2.371 0 I 0.678 0.655 0.886 0.713 0.173 
J4 8 0.157 1 2.667 I 0 0.691 0.674 0.890 1.036 "{).l46 
~5 10 0.475 I 3.535 4 0 0.808 0.692 0.505 0.373 0.132 
~6 8 0.489 1 1.000 0 0 0.714 0.711 0.924 0.781 0.143 
J7 11 0.393 1 1.000 0 0 0.790 0.718 1.036 0.823 0.213 
~8 11 1.026 I 4.268 3 2 0.669 0.633 0.733 0.659 0.074 
~ 9 0.263 0 1.944 I 2 0.3647 0.648 0.952 1.022 -0.070 
Cootinued over page 
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Model 9.7 continued 
-
w.mol Total Rl# Sterimol #N #0 SS SS Actual Pred. Residual 
HA Dipole Amino B3 R2 R2 R2 Ceftnet Cephap Log Log 
10 AR AR 
6} 7 0.824 1 3.052 2 0 0.621 0.691 0.893 0.794 0.099 
62 10 0.788 I 1.941 0 0 0.738 0.734 1.176 0.954 0.222 
63 12 0.626 0 3.376 I 0 0.797 0.761 1.279 1.324 -0.045 
64 5 0.558 0 3.448 0 2 0.754 0.715 1.000 1.077 -0.077 
65 9 0.526 0 1.998 0 2 0.800 0.704 0.875 0.896 -0.021 
66 6 0.634 0 3.458 0 2 0.742 1.000 1.475 1.443 0.032 
67 8 0.793 1 1.954 0 0 0.662 0.524 0.867 0.777 0.090 
68 ID 0.649 0 2.705 4 1 0.688 0.661 0.494 0.495 -0.001 
69 10 0.621 0 5.216 4 0 0.716 0.622 1.025 0.995 0.030 
70 10 0.603 1 2.993 4 0 0.651 0.618 0.551 0.463 0.089 
Mod I 9 7 Cl· M . e orre atlOll atnx 
HA TD RI B3R2 #NR2 #OR2 SS SS Log 10 
10 Aminos Cefinet Cephap AR 
HA 1.0 0.078 0.049 -0.054 0.209 -0.149 0.184 0.090 -0.022 
ID 1.0 0.205 0.186 0.189 -0.041 0.074 0.063 -0.348 
RI Amino 1.0 -0.263 -0.132 -0.335 -0.259 -0.127 -0.273 
83R2 1.0 0.391 0.050 -0.238 -0.255 0.061 
#NR2 1.0 -0.200 -0.184 -0.326 -0.315 
#0R2 1.0 -0.003 0.018 0.161 
SSCefinet 1.0 0.504 -0.230 
SSCep~ 1.0 0.206 
J.ogloAR 1.0 
A3S 
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Model 9. 7 Validity Plots 
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Model 9.8 Oral Cephalosporins 
CLogP SS Cefinet SS Cephap Actual Predicted Residual 
LogJoAR LO~QAR 
30 4.115 0.676 0.639 0.489 0.371 0.1l8 
31 
-1.350 0.685 0.634 0.867 0.854 0.012 
34 0.000 0.619 0.621 1.274 0.977 0.297 
37 1.311 0.782 0.746 0.384 0.551 -0.168 
38 0.979 0.777 0.736 0.493 0.571 -0.078 
49 
-2.082 0.718 0.616 0.587 0.720 -0.133 
SO 
-0.374 0.694 0.732 0.994 1.074 -0.080 
51 3.120 0.789 0.713 0.274 0.219 0.056 
52 
-1.791 0.678 0.655 0.886 1.007 -0.121 
55 
-1.933 0.808 0.692 0.505 0.557 -0.052 
56 0.000 0.714 0.711 0.924 0.868 0.056 
60 0.251 0.647 0.648 0.952 0.922 0.030 
61 2.544 0.621 0.691 0.893 0.971 -0.078 
62 
-1.673 0.738 0.734 1.176 1.008 0.169 
65 
-2.054 0.800 0.704 0.875 0.650 0.226 
70 0.133 0.651 0.618 0.551 0.805 -0.254 
Model 9 8 Correlation Matrix 
CLogP SS Cefinet SS Cephap Lo~AR 
CLogP 1.0 -0.177 0.102 -0.421 
SS Cefinet 1.0 0.632 -0.525 
SS Cephap 1.0 -0.122 
LogloAR 1.0 
A!>1 
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Model 9. 8 Validity Plots 
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Model 9.9 Parenteral Cephalosporins 
Rl# Sterimol L #OR2 f}-ring Actual Predicted Residual 
Amino R2 carbonyl C L08JOAR LogJOAR 
Charge 
29 0 0.586 2 0.289 1.125 1.165 -0.048 
33 1 0.565 0 0.291 0.930 1.020 -0.090 
35 0 0.882 0 0.291 0.769 0.640 0.129 
39 0 0.740 0 0.310 0.041 0.325 -0.284 
40 1 0.740 0 0.310 0.324 0.179 0.145 
41 I 1.004 2 0.291 0.556 0.493 0.063 
42 0 0.836 2 0.291 1.114 ] .102 0.012 
43 0 0.564 0 0.291 1.187 0.232 -0.045 
44 1 0.688 2 0.291 0.305 0.662 -0.357 
45 0 0.399 0 0.309 0.678 0.609 0.068 
46 I 0.581 2 0.292 0.667 0.832 -0.165 
47 1 0.399 0 0.291 0.605 0.702 -0.097 
48 0 0.390 2 0.309 0.792 0.868 -0.076 
54 1 0.552 0 0.291 0.890 0.885 0.005 
57 1 0.209 0 0.291 1.036 0.972 0.064 
58 I 0.935 2 0.291 0.733 0.553 0.180 
63 0 0.448 0 0.291 1.279 1.016 0.262 
64 0 0.434 2 0.291 1.000 ].239 -0.239 
66 0 0.417 2 0.291 1.475 1.254 0.221 
67 1 0.316 0 0.291 0.867 0.774 0.093 
68 0 0.727 1 0.310 0.494 0.442 0.052 
69 0 0.4]2 0 0.310 1.025 0.926 0.099 
Model 9.9 Correlation Matrix 
#Rt Sterimol #OR2 fl-ring Carbooyl C LoglOAR 
Amino LR, Cha~ 
#RI Amino 1.0 -0.003 0.076 -0.136 -0.399 
Sterimol L R2 1.0 0.216 -0.034 -0.422 
#ORl 1.0 0.344 0.01l 
J3-ring Carbonyl C Charae 1.0 -0.479 
.LogIOAR 1.0 
Appendix 4 
Model 9.9 Validity Plots 
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Appendix 4 
Cutaneous Rash 
Model 9.] 0 All -13-1actams 
Sterimol SS BP #C Log SS SS ss SS Actual Predicted Residual 
B2 RI H,O Meth Cefep Ceftib Cefatriz rRash JRash 
(CH-t) sol. 
1 O.40S 0.S37 7 -1.75 0.837 0.716 0.747 0.704 2.002 1.865 0.137 
2 0.667 0.721 7 -2.07 0.725 0.630 0.692 0.621 1.000 1.337 -0.337 
3 0.403 0.987 8 -1.28 0.766 0.653 0.689 0.792 1.709 1.792 -0.083 
4 0.327 0.991 8 -1.11 0.773 0.652 0.675 0.817 2.173 1.794 0.379 
5 0.503 0.756 17 -3.57 0.691 0.615 0.683 0.753 2.415 1.985 0.430 
6 0.453 0.925 8 -1.52 0.796 0.760 0.741 0.765 1.937 1.674 0.263 
7 0.317 0.876 12 -2.18 0.733 0.612 0.739 0.706 1.712 1.711 8.99-4 
8 0.316 0.890 8 -1.83 0.695 0.645 0.643 0.697 1.646 1.179 0.467 
9 0.389 1.000 8 -1.66 0.753 0.674 0.684 0.828 1.643 1.852 -0.209 
10 0.428 0.8"8 9 -1.79 0.776 0.615 0.685 0.775 2.561 1.889 0.662 
11 0.486 0.674 18 -4.67 0.678 0.701 0.710 0.702 0.894 1.850 -0.956 
12 0.503 0.815 IS -3.77 0.710 0.671 0.634 0.694 1.581 2.336 -0.155 
13 0.405 0.843 7 -0.55 0.824 0.766 0.753 0.101 1.319 1.438 -0.119 
14 0.313 0.668 11 -2.91 0.190 0.728 0.793 0.684 1.225 1.668 -0.443 
15 0.313 0.693 11 -3.69 0.740 0.654 0.867 0.663 0.893 l.214 -0.321 
17 0.313 0.688 11 -3.20 0.749 0.685 0.859 0.682 1.825 1.247 0.578 
18 0.673 0.777 8 -0.07 0.736 0.704 0.155 0.742 0.889 1.306 -0.411 
__ 19 0.415 0.725 9 -1.76 1.00 0.633 0.854 0.734 3.299 2.310 0.929 
__ 10 0.416 0.831 13 -1.98 0.631 0.739 0.691 0.636 1.652 0.957 0.695 
21 0.476 0.124 13 -3.36 0.805 0.661 0.836 0.736 2.961 2.071 0.890 
22 0.426 0.827 11 -1.S6 0.720 0.663 0.739 0.778 1.581 1.436 0.145 
23 0.343 0.865 8 -1.S6 0.807 0.754 0.715 0.753 1.449 1.721 .{J.212 
24 0.455 0.573 15 -1.41 0.705 0.590 0.637 0.677 1.127 1.650 .{J.523 
25 0.659 0.871 8 -2.81 0.679 0.702 0.625 0.690 1.792 1.666 0.126 
26 0.529 0.846 8 -2.66 0.700 0.650 0.656 0.700 1.477 1.777 -0.297 
27 0.554 0.770 7 -1.31 0.787 0.684 0.784 0.678 1.581 1.229 0.282 
28 0.419 0.964 7 -0.56 0.780 0.677 0.750 0.767 1.049 1.526 -0.477 
Continued over page 
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Model 9.10 continued 
Sterimol SS BP IIC Log SS SS SS SS Actual Predicted Residual 
B2 RI H,O Meth Cefep Ceftib Cefatriz JRash J1wh 
(CHl1 sol. 
1-.29 0.267 0.792 3 1.68 0.740 0.650 0.646 0.700 0.100 0.536 -0.436 
30 0.549 0.870 8 -0.17 0.795 0.642 0.801 0.760 1.082 1.374 -0.292 
31 0.403 0.864 8 -0.68 0.743 0.751 0.767 0.708 0.693 1.004 -0.311 
33 0.577 0.806 8 -2.69 0.711 0.610 0.702 0.823 1.304 0.622 -0.318 
34 0.569 0.817 8 -0.94 0.741 0.774 0.690 1.000 2.437 0.882 0.555 
35 0.637 0.663 3 -1.59 0.720 1.00 0.715 0.589 1.253 0.189 0.064 
36 0.533 0.646 6 -1.26 0.704 0.648 0.694 0.559 2.236 0.639 0.597 
37 0.542 0.700 7 -0.42 0.718 0.566 0.865 0.655 0.387 0.390 -0.003 
38 0.638 0.641 6 -2.13 0.734 0.719 0.693 0.560 0.917 0.994 -0.027 
39 0.638 0.665 4 -1.27 0.762 0.614 0.742 0.557 0.762 1.108 -0.346 
40 0.635 0.755 5 -1.23 0.720 0.672 0.702 0.518 1.072 0.804 0.268 
41 0.628 0.536 6 0.01 0.699 0.605 0.684 0.552 0.950 0.535 0.424 
42 0.580 0.779 8 -2.05 0.714 0.705 0.696 0.816 1.400 1.555 -0.155 
1-.43 0.482 0.574 15 -2.09 0.651 0.649 0.696 0.579 1.594 1.042 0.552 
_44 0.506 0.735 9 -1.89 0.669 0.739 0.660 0.780 1.285 1.362 -0.077 
45 0.557 0.756 6 -1.99 0.721 0.760 0.694 0.724 1.136 1.618 -0.482 
f-46 0.633 0.695 7 1.27 0.774 0.592 0.699 0.618 1.349 1.217 0.132 
f-47 0.386 0.723 5 -1.01 0.714 0.727 0.683 0.659 0.100 0.647 -0.547 
48 0.573 0.702 6 0.53 0.703 0.676 0.736 0.660 1.565 0.751 0.814 
1-.49 0.552 0.583 15 -2.66 0.658 0.556 0.721 0.594 1.136 1.152 -0.016 
_SO 0.624 0.624 6 -0.70 0.693 0.743 0.649 0.588 0.714 0.596 0.l18 
~1 0.S05 0.693 8 -1.18 0.767 0.663 0.824 0.592 0.949 1.036 -0.087 
S3 0.584 0.760 8 -0.97 0.748 0.727 0.573 0.814 2.345 2.033 .0312 
f-S4 0.599 0.667 9 -1.52 0.681 0.738 0.678 0.641 1.613 1.292 0.321 
ss 0.512 0.647 6 -0.61 0.715 0.663 0.686 0.583 0.100 0.932 -0.832 
1-.S6 0.657 0.704 8 0.76 0.8S4 0.685 1.000 0.690 0.100 0.802 -0.702 
... 57 0.529 0.730 6 -0.24 0.771 0.693 0.801 0.677 0.959 0.958 0.001 
Continued over page 
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Model 9.10 continued 
Sterimol SS #C Log SS SS SS SS Actual Predicted Residual 
B2 BP RI n,o Meth Cefep Ceftib Cefatriz J'Rash J'Rash 
(CH.) sol. 
58 0.589 0.534 6 -1.13 0.685 0.653 0.608 0.558 1.1l4 0.82) -0.293 
59 0.521 0.676 7 0.69 0.864 0.704 0.733 0.723 0.911 1.565 -0.654 
60 0.622 0.735 7 1.17 0.700 0.658 O.s51 0.665 1.007 1.165 -0.088 
62 0.497 0.790 8 -0.51 0.780 0.714 0.775 0.697 1.000 1.342 -0.342 
63 0.638 0.638 6 -0.31 0.713 0.703 0.699 0.657 1.000 1.014 -0.014 
64 0.621 0.697 6 1.40 0.768 0.653 0.796 0.673 1.414 0.621 0.793 
65 0.620 0.672 6 0.94 0.755 0.716 0.737 0.685 0.100 0.981 -0.881 
66 0.512 0.649 7 1.23 0.717 0.648 0.736 0.523 0.100 0.150 -0.050 
f-67 0 . .551 0.831 8 0.01 0.788 0.670 0.773 0.770 2.047 1.422 0.62.5 
1--68 0.637 0.690 4 -1.85 0.690 0.605 0.695 0.638 1.269 0.866 0.403 
_69 0.537 0.716 9 -3.17 0.777 0.726 0.732 0.735 1.549 20.66 -0.517 
70 0.536 0.592 6 -0.60 0.682 0.573 0.658 0.623 0.592 0.457 0.135 
Correlation Matrix Model 9.10 
Sterimol SS BP #C Log SS SS SS SS J'lWh 
B2 RI H,O sol. Metb Cefep Ceftib Cefatriz 
.... 
(CH'l) 
Sterimol B2 1:0 -0.433 -0.306 0.252 -0.204 -0.129 -0.122 -0.290 -0.183 
SS BP 1.0 0.0 -0.078 0.249 -0.192 -0.021 0.663 0.330 
Log H,O sol. 1.0 -0.617 -0.175 0.043 0.050 0.192 0.344 
NCRl 1.0 0.204 0.020 0.037 -0.132 -0.416 
SS Meth 1.0 0.191 0.563 0.289 0.249 
SS Cefep 1.0 0.228 -0.201 0.166 
Ss Ceftib 1.0 0.006 -0.068 
SS Cefatriz 1.0 0.451 
~b 1.0 
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Model 9. 10 Validity Plots 
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Appendix 4 
Model 9.11 Oral P-Lactams 
SS BP Log H20 SS SS Actual Predicted Residual 
sol. Ceftib Cefatriz J"Rash J'Rash 
2 0.721 -2.07 0.692 0.621 1.000 0.981 0.019 
3 0.987 -1.28 0.689 0.792 1.709 1.914 -0.205 
4 0.991 -1.11 0.675 0.817 2.173 2.002 0.171 
6 0.925 -1.52 0.741 0.765 1.937 1.637 0.300 
7 0.876 -2.18 0.739 0.706 1.712 1.458 0.254 
8 0.890 -1.83 0.643 0.697 1.646 1.608 0.038 
11 0.674 -4.67 0.710 0.702 0.894 1.444 -0.550 
12 0.815 -3.77 0.634 0.694 1.581 1.732 -0.151 
13 0.843 -0.55 0.753 0.701 1.319 1.129 0.190 
15 0.693 -3.69 0.867 0.663 0.893 0.911 -0.018 
18 0.717 -0.07 0.755 0.742 0.889 1.053 -0.164 
23 0.865 -1.56 0.715 0.753 1.449 1.542 -0.093 
25 0.871 -2.81 0.625 0.690 1.792 1.719 0.073 
26 0.846 -2.66 0.656 0.700 1.417 1.616 -0.139 
30 0.870 -0. 17 0.801 0.760 1.082 1.209 -0.127 
31 0.864 -0.68 0.767 0.708 0.693 1.180 -0.487 
34 0.817 -0.94 0.690 1.000 2.437 2.152 0.285 
37 0.700 -0.42 0.865 0.655 0.387 0464 -0.077 
38 0.641 -2.13 0.693 0.560 0.917 0.648 0.269 
49 0.583 -2.66 0.721 0.594 1.136 0.649 0.487 
50 0.624 -0.70 0.649 0.588 0.714 0.595 0.119 
51 0.693 -1.18 0.824 0.592 0.949 0.449 0.500 
55 0.647 -0.61 0.686 0.583 0.100 0.994 0.006 
56 0.704 0.76 1.000 0.690 0.100 0.537 -0.437 
60 0.735 1.17 0.551 0.665 1.007 0.140 -0.033 
62 0.790 -0.51 0.775 0.697 1.000 0.991 0.086 
65 0.672 0.94 0.737 0.685 0.100 0.096 0.014 
70 0.592 -0.60 0.658 0.623 0.592 0.557 -0.045 
Appendix 4 
Correlation Matrix Model 9 11 
SS BP Log H,O sol. SS Ceftib SS Cefatriz J"Rash 
SS BP 1.0 -0.040 -0.136 0.655 
Log H.,O sol. 1.0 0.205 0.139 
SS Ceftibut 1.0 -0.001 
SS cefatriz 1.0 
J"Rash 
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Appendix 4 
Model 9. 12 Parenteral -~-Iactams 
Sterimol #C Log SS Actual Predicted Residual 
B2 RI H2O Meth .f'Rash "Rash 
(CH~) sol. 
1 0.408 7 -1.75 0.837 2.002 1.750 -0.252 
5 0.503 17 -3.57 0.691 2.415 2.433 -0.018 
9 0.389 8 -1.66 0.753 1.643 1.308 0.335 
10 0.428 9 -1.79 0.716 2.561 1.648 0.913 
14 0.313 11 -2.91 0.790 1.225 1.894 -0.669 
17 0.313 11 -3.20 0.749 1.825 1.701 0.124 
19 0.415 9 -1.76 1.00 3.299 2.934 0.365 
20 0.416 13 -1.98 0.631 1.652 1.222 0.430 
21 0.476 13 -3.36 0.80S 2.961 2.S94 0.367 
22 0.426 11 -1.56 0.720 1.581 1.486 0.095 
24 0.455 . IS -1.41 0.705 1.127 1.853 -0.736 
27 0.554 7 -1.31 0.787 1.581 1.677 -0.096 
28 0.419 7 -0.56 0.780 1.049 1.240 -0.191 
29 0.267 3 1.68 0.740 0.100 -0.088 0.188 
33 O.S77 8 -2.69 0.711 1.304 1.608 -0.304 
35 0.637 3 -1.S9 0.720 1.253 1.073 0.180 
39 0.638 4 -1.27 0.762 0.762 1.374 -0.612 
40 0.635 5 -1.23 0.720 1.072 1.221 -0.149 
41 0.628 6 0.01 0.699 0.950 0.984 -0.025 
42 0.580 8 -2.05 0.714 1.400 I.S26 -0.126 
43 0.482 15 -2.09 0.651 1.594 1.701 -0.107 
44 0.506 9 -1.89 0.669 1.285 1.192 0.093 
45 0.557 6 -1.99 0.721 1.136 1.301 -0.165 
46 0.633 7 1.27 0.774 1.349 1.333 0.016 
47 0.386 5 -1.01 0.714 0.100 0.650 -0.550 
Continued over page 
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Model 9. 12 continued 
Sterimol #C Log H20 SS Actual Predicted Residual 
B2 (CH1) RI sol. Meth J"Rash .f'Rash 
48 0.573 6 0.53 0.703 1.565 0.813 0.752 
53 0.584 8 -0.97 0.748 2.345 1.555 0.790 
54 0.599 9 -1.52 0.681 1.613 1.387 0.226 
57 0.529 6 -0.24 0.771 0.959 1.251 -0.292 
58 0.589 6 -1.13 0.685 1.114 1.012 0.102 
59 0.521 7 0.69 0.864 0.911 1.734 -0.823 
63 0.638 6 -0.31 0.713 1.000 1.138 -0.138 
64 0.621 6 1.40 0.768 1.414 1.147 0.267 
66 0.512 7 1.23 0.717 0.100 0.761 -0.661 
67 0.551 8 0.01 0.788 2.047 1.563 0.484 
68 0.637 4 -1.85 0.690 1.269 1.046 0.223 
69 0.537 9 -3.17 0.777 1.549 2.100 -0.551 
Correlation Matrix Model 9.12 
Sterimol #C Log H20 SS /Rash 
B2 (CH1) RI sol. Meth 
Sterimol 82 (CH1) 1.0 -0.353 0.205 -0.226 -0.071 
#CRl 1.0 -0.553 -0.121 0.508 
Log H10 sol. 1.0 0.074 -0.499 
SS Meth 1.0 0.407 
J'Rash 1.0 
Appendix 4 
Model 9. 12 Validity Plots 
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Model 9.13 All Penicillins. Model 9.14 Oral Penicillins and Model 9.15 Parenteral Penicillins 
Sterimol SS BP SS Meth AdminlD Actual./ftash All Pens All Pens Oral Pens Oral Pens Par. Pens Par. Pens 
B3JC=O) Predicted.titash Residual Predicted.!Rash Residual Predicted JRash Residual 
1 6.839 0.837 0.837 4 2.002 2.477 -0.475 
- -
2.334 -0.332 
2 8.745 0.721 0.725 3 1.000 1.642 -0.642 1.003 -0.003 
- -
3 6.587 0.987 0.766 3 1.709 1.751 -0.042 2.020 -0.311 
- -
I 4 6.608 0.991 0.773 3 2.173 1.806 0.367 2.036 0.137 
- -
5 7.943 0.756 0.691 4 2.415 1.894 0.521 - - 1.998 0.417 
6 5.972 0.925 0.796 3 1.937 1.530 0.407 1.783 0.154 
- -
7 8.082 0.876 0.733 3 1.712 1.837 -0.125 1.596 0.116 
- -
8 7.893 0.890 0.695 3 1.646 1.601 0.045 1.650 -0.004 
- -
9 5.910 1.000 0.753 4 1.643 2.104 -0.461 
- -
1.397 0.246 
10 7.491 0.848 0.176 4 2.561 2.417 0.144 
- -
2.285 0.276 
11 6.845 0.674 0.678 3 0.894 0.580 0.314 0.824 -0.070 
- -
12 7.491 0.815 0.710 3 1.581 1.344 0.237 1.363 0.218 
- -
13 7.033 0.843 0.824 3 1.319 1.857 -0.538 1.470 -0.151 - -
14 5.904 0.668 0.790 '-------__ 4_ 1.225 1.457 -0.232 - - 1.§J~ _____ ________ 0. 3 87 
-- - ---- -- -
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Models 9.13, 9.14 and 9.15 cootinued 
15 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
~ (1\ 
-
Sterimol 
B3 (C=O) 
6.760 
6.658 
6.312 
6.686 
8.026 
8.096 
6.017 
6.162 
7.728 
8.129 
8.102 
5.988 
SS BP SS Meth 
0.693 0.740 
0.688 0.749 
0.777 0.736 
0.725 1.00 
0.831 0.631 
0.724 0.805 
0.827 0.720 
0.865 0.807 
0.573 0.705 
0.871 0.679 
0.846 0.700 
0.770 0.787 
AdminlD ActualJlbsh 
3 0.893 
4 1.825 
3 0.889 
4 3.299 
4 1.652 
4 2.961 
4 1.581 
3 1.449 
4 1.127 
3 1.792 
3 1.477 
4 1.581 
All Pens All Pens Oral Pens Oral Pens Par. Pens Par. Pens 
PredictedjRash Residual PredictedJRash Residual PredictedJRash Residual 
0.929 -0.036 0.896 -0.003 
- -
1.563 0.262 
- - 1.729 0.096 
0.957 -0.068 1.217 -0.328 
- -
3.008 0.291 
- -
3.223 0.076 
1.794 -0.142 
- -
1.684 -0.032 
2.447 0.484 
- -
2.743 0.218 
1.528 0.053 
- -
1.253 0.328 
1.505 -0.056 1.554 -0.105 
- -
1.425 -0.298 
- -
1.978 -0.851 
1.553 0.239 1.557 0.215 
- -
1.592 -0.115 1.481 -0.004 
- -
1.730 -0.149 - - 1.634 -0.053 
1 
0-
x 
4 
Appendix 4 
Correlation Matrix Model 9.13 
SS BP Sterimol Admin ss TRash 
B3 (C=O) ID Meth 
SS BP 1.0 -0.200 -0.353 -0.009 0.146 
Sterimol B3 (C=O) 1.0 -0.089 -0.366 0.169 
AdminID 1.0 0.229 0.466 
SS Meth 1.0 0.539 
/"Rash 1.0 
Correlation Matrix Model 9.14 
SS BP Aash 
SSBP 1.0 0.907 
/Rash 1.0 
Correlation Matrix Model 9.15 
Sterimol SS rRash 
B3 (C=O) Meth 
Sterimol B3 (C=O) 1.0 -0.305 0.372 
SS Meth 1.0 0.607 
/Rash 1.0 
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Model 9.14 Validity Plots 
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A55 
MO<Iel':l Ib A11l'e )halOSOonns Moael ':1.11 urat ceonalosoonns ana Moael 'i. HS i"uenteral cellhalosoonns 
Admin Log H20 SS SS DVZ SS Actual All Cephs All Cephs Oral Cephs Oral Cephs Par. Cephs Par. Cephs 
ID sol. Cefac Cefep Cefatriz JRash Predicted Residual Predicted Residual Predicted Residual 
~sh ~sh ~sh 
29 4 1.68 1.000 0.650 0.58 0.700 0.100 0.040 0.060 - - 0.190 -0.090 
30 3 -0.17 0.655 0.642 -2.59 0.760 1.082 1.403 -0.321 0.959 0.l23 - -
31 3 -0.68 0.794 0.751 0.31 0.708 0.693 0.602 0.091 0.948 -0.255 - -
33 4 -2.69 0.699 0.610 -1.40 0.823 1.304 1.443 -0.139 - - 1.051 0.253 
34 3 -0.94 0.646 0.774 -0.56 1.000 2.431 2.207 0.230 2.403 0.034 - -
35 4 -1.59 0.726 1.00 -5.88 0.589 1.253 1.087 0.166 - - 1.785 -.0532 
36 4 -1.26 0.663 0.648 -0.70 0.559 2.236 1.991 0.245 - - 2.202 0.034 
37 3 -0.42 0.658 0.566 -0.85 0.655 0.387 0.990 -0.603 0.589 -0.202 - -
38 3 -2.13 0.639 0.719 7.44 0.560 0.917 0.439 0.478 0.918 -0.001 - -
39 4 -1.27 0.708 0.614 5.58 0.557 0.762 0.859 -0.097 - - 0.871 -0.109 
40 4 -1.23 0.633 0.672 3.64 0.518 1.072 0.674 0.398 - - 0.975 0.097 
41 4 0.01 0.597 0.605 6.83 0.552 0.950 1.145 -0.186 - - 1.228 -0.269 
42 4 -2.05 0.653 0.705 -4.73 0.816 1.400 1.679 -0.279 - - 1.493 -0.093 
43 4 -2.09 0.608 0.649 2.48 0.579 1.594 1.311 0.283 - - 1.377 0.217 
44 4 -1.89 0.648 0.739 -6.45 0.780 1.285 1.711 -0.426 - - 1.748 -0.463 
Continued over page f 
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Models 9.16,9.17,9.18 continued 
Admin Log H20 SS SS DVZ SS Actual All Cephs All Cephs Oral Cephs Oral Cephs Par. Cephs Par. Cephs 
ID sol. Cefac Cefep Cefatriz .rRash Predicted Residual Predicted Residual Predicted Residual 
JRash JR8sh ~sh 
45 4 -1.99 0.721 0.760 6.82 0.724 1.136 1.488 -0.352 
- -
0.784 -0.352 
46 4 1.27 0.689 0.592 3.99 0.618 1.349 1.303 0.046 
- -
1.153 -0.196 
47 4 -1.01 0.738 0.727 4.79 0.659 0.100 0.693 -0.593 - - 0.550 -0.400 
48 4 0.53 0.714 0.676 -1.28 0.660 1.565 1.247 0.318 - - 1.368 0.197 
49 3 -2.66 0.626 0.556 -4.77 0.594 1.136 0.987 0.149 1.311 -0.175 - -
50 3 -0.70 0.706 0.743 -2.33 0.588 0.714 0.232 0.482 0.407 0.307 
- -
51 3 -1.18 0.673 0.663 -0.18 0.592 0.949 1.008 -0.059 0.640 0.309 
- -
53 4 -0.97 0.679 0.727 -9.71 0.814 2.345 1.740 0.605 
- -
1.908 0.437 
54 4 -1.52 0.653 0.738 -1.21 0.641 1.613 1.429 0.184 - - 1.557 0.056 
55 3 -0.61 0.712 0.663 -1.62 0.583 0.100 0.795 -0.695 0.334 -0.244 - -
56 3 0.76 0.670 0.685 -1.12 0.690 0.100 - - 0.222 -0.122 - -
57 4 -0.24 0.720 0.693 -1.00 0.677 0.959 1.172 -0.213 - - 1.240 -0.281 
58 4 -1.13 0.584 0.653 0.52 0.558 1.114 1.158 -0.044 
- -
1.459 -0.345 
59 4 0.69 0.706 0.704 -1.32 0.723 0.911 1.440 -0.529 - - 1.336 -0.425 
60 3 1.17 0.731 0.658 1.69 0.665 1.007 0.757 0.320 
- - - -
62 3 -0.51 0.778 0.714 2.35 0.697 1.000 0.868 0.132 0.822 0.178 - -
Continued over page f 
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Models 9.16,9.17,9.18 continued 
Admin Log ss SS DVZ SS Actual All Cepbs All Cepbs Oral Cepbs Oral Cepbs Par. Cepbs Par. Cepbs 
ID H20 sol. Cefae Cefep Cefatriz ./Rasb Predicted Residual. Predicted Residual Predicted Residual 
JR"asb ../Rash v'lUsb 
63 4 -0.31 0.730 0.703 2.88 0.657 1.000 1.089 -0.009 - - 0.954 0.046 
64 4 1.40 0.685 0.653 0.24 0.673 1.414 1.169 0.245 - - 1.157 0.257 
65 3 0.94 0.694 0.716 1.91 0.685 0.100 - - 0.119 -0.019 - -
66 4 1.23 0.666 0.648 -3.13 0.523 0.100 0.669 -0.569 - - - -
67 4 0.01 0.726 0.670 -7.25 0.770 2.047 1.419 0.628 - - 1.612 0.435 
68 4 -1.85 0.656 0.605 2.00 0.638 1.269 0.998 0.271 - - 0.997 0.272 
69 4 -3.17 0.724 0.726 -2.08 0.735 1.549 1.483 . 0.066 - - 1.391 0.158 
70 3 -0.60 0.636 0.573 -3.77 0.623 0.592 0.711 -0.119 0.523 0.069 
- -
a-
~ 
i 
-fIo 
Model 9. 16 Correlation Matrix 
Admin ID SS Cefac SSC~~ SS Cefirtriz .{Rash 
Admin ID 1.0 0.008 0.254 -0.079 0.232 
SS Cefac 1.0 0.096 0.209 -0.322 
SS Cefep 1.0 -0.237 0.289 
SS Cefatriz 1.0 0.444 
rRash 1.0 
Model 9.17 Correlation Matrix 
Log H2O sol SS Cefittriz J'kash 
~H20sol 1.0 0.262 -0.477 
SS Cefatriz 1.0 0.668 
..fkash 1.0 
Model 9.18 Correlation Matrix 
DVZ SS Cefac SSC~ /lWh 
DVZ 1.0 -0.007 0.023 -0.564 
SS Cefae 1.0 0.030 -0.453 
SS Cefep 1.0 0.384 
rRash 1.0 
ASC] 
Model 9. 16 Validity Plots 
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jodel 9. 18 Validity Plots 
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Appendix 4 
GI Disruption 
Model 9.19 All p-Lactams 
RI #S 1: C=O* looistD Admin SS Actual Predicted Residual 
CH~s Charges j)tt ID CephaJOT Log<JJ logGI 
I 0 1 -0.787 8.99 4 0.781 -0.051 -0.210 0.159 
2 0 1 -1.157 8.88 3 0.620 0.522 0.294 0.228 
3 0 1 -1.204 9.00 3 0.649 0.407 0.508 -0.101 
4 0 I -1.204 9.18 3 0.669 0.724 0.496 0.228 
5 0 1 -1.147 8.95 4 0.712 -0.377 -0.160 -0.217 
6 0 1 -1.206 9.10 3 0.692 0.7S1 0.340 0.411 
7 0 1 -2.106 8.94 3 0.749 0.241 0.363 -0.122 
8 0 1 -1.S80 9.03 3 0.604 0.193 0.487 -0.294 
9 0 1 -1.207 9.52 4 0.6S1 0.398 0.398 -3.135-4 
10 0 I -1.5028 8.99 4 0.664 -0.108 0.358 -0.466 
11 0 I -1.568 8.89 3 0.642 0.204 0.449 -0.245 
12 0 1 -1.576 8.97 3 0.652 0.236 0.431 -0.195 
13 0 1 -1.20S 8.97 3 0.717 0.667 0.377 0.290 
14 I 1 -1.211 8.70 4 0.770 0.398 0.185 0.213 
15 I 1 -1.170 9.12 3 0.731 0.568 0.527 0.041 
16 0 I -1.135 9.05 3 0.671 0.782 0.446 0.336 
18 0 I -1.587 9.09 3 0.695 0.104 0.335 -0.231 
19 2 1 -1.210 8.48 4 0.683 1.086 0.764 0.322 
20 I 2 -2.631 9.03 4 0.713 0.297 0.591 -0.294 
21 I 1 -1.209 9.08 4 0.738 0.786 0.319 0.467 
22 1 1 -1.21S 9.09 4 0.654 0.301 0.613 -0.312 
23 0 I -1.203 9.32 3 0.712 0.403 0.327 0.076 
24 1 I -2.026 8.99 4 0.746 0.396 0.363 0.033 
25 0 1 -1.574 8.92 3 0.731 0.241 0.095 0.146 
26 0 1 -1.576 9.19 3 0.717 0.173 0.31S -0.142 
27 0 2 -1.573 7.39 4 0.692 '{).284 0.017 '{).301 
28 0 2 -1.529 8.97 4 0.697 0.230 0.185 0.045 
Continued over page 
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Model 9.19 Continued 
RI #S 1: C=O* lmistD Admin SS Actual Predicted Residual 
CH~s Charges ptl. ID Cephalor ~I LogGI 
29 0 1 -1.565 9.18 4 0.643 0.223 0.394 -0.171 
30 0 1 -1.170 9.03 3 0.690 0.435 0.365 0.070 
31 0 I -1.163 8.72 3 0.681 -0.319 0.322 -0.641 
33 0 2 -1.157 8.87 4 0.614 -0.091 0.080 -0.177 
34 0 2 -1.161 10.10 3 0.657 0.695 0.357 0.338 
35 0 2 -1.162 8.45 4 0.792 -0.444 -0.621 0.177 
36 1 2 -1.120 8.38 4 0.740 0.522 -0.122 0.644 
37 0 2 -1.492 8.83 3 0.773 -0.347 -0.201 -0.146 
38 1 3 -1.126 8.84 3 0.663 -0.119 0.244 -0.363 
39 0 3 -1.156 9.10 4 0.663 -0.569 -0.147 -0.422 
40 0 3 -1.528 9.22 4 0.742 -0.319 0.348 0.029 
41 1 3 -1.126 9.00 4 0.603 0.173 -0.021 0.194 
42 0 3 -1.661 8.78 4 0.666 0.322 -0.200 0.522 
43 I 2 -2.363 9.18 4 0.652 0.507 -0.47] 0.036 
44 0 2 -1.535 9.09 4 0.625 0.00 0.033 -0.033 
45 0 4 -1.975 8.71 4 0.668 0.428 -0.063 0.491 
46 1 2 -1.497 8.80 4 0.736 0.045 0.076 -0.310 
47 0 3 -1.162 8.88 4 0.641 -0.409 -0.293 -0.116 
48 0 2 -1.587 9.28 4 0.872 -0.032 -0.441 0.409 
49 1 2 -1.563 8.82 3 0.653 0.021 0.299 -0.278 
50 1 2 -1.489 8.74 3 0.669 0.631 0.11 0.484 
51 0 1 -1.154 8.51 3 0.701 0.161 0.109 0.052 
52 0 1 -1.183 8.87 3 0.668 0.342 0.389 -0.470 
53 0 2 -1.831 8.94 4 0.600 0.919 0.218 0.701 
54 2 2 -1.560 8.98 4 0.599 0.270 0.692 -0.422 
55 1 2 -1.121 9.34 3 0.771 0.558 0.110 0.448 
56 0 2 -1.529 9.21 3 0.699 0.740 0.235 0.505 
57 I 2 -1.121 8.82 4 0.683 -0.108 0.296 -0.404 
Continued over page 
Appendix 4 
Model 9.19 Continued 
RI #S 1: C=O* lmistD Admin SS Actual Predicted Residual 
CH3S Charges ptl. ID Cephalo LogGI LogG! 
r 
58 1 3 -1.560 9.09 4 0.689 0.405 0.074 -0.331 
59 1 1 -1.552 9.16 4 0.818 -0.143 0.031 -0.174 
60 1 1 -1.919 7.54 3 0.711 0.554 0.204 0.350 
61 1 3 -1.126 9.01 3 0.712 -0.638 0.009 -0.647 
62 0 1 -1.159 9.52 3 0.692 0.522 0.417 0.105 
63 0 2 -1.162 9.23 4 1.000 -2.000 -1.031 -0.969 
64 0 22 -1.535 9.17 4 0.658 -0.155 0.173 -0.328 
65 0 1 -1.910 9.52 3 0.659 0.398 0.518 -0.128 
66 0 2 -1.535 8.93 4 0.632 -0.097 0.112 -0.209 
67 0 I -1.161 9.18 4 0.679 0.389 0.219 0.170 
68 0 2 -1.161 9.20 4 0.618 -0.119 -0.103 -0.016 
69 0 1 -1.533 9.40 4 0.603 0.373 0.251 0.122 
70 I 2 -1.487 9.00 3 0.531 0.086 0.623 -0.537 
Values ofK3 were not recorded. 
Correlation Matrix Mode) 9. 19 
RI #S 1: C=O* K3 IooistD Admin SS LogOI 
CH3S Charges pd. ID Cephalor 
RI CH~s 1.0 0.132 -0.098 0.306 -0.204 0.162 -0.005 0.200 
#S 1.0 -0.043 0.462 -0.041 -0.103 0.090 -0.348 
1: C=O* Charges 1.0 -0.454 0.098 -0. )03 0.074 -0.140 
K~ 1.0 -0.087 0.016 -0.285 -0.093 
looistD ptl. 1.0 -0.093 -0.042 -0.092 
AdminID 1.0 0.090 -0.256 
SS Cephalor 1.0 -0.396 
LoglOGI 1.0 
Appendix 4 
Model 9. 19 Validity Plots 
. 
-.' 
>. 
u 
is 
= [ 
"'" 
-0 
"'S -u.s 
~ ] 
a.. 
! 
Plot of Actual Log GI FrequenciesVerses Predicted 
Log GI Frequencies for All P-Lactam Antibiotics 
-I 
• 
• 
• -O.S 
I.S 
1 • 
., .. 
~ ..... . 
.' ...... . ~.~ .... . 
........ 
., r • O.S 
"*.5 r 
-l~~ f 
-2 
Log Actual GI Frequency 
• 
Plot of Residual Values Against Predicted Log GI Frequency 
for All P-Lactam Antibiotics 
9.8 , 
• 
-0.8 -0.6 
• 
• 
-0.4 
".6 t: • 
• • ••• 
0.4 • • • • 
• 0.2 
• "';-0.2 
..0.4 
-0.6 
-0.8 
• •• 
• • 
• 
• 0.2 .~ ~ 0.6 
• •• ... . .. 
•• .. 
• 
Predicted LogOI FRIqUfIlCY 
• 
018 
Appendix 4 
M ode19.20 OralB-T IclAmS 
RI SA Total Dipole RI Actual Predicted Residual 
CH~s 10 HA LogGI ~I 
2 0 30.64 0.593 I 0.522 0.560 -0.038 
3 0 31.64 0.415 3 0.407 0.488 -0.081 
4 0 28.70 0.359 2 0.724 0.675 0.049 
6 0 29.69 0.497 1 0.751 0.639 0.112 
7 0 37.42 0.412 6 0.241 0.109 0.132 
8 0 33.94 0.506 2 0.193 0.435 -0.242 
I1 0 40.62 0.208 2 0.204 0.376 -0.172 
12 0 36.80 0.711 2 0.236 0.239 -0.003 
13 0 30.01 0.323 2 0.667 0.652 0.015 
15 I 36.97 0.413 2 0.568 0.746 -0.] 78 
16 0 30.36 0.607 2 0.782 0.496 0.286 
18 0 36.52 0.466 2 0.104 0.374 -0.270 
23 0 30.83 0.403 2 OA03 0.585 -0.182 
25 0 40.93 0.558 2 0.241 0.187 0.054 
26 0 38.25 0.676 2 0.173 0.211 -0.038 
30 0 30.66 0.721 2 0.435 0.428 0.007 
34 0 33.20 0.100 3 0.695 0.600 0.095 
37 0 35.55 0.590 7 -0.347 0.011 -0.358 
38 1 39.60 0.884 5 -0.119 0.224 -0.343 
49 I 51.28 0.750 6 0.021 -0.]43 0.164 
50 1 37.86 0.604 5 0.631 0.422 0.209 
51 0 34.21 0.959 3 0.161 0.128 0.033 
52 0 30.15 1.014 I 0.342 0.360 -0.018 
55 1 39.59 0.475 5 0.558 0.433 0.125 
56 0 34.20 0.489 3 0.740 0.369 0.371 
60 I 42.66 0.263 3 0.554 0.576 -0.022 
62 0 29.45 0.788 3 0.522 0.432 0.090 
65 0 37.68 0.526 5 0.398 0.240 0.158 
70 1 49.90 0.603 0.086 0.041 0.045 
A&1 
AppendIx ~ 
Cl· M . M d J 9 20 orre atlon atnx tOI e 
SA ID RI HA RI CHi LogOI 
SA 1.0 0.023 0.584 0.674 -0.501 
ToraI Dipole 1.0 0.060 0.059 -0.391 
RI HA 1.0 0.513 -0.496 
RI CH~s 1.0 -0.096 
.LogloGI 1.0 
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Appendix 4 
M ode) 9.21 ParenteraL8-~ tms 
RI CH~s SS CefsuJ Actual LogOI Predicted LogGI Residual 
1 0 0.731 -0.051 0.033 -0.084 
5 0 0.719 -0.377 7.534 -0.378 
9 0 0.760 0.398 0.112 -0.286 
10 0 0.782 -0.108 0.172 -0.280 
14 1 0.675 0.398 0.375 0.023 
19 2 0.748 1.086 1.066 0.020 
20 1 0.672 0.297 0.367 -0.070 
21 1 0.714 0.786 0.508 0.278 
22 1 0.756 0.301 0.594 -0.293 
24 1 0.689 0.396 0.413 -0.017 
27 0 0.707 
-0.284 -0.032 -0.252 
28 0 0.781 0.230 0.169 0.061 
29 0 0.695 0.223 -0.064 0.287 
35 0 0.648 -0.444 -0.192 -0.252 
36 1 0.658 0.522 0.329 0.193 
39 0 0.660 -0.569 -0.159 -0.410 
40 0 0.696 -0.319 -0.062 -0.257 
41 1 0.577 0.173 0.109 0.064 
42 0 0.753 0.322 0.093 0.229 
43 1 0.763 0.507 0.071 0.436 
44 0 0.783 0.00 0.174 -0.174 
45 0 0.771 0.428 0.142 0.286 
46 I 0.590 0.045 0.144 -0.099 
47 0 0.664 -0.409 -0.148 -0.261 
48 0 0.690 -0.032 -0.078 0.046 
53 0 1.000 0.919 0.763 0.156 
54 2 0.561 0.270 0.559 -0.289 
57 1 0.570 -0.108 0.090 -0.198 
58 1 0.519 0.405 -0.048 0.453 
59 1 0.569 -0.143 0.088 -0.231 
64 0 0.641 -D.155 -D.211 0.056 
66 0 0.573 -D.097 -0.396 0.298 
67 0 0.851 0.389 0.359 0.030 
68 0 0.618 -0.119 -0.273 0.154 
69 0 0.787 0.373 0.185 0.188 
Appendix 4 
Correlation Matrix Model 9 21 
RI CH1S SS Cefsul LogGI 
RI CH;s 1.0 -0.431 0.484 
SS Cephalor l.0 0.348 
LogloGI 1.0 
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Appendix 4 
Models 9.22 All Penicillins. 9.23 Oral Penicillins and 9.24 Parenteral Penicillins 
RI # SA Actual All All OraJ Oral Par. Pens. Parent. 
CH3 CH3 LogOJ Pens Pens Pens Pens. Pred. Pens. 
Pred. Resid. Pred. Resid. LogGJ Resid. 
LogOI LogGI 
I 0 2 30.23 -0.051 0.130 -0.181 
- -
0.081 -0.132 
2 0 5 30.64 0.522 0.528 -0.005 0.563 -0.040 
- -
3 0 2 31.64 0.407 0.486 -0.080 0.5]6 -0.109 
- -
4 0 2 28.70 0.724 0.608 0.116 0.654 0.070 
- -
5 0 2 40.97 -0.377 -0.316 -0.061 
- - -0.301 -0.076 
6 0 2 29.69 0.75] 0.568 0.183 0.608 0.]43 
- -
7 0 2 37.42 0.241 0.246 -0.005 0.224 -0.003 
- -
8 0 4 33.94 0.193 0.391 -0.198 0.407 -0.2]4 
- -
9 0 2 27.34 0.398 0.250 0.148 
- -
0.184 0.2]4 
10 0 2 30.99 "().l08 0.098 -0.206 
- - 0.054 -0.162 
lJ 0 2 40.62 0.204 0.113 0.091 0.093 O.Ill - -
12 0 2 36.80 0.236 0.272 -0.036 0.273 -0.037 - -
13 0 2 30.01 0.667 0.554 0.113 0.593 0.074 
- -
14 1 3 35.60 0.398 0.439 -0.041 - - 0.460 -0.062 
15 1 3 36.97 0.568 0.796 -0.228 0.568 -1.11-]6 
- -
16 0 2 30.36 0.782 0.540 0.242 0.576 0.206 - -
18 0 3 36.52 0.104 0.283 -0.179 - - 1.138 -0.052 
19 2 4 32.56 1.086 1.097 -0.011 0.286 -0.182 - -
20 1 3 42.11 0.297 0.]68 0.129 - - 0.229 0.068 
21 1 3 33.14 0.786 0.541 0.245 - - 0.548 0.238 
22 I 3 32.46 0.301 0.570 "().269 - - 0.572 -0.271 
23 0 2 30.83 0.403 0.520 ..Q.117 0.554 -0.151 - -
24 I 3 41.11 0.396 0.210 0.186 - - 0.264 0.132 
25 0 5 40.93 0.241 0.100 0.141 0.078 0.163 - -
26 0 2 38.25 0.173 0.211 -0.038 0.204 -0.031 - -
27 0 3 39.74 -0.284 ..Q.265 -0.019 - - -0.257 -0.027 
28 0 2 29.73 0.230 0.151 0.079 - - 0.099 0.131 
A11 
Appendix 4 
Correlation Matrix Model 9.22 
SA #CH'l Adrnin ID LogG) 
SA 1.0 0.175 0.049 -0.444 
#CH~ 1.0 0.483 0.460 
Admin ID 1.0 -0.240 
J.<>glO GI 1.0 
Correlation Matrix Model 9.23 
SA #CH3 UlgQI 
SA 1.0 0.181 -0.775 
#CH'l l.0 0.180 
l.oglO GI 1.0 
Correlation Matrix Model 9.24 
SA #CH3 RI LogOI 
SA 1.0 0.184 '().265 
#CHl RI 1.0 0.825 
Logln GI 1.0 
A11 
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Mode19.24 Validity Plots 
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Models 9.25 All Cephalosporins. 9.26 Oral Cephalosporins and 9.27 Parenteral Cephalosporins 
DVz 1: C=O· TD SS SS Actual An Cephs All Cepbs Oral Cepbs Ort Cepbs Par. Cepbs P.Cepbs 
Charges 10 Cepbalex Cepbalor LogOI P. LogOI Resid. P.LogGI Resid. P.LogOI Resid. 
29 0.58 -1.565 0.159 0.780 0.643 0.223 0.486 -0.257 
- -
0.398 -0.175 
30 -2.59 -1.170 0.721 0.784 0.690 0.435 0.087 0.348 0.407 0.028 
- -
31 0.31 -1.163 0.207 0.772 0.681 -0.319 -0.005 -0.314 - - - -
33 -1.40 -1.157 0.494 0.704 0.614 -0.097 0.110 -0.207 
- -
0.036 -0.133 
34 -0.56 -1.161 0.100 0.683 0.657 0.695 -0.139 0.834 0.793 -0.098 
- -
35 -5.88 -1.162 0.942 0.716 0.792 -0.444 -0.408 -0.036 
- -
-0.477 0.033 
37 -0.85 -1.492 0.590 0.681 0.773 -0.347 -0.321 -0.026 
- - - -
38 7.44 -1.126 0.884 0.683 0.663 -0.119 -0.431 0.312 0.105 -0.224 - -
39 . 5.58 -1.156 0.601 0.739 0.663 -0.569 -0.193 -0.376 - - -0.299 -0.270 
40 3.64 -1.528 0.788 0.753 0.742 -0.319 -0.104 -0.215 - - -0.205 -0.114 
41 3.83 -1.126 0.750 0.669 0.603 0.l73 -0.129 0.302 - - -0.223 0.396 
42 -4.73 -1.661 0.706 0.697 0.666 0.322 0.393 -0.071 - - 0.332 -0.010 
43 2.48 -2.363 0.469 0.651 0.652 0.507 0.662 -0.155 
- -
0.580 -0.013 
44 -6.45 -1.535 0.100 0.658 0.625 0.00 0.393 -0.393 - - 0.342 -0.342 
45 6.82 -1.915 0.962 0.138 0.668 0.428 0.404 0.024 
- -
0.299 0.129 
46 3.99 -1.497 0.654 0.745 0.136 0.045 -0.138 0.183 
- -
-0.240 0.285 
Continued over page 
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Models 9.25, 9.26 and 9.27 continued 
DVz 1: C=O· Total SS SS Actual All Cephs All Cephs Oral Cephs Orl Cephs Par. P.Cephs 
Charges Dipole Cephalex Cephalor LogOI P. LogOI Resid. P.LogGI Resid. Cephs Resid. 
P.LogGI 
47 4.79 -1.162 0.877 0.663 0.641 -0.409 0.294 -0.115 
- -
-0.394 -0.015 
48 -1.28 -1.587 0.596 0.820 0.872 -0.032 -0.223 0.191 
- -
-0.314 0.282 
49 -4.77 -1.563 0.750 0.658 0.653 0.021 0.255 -0.234 0.183 -0.162 
- -
50 -2.33 -1.489 0.604 0.710 0.669 0.631 0.207 0.424 0.393 0.238 
- -
51 -0.18 -1.154 0.959 0.771 0.701 0.161 0.164 -0.003 0.177 -0.016 
- -
52 -0.83 -1.183 1.014 0.758 0.668 0.342 0.298 0.044 0.109 0.233 
- -
53 -9.71 -1.831 0.893 0.685 0.600 0.919 0.902 0.017 - - 0.868 0.051 
54 -1.21 -1.560 0.157 0.737 0.599 0.270 0.579 -0.309 - - 0.508 -0.238 
55 -1.62 -1.121 0.475 0.682 0.771 0.558 0.228 -0.330 0.462 0.096 
- -
56 -1.12 -1.529 0.489 0.775 0.699 0.740 0.270 0.470 0.595 0.145 
- -
57 -1.00 -1.121 0.393 0.767 0.683 -0.108 -0.021 -0.087 
- -
-0.102 -0.006 
58 0.52 -1.560 1.026 0.668 0.689 0.405 -0.018 0.423 
- -
-0.102 0.507 
59 -1.32 -1.552 0.312 0.793 0.818 -0.143 -0.117 -0.026 - - -0.204 0.061 
60 1.69 -1.919 0.263 0.629 0.711 0.554 0.038 0.516 0.565 -0.011 
- -
61 5.01 -1.126 0.814 0.724 0.712 -0.638 -0.432 -0.206 
- -
-1.668 -0.332 
62 2.35 -1.159 0.788 1.000 0.692 0.522 0.533 -0,(>11 __ L- 0.6_87 -0.165 - -
~ Continued over page 
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Models 9.25, 9.26, 9.27 Continued 
DVz 1:C=O' Total SS SS Actual All Cephs All Cephs Oral Cephs Orl Cephs Par. Cephs P.Cephs 
Charges Dipole Cephalex Cephalo LogOI P. LogGI Resid. P.LogGI Resid. P.LogGI Resid. 
r 
63 2.S8 -1.162 0.626 0.692 1.000 -2.000 -1.549 -0.451 - - 0.258 -0.413 
64 0.24 -1.535 0.558 0.756 0.65S -0.155 0.340 -0.495 - - - -
65 1.91 -1.910 0.526 0.662 0.659 0.398 0.320 0.078 0.386 0.012 
- -
66 -3.13 -1.535 0.634 0.562 0.632 -0.097 -0.006 -0.091 - - -0.070 --0.027 
67 -7.25 -1.161 0.793 0.745 0.679 0.389 0.153 0.236 
- -
0.098 0.291 
6S 2.00 -1.161 0.649 0.677 0.618 -0.119 -0.001 -0.038 - - -0.169 0.050 
69 -2.0S -1.533· 0.621 0.669 0.603 0.373 0.376 -0.003 - - 0.309 0.064 
70 -3.77 -1.487 0.603 0.563 0.531 0.086 0.370 -0.284 0.163 -0.077 
- -
~ 
aft t 
;( 
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Appendix 4 
Model 9.25 Correlation Matrix 
DVz L Charge SS SS LogGI 
C=Q* Cephalor Cephalex 
DVz 1.0 -0.008 0.134 0.060 -0.311 
L Charge C=O* 1.0 0.105 0.278 -0.416 
SS Cephalor 1.0 0.325 -0.576 
SS Cephalex 1.0 0.066 
LogGI 1.0 
Model 9.26 Correlation Matrix 
ID SS LogGI 
Cephalex 
TD 1.0 0.376 -0.623 
SS Cephalex 1.0 0.288 
LogGI 1.0 
Model 9.27 Correlation Matrix 
DVz L Charge SS SS LogGI 
C=O* Cephalor Cephalex 
DVz 1.0 0.022 0.121 0.110 -0.334 
L Charge C=O* 1.0 0.138 0.073 -0.540 
SS Cephalor 1.0 0.338 -0.691 
SS Cephalex 1.0 -0.047 
LogGI 1.0 
Mrulel 9.25 Validity Plots 
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Plot Predicted. Log GI Frequencies Against Actual 
Log GI Frequencies for All Cephalosporin Antibiotics 
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Plot Predicted Log GI Frequencies Against Actual 
Log GI Frequencires for Oral Cephalosporin Antibiotics 
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Model 9.27 Validity Plots 
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Appendix 5 
Therapeutic Dose Levels and Plasma Half-Lives of the 
70 p-Lactam Antibiotics Investigated in 9.0 [193] 
HR TDD = highest recommended therapeutic daily dose in grammes. 
Penicillin Mode of CAS HRTDD Plasma Peak Plasma Cone 
Admin. Number (g) Half-Life forHRTDD@ 
(hours) tl/2 (Ilg/ml) 
Amdinocillin parenteral 32889-01-7 2.0 1.0 60 
Amdinocillin-pivoxil oral 32887-03-9 1.6 1.0 20 
Amoxycillin oral 26787-78-0 4.0 1.5 80 
Ampicillin oral 69-53-4 5.0 1.5 60 
AQacillin parenteral 63469-19-2 9.0 1.0 180 
Azidocillin oral 17243-38-8 1.5 0.5 15 
Azlocillin oral 37091-66-0 6.0 1.0 
-
Bacampicillin oral 50972-17-3 2.4 0.5 120 
Benzylpenicillin parenteral 61-33-6 1.2 0.5 24 
Carbenicillin parenteral 4697-36-3 4.0 1.5 94 
Carindacillin oral 35531-88-5 3.06 1.5 71 
Carfecillin oral 27025-49-6 3.0 1.5 70 
Cyclacillin oral 3485-14-1 2.0 1.5 -
Cloxacillin parenteral 61-72-3 2.0 0.5 56 
Dicloxacillin oral 3116-76-5 1.0 0.5 38 
Epicillin oral 26774-90-3 2.0 1.5 -
Flucloxacillin parenteral 5250-39-5 1.0 1.0 15 
LenampiciIlin oral 86273-18-9 2.0 1.5 60 
Methicillin parenteral 61-32-5 6.0 10.5 108 
MezlociIlin parenteral 51481-65-2 16.0 0.5 400 
Nafcillin parenteral 147-52-4 4.0 0.5 32 
Oxacllin parenteral 66-79-5 6.0 0.5 72 
Phenoxymethylpenicillin oral 87-08-1 2.0 0.5 20 
Piperacillin parenteral 61477-96-1 8.0 1.0 160 
Pivampicillin oral 33817-20-8 2.0 1.5 180 
T alampicillin oral 47747-56-8 1.5 1.5 60 
Temocillin parenteral 66148-78-5 4.0 4.5 -
Ticarcillin parenteral 34787-01-4 20.0 1.2 600 
Continued over page 
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A d" lppen IX 5 contmue d 
Cephalosporin Mode CAS HRTDD Plasma Peak Plasma Cone 
of Number Half-Life forHRTDD@ 
Admin. (hours) tIt-, (mg/ml) 
Cefacetrile parenteral 10206-21-0 4.0 0.8 
-
Cefaclor oral 53994-73-3 4.0 0.5 104 
Cefadroxil oral 50370-12-2 2.0 1.5 60 
Cefaloglycin( e) oral - - - -
Cefamandole parenteral 34444-01-4 12.0 - 300 
Cefatrizine oral 51627-14-6 1.0 1.0 30 
Cafazolin parenteral 25953-19-9 4.0 1.8 240 
Cefepirome parenteral - - - -
Cefixime oral 79350-37-1 0.4 4.0 6 
Cefinenoxime oral 65085-01-1 4.0 1.0 100 
Cefinetazole parenteral 56796-20-4 4.0 1.5 276 
Cefininox parenteral 75481-73-1 6.0 1.0 360 
Cefodizime parenteral 69739-16-8 2.0 1.0 50 
Cefonicid parenteral 61270-58-4 1.0 4.5 126 
Cefoperazone parenteral 62893-19-0 4.0 2.0 194 
Ceforanide parenteral 60925-61-3 2.0 3.0 140 
Cefotetan parenteral 69712-56-7 4.0 4.6 280 
Cefotaxime parenteral 63527-52-6 6.0 1.0 150 
Cefotiam parenteral 61622-34-2 4.0 1.2 100 
Cefoxitin parenteral 35607-66-0 6.0 1.0 300 
Cefpiramide oral 70797-11-4 4.0 4.5 194 
C~odoxime oral 80210-62-4 0.4 4.0 6 
Cefprozil oral 92665-29-7 1.0 1.4 26 
Cefroxadine oral 51762-05-1 2.0 1.0 72 
Cefsulodin parenteral 62587-73-9 4.0 1.6 -
Ceftazidime parenteral 72558-82-8 6.0 2.0 534 
Cefteram oral 82547-58-8 2.0 1.5 180 
Ceftibuten oral 97519-39-6 0.4 4.0 6 
Continued over page 
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A d' 5 ~en IX contmue d 
Cephalosporin Mode CAS HRTDD Plasma Peak Plasma Cone 
of Number (g) Half-Life forHRTDD@ 
Admin (hours) tl/1 (mg/ml) 
Ceftizoxime parenteral 68401-81-0 4.0 1.7 156 
Ceftriaxone ~arenteral 73384-59-5 2.0 9.0 160 
Cefuroxime parenteral 55268-75-2 2.25 1.2 216 
Cefuroxime-axetil oral 64544-07-6 1.0 6.0 35 
Cefuzonam oral 82219-78-1 - - -
Cephalexin oral 15686-71-2 6.0 1.0 72 
Cephaloridine parenteral 50-59-9 2.0 0.8 40 
Cephalothin parenteral 153-61-7 4.0 0.8 80 
Cephamycin oral - - - -
Cephapirin parenteral 21593-23-7 4.0 0.8 80 
CeQhradine parenteral 38821-53-3 4.0 1.0 136 
Flomoxef parenteral 99665-00-6 - - -
Latamoxef parenteral 64952-97-2 4.0 1.0 100 
T-2588 oral - - - -
ASS 
APPENDIX 6 
Antibiotic 
Amoxycillin 
Ampicillin 
AzlociJlin 
Bacampicillin 
Benzylpenicillin 
Qubenicllin 
Cloxacillin 
Dicloxacillin 
Epicillin 
Methicillin 
Nafcillin 
Oxacillin 
Piperacillin 
Ticarcillin 
Cefaclor 
Cefadroxil 
Cafamandole 
Cefazolin 
Cefoperazone 
Cefotaxime 
Cefoxitin 
Cefsulodin 
Ceftazidime 
Ceftriaxone 
Cefuroxime 
Cephalexin 
Cephalothin 
Cenhaloridine 
Cenhapirin 
Cephradine 
Latamoxef 
Appendix 6 
mglml Quantities of P-Lactam Antibiotics Used to Give 3mM 
and HRTDD concentrations for ELISA Analysis 
mg/ml to give HRTDD Mwt (g) mglml to give Ratio HRTDD/3mM 
3mM 
4.0 356.4 1.07 3.74 
5.0 371.4 1.11 4.50 
6.0 483.5 1.45 4.05 
2.4 502.0 1.51 1.58 
1.0 356.4 1.07 1.00 
4.0 422.4 1.27 3.15 
2.0 475.9 1.43 1.40 
1.0 492.3 1.48 0.66 
2.0 351.4 1.05 1.91 
6.0 
- - -
4.0 436.5 1.31 3.05 
6 .. 0 423.4 1.27 4.72 
8. 539.5 1.62 4.94 
20.0 428.4 1.29 15.50 
4.0 367.8 UO 3.64 
2.0 363.4 1.09 1.84 
12.0 484.5 1.45 8.28 
4.0 476.5 1.43 2.80 
4.0 667.6 2.00 2.00 
6.0 
- - -
6.0 450.4 1.35 4.44 
4.0 554.5 1.66 2.41 
6.0 
- - -
2.0 598.5 1.80 l.ll 
2.25 446.4 1.34 1.68 
6.0 
- - -
4.0 418.4 1.26 3.18 
2.0 415.5 1.25 1.60 
4.0 445.4 1.34 3.00 
4.0 349.4 1.05 2.67 
4.0 520.5 1.56 2.56 
ur 
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APPENDIX 7 Compounds. Descrivtor Variable Values, 
Actual & Predicted Cross-Reactivity Values. Residual Values. 
Correlation Matrices and Validity Plots 
for QSARs Generated in ]0.3 
Cross-Reactivity at 3mM Concentration 
Models 10.1 AIl f3-Lactams, 10.2 Oral f3-Lactams, 10.3 Parenteral fl-Lacams 
10.4 AIl Penicillins, 10.5 Oral Penicillins, 10.6 Parenteral PeniciIlins 
10.7 AIl Cephalosporins, 10.8 Oral Cephs. & 10.9 Parenteral Cephs. 
Admin Sterimol ASA SA DVx DVy 
ID 81((,=£)\ 
3 3 2.264 0.686 31.64 -2.52 1.24 
4 3 2.137 0.668 28.70 -3. ]9 O.ll 
7 3 2.462 0.847 37.42 -2. ]6 3.14 
8 3 2.637 0.602 33.94 -2.04 0.69 
9 4 2.151 0.660 27.34 -3.78 0.78 
10 4 3.313 0.709 30.99 -3.76 0.17 
14 4 1.819 0.816 35.60 -4.46 5.28 
15 3 1.880 0.777 36.97 -2.99 -0.06 
16 3 1.500 0.695 30.36 -3.80 4.07 
19 4 1.500 0.735 32.56 -1.31 4.62 
21 4 3.342 0.789 33.14 -2.26 6.92 
22 4 3.491 0.761 32.46 -0.04 2.49 
24 4 3.565 0.947 41.11 -4.15 2.93 
28 4 3.620 0.677 29.73 -2.79 -0.68 
30 3 3.326 0.913 30.08 2.53 2.42 
31 3 1.992 0.904 29.29 -4.04 0.51 
33 4 4.186 0.653 35.31 -3.15 2.80 
35 4 2.261 0.771 35.85 -1.38 -1.19 
43 4 3.318 0.91 I 53.13 -4.50 0.78 
46 4 1.987 0.675 33.78 3.60 3.61 
48 4 2.473 0.935 33.16 -1.69 5.58 
53 4 4.025 0.839 39.34 1.80 -0.12 
54 4 3.910 0.792 46.48 0.66 -0.73 
58 4 4.619 0.790 46.18 2.16 9.41 
59 4 3.408 0.882 35.32 1. 71 0.39 
62 3 2.234 0.870 29.45 -3.42 3.86 
63 4 2.915 1.103 34.73 -0.23 5.63 
64 4 2.590 0.637 32.60 0.91 5.26 
66 4 2.757 0.675 31.81 -2.43 2.64 
67 4 3.323 0.923 28.88 -2.45 1.94 
69 4 3.588 0.864 47.50 7.23 2.48 
Appendix 7 
Actual AIl PLs All PLs Oral PLs Oral PLs Parenteral Parenteral 
JXr Predicted Residual Predicted Residual PLs Pred. PLs 
.1Xr rxr ./Xr Residual. 
3 3.02 4.91 -1.089 
- - 5.23 -2.) 8 
4 6.87 5.16 1. 71 5.80 O. J7 
- -
7 4.38 3.99 0.39 4.24 0.14 - -
8 4.31 4.26 0.05 4.85 -0.54 
- -
9 10.00 6.82 3.18 
- - 6.80 3.20 
10 8.91 6.57 2.34 - - 6.06 2.85 
14 6.80 5.43 1.37 - - 5.59 1.21 
15 3.56 4.22 -0.66 4.35 -0.79 
- -
16 4.23 2.07 2.16 
-
- - -
19 5.26 5.91 -0.65 
-
- 4.61 0.66 
21 3.77 5.84 -2.07 
- -
4.97 - 1.20 
22 4.93 5.49 -0.56 
- -
4.00 0.93 
24 4.38 5.44 -1.06 - - 4.41 -0.03 
28 6.73 6.55 0.18 
- -
5.87 0.87 
30 0.10 -0.30 0.40 -0.883 0.93 - -
31 0.10 2.56 -2.46 1.33 -1.23 - -
33 2.57 3.82 -1.25 - - 5.00 -2.43 
35 0.10 2.83 -2.73 - - - -
43 1.87 2.85 -0.98 - - 2.33 -0.46 
46 1.61 1.83 -0.22 - - 1.48 0.13 
48 2.65 1.58 1.07 - - 4.68 -2.03 
53 0.89 1.74 -0.85 - - 1.80 -0.91 
54 3.36 2.86 0.50 - - 3.15 0.25 
58 1.05 2.32 -1.27 
-
- 0.35 0.71 
59 0.10 1.61 -1.51 - - 2.60 -2.50 
62 4.46 4.15 0.31 4.04 0.43 - -
63 3.27 0.80 2.47 - - 3.67 -0.40 
64 3.35 2.98 0.37 - - 3.50 -0.15 
66 3.55 3.94 -0.39 - - 5.30 -1. 75 
67 2.37 1.21 1.16 - - 3.44 -1.07 
69 0.10 -1.07 1.17 
-
-
-2.40 2.50 
Appendix 7 
Model 10.1 Correlation Matrix 
DVx Sterimol B1 ASA Admin ID ./3mM Xr 
DVx 1.0 0.581 0.251 0.243 -0.561 
Sterimol B1 1.0 0.314 0.274 -0.705 
ASA 1.0 0.122 -0.442 
Admin ID 1.0 0.033 
../3mMXr 1.0 
Model 10.2 Correlation Matrix 
Sterimol Bl ASA IJ3mMXr 
Sterimol Bl 1.0 0.382 -0.847 
ASA 1.0 -0.689 
.{3mMXr 1.0 
Model 10.3 Correlation Matrix 
SA DVx ./JmMXr 
SA 1.0 0.231 -0.585 
DVx 1.0 -0.654 
.JJmMXr 1.0 
Appendix 7 
Model 10.1 Validity Plots 
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Model 10.2 Validity Plots 
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Model 10.3 Validity Plots 
Plot of Predicted J-cross-Reactivity Against 
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Actual All Pens All Pens. Oral Oral Pens Parenteral Parenteral 
..fXr Predicted Residual Pens Residual Pens Pred. Penicillins 
..rXr Predicted ...1Xr Residual. 
rXr 
3 3.02 - - - - - -
4 6.87 0.82 -1.30 6.62 0.25 - -
7 4.38 3.91 0.47 3.73 0.65 - -
8 4.31 5.18 -0.87 4.89 -0.58 - -
9 10.00 9.19 0.82 
- -
6.70 0.31 
10 8.91 7.66 1.25 - - 8.12 0.80 
14 6.80 6.50 0.30 - - 6.90 -0.91 
15 3.56 4.76 -1.20 3.88 -0.32 - -
16 4.23 
- - - - - -
19 5.26 5.12 0.14 - - 5.51 -0.25 
21 3.77 - - - - - -
22 4.93 4.13 0.80 - - 4.50 0.43 
24 4.38 4.08 0.30 - - 4.40 -0.02 
28 6.73 7.44 -0.71 - - 7.90 -1.17 
Model 10 4 Correlation Matrix 
SA DVx .{jmMXr 
SA 1.0 -0.105 -0.741 
DVx 1.0 -0.438 
.{3mM Xr 1.0 
Model 10 5 Correlation Matrix 
SA 1J"3mMXr 
SA 1.0 -0.924 
{3mMXr 1.0 
Model 10 6 Correlation Matrix 
SA DVx lJ3mMXr 
SA 1.0 -0.234 -0.715 
DVx 1.0 -0.447 
..!3mMXr 1.0 
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Model 10.4 Validity Plots 
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Model 10.5 Validity Plots 
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Model 10.6 Validity Plots 
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Actual All All Oral Oral Parenteral Parenteral 
f"xr Cephs. Cephs. Cephs. Cephs. Cephs. Cephs. 
Predicted Residual Predicted Residual Pred. Residual. 
";-Xr .fXr JXr 
30 0.10 1.30 -1.20 1.75 - - -
31 0.10 1.61 -1.51 -0.61 -1.65 
- -
33 2.57 2.61 -0.04 
- -
2.68 -0.11 
35 0.10 0.20 -0.10 - - 0.62 -0.52 
43 1.87 1.84 0.03 
- -
2.06 -0.19 
46 1.61 l.47 0.14 
- - 1.74 -0.13 
48 2.65 3.75 -1.10 
- - 3.59 -0.94 
53 0.89 0.14 0.75 - - 0.50 0.39 
54 3.36 2.98 0.38 - - 4.06 -0.70 
58 1.05 - - - - - -
59 0.10 0.42 -0.32 - - 0.73 -0.63 
62 4.46 3.20 l.26 3.52 0.94 - -
63 3.27 3.48 -0.21 - - 3.34 -0.07 
64 3.35 3.07 0.28 - - 2.97 0.38 
66 3.55 2.39 1.17 - - 2.47 1.08 
67 2.37 l.07 1.30 - - l.26 1. 11 
69 0.10 0.41 -0.31 - - 0.59 -0.49 
Model 10 7 Correlation Matrix 
DVx DVy .r.;mMXr 
DVx 1.0 0.006 -0.408 
DVy 1.0 0.707 
.J1mM Xr 1.0 
Model 10 8 Correlation Matrix 
DVy J"3mM Xr 
DVy 1.0 0.823 
.J)mMXr 1.0 
Model 10 9 Correlation Matrix 
DVx DVy IJ3mMXr 
DVx 1.0 -0.025 -0.465 
DVy 1.0 0.746 
../)mM Xr 1.0 
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Model 10.7 Validity Plots 
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Model 10. 9 Validity Plots 
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Cross-Reactivity at Concentration Equivalent to HRTDD 
Models 10.10 All IJ-Lactams, 10.11 Oral IJ-Lactams, 10.12 Parenteral p-Lacams 
10.13 All Penicillins, IQ.14 Oral Penicillins, IQ.15 Parenteral Penicillins 
10. 16 All Cephalosporins, 10.17 Oral Cephs. & 10.18 Parenteral Cephs. 
Admin HOMO Sterimol SA Sterimol # CH3 SS BP DVx 
ID L B4 (('=0) 
(CH,3) 
3 -9.003 1.124 31.64 8.763 2 0.987 -2.52 
3 -9.177 1.125 28.70 8.160 2 0.991 -3.19 
3 -8.942 1.576 37.42 10.860 2 0.876 -2.16 
3 -9.030 0.372 33.94 8.344 2 0.890 -2.04 
4 -9.522 1.007 27.34 8.169 2 1.000 -3.78 
4 -8.989 1.225 30.99 8.106 2 0.848 -3.76 
4 -8.698 1.378 35.60 9.911 3 0.668 -4.46 
3 -9.115 1.301 36.97 10.150 3 0.693 -2.99 
3 -9.050 1.084 30.36 5.758 2 0.889 -3.80 
4 -8.475 1.282 32.56 9.210 4 0.725 -1.31 
4 -9.079 0.657 33.14 11.640 3 0.724 -2.26 
4 -9.085 0.656 32.46 8.150 3 0.827 -004 
4 -8.987 0.651 41.11 13.170 3 0.573 -4.15 
4 -8.970 1.245 29.73 8.077 2 0.770 -2.79 
3 -9.032 0.421 30.08 6.420 0 0.870 2.53 
3 -8.720 0.612 29.29 7.140 1 0.864 -4.04 
4 -8.872 0.616 35.31 6.217 1 0.806 -3.15 
4 -8.445 0.784 35.85 11.220 1 0.663 -1.38 
4 -9.176 0.862 53.13 14.300 2 0.574 -4.50 
4 -8.795 0.436 33.78 10.540 2 0.695 3.60 
4 -9.277 0.422 33.16 8.819 1 0.702 -1.69 
4 -8.939 0.697 39.34 7.298 0 0.760 1.80 
4 -8.979 0.849 46.48 9.779 2 0.667 0.66 
4 -9.092 0.863 46.18 9.963 2 0.534 2.16 
4 -9.159 0.425 35.32 9.337 1 0.676 171 
3 -9.520 0.431 29.45 8.582 1 0.790 -3.42 
4 -9.229 0.399 34.73 8.596 0 0.638 -0.23 
4 -9.165 0.422 32.60 8.411 1 0.672 0.91 
4 -8.931 0.762 31.81 10.560 1 0.649 -2.43 
4 -9.182 0.438 28.88 5.634 1 0.831 -2.45 
4 -9.401 0.704 47.50 7.642 2 0.716 7.23 
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Actual All aLs All aLs Oral PLs Oral PLs Parenteral Parenteral 
./X.r Predicted Residual Predicted Residual PLs Pred. PLs 
.rAr J"xr ~r Residual. 
3 6.57 4.26 2.31 4.15 2.43 -
-
4 5.60 5.79 -0.19 5.11 0.50 
- -
7 5.88 5.14 0.74 6.09 -0.21 - -
8 0.10 0.05 0.05 0.50 -0.40 
- -
9 10.00 10.34 -0.34 
- - 7.82 2.18 
10 9.31 8.00 1.31 - - 7.82 1.49 
14 5.71 6.14 -0.43 
- - 6.53 -0.82 
IS 3.59 4.75 -l.16 5.65 -2.06 
- -
16 4.14 4.56 -0.42 4.20 -0.06 - -
19 2.76 5.02 -2.26 - - 5.33 -2.57 
21 3.13 4.96 -1.83 - - - -
22 5.44 5.13 0.31 
- -
5.64 -0.20 
24 5.23 2.87 2.36 
- -
3.16 2.07 
28 8.90 8.09 0.81 - - 7.32 1.58 
30 0.10 0.96 -0.86 0.76 -0.66 - -
31 0.10 0.51 -0.41 0.01 0.09 - -
33 4.87 3.19 l.68 
- -
- -
35 1.67 1.62 0.05 - - 3.36 -1.69 
43 1.79 2.63 -0.84 - - 2.26 -0.47 
46 1.87 2.14 -0.28 - - 1.09 079 
48 3.78 4.82 -1.04 - - 5.94 -2.16 
53 3.74 3.19 0.55 - - 5.34 -1.60 
54 3.09 2.80 0.29 - - 3.59 -0.50 
58 4.25 3.55 0.70 - - 2.51 1.74 
59 3.82 3.77 0.05 - - 3.40 0.43 
62 2.90 3.92 -0.06 3.49 0.37 - -
63 5.53 4.13 1.39 - - - -
64 5.22 4.32 0.34 - - 4.78 -0.] 2 
66 3.76 4.96 -1.20 - - 4.68 -0.92 
67 2.51 2.86 -0.35 - - 3.06 -0.55 
69 2.51 4.15 -1.64 - - 1. 75 0.76 
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Model 10. 10 Correlation Matrix 
SA HOMO Sterimol L Admin ID JHRTDD Xr 
SA 1.0 -0.039 -0.008 0.042 -0.281 
HOMO 1.0 0.270 0.099 -0.287 
Sterimol L 1.0 0.153 0.500 
Admin ID 1.0 0.234 
_.fHRTDDXr 1.0 
Model 10.11 Correlation Matrix 
Sterimol L HOMO I.(HRTDD Xr 
Sterimol L l.0 0.178 0.775 
HOMO 1.0 -0.296 
IJ""HR TDD Xr 1.0 
Model 10. 12 Correlation Matrix 
DVx Sterimol B4 ./lIRTDD Xr 
DVx l.0 -0.396 -0.471 
Sterimol84 l.0 -0.423 
£HRTDDXr 1.0 
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Appendix 7 
Actual All Pens All Pens. Oral Oral Pens Parenteral Parenteral 
J"Xr Predicted Residual Pens Residual Pens Pred. Penicillins 
~Xr Predicted fxr Residual. 
.fXr 
3 6.57 5.88 -0.69 5.62 -0.95 - -
4 5.60 5.88 -0.28 5.62 -0.02 - -
7 5.88 5.88 0.00 5.62 0.26 - -
8 0.10 -0.40 0.50 0.39 -0.29 -
-
9 10.00 9.67 0.33 
- -
9.06 0.94 
10 9.31 0.67 0.65 - - 9.06 0.25 
14 5.71 5.53 0.19 - - 5.39 0.32 
15 3.59 2.74 0.85 3.01 0.58 - -
16 4.14 5.88 --1.74 5.62 1.48 
- -
19 2.76 2.39 0.38 - - 1.73 1.03 
21 3.13 5.53 --2.40 - - 5.39 -2.26 
22 5.44 5.53 -0.09 - - 5.39 0.05 
24 5.23 5.53 -0.30 - - 5.39 -0.16 
28 8.90 8.67 0.24 - - 9.06 -0.16 
Model 1 0 13 Correlation Matrix 
CH3 Admin JHRTDDXr 
CH] 1.0 0.172 -0.772 
Admin 1.0 0.378 
J"HRTDD Xr 1.0 
Model 10 14 Correlation Matrix 
CH, J"HRTDD Xr 
CH, 1.0 -0.933 
./l-IR TDD Xr 1.0 
Model 10 15 Correlation Matrix 
CH3 JHRIDDXr 
CHl 1.0 -0.930 
J'HRTDD Xr 1.0 
A t01 
Appendix 7 
Model 10.13 Validity Plots 
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Actual All All Oral Oral Parenteral Parenteral 
...rXr Cephs. Cephs. Cephs. Cephs. Cephs. Cephs. 
Predicted Residual Predicted Residual Pred. Residual. 
rxr J')(.r JXr 
30 0.10 -0.45 0.35 -0.44 0.54 - -
31 0.10 0.08 -0.18 0.91 -0.81 - -
33 4.87 - - - - -5.64 0.77 
35 1.67 -2.15 0.48 - - -1.45 0.22 
43 1.79 -1.88 0.09 
- - -1.36 0.43 
46 1.87 -1.83 -0.04 
- - -2.56 0.78 
48 3.78 -3.32 -0.46 - - -4.01 0.23 
53 3.74 -3.02 -0.72 - - -3.09 0.65 
54 3.09 -3.47 0.38 - - -3.42 0.33 
58 4.25 
- - - -
-3.69 0.56 
59 3.82 -3.62 -0.20 - - -3.67 0.15 
62 2.90 
- -
3.59 0.27 - -
63 5.53 -5.55 0.03 - - -5.09 0.43 
64 5.22 -3.89 -0.77 - - -4.61 0.05 
66 3.76 -3.25 -0.51 - - -3.02 0.74 
67 2.51 -2.86 0.35 - - -3.65 1.14 
69 2.51 -4.06 1.55 - - - -
Model 10 16 Correlation Matrix 
SSBP Sterimol B4 Ji-IRTDD Xr 
SSBP 1.0 0.814 0.561 
Sterimol B4 1.0 -0.028 
./HR TDD Xr 1.0 
Model 10 1 7 Correlation Matrix 
Sterimol B4 J'HRTDDXr 
Sterimol B4 1.0 0.945 
JRRTDDXr 1.0 
Model 10 18 Correlation Matrix 
DVx Sterimol B4 J}lRTDDXr 
DVx 1.0 0.092 0.311 
Sterimol B4 1.0 -0.721 
J'HRTDDXr 1.0 
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Model 10.16 Validity Plots 
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Model 10.18 Validity Plots 
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